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The endonuclease VIII family of DNA glycosylases initiate repair of oxidative DNA base damage 
through BER and have been shown to resolve DNA inter-strand crosslinks (ICLs), arising from 
exogenous agents. Human NEIL1 (hNEIL1) activity on psoralen generated mono-adducts 
(MAs) and three-stranded DNA ICLs was previously described and recently NEIL3 from 
Xenopus laevis was reported to repair psoralen generated MAs and apurinic/apyrimidinic site 
DNA ICLs. Here, complementary roles of hNEIL1 and hNEIL3 in the removal of two oxidized 
pyrimidine bases were identified within a model DNA replication fork structure in vitro. 
Further investigation revealed a novel activity of truncated and full-length recombinant 
hNEIL3 proteins in vitro on single-stranded psoralen MAs and three-stranded and four-
stranded psoralen ICL DNA substrates, highly toxic replication stalling lesions. For the first 
time it was shown that NEIL1/3 possess activity on four-stranded DNA ICLs. With the hNEIL3 
catalytic knockout mutation K81A, elimination of activity on three- and four-stranded DNA 
ICLs was confirmed. hNEIL1 was recently shown to be ubiquitinated by the E3 ubiquitin-ligase, 
tripartite motif-containing protein 26 (TRIM26). Here, TRIM26 was identified as the major 
ubiquitin ligase for hNEIL3 through HeLa cell fractionation and in vitro ubiquitination assays. 
TRIM26 RNAi in U2OS cancer cells increased steady state levels of hNEIL1/3 and resulted in 
resistance to the ICL inducing agent cisplatin, determined through clonogenic survival assays. 
Transient overexpression of hNEIL1/3 complemented the observed phenotype. Finally, a 
model is proposed for incision-independent ICL repair in mammalian cells. FANCM - facilitated 
replication traverse of an ICL is envisaged, followed by NEIL1/NEIL3 initiated repair of ICL 
structures, independent of the induction of double-strand DNA breaks. This pathway is 
proposed to be modulated by TRIM26, providing resistance to ICL-inducing agents in cancer 
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With an estimated 30,000 deoxyribose nucleic acid (DNA) damaging events per cell, per day, 
DNA repair is an essential line of defence against mutation and cytotoxicity (Wallace et al., 
2012). Without efficient DNA repair, DNA damage significantly contributes to mutagenesis 
and carcinogenesis (Maynard et al., 2009; Wallace et al., 2012; Kelley et al., 2014). In 
eukaryotes the DNA glycosylases 8-Oxoguanine DNA glycosylase (OGG1), MutY homolog 
(MUTYH), endonuclease III homolog (NTH1), endonuclease VIII-like 1 (NEIL1), 2 (NEIL2) and 3 
(NEIL3) are responsible for initiating base excision repair (BER) in the removal and repair of 
oxidative DNA damage (Krokan and Bjørås, 2013). However, the NEIL3 protein remains 
relatively uncharacterised (Liu et al., 2013a). That said, an emerging role in the resolution of 
DNA interstrand crosslinks by NEIL1 and NEIL3 is becoming apparent (Couvé-Privat et al., 
2007; Couvé et al., 2009; Semlow et al., 2016; Yang et al., 2017). Thus, the repair of these 
diverse DNA lesions, implicates the human NEIL proteins in the maintenance of faithful DNA 
replication, highlighting their relevance as potential targets for therapeutic treatment of 
malignant tumours. 
NEIL3 has been shown to be overexpressed in proliferating cells such as in the testes, thyroid 
and malignant tumours (Kauffmann et al., 2008; Liu et al., 2013a; Shinmura et al., 2016). In 
healthy cells NEIL1 and NEIL3 are tightly regulated during the synthesis phase (S-phase), 
through to the gap 2 phase DNA damage checkpoint (G2/M phase) of the cell cycle (Hazra and 
Mitra, 2006; Neurauter, 2012; Liu et al., 2013a). Initial biochemical studies on the core 
glycosylase domain of human endonuclease VIII-like-3 (hNEIL3) have shown affinity for single 
stranded (ss) DNA substrates (Liu et al., 2013b). NEIL1 knockout mice displayed no significant 
accumulation of oxidative lesions, suggesting the presence of backup DNA repair systems 
present within the cell which may also resolve lesions excised by NEIL1 (Parsons and Elder, 
2003). Interestingly, overexpression of NEIL1 in Fanconi anemia (FA) deficient cells partially 
rescued sensitivity to the interstrand DNA crosslinking (ICL) inducing agents mitomycin C 
(MMC) and 8-methoxyporalen (8-MOP; Macé-Aimé et al., 2010). NEIL3 knockout mouse 
embryonic fibroblast (MEF) cells display sensitivity to cisplatin (Rolseth et al., 2013). 
Furthermore, preliminary work has revealed hNEIL3 ribonucleic acid interference (RNAi) 
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knockdown leads to sensitivity to oxaliplatin in HCT116 cells (Taylor et al., 2015). However, 
the biochemical mechanism of hNEIL3 in ICL repair remains to be understood. The focus of 
the work presented here was to provide further understanding of the biochemical mechanism 
of human endonuclease VIII-like-1 (hNEIL1) and hNEIL3 in the maintenance of the DNA 
replication fork and removal of replication blocking lesions. To investigate this, biochemical 
analysis of recombinant hNEIL1 and hNEIL3 proteins was undertaken in the presence of model 
DNA replication fork oligonucleotide structured substrates containing oxidative lesions and 
psoralen monoadducts, three- and four- stranded structured ICL containing oligonucleotide 
substrates. 
In addition, an emerging view is that the BER pathway is modulated through the ubiquitin 
proteasome system (UPS; Edmonds and Parsons, 2016; Carter and Parsons, 2016). Thus, the 
identification and investigation of a novel NEIL3 interacting E3 ubiquitin ligase was 
undertaken and determined to be the same major E3 ubiquitin ligase previously identified for 
NTH1 and hNEIL1, i.e. tripartite motif containing protein 26 (TRIM26). The effect of TRIM26 
modulation on NEIL3 protein levels was determined in human bone osteosarcoma epithelial 
cells (U2OS). Finally, U2OS survival after TRIM26 RNAi and transient overexpression of hNEIL1 
or hNEIL3 in response to cisplatin was determined. 
This study, therefore, aims to provide evidence that supports distinct biochemical roles of the 
hNEIL1 and hNEIL3 DNA glycosylases at the DNA replication fork. Furthermore, to 
demonstrate the modulation of hNEIL1 and hNEIL3 by the ubiquitin post-translational 
modification (PTM) in response to the DNA crosslinking agent cisplatin. Consequently, 
highlighting links between BER and resistance to chemotherapy of cancer by upregulation, or 
dysfunction, of cellular mechanisms. 
1.1. Cancer. 
 
Cancer refers to more than 277 different types of disease which share six common definable 
hallmarks (Hanahan and Weinberg, 2011; Hassanpour and Dehghani, 2017). These six 
hallmarks are grouped under the ability of cells to resist cell death, possess the ability to 
undergo invasion/metastasis, induce angiogenesis, display proliferative immortality, evade 
growth suppressors and demonstrate sustained proliferative signalling (Hanahan and 
Weinberg, 2011). The root cause of these phenotypes is genomic instability and subsequent 
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mutation leading to these malignant phenotypes (Hanahan and Weinberg, 2011; Yao and Dai, 
2014). 
Sustained proliferative signalling is considered one of the core characteristics of cancer cells, 
resulting in indefinite proliferation. This is achieved by dysregulation of the cell cycle with the 
disruption of cell cycle check points through mutation and or loss of function in oncogenes, 
tumour-suppressors such as cyclin proteins, cyclin dependent kinases, and mitotic checkpoint 
proteins (Wenzel and Singh, 2018)    
Worldwide, cancer is the second leading cause of human mortality, with the overall 
prevalence of cancer increasing. In 2018, 1,735,350 new cancer cases were observed, with 
609,640 expected deaths in the USA alone (Siegel et al., 2018). In the UK in 2015, 359,960 
new cases of all cancers were observed with 163,444 deaths due to cancer being observed in 
2016; together these findings demonstrate the scale and impact of cancer in Western 
societies (Cancer Research UK, 2015; 2016). 
For Men the highest percentages of cancer present in the prostate, lung and bronchus, colon 
and rectum, respectively. Whereas for Women, they are estimated to display the highest 
percentages of cancer in the breast, lung and bronchus, colon and rectum, respectively. 
(Siegel et al., 2018). Cancer in young adults and children is rare, accounting for 1.5% of all 
cancers. In the UK, within the0-14-year-old age group the highest percentage of cancers 
observed per year are leukaemia, cancers of the central nervous system and lymphomas. 
While in the 15-24-year-old age group the highest percentage of yearly observed cancers is 
lymphomas, carcinomas and germ cells (Pesola et al., 2017).  It was also estimated that 
prevalence of cancers in the UK in 0-24-year-old was likely to increase up to 2030 (Pesola et 
al., 2017). Despite the increase in prevalence of cancers, individuals are now much more likely 
to survive than ever before. Over a 40-year period, Quaresma et al. (2015) found that 50% of 
individuals diagnosed in 1971-1972 were likely to survive for 1-year post-diagnosis, while 
between 2005-2006 survival was 50%, 5 years after diagnosis and in 2011 the survival rate of 
50% was extended to 10 years post-diagnosis.  
Cancer occurs through the spontaneous mutation of genes through damage to DNA, changing 
their function and regulation of biological processes within the cell. Lawley and Brookes 
(1960) discovered that carcinogenesis may be a result of damage to the DNA molecule, 
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demonstrating that mustard gas reacted with DNA, modifying guanine residues in vitro and 
in vivo. Brookes and Lawley (1964) then demonstrated that a radioactively labelled tobacco 
carcinogen (polycyclic-aromatic-hydrocarbon) had the ability to induce tumours in mice and 
this phenotype correlated with its binding to DNA. It is now known that both environmental 
risk factors and genetic predisposition play a significant role in the development of cancer. 
Tobacco smoke, chemical pollutants, UV and ionising radiation (IR) have all been identified as 
examples of exogenous influences which promote genetic mutation within the cell (Poon et 
al., 2014; Aizawa et al., 2016). Since the first conclusive evidence that cancer was caused 
through damage to DNA by Brookes and Lawley in 1964, 120 agents have been identified by 
the International Agency for Research on Cancer as group 1 carcinogens with “sufficient 
evidence of carcinogenicity in humans”, 82 group 2A “probably carcinogenic to humans”, 302 
group 2B “Possibly carcinogenic to humans” (IARC, 2018). 
Acquired drug resistance is one of the primary challenges faced in the treatment of cancer as 
it abrogates the clinical response of the therapy (Foo and Michor, 2014). Platinums and 
alkylating agents are molecules used with widespread clinical application for the broad-
spectrum treatment of cancer. They represent a class of agents known to induce interstrand 
DNA crosslinks amongst other forms of DNA damage (Fu et al., 2012; Deans and West, 2011). 
Cancer often becomes resistant to these agents reducing their efficacy (Shen et al., 2012). 
One such mechanism of acquired resistance to these agents is the enhancement of the 
capacity of the cell to remove DNA adducts, through the upregulation of associated DNA 
repair pathways. It has been shown that a pattern of cross resistance is acquired in response 
to the use of ICL inducing agents (Torres-Garcia et al., 1989). One such example is the acquired 
resistance to cisplatin, one type of crosslinking agent, which may additionally facilitate cross 
resistance to other ICL inducing agents (Taniguchi et al., 2003). This indicates common 
underlying mechanisms of acquired resistance to this class of genotoxic agents. Thus, the 
molecular targeting of DNA repair pathways associated with the repair of ICL DNA adducts 
provides a promising therapeutic strategy (Seetheram et al., 2010; Huang and Li, 2013). 
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1.2. DNA damage.  
 
The genomic stability of a cell is crucial for its survival in the face of endogenous and 
exogenous genotoxic insult. The cellular response to DNA damage is synchronised with the 
initiation of DNA repair pathways or apoptosis (cell death). Apoptosis (cell death), is initiated 
following significant DNA damage, removing cells which may proliferate with further harmful 
potential (Schärer, 2003). DNA damage can arise from the generation of reactive oxygen 
species (ROS), IR, ultraviolet (UV) and chemical agents targeting DNA (Ciccia and Elledge, 
2010). Such damage leads to modifications of the DNA molecule including, oxidative base 
damage, single- and double-strand breaks (SSBs and DSBs), alkylation, intra and interstrand 
DNA crosslinks, all of which have a deleterious effect on the cell (Klaunig et al., 1998). 
1.2.1. Oxidative DNA damage  
 
Healthy cells balance antioxidant defence mechanisms with ROS levels; if this balance is lost, 
cellular oxidative stress results. ROS are generated endogenously through leakage of 
electrons to oxygen in the electron transport chain and through lipid peroxidation (Jena, 
2012; Ayala et al., 2014). Alternatively, ROS are generated as a result of oxidative stress from 
exogenous agents such as tobacco smoke, diesel exhaust particulates found in the air, 
chemical agents, UV and IR (Krokan and Bjørås, 2013). The generation of ROS can form DNA 
intrastrand crosslinks, SSBs and DSBs, oxidisation of apurinic/apyrimidinic (AP) sites, 
oxidisation of sugar fragments, formation of deamination products and many different 
oxidised bases (Schärer, 2003; Jiang et al., 2007; van Loon et al., 2010; Jena, 2012).  
Oxygen free radicals are generated through the reduction of molecular oxygen and have a 
short half-life, therefore causing damage locally. ROS are generated during normal cellular 
metabolism, including the super-oxide radical anion (O2−), peroxynitrite (ONOO-) and hydroxyl 
radicals (.OH). Hydroxyl radicals are produced through dismutation of O2− to hydrogen 
peroxide (H2O2) by superoxide dismutase. Hydrogen peroxide is usually cleansed by 
glutathione peroxidase and converted into innocuous H2O by catalase, but excess O2− allows 
.OH production (Figure 1.1). Formation of highly reactive hydroxyl radicals is a major 
contributor to DNA damage (Bandaru et al., 2002; Wallace et al., 2003).  Hydroxyl radicals can 
also be generated through UV-induced photolysis of H2O2 and finally through the presence of 
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transition metals allowing the generation of .OH through the Fenton reaction (Figure 1.2; Lu 
et al., 2007; Jena, 2012).  
Figure 1.1: Schematic representation of ROS generation through the consecutive reduction of cellular oxygen 
and superoxide radical catalysis by superoxide dismutase.  
Figure 1.2: Fenton reaction formula showing the generation of ROS as result of the presence of Iron (Fe). 
Oxidative lesions are generated at a frequency of 10,000 DNA lesions per cell per day and are 
responsible for over 100 different types of oxidative molecular modification (Klaunig et al., 
2011). Guanine has the lowest redox potential of the four nitrogenous bases and as result is 
readily oxidised by ROS (Kino et al., 2017). Important examples of oxidative lesions include 
the mutagenic formamidopyridimines (Fapy) such as FapyG, generated through ROS attack of 
C8, opening the 5 carbon ring and resulting in FapyG-A mispairs (Figure 1.3; Jena and Mishra, 
2013). Additionally, the abundant 8-oxoguanine (8-OxoG) can be generated by addition at C8 
and its further oxidation generates the spiroiminodihydantoin (Sp) and guanidinohydantoin 
(Gh) DNA lesions (Figure 1.3; Niles et al., 2004; Jena and Mishra, 2012). 8-OxoG is associated 
with aging and cancer due to frequent mispairing with adenine by both eukaryotic and 
prokaryotic DNA polymerases resulting in GC to TA transversion mutations (Klaunig et al., 
2011; Krokan and Bjørås, 2013).  
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Figure 1.3: Schematic representation of the major DNA lesions generated through oxidation of guanine, 8-
oxoguanine (8-OxoG) and 2,6-diamino-4-hydroxy-5-formamidopyrimidine (FapyG). Further oxidation of 8-
OxoG may lead to the formation of open ring Guanidinohydantoin (Gh) and closed ring Spiroiminodihydantoin 
(Sp). Positions highlighted in red represent those modified. 
Hydroxyl radicals, peroxyl radicals and hydroperoxides may interact with cytosine, with the 
latter accounting for the generation of the stable 5-hydroxyuracil (5-OHU) DNA lesion after 
rapid decomposition of oxidised cytosine (Cadet and Wagner, 2013). Initially oxidation leads 
to generation of cytosine-glycol which is highly unstable and can dehydrate, deaminate or 
both to sequentially generate 5-hydroxycytosine, uracil glycol and 5-OHU, respectively (Figure 
1.4; Thiviyanathan et al., 2008). This spontaneous deamination and incorporation of 5-OHU 
into DNA may promote mutagenesis if not removed, through mispairing adenine after DNA 
replication leading to CG-TA transition, that account for the most abundant base substitutions 
observed in DNA (Thiviyanathan et al., 2008). 
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Figure 1.4: Schematic representation of the spontaneous dehydration and deamination of cytosine post-
oxidation, leading to the formation of the 5-hydroxyuracil (5-OHU) lesion (Adapted from Thiviyanathan et 
al., 2008). Positions highlighted in red represent those modified. 
Thymine may be oxidised by •OH, with H-atom abstraction from the methyl group and the 
5,6-pyrimidine bond (Figure 1.5). This in turn results in rapid addition of cellular O2 to the 
radical site to generate an intermediate product which degrades to generate thymine glycol 
(Tg; Figure 1.5). Thymine glycol has been demonstrated to be the most abundant base 
modification generated as a product of IR and oxidation of thymine (Pouget et al., 2002; Yoon 
et al., 2010). Thymine glycol stalls DNA replication due to the modification of the 5, 6-double 
bond of thymine, resulting in the loss of aromatic character and conversion into a planar 
structure. As a result, the C5 methyl group projects in a perpendicular direction blocking 
replicative DNA polymerases (Aller et al., 2007; Yoon et al., 2010). If left unrepaired, Tg 
requires the activation of translesion synthesis (TLS) with the recruitment of low-fidelity TLS 
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DNA polymerases which can synthesise past a replication blocking lesion with varied 
efficiency and accuracy, potentially resulting in TA to GC transversions, highlighting the 
mutagenic potential of Tg (Yoon et al., 2010). Furthermore, the stalling of the replication 
machinery may activate the DNA damage response and lead to DNA replication stress. This 
has been demonstrated with the stalling of the FANCJ helicase in association with replication 
protein A (RPA) in the presence of Tg (Suhasini et al., 2009). 
 
Figure 1.5: Schematic representation of the generation of Thymine glycol (Tg) through •OH oxidisation of the 
5,6 double bond of thymine followed by O2 addition and decomposition (Adapted from Cadet and Wagner, 
2013). Positions highlighted in red represent those modified. 
Prokaryotic and eukaryotic cells have evolved complex DNA repair mechanisms to counter 
potential mutagenic events. The pathway responsible for the removal of oxidised bases is 
BER, initiated in prokaryotes by the endonuclease VIII (Nei), formamidopyrimidine DNA 
glycosylase (Fpg), and endonuclease III (Nth) DNA glycosylases, whereas mammalian cells 
possess the DNA glycosylases 8-oxoguanine DNA glycosylase (OGG1), NTH1 and Nei-like DNA 
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1.2.2. Alkylation of DNA. 
 
Extracyclic oxygen and ring nitrogens in DNA bases are vulnerable to alkylation. 
Monofunctional or bifunctional alkylating agents can modify the DNA at one or two sites, 
respectively. Monofunctional alkylating agents such as dacarbazine, procarbazine, 
temozolomide (TMZ) and streptozotocin result in complex DNA lesions that may distort the 
DNA helix, potentially blocking transcription and or DNA replication (Fu et al., 2012). 
Additionally, bifunctional agents such as melphalan, mechloroethamine, cyclophosphamide 
and bendamustine may form interstrand DNA crosslinks, which are highly toxic due to their 
ability to also prevent the progression of transcription and DNA replication leading to 
replication stress and possible DNA replication fork collapse (Fu et al., 2012; Soll et al., 2017). 
It is thought that ICLs are subsequently processed through nucleotide excision repair (NER) 
and FA initiated repair pathways (Wang, 2007; Deans and West, 2011). 
Alkylating agents can generate different DNA damage based on their mode of interaction with 
DNA and are sub-categorised based on their mechanism of nucleophilic substitution as 
substitution nucleophilic unimolecular (SN1) or substitution nucleophilic bimolecular (SN2) 
alkylating agents. SN1 agents can target both extracyclic oxygens and ring nitrogens, while SN2 
agents mainly target ring nitrogens. Due to the additional reactivity possessed by SN1 agents, 
they include the most commonly used chemotherapeutic alkylating agents such as TMZ and 
melphalan (Shrivastav et al., 2010; Fu et al., 2012).  
The simplest form of alkylation damage is a result of the transfer of a single methyl group to 
a DNA base. A methyl donor may react extracyclic oxygen or ring nitrogens to generate one 
of 12 diverse DNA lesions. The prominent lesion generated in this manner is N7-methyl-
guanine (7meG), which accounts for ~75% of all methylation damage (Baranek, 1990). 7meG 
is not a particularly toxic lesion, however it is vulnerable to depurination which leads to the 
generation of an apurinic/apyrimidinic site (AP site), which is potentially mutagenic and can 
be a source of spontaneous SSB generation (Soll et al., 2017). Other forms of DNA damage 
resulting from methyl group transfer may be cytotoxic due to their ability to block replicative 
DNA polymerases, thus activating a low-fidelity DNA polymerase (pol) to facilitate trans-lesion 
synthesis (TLS) and implicating these forms of DNA damage as sources of mutagenesis due to 
the error prone nature of TLS (Fu et al., 2012). 
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O6-methylguanine (O6meG) is another lesion of interest that is both cytotoxic and readily 
forms mispairing with thymine within the DNA duplex leading to GC to AT transitions. In 
addition, O6-ethylguanine is the major lesion generated by ethylating agents and is also a 
significant contributor to mutagenesis inducing GC to AT transitions (Fu et al., 2012). O6meG 
may be directly reversed by O6-methylguanine DNA methyltransferase (MGMT) which 
transfers the methyl group to a catalytic cysteine residue (Olsson and Lindahl, 1980). 
Subsequently, MGMT-O6meG is targeted for proteasomal degradation through ubiquitination 
by the Skp1, Cul1/Cdc53, Roc1, and an F-box-containing (SCF) E3 ubiquitin ligase complex (Soll 
et al., 2016). O6meG is generated in abundance when DNA is exposed to agents such as TMZ. 
Resistance to TMZ has been demonstrated by the over expression of MGMT and thus, cancer 
cells that display inactivated MGMT are more sensitive to TMZ (Christmann et al., 2011). 
Subsequently, methylation of the promoter of MGMT, often observed in tumours, is a useful 
biomarker for resistance to TMZ treatment (Esteller et al., 2000; Hegi et al., 2005; Weller et 
al., 2010). Mismatch repair (MMR) is implicated in the removal of thymine mispaired with 
O6meG. MMR competency is essential for O6meG cytotoxicity and has been proposed to be 
as result of two models. The first model, “the futile cycle” model, requires recruitment of the 
putative DNA mismatch repair protein, C-terminal (MutSα) and DNA mismatch repair protein 
MutL (MutLα) complexes facilitating removal and resynthesis of the thymine containing DNA 
strand. If this process replaces the mispaired thymine multiple times, it is suggested to 
promote DSB formation with increased levels of sister chromatid exchange implicating 
homologous recombination (HR), defects in which may lead to apoptosis (Mojas et al., 2007; 
Quiros et al., 2010). Alternatively, it has been suggested that MutSα and MutLα may bind and 
lead to DNA damage response signalling through ataxia telangiectasia mutated kinase and 
Rad3-related kinase (ATR) and ATR interacting protein (ATRIP) leading to cell cyle arrest and 
apoptosis (Yoshioka et al., 2006). 
N1-methyladenine (1meA) and 3-methylcytosine (3meC) may be generated in single-stranded 
DNA context, with normal base pairing usually protecting against their formation (Shrivastav 
et al., 2010). 1meA and 3meC are produced by the SN2 alkylating agent 
methylemethanesulfonate (MMS) and are cytotoxic due to their ability to prevent the 
progression of DNA replication by blocking replicative DNA polymerases. To deal with this 
form of DNA damage, human cells respond through DNA oxidative demethylase 2 and 3 
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(ALKBH2 and ALKBH3) enzymes. These enzymes achieve repair through α-ketoglutarate- and 
iron dependent oxidation of the base to release the methyl group in the form of 
formaldehyde, subsequently regenerating the undamaged base (Duncan et al., 2002). 
Additionally, methylation of adenine bases after monofunctional alkylating agent treatment 
can generate 3-methyladenine (3meA) that is cytotoxic due to its ability to block DNA 
replication, indicated through activation of cellular tumour antigen p53 (p53), S-phase arrest 
and chain termination (Engelward et al., 1998; Elder et al., 1998). Alkyl-Adenine-DNA 
glycosylase (AAG) has been shown to be the major DNA glycosylase responsible for the 
removal of 3meA, initiating BER, in vitro and in vivo (Smith and Engelward, 2000). 
Taken together, DNA alkylation includes several events that lead to a diverse set of DNA 
lesions that require multiple DNA repair pathways for their efficient removal, protecting 
against the possible cytotoxic or mutagenic affects they may impose. These pathways include 
direct reversal by MGMT, ALKBH2, ALKBH3 BER, NER, FA and MMR (Fu et al., 2012; Soll et al., 
2017). 
1.2.3. Crosslinking of DNA. 
 
Interstrand DNA crosslinks are highly toxic DNA lesions (Muniandy et al., 2010). Interstrand 
DNA crosslinks block DNA replication, recombination and transcription by preventing strand 
separation by helicases (McCabe et al., 2009, Deans and West, 2011). In prokaryotic 
organisms just one lesion may be responsible for cell death, whereas in mammalian cells 20-
40 lesions left unrepaired may induce cell death (Lawley and Phillips, 1996). Intrastrand 
crosslinks may also be formed, crosslinking DNA on the same strand, but are more readily 
removed through the NER pathway and do not block DNA replication (Huang and Li, 2013). 
Crosslinking agents are in widespread use in the chemotherapy of cancer, due to the highly 
toxic nature of the induced DNA damage (Deans and West, 2011). Exogenous ICL inducing 
agents introduce genotoxic links within the DNA molecule inducing cellular apoptosis when 
unrepaired, through the activation of the DNA damage response (DDR) pathway. Interstrand 
DNA crosslinks can also be generated by endogenous agents, with acetaldehyde, 
formaldehyde and malondialdehyde being products of alcohol metabolism, histone 
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demethylation and lipid peroxidation, respectively (Cho et al., 2006; Marietta et al., 2009; 
Huang and Li, 2013; Ayala et al., 2014; Wallace et al., 2014).  
Examples of ICL inducing agents include oxaliplatin, cisplatin, carboplatin, cyclophosphamide, 
MMC, melphalan, nitrogen mustard derivatives, nitrosoureas and psoralens amongst others 
(Dronkert and Kanaar, 2001; Siddik, 2003; Muniandy et al., 2010; Huang and Li, 2013). These 
molecules contain two reactive groups that react with two nucleotides on opposite strands 
of a DNA duplex to generate an ICL or a ‘bulky’ mono-adduct (Couvé-Privat et al., 2007; Couvé 
et al., 2009). In the case of platinating agents, this is usually at the N2 or N7 position of 
guanine, resulting in the covalent modification of both DNA strands (Siddik, 2003; Couvé –
Privat et al., 2007; Deans and West, 2011; Huang and Li, 2013). The mode of action of 
crosslinking agents is similar, differing in the DNA sequence specificity and the extent to which 
they distort DNA, producing bends, kinks and unwinding, inducing a varying proportion of ICLs 
compared to other lesions such as oxidative damage, alkylation, helical distortions and DNA 
breaks (Table 1.1; Dronkert and Kanaar, 2001; Deans and West, 2011; Slyskova et al., 2018). 
As an example, cisplatin induces a wide variety of DNA damage, with up to 90% being 
intrastrand crosslinks and less than 5% ICLs, whilst forming major distortion to the DNA duplex 
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Table 1.1: ICL agent class, DNA sequence context of ICLs and relative level of DNA distortion. (Adapted from 
Dronkert and Kanaar, 2001). 
Psoralens are model agents for the study of ICLs due to 5’-TpA-3ʹ site selectivity and ability to 
generate a high percentage of ICLs and low percentages of other lesions (Dronkert and 
Kanaar, 2001; Couvé-Privat et al., 2007; Couvé et al., 2009). Psoralens are furanocoumarins, 
a class of organic compounds generated by a variety of plants, which are used in the 
treatment of psoriasis, vitiligo and other skin diseases, but are also used for the treatment of 
T-cell lymphomas (Huang and Li, 2013). Commonly used psoralen agents include 8-MOP and 
trimethylpsoralen (HMT; Dronkert and Kanaar, 2001; Deans and West, 2011). With 8-MOP 







Figure 1.6: Skeletal formula of the psoralen interstrand crosslinking agents 8-methoxypsoralen (8-MOP) and 
trimethylpsoralen (HMT). 
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When exposed to UVA light at a 310-400 nm wavelength, psoralen intercalated DNA becomes 
covalently adducted. The UVA absorption of psoralen is higher than DNA and proteins, 
facilitating crosslinking without additional damage to DNA and proteins (Sastry et al., 1997). 
Crosslinking is facilitated by initial cycloaddition at the 5,6-double bond of pyrimidines and 
single molecule addition at the 3,4-double bond of the pyrone ring or the 4,5-double bond of 
the furan ring of psoralen, activated by a UVA photon. Generating a pyrone-side 8-MOP-dT 
mono-adduct (MAp) or a furan-side 8-MOP-dT mono-adduct (MAf), the absorption of a 
second photon then facilitates interstrand crosslinking at the available pyrone or furan double 
bond, in a 5’-TpA-3ʹ sequence context (Figure 1.7; Figure 1.8; Sastry et al., 1997; Couvé-Privat 






Figure 1.7: Skeletal formula of 8-MOP-thymine mono-adducts. MAp. Pyrone-side 8-MOP-dT mono-adduct and 
MAf. The furan-side 8-MOP-dT mono-adducts shown in two diastereomeric representations. Red structure 
indicates the thymine nitrogenous base with green bonds representing those formed after covalent modification 







Figure 1.8: Skeletal formula of 8-MOP mediated ICL generation with UVA exposure. 8-MOP intercalates 
between two opposing thymine nucleotides and is activated on exposure to UVA generating a thymine-thymine 
ICL in a 5ʹ-TpA-3ʹ specific manner.’dR’ denotes deoxyribose sugar and phosphodiester backbone of DNA. Red 
structures indicate thymidine residues, black structure represents 8-MOP and green bonds represent those 
formed after UVA activation (Adapted from Deans and West, 2011). 
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Endogenous sources of ICLs have been identified and provide clues to the evolutionary 
selective pressure that provided the requirement for the development of ICL repair pathways. 
Linkage of C4ʹ-oxidised abasic-site (C4-AP) to an adenine or a guanine is one such example 
(Dutta et al., 2006; Sczepanski et al., 2008; Semlow et al., 2016). The estimated number of AP 
sites present at steady state levels in a normal tissue are between 50,000-200,000 sites per 
cell, making it the most common form of DNA lesion after DNA breaks and thus, providing 
suitable opportunity for spontaneous abasic site ICL generation. Furthermore, it has been 
shown that AP site ICLs are relatively stable in duplex with a half-life of between 66 h and 85 
h at 37°C (Nakamura and Swenberg, 1999; Dutta et al., 2006; Sczepanski et al., 2008; Price et 
al., 2015). Taken together AP site ICLs may be a physiologically relevant endogenous DNA 
replication blocking structure. 
Other candidates for endogenous sources of ICLs are reactive aldehydes (Voulgaridou et al., 
2011). Malondialdehyde, crotanaldehyde and 4-hydroxynonenal are produced through lipid 
peroxidation and have been shown to form DNA ICLs (Summerfield and Tappel, 1984; 
Voulgaridou et al., 2011). Specifically, malondialdehyde generates etheno-adducts that may 
become rearranged to form ICLs. This has been demonstrated in vivo, with mice that were 
fed malondialdehyde displaying an increase in ICLs (Summerfield and Tappel, 1984). 
Formaldehyde is another endogenous source of ICLs and may be generated as a product of 
DNA demethylation by ALKBH2 and 3 or through histone demethylation. Formaldehyde may 
subsequently form ICLs through the production of a methylene bridge between exocyclic 
groups of nucleotides (Huang and Hopkins, 1993; Mosammaparast and Shi, 2010; Shen et al., 
2014). 
Acetaldehyde is another source of endogenous DNA ICLs, being a metabolic intermediate 
product of carbohydrates and a bi-product of ethanol oxidation (Brooks and Zakhari, 2003). 
Acetaldehyde and crotanaldehyde generate N2-propano-2’-deoxyguanosine (PdG), 
demonstrated by PdG generation after incubation with two molecules of acetaldehyde with 
mammalian DNA (Garcia et al., 2011). The PdG lesion may then react with a deoxyguanosine 
opposite to form a DNA ICL (Cho et al., 2006).  
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1.3. DNA damage response. 
 
The cell responds to DNA damage through the DDR, limiting further damage to the cell 
through the loss of genome integrity. The response is influenced by the stage of the cell cycle, 
damage type and load (Liang et al., 2009; O’Connor, 2015).  
At the core of the DDR are two protein kinases that work in parallel, the ataxia telangiectasia 
mutated serine/threonine kinase (ATM) and ATR. ATM and ATR initiate a protein cascade 
composed of transducers, sensors and effectors (Elledge, 2015). The ATM branch, is 
responsible for DSB detection, and the ATR branch is associated with SSB detection. ATM and 
ATR are responsible for activating transduction through checkpoint kinase 1 (Chk1) and 2 
(Chk2). Chk1 is activated by ATM and ATR whilst Chk2 is only associated with ATM.  Chk1 and 
Chk2 are recruited by DNA damage specific recognition proteins, meiotic recombination 11 
homolog A (MRE11), RAD50, Nibrin (NBS1) in complex, in ATM dependent recruitment to 
DSBs. Chk1 is recruited by RPA through ATR dependent recruitment to SSBs (Liang et al., 
2009). The effectors in the resulting cascade currently include over a thousand proteins that 
are involved in apoptosis, DNA repair, DNA transcription, cell cycle regulation and DNA 
replication, including p53 (Liang et al., 2009; Ellege, 2015). The DNA damage response can be 
initiated in a multiple pathway manner (Chou et al., 2008; O’Connor, 2015). 
The DNA damage response is controlled through the PTMs, phosphorylation, ubiquitination, 
poly(ADP-ribosyl)ation, acetylation and methylation. These modifications relocalise proteins 
temporally and spatially, altering the interactions within the DDR and the response (Huen and 
Chen, 2008). 
SSBs are repaired through BER, MMR and NER. DSBs are repaired by HR repair and non-
homologous end joining (NHEJ; Ciccia and Elledge, 2010; O’Connor, 2015). The loss of proteins 
involved in these pathways is concomitant with predisposition to oncogenesis, however the 
maintenance of cancer cell genomic stability by DNA repair enzymes is well established and 
is consequently targeted therapeutically (O’Connor, 2015). 
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1.4. DNA replication stress response (RSR). 
 
Human DNA replication is initiated at specific sites within the chromosome, known as origins 
of replication. Human chromosomes possess thousands of origins of replication, while yeast 
possess just a few hundred (Sacco et al., 2012). Firstly, origin licencing commences as early as 
early gap 1 phase during cell cycle interphase (G1 phase) or late G2/M phase of the cell cycle, 
where the pre-replication complex is assembled. This complex consists of, the 
minichromosome maintenance proteins 2-7 (Mcm2-Mcm7), the origin recognition complex 
(ORC1-6) the cell division cycle 6 (Cdc6) and cell division cycle 10-dependent transcript 1 
(Cdt1; Gambus et al., 2011; Yamazaki et al., 2013). The Mcm2-7 complex then assemble into 
two oppositely oriented DNA replication forks with one hexamer of the Mcm2-7 complex at 
the junction of the fork (Boos et al., 2012). The recruitment of multiple additional proteins 
then initiates the conversion of the Mcm2-7 complex into the Cdc45-Mcm2-7- go-ichi-ni-san 
complex (GINS (CMG)) complex. The CMG complex facilitates the unwinding of the DNA at 
the origin of replication, followed by replisome assembly and progression of two replication 
forks in opposite directions along the chromosomal DNA (Ilves et al., 2010; Tanaka and Araki, 
2010). 
Efficient and faithful DNA replication is crucial to maintain genome stability to prevent 
mutagenesis. Cells have evolved mechanisms to inhibit the impact that endogenous and 
exogenous stress has upon the cell during DNA replication within the S-phase of the cell cycle, 
to facilitate faithful replication of DNA and transfer to daughter cells on completion of mitosis. 
These include BER, HR and FA pathways (Wang, 2007, Petermann and Helleday, 2010; Ronson 
et al., 2018). Replication stress is defined as the stalling or slowing in the progression of the 
DNA replication fork and does so to enable the restoration of the DNA. Replication stress may 
originate from many different sources and includes the incorporation of ribonucleotides, 
secondary DNA structures, early-replicating fragile sites (ERFSs) and common fragile sites 
(CFSs). However, some of the most common sources of replication stress are DNA lesions that 
inhibit the progression of the replisome (Zeman and Cimprich, 2013).  
Fragile sites are loci within the human genome that appear to be particularly difficult to 
replicate. ERFs are G/C rich regions of DNA in open chromatin that display early initiation of 
DNA replication. CFSs have a high number of A/T nucleotides, are susceptible to formation of 
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secondary structure and appear in compact chromatin, demonstrating late initiation of DNA 
replication (Mortusewicz et al., 2013; Glover, 2017). CFSs are prone to replication stress 
induced DSBs, prevention of which is postulated to be specific to the action of structure 
specific endonucleases Crossover junction endonuclease MUS81 (MUS81)-crossover junction 
endonuclease EME1 (EME1) and bloom syndrome protein (BLM) helicase removing 
replication intermediates (Naim et al., 2013). CFSs can range from 1 Mb to 10 Mb in size and 
consequently the study of CFSs has led to the identification of large genes, some of which 
have been implicated as tumour suppressors (Mazouzi et al., 2014). For example, PARK2 
encodes for the E3 ubiquitin ligase PARKIN and is often deleted in colorectal cancer cells 
(Poulogiannis et al., 2010). 
Single-stranded DNA and SSBs are by association tied to replication stress, being both sources 
and signs of stress. DNA breaks are generated as intermediates in several DNA repair 
pathways including BER (Krokan and Bjørås, 2013). Stretches of ss-DNA in the DNA replication 
fork become coated with the single-stranded DNA binding protein RPA, the persistence of this 
interaction signals the activation of the replication stress response (RSR; Byun et al., 2005). In 
turn this structure facilitates the recruitment of multiple replication stress response proteins, 
crucial components of the DNA damage response pathway (Zou and Elledge, 2005, Nam and 
Cortez, 2011).  The study of ATR function at stalled DNA replication forks has revealed that it 
actively inhibits cell-cycle progression through phosphorylation of Chk1 (Lopez-Contreras and 
Fernandez-Capetillo, 2013). Dysregulation of ATR or Chk1 lead to checkpoint defects and 
chromosomal breakage (Fernandez-Capetillo and Nussenzweig, 2013). In addition, ATR can 
promote replication restart after successful removal of DNA lesions (Nam and Cortez, 2011).  
The replication fork may fail to restart when replication stress persists. It is postulated that 
absence in ATR signalling pathway components leads to dissociation of the replisome, leading 
to DNA replication fork collapse (Ragland et al., 2013). Evidence also exists for the formation 
of DSBs involved in fork collapse. The absence of ATR has been shown to enhance the 
formation of DSBs associated with DNA replication fork collapse and the activation of ATM 
signalling, through the phosphorylation of histone 2 A X (H2AX) on serine 139 (Chanoux et al., 
2009). It has been shown that single-stranded DNA and unrepaired SSBs present at a 
persistently stalled DNA replication fork may be prone to passive conversion into a DSB, 
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possibly through HR based replication restart or aberrant MUS81-EME1 cleavage (Kuzminov, 
2001; Pascucci et al., 2005; Hanada et al., 2006; Petermann and Helleday, 2010).  
Furthermore, DNA replication fork reversal and remodelling can be initiated at stalled 
replication forks, with four-way junctions and chicken foot structures being described 
(Singleton et al., 2001; Quintet et al., 2017). When ATR mediated DNA replication restart fails, 
fork reversal is observed and can lead to HR based repair of the replication fork and restart of 
replication (Peterman and Helleday, 2010). Indeed, it has been shown that many DSB repair 
proteins help regulate the reversal of the replication fork and prevent its aberrant 
degradation by extended nucleolytic degradation in a non-canonical manner, such as BRCA2 
and PARP1 (Mijic et al., 2017; Quintet et al., 2017).  
DNA damage promotes DNA replication stress directly, with UV irradiation, cisplatin and 
aphidicolin being shown to uncouple the CMG helicase complex and inhibit DNA polymerase 
activity during DNA replication. Furthermore, it was shown that this uncoupling was essential 
for the Chk1 phosphorylation by ATR (Byun et al., 2005). Replication blocking lesions are a 
source of DNA replication stress and include ICLs and the oxidative DNA lesion Tg (Aller et al., 
2007; Suhasini and Brosh, 2010; Yang et al., 2017). When ICLs are encountered the 
progressing CMG helicase complex becomes stalled and initiates replication stress and FA 
pathway-initiated repair (Wang et al., 2007; Yang et al., 2017). In addition, Tg blocks the action 
of replicative DNA polymerases and leads to the initiation of DNA damage tolerance pathways 
(DDT) including TLS (Suhasini and Brosh, 2010).  
1.5. DNA damage tolerance pathways. 
 
While the replication stress response aims to repair DNA damage responsible for the initiation 
of the response, it is not always possible. When significant blocks to DNA replication 
accumulate it may be more appropriate to bypass the replication stalling lesion instead of 
potential fork collapse (Ghosal and Chen, 2013). In this context the cell has evolved DNA 
damage tolerance pathways that bypass DNA lesions for the continuation of replication to 
prevent prolonged DNA replication fork stalling and possible fork collapse.  Two DDT 
pathways have been proposed. These pathways restart the stalled replication fork by 
initiating synthesis downstream of DNA damage and facilitate repair in a post-replicative 
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manner. This is facilitated by TLS and template switching (TS) pathways (Ghosal and Chen, 
2013; Xin, 2015).  
Conserved from prokaryotes through to higher eukaryotes, TLS is an error prone process that 
involves the replacement of replicative DNA polymerases when encountering a DNA 
replication blocking lesion. The replicative DNA polymerase is transiently replaced by low-
fidelity DNA polymerases (Fuchs and Fujii, 2013; Trakselis et al., 2017). Mammalian cells 
possess seven characterised low-fidelity DNA polymerases, two A family DNA polymerases 
(pol θ and pol ν), one B-family DNA polymerase (pol ζ) four Y family DNA polymerases (pol η, 
pol ι, pol κ, Rev1) that possess the ability to synthesise past a DNA lesion and are capable of 
inserting a small number of nucleotides (Sale et al., 2012; Fuchs and Fujii, 2013; Ghosal and 
Chen, 2013). Each of these error-prone DNA polymerases is recruited in a DNA damage 
specific manner. Pol ζ has been reported to perform DNA synthesis in an error-free manner 
in the presence of Tg lesions (Johnson et al., 2003). The DNA repair protein REV1 (Rev1) inserts 
cytosine opposite (cytosine void of OH at the 2' position) opposite guanine, AP sites, 8-OxoG 
and O6meG (Haracsksa et al., 2002). Together Pol ζ and Rev1 are implicated in resistance to 
DNA damage, with deletion leading to sensitivity to UV, MMS, ICL inducing agents and DSB 
induction. Polymerase ζ and Rev1 were first implicated in the repair of cisplatin and MMC 
induced DNA damage in a FANCC dependent epistasis and are now associated with canonical 
FA pathway repair of ICLs (Niedzwiedz et al., 2004; Wang, 2007). However, these DNA 
polymerases lack any proof-reading capability, which enables them to recognise modified 
bases but may lead to incorporation of incorrect nucleotides. For this reason, TLS is 
considered a source of cellular mutagenesis (Ghosal and Chen, 2013).  
Template switching is an error-free method of DNA damage tolerance. In this instance the 
stalled nascent DNA strand temporarily switches to the nascent sister strand. Once gap filling 
using the sister-DNA strand as a non-damaged template has completed, a sister chromatid 
junction (SCJ) is formed and then resolved (Xin, 2015).  
Both DDT pathways are regulated by the proliferating cell nuclear antigen (PCNA). PCNA is a 
ring heterotrimer that interacts with replicative DNA polymerases affecting their processivity, 
after being loaded to primed DNA by the clamp loader replication factor C (RFC; Kannouche 
et al., 2004). The ubiquitin proteasome system regulates the choice in DDT pathway. 
Monoubiquitination of PCNA on Lys164 has been confirmed to promote TLS by facilitating 
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replacement of the replication DNA polymerase by binding the error-prone DNA polymerases 
pol ζ and pol η (Stelter and Ulrich, 2003; Kannouche et al., 2004). Ubiquitination of PCNA has 
been shown to be essential for the repair of UV-induced DNA damage in yeast. It is thought 
that ubiquitination strengthens the PCNA interacting protein box (PIP-box) domain 
interactions with associated DNA polymerases, acting as an anchor. Despite this, several 
examples of ubiquitin independent TLS are reported and include TLS facilitated by Rev1, pol ζ 
and pol κ (Xin, 2015). Where Rev1 and pol ζ play important roles in the repair of ICL lesions 
and resistance through error-prone synthesis (Zafar and Eoff, 2017). Poly-ubiquitination of 
PCNA has been indicated to promote TS however, the exact mechanisms in which it achieves 
this remains unknown (Xin, 2015).  
1.6. Fanconi anemia pathway. 
 
The Swedish physician Guido Fanconi first described FA in 1927, nearly a century ago (Lobitz 
and Velleuer, 2006).  Since then, the disease has been shown to be a mainly autosomal 
recessive disorder with mutations in one or more of the FA gene family that consists of over 
21 genes (A-V with two characterised D proteins, D1 and D2; Nalepa and Clapp, 2018). FA 
patients display a high frequency of congenital, haematological disorders and predisposition 
to cancer (Kee and D’Andrea, 2012). The X-linked FA complementation group B (FANCB) is the 
only observed case of FA where dominant-negative mutations lead to a rare sub-type of FA 
(Ameziane et al., 2015). FA is rare and affects 1 in every 100,000 individuals (Rosenberg, et 
al., 2011). 
Fanconi anemia is characteristically associated with genomic instability, bone marrow failure, 
haematopoietic stem cell dysfunction, predisposition to cancer and myelodysplastic 
syndromes (Cheung and Taniguchi, 2017; Nalepa and Clapp, 2018). However, multiple other 
clinical manifestations have been observed and include osteoporosis (Giri et al., 2007), 
immune deficiency (Fagerlie and Bagby, 2006), endocrine dysfunction (Giri et al., 2007) and 
sarcopenia (Neveling et al., 2009). 
Due to the associated predisposition to cancer and genomic instability, the FA pathway is 
largely studied as a model for mechanisms of carcinogenesis (Nalepa and Clapp, 2018). The 
FA pathway has been primarily characterised, as a DNA damage response pathway associated 
with the repair of ICLs in a DNA replication associated manner (Duzin and Walter, 2013; 
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Clauson et al., 2013). This was identified due to the characteristic hypersensitivity to ICL 
inducing agents that FA dysfunctional cells display. Cells derived from patients that are 
treated with low doses of the ICL inducing agent MMC also display chromosome breakage. 
Concomitantly, treatment of patient derived cells with ICL inducing agents and surveillance 
for chromosomal breakage is a diagnostic tool for the FA disease (Nalepa and Clapp, 2018). In 
addition, FA dysfunctional cells display an oxidative stress sensitive phenotype with evidence 
suggesting an associated downregulation of the human oxidative DNA glycosylase NEIL1 
(Macé-Aimé et al., 2010). 
When ICL damage occurs, DNA replication stalls due to the ICL block, in turn activating the 
DNA replication stress response, initiated through ATR and subsequent activation of Chk1, 
stalling cell cycle progression. ATR also phosphorylates multiple FA proteins including the 
Fanconi anemia complement group (FANC) M protein (Andreassen et al., 2004; Singh et al., 
2013). The CMG helicase complex stalls 20-40 bases away from the ICL. Breast cancer 
associated protein 1 (BRCA1) in association with BRCA1-associated really interesting new 
gene (RING) domain protein 1 (BARD1) unloads the CMG helicase complex, possibly through 
associated ubiquitination activity possessed by BRCA1 which may target CMG subunits for 
removal (Ceccaldi et al., 2016). However, it was shown that CMG unloading defects observed 
by BRCA1 deficient cells cannot be rescued with the addition of recombinant BRCA1, alluding 
to the involvement of other proteins (Long et al., 2014). The leading strand is then extended 
to within ~1 nucleotide of the ICL (Semlow et al., 2016). The ICL is then recognised through 
FANCM recruitment, with FA associated protein of 24 kDa (FAAP24), histone fold protein 
complex 1 (MHF1) and histone fold protein 2 (MHF2) in an ATR dependent phosphorylation 
manner (Ceccaldi et al., 2016). FANCM is a protein highlighted as an ICL sensor and 
translocase that interacts with PCNA, with the ability to facilitate replication fork remodelling 
at the site of an ICL leading to the formation of ss-DNA gaps with RPA bound and DNA 
replication fork reversal (Gari et al., 2008; Huang et al., 2013; Rohleder et al., 2016).  
FANCM subsequently functions as a platform for the recruitment of the FANC core complex 
consisting of FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, FANCT, FA associated 
protein of 100 kDa (FAAP100) and FA associated protein of 20 kDa (FAAP20; Shimamura et 
al., 2002; Ceccaldi et al., 2016). The FANCI-FANCD2 heterodimer is then recruited by 
phosphorylation by ATR (Andreassen et al., 2004; Ishiai et al., 2008; Roques et al., 2009). 
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Subsequently, the core complex activates the FANCI-FANCD2 heterodimer through 
monoubiquitination, facilitated by the E2 ubiquitin conjugating enzyme FANCT and the RING 
E3 ubiquitin ligase FANCL, subunits of the FANC core complex. More than 90% of patients who 
have upstream mutations display abnormalities in this FANCI-FANCD2 monoubiquitination 
step, highlighting its importance in ICL repair (Shimamura et al., 2002). Consecutively, the 
structure specific endonucleases MUS81 in complex with crossover junction endonuclease 
EME1 and excision repair cross complementing protein 1 endonuclease (ERCC1) in complex 
with xeroderma pigmentosum complementation group F (XPF) are recruited with the scaffold 
protein structure specific endonuclease subunit (SLX4) and together facilitate ICL incision. The 
MUS81-EME1 heterodimer is associated with the first incision and its absence has been 
reported to inhibit the accumulation of DSBs associated with ICL agent treatment (Hanada et 
al., 2006). ERCC1-XPF endonuclease has been proposed to undertake the second incision as 
significant sensitivity to ICL agents has been observed upon its depletion (Niedernhofer et al., 
2004; Seetheram et al., 2010). At this stage the ICL swings free, generating a DSB within the 
DNA and a ss-DNA gap directly opposite the ICL (Wang et al., 2007; Martin et al., 2017). Next 
TLS, facilitated by the low-fidelity DNA polymerases Rev1 and Pol ζ seals the ss-DNA-gap 
(Niedzwiedz et al., 2004; Wang, 2007). NER or BER then complete the removal of the ICL 
remnant (Wang, 2007; Couvé et al., 2009; Clauson et al., 2013; Martin et al., 2017). The FANCI-
FANCD2 heterodimer is then deactivated, facilitated by the Ubiquitin-specific-processing 
protease 1 (USP1) deubiquitinase enzyme (Nijman et al., 2005). TLS DNA polymerases and HR 
proteins are thenrecruited to rescue the stalled replication fork (Wang, 2007; Duxin and 
Walter, 2015). 
More recently reactive aldehyde metabolism has been linked to the FA repair pathway. This 
was shown through aldehyde dehydrogenase 2 (ALDH2)-/- and FANCD2-/- double knockout 
mice which displayed an associated spontaneous development of acute lymphoblastic 
leukemia and reduction in survival when compared to FANCD2-/- or ALDH2 -/- single gene 
knockout mice (Langevin et al., 2011; Garaycoechea et al., 2012). ALDH2-/- and FANCD2-/- mice 
that did not display lethality developed bone marrow dysfunction, displayed a significant 
reduction in haematopoietic stem cells (HSCs). Additionally, ALDH2-/- and FANCD2-/- HSCs 
displayed a significant increase in sensitivity compared to WT, ALDH2-/- or FANCD2-/- mice 
derived HPCs to acetaldehyde (Garaycoechea et al., 2012). Furthermore, an associated role 
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of aldehyde dehydrogenase 5 (ALDH5) with FA was also shown, with double FANCD2-/- ALDH5-
/- mice observed to developed hematopoietic stem cell depletion and bone marrow failure 
earlier than ALDH2-/- FANCD2-/- mice. FANCD2-/- ALDH5-/- mice also demonstrated a significant 
reduction in survival vs FANCD2-/- or ALDH5-/- single gene knockout mice.  Splenic B cells grown 
in formaldehyde from FANCD2-/- ALDH5-/- mice also displayed a significant increase in 
sensitivity compared to splenic B cells derived from WT, FANCD2-/-, ALDH5-/- or mice (Pontel 
et al., 2015). It was also shown that chicken lymphoblast (DT40) FANCL knockout cells were 
hypersensitive to formaldehyde when compared to WT cells (Rosado et al., 2011). Therefore, 
it was proposed that DNA damage generated by formaldehyde is removed by the FA pathway 
and formaldehyde is a greater source of endogenous DNA damage compared to acetaldehyde 
(Rosado et al., 2011; Pontel et al., 2015). Further evidence for the activation of FA pathway in 
response to reactive aldehydes was previously shown by dose-dependent stimulation of the 
monoubiquitination of the FANCI-FANCD2 heterodimer in response to acetaldehyde 
treatment of lymphoblastoid cell lines (Marietta et al., 2009). Taken together these studies 
provide in vitro and in vivo evidence indicating that aldehydes are an important source DNA 
damage associated with the FA pathway, presumably through the generation of ICLs. 
AP site ICLs, generated by the linkage of the C4-AP site to an adenine, have also been shown 
to be repaired by the FA pathway in the absence of the NEIL3 DNA glycosylase in a X. laevis 
egg extract system (Sczepanski et al., 2008; Semlow et al., 2016). Evidence indicates that 
endogenous ICLs pose a significant threat to genomic instability, requiring the evolution of 
distinct DNA repair mechanisms, such as the FA pathway, to counter their detrimental effects 
(Nalepa and Clapp, 2018). 
1.7. Nucleotide excision repair. 
 
The nucleotide excision repair pathway is unique in its ability to remove a wide range of helix 
distorting DNA damage. NER is responsible for repair of DNA lesions that form helical 
distortions, termed ‘bulky’ DNA lesions including those induced by UV damage (Kamileri et 
al., 2012). NER comprises global genome NER (GG-NER) and transcription-coupled NER (TC-
NER). In humans it has been shown that defects in NER proteins give rise to the rare genetic 
disease, xeroderma pigmentosum with a predisposition to skin cancer and other syndromes 
resulting in photosensitivity such as Cockayne syndrome and trichothiodystrophy (Kraemer 
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et al., 2007). NER is implicated in ICL repair in quiescent cells, with initial incision followed by 
TLS and a second round of incision followed by gap filling by DNA polymerases (Wang, 2010; 
Deans and West, 2011; Hashimoto et al., 2016). Indeed, cells deficient in the Cockayne 
syndrome protein B (CSB), treated with FANCD2 siRNA, are more sensitive to MMC and 
cisplatin than FANCD2 siRNA treated CSB complemented fibroblast cells (Enoiu et al., 2012). 
As indicated earlier in (Section 1.6) NER is also associated with replication dependent ICL 
repair initiated by the FA pathway followed by the involvement of the ERCC1-XPF nuclease 
(Wang, 2007; Deans and West, 2011; Clauson et al., 2013).  
1.7.1. Global Genome Nucleotide Excision Repair. 
 
Proteins involved in GG-NER scan the genome to detect helical distortions, such as those 
produced by the cyclobutane–pyrimidine dimer (CPD) as result of UV irradiation (Schärer, 
2013). The xeroderma pigmentosum, complementation group C (XPC) protein in association 
with Centrin 2 (CETN2) and UV excision repair protein radiation sensitive 23B (RAD23B), act 
as the primary DNA sensor. This sensor searches for disrupted DNA in a single-stranded (ss) 
conformation, caused by DNA mispairing due to the incorporation of bulky DNA damage 
(Masutani et al., 1994; Schärer, 2013). Investigation, by crystallography of the XPC ortholog 
in fission yeast, Rad4, revealed that it inserts a C-terminal double β-hairpin in the junction 
between ss-DNA and double-stranded (ds-DNA; Min and Pavletich, 2007). This is suggested 
to be a fundamental process that enables broad spectrum recognition of lesions. However, 
additional recognition factors have been identified and are required for CPD repair. These 
include DNA damage binding protein 1 (DDB1) and 2 (DDB2), that form a complex with cullin 
4A–regulator of cullins 1 E3 ubiquitin ligase (CRL). This complex facilitates DDB2 binding to 
the DNA lesion which kinks the DNA to facilitate XPC recognition of ss-DNA (Groisman et al., 
2003; Scrima et al., 2008). 
Xeroderma pigmentosum complementation group C serves as a substrate for the 
transcription initiation factor II H (TFIIH) complex. TFIIH consists of 10 subunits that may also 
function in TC-NER (Yokoi et al., 2000; Compe and Egyl, 2012). Within this complex Xeroderma 
pigmentosum complementation group B (XPB) and Xeroderma pigmentosum 
complementation group D (XPD) serve as helicases that unwind the DNA from the site of the 
lesion creating an open conformation within the DNA (bubble structure) in opposite 
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directions (Compe and Egly, 2012). TFIIH scans the DNA for the helix distorting lesion in a 5ʹ-
3ʹ direction and if the XPD helicase does not detect a DNA lesion, the process is aborted at 
this stage (Mathieu et al., 2013). The structure specific endonuclease ERCC1-XPF and 
xeroderma pigmentosum complementation group G (XPG) are then recruited, cleaving the 
damaged DNA 5’ and 3’ a small number of nucleotides from the lesion, respectively (Fagbemi 
et al., 2011). The accuracy of this incision step requires the presence of RPA and Xeroderma 
complementation group A (XPA) at the site of the lesion, where XPA acts as a coordinator 
possessing the ability to interact with most NER proteins, while RPA protects the non-
damaged DNA strand (Marteijn et al., 2014). The ERCC1-XPF structure specific endonuclease, 
initiates incision prior to XPG, creating a ss-DNA-gap, releasing an oligonucleotide containing 
the ‘bulky’ DNA damage (Staresincic et al., 2009). DNA polymerases and DNA ligases then fill 
the gap, such as X-ray repair cross complementing 1 (XRCC1) in complex with Ligase (Lig) III 
or Pol δ, Pol ε, Pol κ and Lig I, coordinated by PCNA. With XRCC1-Lig III and Pol ε being most 
active in non-proliferating cells whilst Pol δ and Pol κ have been found to be the main NER 
DNA polymerases in replicating cells (Moser et al., 2007; Ogi et al., 2010). 
1.7.2. Transcription coupled repair (TC-NER). 
 
Bulky DNA lesions can hinder the processes of transcription and DNA replication despite GG-
NER efficiency. As previously discussed, the stalling of DNA replication activates the DDR 
through the RSR and in turn activates many different repair pathways to compensate to avoid 
the detrimental generation of DSBs, such as HR, TLS and FA repair. This said, no dedicated 
translesion ribonucleic acid (RNA) polymerases have been identified for the continuation of 
transcription. Thus, the TC-NER sub pathway of NER facilitates the removal of bulky DNA 
adducts that block transcription, a crucial requirement as it has been reported that lack of 
repair of these lesions may promote cell death (Ljungman and Zhang, 1996). Furthermore, 
deficiencies in cockayne proteins lead to hypersensitivity to oxidative DNA damage, 
suggesting that GG-NER may not efficiently recognise the range of lesions that the TC-NER 
machinery can. It may also indicate overlapping roles between TC-NER and BER (de Waard et 
al., 2004; Stevnsner et al., 2008). During transcription, the RNA DNA polymerase becomes 
stalled when encountering a DNA lesion, recruiting the TC-NER specific proteins cockayne 
syndrome protein A (CSA) and B (CSB), ubiquitin–specific-processing protease 7 (USP7), XPA-
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binding protein 2 (XAB2), UV-stimulated scaffold protein A (UVSSA), high mobility group 
nucleosome-binding domain-containing protein 1 (HMGN1; Fousteri et al., 2006). Once 
localised CSA and CSB reverse-translocates RNA DNA polymerase II, allowing TFIIH to bind, 
recruiting downstream proteins as in GG-NER (Marteijn et al., 2014).    
CSB has been shown to interact with PARP1 and it has been shown that poly(ADP-ribosyl)ation 
of CSB inhibits DNA dependent adenosine triphosphatase activity possessed by CSB 
(Thorslund et al., 2005). CSB has also been shown to interact with APE1, with evidence 
suggesting CSB stimulates APE1 incision of AP sites in duplex and in bubble structured DNA 
(Wong et al., 2007). Furthermore, it was shown that deficiency in CSB leads to the 
accumulation of 8-OxoG in nuclear and mitochondrial DNA through the downregulation of 
OGG1, however CSB had no effect on the status of thymine DNA glycosylase (TDG) and uracil 
DNA glycosylase (UDG) BER proteins (Dianov et al., 1999; Stevnsner et al., 2002).  
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Figure 1.9: Schematic representation of GG-NER and TC-NER pathways. IN GG-NER, XPC in complex with CETN2, 
RAD23 probe for ss-DNA formed by helical distorting lesions. DDB1 and DDB2 facilitate detection through XPC 
interaction. In TC-NER RNA pol II stalls and CSB and CSA proteins are recruited and backtracks the RNA pol II 
along the DNA. The TFIIH complex is then recruited and the lesion is verified through XPD, XPA and XPB. RPA 
coats the non-damaged ss-DNA. ERCC1-XPF and XPG sequentially incised the DNA releasing the damaged DNA. 
PCNA recruits DNA polymerases to conduct gap filling synthesis and the nick is sealed by DNA ligase I or III 
(Adapted from Marteijn et al., 2014). 
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1.8. Repair of DNA Interstrand crosslinks. 
 
As previously discussed, repair of ICLs is essential for the avoidance of persistent replication 
stress and DNA replication fork collapse, to ensure the maintenance of genomic stability. 
Many different models have been proposed for the repair of an ICL, however there is general 
agreement that differential processing of an ICL occurs in a cell cycle dependent manner. ICL 
repair may therefore be conducted in a replication associated manner or a replication 
independent manner (Wang, 2007; Deans and West, 2011). 
The repair of an ICL in quiescent cells in eukaryotic organisms relies on the NER machinery, 
with the lesion recognised as ‘bulky’ with distortion to the DNA helix. An initial round of GG-
NER or TC-NER flips out the ICL, followed by TLS across the ss-DNA break generated, by pol κ, 
Pol ζ and Rev1 (Sarkar et al., 2006; Wood, 2010; Deans and west, 2011 Williams et al., 2012). 
The three-stranded intermediate is then subsequently processed by a second incision round 
followed by gap filling by Pol δ in association with PCNA (Wang, 2007; Hashimoto et al., 2016). 
Replication associated repair of an ICL is currently suggested to be initiated by the FA pathway 
and as previously discussed, ICL repair is initiated when the replisome becomes stalled by an 
ICL, with the CMG helicase complex stalling 20-40 bases from the ICL (Muniandy et al., 2010; 
Semlow et al., 2016 Yang et al., 2017). The single strand binding protein, RPA binds to ss-DNA 
initiating ATR signalling (Zou and Elledge, 2003). Single-stranded DNA may be converted to 
DSBs and in cases of ATR deficiency the DNA replication fork may be destabilised and induce 
DNA replication fork collapse. Subsequently, DSBs are detected after treatment with DNA 
replication fork stalling agents, with initiation of ATM and the DDR. The effect of this is 
stimulated in the presence of ATR defects and has been demonstrated in mammalian cells 
(Zeman and Cimprich, 2014; Cortez, 2015). When a DNA replication fork collapses, it is 
suggested DSBs are processed through HR, which can lead to mutagenic chromosomal 
rearrangement, through sister chromatin exchange (de Silva et al., 2000). 
Subsequently the RSR is initiated through ATR and cell cycle arrest proceeds via Chk1 
phosphorylation. ATR also phosphorylates FANCM, recruiting it to the stalled DNA replication 
fork with MHF1, MHF2 and FAAP24 (Singh et al., 2013; Ceccaldi et al., 2016). At this stage the 
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remodelling of the replication fork may be stimulated, with the formation of ss-DNA gaps 
(Gari et al., 2008).  
The FANCM and FAAP24 proteins then proceed to recruit the FANC core complex followed by 
FANCD2-FANCI which are then monoubiquitinated by FANCT and FANCL, subunits of the FANC 
core complex (Kim et al., 2008; Liang et al., 2016).  Henrietta Lacks derived cervical 
adenocarcinoma (HeLa) cells depleted of FANCM, displayed an inhibition of the recruitment 
of the FA core complex to an ICL and by association, depletion of FAAP24 inhibited FANCM 
recruitment to chromatin and the downstream FANC core complex recruitment (Kim et al., 
2008). 
The FANCD2-FANCI complex then associates with the structure specific endonucleases such 
as MUS81-EME1, ERCC1-XPF, Fanconi associated nuclease 1 (FAN1) under the coordination 
of the scaffold protein SLX4 (Kim et al., 2011b; Clauson et al., 2013; Kottemann and 
Smogorzewska, 2013). It has been suggested that cleavage on the 5’ side of the ICL occurs, 
facilitated by the MUS81-EME1 heterodimer followed by the 3’ side by ERCC1-XPF (Couvé et 
al., 2009; Clauson et al., 2013; Douwel et al., 2014; Semlow et al., 2016; Douwel et al., 2017). 
However, MUS81-EME1 has the same polarity as ERCC1-XPF and thus, may or may not 
undertake 5ʹ incision. Indeed, ERCC1-XPF has been shown to cleave both 5ʹ and 3ʹ of an ICL in 
vitro (Kuraoka et al., 2000). However, DSB formation at an ICL has been shown to be 
dependent on MUS81-EME1 thus indicating a role in 5ʹ incision releasing the splayed strand. 
Therefore, it has been proposed that the ERCC1-XPF and MUS-EME1 nucleases incise different 
ICL intermediates (Hanada et al., 2006; 2007). Concomitantly, MUS81-EME1 has been shown 
to play a role in the resolution of Holliday junctions, a result of recombination events at a 
persistently stalled DNA replication fork (Chen et al., 2001). FAN1 has also been shown to 
incise within unwound 5’-flap structures and degrade ds-DNA 5ʹ-3ʹ containing an ICL. 
However, FAN1 cleavage required an ~10 nucleotide region of ds-DNA surrounding an ICL to 
conduct incision activity in vitro (Pizzolato et al., 2015). Additional, evidence for the role of 
FAN1 in ICL repair comes from its direct interaction with mono-ubiquitinated FANCD2, 
however enzymatic redundancy is observed as ICL sensitivity/FA is not observed in the 
absence of FAN1 (Ceccaldi et al., 2016). Subsequently MUS81-EME1 is a prime candidate for 
5ʹ ICL incision based on hypersensitivity observed in mouse embryonic stem (ES) cells 
deficient in MUS81 to ICL inducing agents (Hanada et al., 2006). In addition, the DNA cross-
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link repair 1A protein (SNM1A) nuclease, exhibits 5ʹ-3ʹ exonuclease activity from a ss-DNA-
nick past an ICL, with its depletion yielding ICL sensitivity and MUS81 dependent replication 
associated DSBs (Wang et al., 2011). Also, SLX4 is highlighted as an important component of 
the ICL incision machinery, with evidence demonstrating that it may bind the nucleases 
MUS81 and XPF, while maintaining interaction with monoubiquitinated FANCD2 (Fekairi et 
al., 2009). Furthermore, lack of SLX4 results in ICL sensitivity, however mutational analysis of 
SLX4 revealed that this sensitivity was ERCC1-XPF binding dependent (Yamamoto et al., 2011; 
Kim et al., 2013). Taken together, SLX4 is likely a scaffold protein important for nuclease 
choice and recruitment to the site of an ICL. In conclusion, incision steps in ICL repair, have 
been proposed to involve multiple structure specific nucleases, however the exact 
mechanisms of this ICL incision are a subject of ongoing study (Ceccaldi et al., 2016). 
The incision step, unhooks an ICL, inducing a single ended DSB on the incised strand, but 
permits TLS by the consecutive action of DNA polymerases such as Pol ν, Pol κ or Pol η, 
extension then by REV1 and pol ζ , filling the gap created to generate an intact sister chromatid 
(Hanada et al., 2006; Ho and Schärer, 2010; Hicks et al., 2010; Ho et al., 2011; Clauson et al., 
2013). This generates a three-stranded DNA structure in the form of a crosslink remnant 
attached to a DNA duplex. The ICL remnant is then proposed to be removed by the NER 
machinery resulting in a DNA duplex, potentially forming further DSBs (Cipak et al., 2006; 
Sczepanski et al., 2009; Clauson et al., 2013; Wakasugi et al., 2014). At this stage it is suggested 
that HR would take place to rescue the DSB (Michl et al., 2016). This proceeds via 5ʹ strand 
resection in part due to the 5ʹ-3ʹ exonuclease activity of exonuclease 1 (EXO1), which 
subsequently generates a ss 3ʹ overhang, a structure that promotes both ATR and ATM 
signalling (Liu and Huang, 2016). Then the ss 3ʹ DNA may invade the homologous sister 
chromatid duplex, generating a Holliday junction and a D-loop structure (Hinz et al., 2010).  
The invading 3ʹ strand is then primed for DNA synthesis. The Holliday junctions generated 
may then be cleaved by endonucleolytic incision, possibly by MUS81-EME1 (Chen et al., 2001; 
Hinz, 2010; Clauson et al., 2013). The accuracy in this terminal step of conventional ICL repair 
is vital to avoid gross genomic instability through chromosomal breakage, which in turn may 
promote tumorigenesis and lethality (Hinz et al., 2010). 
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Figure 1.10: Schematic model of Fanconi anemia initiated replication associated ICL repair. The CMG complex 
stalls and is dissociated by BRCA1/BARD1 and the strand is extended towards the ICL. The FA pathway is then 
initiated through FANCM recruitment of the FANC core complex. Subsequently the FANCI/D2 heterodimer is 
recruited and monoubiquitinated by FANCT and FANCL. The ICL is incised near an ICL by Mus81/EME1 and 
XPF/ERCC1, respectively, flipping out the ICL. TLS proceeds generating a three-stranded structure. NER is 
proposed to remove the ICL remnant followed by homologous recombination to yield two homologous DNA 
duplex. 
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Additionally, Saparbaev’s group demonstrated that the hNEIL1 DNA glycosylase can excise an 
ICL in a three-stranded structure and MAs in a DNA duplex context. This unhooking activity 
generated a ss-DNA-nick flanked by a 5ʹ and a 3ʹ phosphate at the site of the ICL, that is then 
proposed to be processed by BER (Couvé-Privat et al., 2007; Couvé et al., 2009). This 
highlighted a role of hNEIL1 in the resolution of a three-stranded ICL structure that represents 
the intermediate product generated by structure specific endonuclease unhooking of an ICL 
(Couvé et al., 2009). This was the first time that mechanistic evidence was provided for the 
role of a DNA glycosylase and BER in ICL repair.  
Despite the accepted notion that an ICL is an absolute block to DNA replication, Seidman’s 
group demonstrated that the FANCM-MHF complex possessed an unconventional activity in 
the presence of a labelled psoralen ICL (Huang et al., 2013). It was shown that the 
FANCM/MHF complex can promote replication traverse across an ICL in DNA, with DNA 
combing analysis demonstrating continued DNA replication past ~85% of MA and HMT ICLs 
after 60 min. This observation was inhibited in FANCM-/- cells in an ICL specific manner. 
Thus, it was suggested that FANCM facilitates the traverse of the replication machinery 
past an ICL in cells (Huang et al., 2013). It was later shown that this activity was stimulated 
by interaction with PCNA through the PIP box domain. This interaction increased 10-fold 
under DNA replication stress induced by hydroxyurea (HU) treatment of HeLa cells 
(Rohleder et al., 2016). 
In addition, Walter’s group proposed that dual collision of DNA replication forks with an ICL 
was required for its subsequent repair. Evidence was provided for this with incubation of X. 
laevis egg extracts with a DNA plasmid containing a cisplatin ICL. It was observed that in the 
presence of a plasmid structure representing a single replication fork an ICL could not be 
excised and the CMG helicase did not dissociate (Zhang et al., 2015). This plasmid structure 
contained a lacO array which inhibited fork progression from the opposite direction 
independent of an ICL for 3 hours. Subsequently it was found that in a plasmid structure that 
did not contain the lacO array DNA repair of a cisplatin ICL proceeded, indicating the 
requirement of an X-shaped structure mimicking dual replication fork collision (Zhang et al., 
2015).  Despite these findings the role of repair components, downstream of the incision step 
of ICL repair, was not addressed. It was also acknowledged that FANCM replication traverse 
was not observed in their model system (Huang et al., 2013: Zhang et al., 2015).  
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More recently, Walter’s group revealed a novel role of the NEIL3 DNA glycosylase in the repair 
of AP site ICLs and psoralen ICLs with incubation of plasmids containing AP site, psoralen and 
cisplatin ICLs with NEIL3 competent and NEIL3-/-  X. laevis egg extracts. It was observed that 
NEIL3 could resolve an AP-site ICL and a psoralen ICL independent of the FANCD2-FANCI 
heterodimer. Absence of NEIL3 resulted in the activation of FA initiated repair of AP-site and 
psoralen ICLs. In addition, psoralen ICL repair did not require the dissociation of the CMG 
complex. Furthermore, it was shown that the cisplatin ICL was refractory to NEIL3 initiated 
repair and the FA pathway was the primary pathway responsible for its resolution. 
Importantly, NEIL3 dependent ICL excision did not generate DSBs and resolution was faster 
than that typically associated with FA initiated repair (Semlow et al., 2016). This was the first 
mechanistic evidence in support of the role of NEIL3 in the repair of ICLs. It was proposed 
NEIL3 dependent excision is the primary pathway for the resolution of AP-site ICLs and 
psoralen ICLS. The fact that NEIL3 may resolve AP site ICLs is of significance due to the 
abundance of AP sites in the cell, which present suitable opportunity for spontaneous cross-
linking (Nakamura and Swenberg, 1999; Dutta et al., 2006; Sczepanski et al., 2008). 
Furthermore, the repair of AP sites is essential in mammals, with embryonic lethality 
observed in APE1-/- mice (Izumi et al., 2005). It may be speculated that AP-site ICL excision by 
the NEIL3 DNA glycosylase may be an essential function that defines it from its homologs 
NEIL1 and NEIL2, while redundancy is observed with the FA pathway (Semlow et al., 2016). 
However, the data presented by Semlow et al. (2016) also demonstrated that cisplatin ICLs 
were refractory to NEIL3 excision despite the sensitivity of NEIL3-/- MEFs to cisplatin previously 
observed (Rolseth et al., 2013). 
1.9. Base excision repair. 
 
The BER pathway is the primary repair pathway initiated in response to single DNA base 
damage and SSBs. The discovery of BER was marked by the identification of the uracil-DNA 
glycosylase (UNG) by Tomas Lindahl (1974). Lindahl set out to discover the enzyme 
responsible for deaminating cytosine and instead identified the enzyme which cleaved the N-
glycosydic bond between uracil and the deoxyribose sugar, thus generating an AP site. 
Furthermore, Lindahl suggested that this site was further processed by exonuclease, DNA 
polymerase and DNA ligase activity, resulting in the removal and repair of DNA damage 
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(Lindahl, 1990). His further discoveries and propositions provided the foundations for the 
current understanding of BER (Krokan and Bjørås, 2013).  
BER functions to remove and replace chemically modified, non-helix distorting nitrogenous 
bases in a series of sequential steps, conducted through the recruitment of the DNA 
glycosylase, AP-endonuclease, DNA polymerase and DNA ligase enzymes (Liu et al., 2013a; 
Krokan and Bjørås, 2013). 
Base excision repair occurs in both the nucleus and the mitochondria, recruiting genetically 
distant isoforms of proteins (Mandal et al., 2011; Prakash and Doublié, 2015). The first step 
of BER is facilitated by DNA glycosylases, which cleave the N-glycosydic bond, through 
hydrolysis, between the damaged nucleotide base and the deoxyribose sugar. Hydrolysis 
conducted by a monofunctional DNA glycosylase forms an AP site which is further processed 
by APE1, Pol β and the XRCC1-Ligase III complex. In general, DNA glycosylases are 
independently active upon DNA substrates, allowing activity in vitro and in vivo to be studied 
(Krokan and Bjørås, 2013; Wallace, 2014). 
1.9.1. Short-patch BER. 
 
In short-patch BER, a mono-functional DNA glycosylase catalyses the hydrolysis of the N-
glycosydic bond producing an AP site, which may be processed by the apurinic/apyrimidinic 
endonuclease I (APE1), cleaving the phosphodiester backbone resulting in a 5’-deoxyribose 
phosphate (5’-dRP) moiety and a 3’ hydroxyl (3’-OH) moiety (Balakrishnan and Bambara, 
2013). A bifunctional DNA glycosylase may cleave the phosphodiester backbone in addition 
to DNA glycosylase activity through associated AP lyase activity. This lyase activity may 
proceed via β-elimination or β,δ-elimination. β-elimination of the phosphodiester backbone 
generates a 3ʹ-phosphor-α, β-unsaturated aldehyde (PA) and a 5ʹ-phosphate (P). The 3ʹ end 
at the site of the ss-nick produced after β-elimination is then processed by the 3’-
phosphodiesterase activity of APE1 to yield a 3’-OH (Hegde et al., 2008). A bifunctional 
enzyme with associated AP-lyase activity that conducts β,δ-elimination of the phosphodiester 
backbone generates a 3’-P and a 5ʹ-P. However, the 3ʹ end generated by β,δ-elimination 
requires the 3ʹ-phosphatase activity of poly-nucleotide kinase (PNKP) to generate a 3ʹ-OH 
(Hegde et al., 2008; Kim and Wilson, 2012). The 5’-dRP, generated by APE1 cleavage of an AP 
site subsequently employs the associated lyase activity of Pol β to eliminate the sugar to 
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generate a 5ʹ-P (Balakrishnan and Bambara, 2013). Pol β may then conduct gap filling 
synthesis through DNA polymerase activity, inserting the missing nucleotide between the 3ʹ-
OH and the 5ʹ-P. The nick is subsequently sealed by DNA ligase III in complex with the scaffold 
protein XRCC1 restoring the DNA duplex and preventing potential mutagenesis associated 
with DNA base modification (Figure 1.11; Wallace et al., 2012). 
Figure 1.11: Schematic representation of the short-patch BER pathway. N-glycosydic bond is hydrolysed by 
DNA glycosylase activity generating an AP-site. The phosphodiester backbone is then processed through APE1 
cleavage of an AP site or associated lyase activity of the DNA glycosylase, to generate a ss-nick. End processing 
by APE1 or PNKP for then proceeds yielding a 3ʹ-OH group. Pol β may remove the 5ʹ-dRP yielding a 5ʹ-Phosphate 
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1.9.2. Long-patch BER. 
 
Long-patch BER is a sub-pathway of BER and is suggested to be activated when a cleaved AP 
site is further oxidised or reduced to generate a 5’-blocking lesion, suggested to be refractory 
to the lyase activity of pol β (Wallace et al., 2012). Thus, gap filling proceeds through the DNA 
polymerase activity of pol δ or ε which continues to synthesise new DNA, between 2 and 6 
nucleotides, thus shifting DNA downstream of the damage site in a process called strand 
displacement (Kim and Wilson 2012; Balakrishnan and Bambara, 2013). This results in a flap 
DNA structure which is a substrate for removal by the flap endonuclease 1 (FEN1), which is 
stimulated by PCNA creating a nick which is sealed by DNA ligase I restoring the DNA duplex 
(Figure 1.12; Kim and Wilson, 2012; Wallace, 2014).  
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Figure 1.12: Schematic representation for long-patch BER pathway. 5ʹ-dRP becomes modified after APE1 
cleavage, preventing removal by Pol β. As result specialised DNA polymerases δ or ε undertake strand 
displacement, replacing >1 nucleotide generating a flap structure, a substrate for FEN1. The flap is excised, and 
the ss-DNA nick is sealed by Lig I and restores the duplex. 
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1.10.  DNA glycosylases. 
 
To date, eleven distinct DNA glycosylases have been described in Homo sapiens: UDG, single-
strand-selective monofunctional Uracil-DNA Glycosylase 1 (SMUG1), TDG, methyl-CpG 
Binding Domain 4, DNA Glycosylase (MBD4), AAG, OGG1, MUTYH, NTH1, NEIL1, NEIL2 and 
NEIL3 (Krokan and Bjørås, 2013; Wallace, 2014). In general, these proteins locate and remove 
chemically modified DNA bases through hydrolysis of the N-glycosidic bond and initiate BER 
(Table 1.2; Krokan and Bjørås, 2013).  
In mammals, four DNA glycosylases are responsible for the removal of mispaired thymine and 
uracil, six are involved in the removal of oxidative base damage and one for the removal of 
certain alkylated bases and lipid peroxidation derived ethenoadducts (Table 1.2; Krokan and 
Bjørås, 2013 Wallace 2014). The DNA glycosylases are divided into four structural groups the 
UNG sub-family (UNG, SMUG1 and TDG), the Helix-hairpin-Helix structural family (HhH; 
OGG1, NTH1, adenine DNA glycosylase homolog (MUTYH) and methyl-CpG Binding Domain 
4, DNA Glycosylase/Mediator Complex Subunit 1 (MBD4)), the Helix-two-Turn-Helix structural 
family (H2tH; NEIL1, NEIL3 and NEIL3) and a unique structural family containing AAG (Wallace, 
2014).  
Table 1.2: The Mammalian DNA glycosylases, their cellular location and their enzyme functionality. 
Monofunctional DNA glycosylases demonstrate DNA glycosylase activity only producing an AP-site. Bifunctional 
DNA glycosylases possess DNA glycosylase activity and an associated lyase which conducts β-elimination or β,δ-
elimination of an AP-site. DNA glycosylases listed as Monofunctional/Bifunctional display bifunctionality in a 
substrate specific manner. (Adapted from Krokan and Bjørås (2013)). 
Enzyme Subcellular localisation 
Monofunctional or   
Bifunctional 
DNA glycosylase 
UNG2 Nucleus Monofunctional 
UNG1 Mitochondria Monofunctional 
SMUG1 Nucleus Monofunctional 
TDG Nucleus Monofunctional 
MBD4/MED1 Nucleus Monofunctional 
AAG Nucleus Monofunctional 
OGG1 Nucleus Monofunctional/ Bifunctional 
MUTYH Nucleus Monofunctional 
NTH1 Nucleus/Mitochondria Bifunctional 
NEIL1 Nucleus Bifunctional 
NEIL2 Nucleus Bifunctional 
NEIL3 Nucleus Monofunctional/ Bifunctional 
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1.11. Prokaryotic DNA glycosylases. 
 
BER is a highly conserved DNA repair pathway, present in prokaryotic and eukaryotic 
organisms (Wallace et al., 2012; Krokan and Bjørås, 2013). Distinct DNA glycosylases have 
been identified and subsequently characterised from prokaryotic organisms (Prakash et al., 
2012). The homology shared between prokaryotic and eukaryotic DNA glycosylases has been 
crucial in driving hypotheses for the characterisation of DNA glycosylases found in higher 
organisms. An example of this is the homology shared between Fpg, Nei and their human 
homologs hNEIL1, human endonuclease VIII-like-2 (hNEIL2) and hNEIL3 DNA glycosylases 
(Figure 1.13). The biochemical characterisation of Fpg and Nei in vitro and in vivo have 
provided important insights into the evolutionary conserved function of the NEIL DNA 
glycosylases in humans. 
 
Figure 1.13: Multiple sequence alignment of the amino acid sequence of E. coli Nei, E. coli Fpg, hNEIL1, hNEIL2 
and hNEIL3. CLUSTAL O (1.2.4) multiple sequence alignment was used to generate alignment and amino acid 
sequence conservation was generated with Jalview (2.10.5). Conservation histogram displays the conservation 
of amino acid domains with a value 0-9 (less conserved to most conserved), where “–“ denotes no conservation, 
“+” denotes conservation of amino acid residue properties and “*” denotes absolute conservation. Columns 
displaying no alignment have been removed. 
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1.11.1. Formamidopyrimidine DNA glycosylase (Fpg). 
 
Formamidopyrimidine DNA glycosylase (Fpg) is a 30.2 kDa protein consisting of 269 amino 
acids in E. coli, initially discovered by Tomas Lindahl’s laboratory, when studying the removal 
of methylFapyG from alkylated DNA (Chetsanga and Lindahl, 1979). Fpg is a bifunctional DNA 
glycosylase, that cleaves on the 3ʹ side of an AP site followed by the 5ʹ side, via β,δ-elimination 
(Bhagwat and Gerlt, 1996). Investigation revealed that Fpg was responsible for the excision 
of 4,6-diamino-5-formamidopyrimidine (FapyA), 2,6-diamino-4-hydoxy-5-
formamidopyrimidine (FapyG) and 8-OxoG, determined by gas chromatography-mass 
spectrometry (GC-MS) analysis of cleavage activity of DNA (Boiteux et al., 1992). However, 
Fpg was also revealed to process uracil glycol (Ug; Prakash et al., 2012). Determination of 
protein kinetics revealed similar affinity for FapyA, FapyG and 8-OxoG (Karakaya, et al., 1997). 
Due to the affinity displayed by Fpg for 8-OxoG and the high frequency of adenine mispairing 
after DNA replication associated with 8-OxoG, it was suggested that the removal of 8-OxoG 
was the most biologically relevant substrate for Fpg. Subsequently the ‘GO’ model was 
proposed, which suggested that if 8-OxoG is not removed by Fpg and DNA replication 
proceeds without repair, the complementary bacterial DNA glycosylase, adenine DNA 
glycosylase (MutY), removes mispaired adenine. Furthermore, 8-dihydroguanine-
triphosphatase (MutT) can convert 8-OxoG triphosphates present in the dNTP pool to 8-OxoG 
monophosphate preventing their incorporation into DNA (Maki and Sekiguchi, 1992; Michaels 
and Miller, 1992; Michaels, et al., 1992). More recently it was shown that Fpg removes Sp, a 
further oxidation product of 8-OxoG from ds-DNA with greater processivity than 8-OxoG (Luo 
et al., 2000; Guo et al., 2010). Fpg was also shown to possess the ability to unhook psoralen 
ds-MAs and three-stranded ICL structures through DNA glycosylase activity and β,δ-
elimination (Couvé-Privat et al., 2007; Couvé et al., 2009). 
1.11.2. Endonuclease VIII (Nei). 
 
Originally discovered by Wallace’s group, the 29.8 kDa endonuclease VIII (Nei) is a DNA 
glycosylase principally associated with the removal of oxidized pyrimidines from DNA 
(Prakash et al., 2012). The Nei protein possesses sequence homology with Fpg but is distinct 
to Nth that also removes oxidized pyrimidines in DNA from prokaryotic cells. Nei has been 
reported to remove a variety of oxidised pyrimidines, including the replication blocking lesion 
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Tg, dihydrothymine, Ug, dihydrouracil, 5-OHU and 5-hydroxycytosine (5-OHC) while also 
cleaving DNA containing an AP-site. Thus, has overlapping substrate specificity with 
endonuclease III (Nth; Melamede et al., 1994). Indeed, Nei and Nth double mutants are 
observed to be prone to mutation and are sensitized to ROS induced DNA damage by H2O2 
and ionising radiation, while single Nei mutants present no observable phenotype (Jiang et 
al., 1997a). Nei processes oxidative lesions through DNA glycosylase activity and β,δ-
elimination of the phosphodiester backbone (Jiang et al., 1997b). Interestingly, the double 
Nth and Nei double mutants display accumulation of only C-T transition. This may suggest 
that cytosine lesions are the most biologically relevant substrates for Nei, as 5-OHU and Ug 
mispairs with adenine leading to C-T transitions (Purmal et al., 1998). Furthermore, the 
addition of a Nei mutation, to an Fpg and MutY double mutant resulted in a three-fold 
increase in spontaneous mutations that were found to be G-T transversions (Blaisdell et al., 
1999). This indicated that Nei serves as a backup for Fpg for the removal of 8-OxoG a lesion 
that if left unrepaired would lead to adenine mispairing. Subsequently biochemical analysis 
revealed that at relatively high concentrations Nei could excise 8-OxoG paired with cytosine, 
adenine or guanine (Hazra et al., 2000). Nei was also shown to possess the ability to unhook 
psoralen ds-MAs and three-stranded ICL structures through DNA glycosylase activity and 
associated β,δ-elimination, to a greater extent than Fpg (Couvé-Privat et al., 2007; Couvé et 
al., 2009). 
1.12. Non-Oxidised base eukaryotic DNA glycosylases. 
 
1.12.1. Uracil DNA glycosylases. 
 
The first of the DNA glycosylases to be discovered was the Uracil DNA glycosylase (UNG), 
responsible for the cleavage of the N-glycosidic bond of uracil from the misincorporation of 
deoxyuridine monophosphate (Krokan et al., 1997). Also, cytosine deamination is estimated 
to generate 100-500 residues of uracil in the mammalian genome every day (Lindahl, 1993). 
The DNA glycosylase encoded for by the SMUG1 gene has a more invasive structural affinity 
than other members of the UDG superfamily but has overlapping substrate specificity. 
SMUG1 cleaves the N-glycosidic bond between the deaminated cytosine product uracil 
mispaired with guanine bases. The UNG family possess only DNA glycosylase activity and are 
therefore monofunctional (Krokan & Bjørås, 2015). 
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1.12.2. Thymine DNA glycosylase (TDG) and methyl-CpG-binding domain4, DNA 
glycosylase (MBD4). 
 
Mismatch specific DNA glycosylases have been identified and characterised. In humans these 
include TDG and MBD4. Thymine DNA glycosylase can effectively remove thymine mispaired 
with guanine and can also efficiently remove uracil mispaired with guanine (Krokan et al., 
1997). The other human mismatch DNA glycosylase, MDB4, contains domains that remove 
thymine and uracil mispaired with guanine in hemimethylated and methylated CpG islands. 
MBD4 has also been shown to play a role in demethylation removing thymine as result of 
activation-induced cytidine deaminase conversion of 5-methyl-cytosine to uracil, ultimately 
leading to the misincorporation of thymine (Wallace et al., 2012).   
1.12.3. Alkyladenine DNA glycosylase (AAG) 
 
Alkyladenine DNA glycosylase is a monofunctional DNA glycosylase with no prokaryotic 
homologs, which recognises alkylated purines (7meG, 3meA), deaminated adenine 
(hypoxanthine) and the oxidative lesion 8-OxoG (Bessho et al., 1993; Wallace et al., 2012; 
Krokan & Bjørås, 2013). Although, 7meG and 3meA are likely to be the primary biological 
substrates of AAG, 1,N6-ethenoadenine, which is a product of the environmental carcinogens 
ethyl carbamate and vinyl chloride, is processed with a greater efficiency than 3meA by AAG 
(Saparbaev et al., 1995; Hang et al., 1997). AAG is structurally unique and possesses a positive 
DNA binding groove within a single domain (Prakash & Doublié, 2015). 
Over expression of AAG has been shown to result in the accumulation of AP sites that are a 
substrate for APE1 (Wallace et al., 2012). However, AAG-/- mice accumulate 7meG when 
treated with the alkylating agent N-methyl-N-nitrosourea (Smith and Engelward, 2000). In 
addition, a significant increase in AT-TA and GC-TA mutations at the hypoxanthine guanine 
phosphoribosyl transferase gene, is observed post methyl-methanesulfonate (MMS) 
treatment in splenic T lymphocytes (Elder et al., 1998). It was suggested that this increase in 
mutagenesis was due to the persistence of 3meA and 3 or 7meG induced mispairing in the 
absence of AAG (Elder et al., 1998). Furthermore, previous investigation determined AAG-/- 
embryonic fibroblasts display sensitivity to MMC and  1,3-bis(2-chloroethyl)-1-nitrosourea 
(BCNU) with additional study identifying AAG-/- MEFs were also sensitive to MeOSO2(CH2)2-
lexitropsin an agent that induces 3MeA and 1, N6-ethenoadenine lesions (Engelward et al., 
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1996; Engelward et al., 1997). As result AAG is highlighted as the only DNA glycosylase 
responsible for the excision of alkylated DNA (Krokan and Bjørås, 2013). 
However, AAG-/- MEFs display residual 3meA repair capabilities, indicating that additional 
methods of DNA repair for 3meA exist within the cell (Smith and Engelward, 2000). 
Additionally, it was revealed that no significant displayed phenotype was observed in AAG-/- 
mice, which remained fertile and their MEF cells displayed similar response to treatment 
when compared to wild type (WT) cells in response to BCNU, mitozolamide and TMZ. 
However, in support of previous studies sensitivity was observed in response to MMC and 
was proposed to be a result of the lack of 3meA repair (Elder et al., 1998). This may suggest 
that alternate DNA repair mechanisms act as a backup to AAG. 
Nonetheless, the balance of AAG in mouse cells has been demonstrated to be important (Fu 
et al., 2012). It was revealed that, AAG-/- whole mice display no change in sensitivity, are 
resistant to retinal degradation, resistant to cerebellar degeneration, display resistant bone 
marrow cells, have increased mutagenesis in the spleen and are more likely to develop colon 
tumours in response to alkylating agents. Interestingly, transgenic AAG whole mice are 
sensitive, have increased cellular sensitivity in brain, spleen, thymus, pancreas and bone 
marrow cells while displaying increased retinal degeneration in response to alkylating agents 
(Fu et al., 2012).  
It is proposed that AAG overexpression leads to an increase in the accumulation of AP sites, 
which in turn are vulnerable to SSB formation and cellular apoptosis. This is demonstrated by 
alkylating agent treatment of AAG-/- mice cells displaying resistance and AAGTgen mice cells are 
hypersensitive to MMS treatment (Meira et al., 2009; Margulies et al., 2017).  
Interestingly, AAG has also been shown to confer cellular resistance to the class of ICL 
inducing agents, psoralen (Maor-Shoshani et al., 2008). It was revealed that AAG-/- mouse 
embryonic stem cells displayed increased sensitivity to HMT/UVA treatment than that 
observed in response to MMS treatment when compared to WT cells, in addition displaying 
increased γ-H2AX foci, a marker of DSB induction. Furthermore, it was demonstrated that 
AAG-/- mouse embryonic stem cells were also sensitised to the ICL inducing agents MMC and 
BCNU. However, AAG failed to bind and cleave MMC ICLs, monoadducts produced by 8-MOP, 
HMT or N2-guanine monoadduct in vitro (Maor-Shoshani et al., 2008). Subsequently it has 
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been proposed that AAG may have non-canonical roles in the repair of ICLs produced by 
bifunctional alkylating agents such as BCNU and nitrogen mustards (Yang et al., 2017).  
1.13. Oxidised base DNA glycosylases. 
 
In eukaryotic organisms the DNA glycosylases OGG1, MUTYH, NTH1, NEIL1, 2 and 3 are 
responsible for initiating BER in response to oxidative DNA damage. They are highlighted as 
of particular importance due to the high frequency of oxidative lesions formed in the cell 
(Klaunig et al., 2011; Krokan and Bjørås, 2013). 
1.13.1. 8-Oxoguanine DNA glycosylase (OGG1). 
 
Guanine has the lowest redox potential of the four nitrogenous DNA bases and is frequently 
oxidised to 8-OxoG, leading to GC-TA transversions, due to the formation of 8-OxoG:A 
mispairs during DNA replication (Wallace et al., 2012). In prokaryotes both Fpg and MutY act 
to reduce transversion mutations, in eukaryotic cells OGG1 removes 8-OxoG and MUTYH 
removes mispaired adenine (Boiteux and Radicella, 2000). OGG1 is a member of the Helix-
hairpin-helix motif (HhH) structural family of bifunctional DNA glycosylases, possessing β-
elimination AP-lyase activity (Lu et al., 1997; Wallace et al., 2012). OGG1 has also been 
successfully characterised and crystallised bound to the 8-OxoG lesion (Wallace et al., 2012). 
Additionally, the amino acid mutation of serine to cysteine at amino acid position 326 of 
OGG1 is observed in approximately 32% of humans, predisposing them to lung, 
nasopharyngeal, oesophageal, prostate and oropharyngeal cancer (Weiss et al., 2005; 
Wallace et al., 2012). 
 
1.13.2. MutY DNA glycosylase (MUTYH). 
 
The mono-functional DNA glycosylase, MUTYH, is a 60 kDa protein and is a homolog of the 
bacterial MutY protein. MUTYH removes mispaired adenines base paired to 8-OxoG, 5-OHU, 
2-Hydroxyadenine and FapyG (Markkanen et al., 2013; Wallace, 2014). Mutations within the 
MUTYH protein have been associated with the colorectal cancer syndrome MUTYH-
associated polyposis (MAP; Cheadle and Sampson, 2007; Palles et al., 2013). This may be in 
part due to the protective role in which MUTYH plays in the repair of mispaired adenine with 
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the 8-OxoG lesion. It was shown that MUTYH RNAi sensitised HeLa cells to H2O2, affected the 
cell morphology, increased the 8-OxoG foci, altered cell cycle progression and reduced cell 
cycle signalling by phosphorylation of Chk1 (Hwang et al., 2014). In contrast overexpression 
of MUTYH in mismatch repair deficient human Dukes' type C, colorectal adenocarcinoma 
(HCT15) cells resulted in resistance to H2O2 induced apoptosis and an increase in 
phosphorylated Chk1 levels. Taken together MUTYH deficiency may lead to an increase in 
mutagenesis associated with 8-OxoG and also disruption of cell cycle signalling through 
phosphorylation of Chk1 (Hwang et al., 2014) 
1.13.3. Nth-like DNA glycosylase 1 (NTH1). 
 
Nth-like DNA glycosylase 1 (NTH1) is a mammalian HhH DNA glycosylase, a homolog of the 
bacterial Nth protein and is constitutively expressed throughout the cell cycle (Ikeda et al., 
1998; Galick et al., 2013). NTH1 is a bifunctional DNA glycosylase, with associated β-
elimination AP-lyase activity and is found in both the nucleus and mitochondria of the cell 
(Ikeda et al., 1998; Galick et al., 2013). NTH1 has been shown to excise the oxidised bases 5-
hydroxycytosine (5-OHC), 5-hydroxyuracil (5-OHU), Tg and 5-formamidopyrimidine (Fapy) 
(Ikeda et al., 1998; Prakash and Doublié, 2015). It has been shown that NTH1 has overlapping 
substrate specificity with NEIL1, NEIL2 and NEIL3 releasing open ring purines and oxidised 
pyrimidines (Krokeide et al., 2013; Krokan and Bjørås, 2013). NTH1 knockout mice displayed 
no observable phenotype. However, mice with a double-knockout of NTH1 and NEIL1 were 
predisposed to lung and liver tumours (Krokan and Bjørås, 2013; Kuiper and Hoogerbrugge, 
2015). Recently, steady state levels of the NTH1 protein in human colorectal carcinoma 
epithelial cells (HCT116) and U2OS cells were shown to be regulated by the UPS through the 
E3 ubiquitin ligase tripartite motif containing protein 26 (TRIM26), previously shown to 
regulate hNEIL1. Downregulation of TRIM26 by RNAI increased cellular resistance to H2O2 as 
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1.13.4. Endonuclease VIII-like 1 (NEIL1). 
 
The NEIL1 DNA glycosylase is a 44 kDa, bifunctional DNA glycosylase conducting β,δ-
elimination of the phosphodiester backbone and part of the Helix-two-turn-helix domain 
(H2TH) structural family. The activity of NEIL1 is highest during DNA replication, based upon 
observed interactions with DNA replication proteins and higher expression during the S-phase 
of the cell cycle (Hazra et al., 2002a; Hazra and Mitra, 2006; Hegde et al., 2013). NEIL1 is a 
functional hybrid of the bacterial homologs Fpg and Nei, but a closer nucleotide sequence 
match with Nei, than Fpg (Figure 1.14; Hazra et al., 2002b; Hazra and Mitra, 2006).  
 
Figure 1.14: Conserved domain analysis of the human endonuclease VIII like 1 (hNEIL1) DNA glycosylase. 
Fpg/Nei superfamily domain, helix-two-turn helix (H2TH) domain and the NEIL1 DNA binding domain. 
 
Substrates for NEIL1 include the oxidised pyrimidines 5-OHU and Tg but it is also active on 
meFapyG but shows highest activity on Sp and Gh DNA lesions (Bandaru et al., 2002; Hazra et 
al., 2002a Dou et al., 2003; Krishnamurthy et al., 2008; Rosenquist et al., 2003; Krokeide et 
al., 2013). NEIL1 recognises ss-DNA, ds-DNA and bubble structured DNA, unlike OGG1 and 
NTH1, which require double-stranded DNA substrates (Dou et al., 2003; Hazra and Mitra, 
2006). Furthermore, hNEIL1 can excise Gh and Sp in G-quadruplex structures and displays a 
preference for Gh in a telomeric sequence context. G-quadruplex structures may form in 
guanine rich telomeric TTAGGGn repeat sequences and are generated when four guanines are 
Hoogstein base paired, which form layers sandwiching a monovalent cation such as K+ or Na+ 
(Williamson, et al., 1989; Smith and Feigon, 1992; Zhou et al., 2013).  
 
Evidence suggests that NEIL1 has a putative associated role within the maintenance of DNA 
replication and was recently enriched on nascent DNA by immunoprecipitation on nascent 
DNA (IPOND) in the absence of oxidative stress and was suggested to be indicative of a post-
replicative repair function (Bjørås et al., 2017). However, Das et al. (2007) provided the 
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foundations for an emerging model of function of the NEIL1 DNA glycosylase in association 
with DNA replication. Their experiments demonstrated that the Werner syndrome RecQ 
helicase (WRN), a helicase associated with DNA replication fork remodelling and promotion 
of DNA end joining in response to cisplatin treatment, stimulated NEIL1 DNA glycosylase 
activity in the presence of a 5-OHU lesion substrate. Interestingly, WRN deficient cells 
accumulate 8-OxoG, FapyG and Fapy A lesions. In addition, this interaction was enhanced with 
observed colocalisation of NEIL1 and WRN in the nucleus of HCT116 cells after oxidative 
stress, induced by glucose oxidase treatment (Das et al., 2007). It was subsequently shown 
that the WRN helicase was the only ATP-dependent DNA helicase (RecQ) that stimulated 
NEIL1 activity (Popuri et al., 2010). Further investigation of NEIL1 demonstrated direct 
interaction with RPA and PCNA that inhibited activity in an open DNA replication primer 
template structure (Theriot et al., 2010). However, RPA was shown to moderately stimulate 
NEIL1 excision activity in duplex DNA when compared to an RPA interacting domain (aa 312-
349) mutant. The inhibition of activity was then demonstrated to be relieved in the presence 
of PCNA in ds-DNA context. Taken together this interaction with RPA and PCNA displayed 
modulation of NEIL1 activity at a DNA replication fork (Theriot et al., 2010).  
 
More recently the function of hNEIL1 at the DNA replication fork was elaborated by Hegde et 
al (2013), who showed using a ss-RPA coated template DNA containing a 5-OHU DNA lesion, 
that DNA synthesis by Pol δ was significantly enhanced by the addition of PCNA but could not 
proceed past the lesion in the presence of hNEIL1. Furthermore, a lack of excision activity was 
observed in ss-DNA, thus avoiding replication associated DSB induction. It was subsequently 
proposed that hNEIL1 acts as a DNA replication machinery ‘cowcatcher’, in a prereplicative 
manner, preventing DNA replication fork progression when an oxidised base is encountered. 
Then the promotion of DNA replication fork regression and chicken foot structure formation, 
presumably by WRN or other helicases may take place. The subsequent oxidised base, now 
remodelled into a ds-DNA context, is then processed by NEIL1 and short-patch BER (Hegde et 
al., 2013). Finally, Hegde et al. (2015) demonstrated that hNEIL1 was present in multiprotein 
complexes, containing replication associated proteins, which could conduct efficient BER in 
vitro. The C-terminal domain of hNEIL1 was shown to interact with the PCNA associated 
replication clamp loader RFC, DNA polymerase δ and DNA ligase I. It was also revealed that 
this RFC interaction stimulated hNEIL1 activity ~8 fold in the presence of 5-OHU in DNA. These 
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interactions were inhibited in a hNEIL1 N311 deletion mutant lacking the C-terminal domain 
(Hegde et al., 2015). It has also been shown that the replication associated function of hNEIL1 
may affect cellular sensitivity to oxidation; this was demonstrated by generation of mNEIL1 
short hairpin ribonucleic acid interference (shRNAi) knockdown MEF cells, which displayed a 
significant increase in sensitivity to H2O2 during the S-phase of the cell cycle (Yamamoto et al., 
2014). These experiments provide biochemical and cellular evidence that NEIL1 is a 
replication associated DNA glycosylase and is active under replicative stress conditions. 
 
NEIL1 was the first human DNA glycosylase shown to play an active role in the resolution of 
psoralen MAs in duplex DNA and ICLs in a three-stranded context (Couvé-Privat et al., 2007; 
Couvé et al., 2009. Furthermore, sensitivity to the ICL inducing agent 8-MOP and UVA on 
knockout of hNEIL1 and APE1 in HeLa cells was demonstrated (Couvé-Privat et al., 2007; 
Couvé et al., 2009). Subsequent investigation by Macé-Aimé et al. (2010) revealed that FANCA 
and FANCC deficient cell lines displayed resistance to the ICL inducing agent MMC and 8-MOP 
when hNEIL1-FLAG was transiently overexpressed and that expression levels of NEIL1 were 
associated with an intact FA repair pathway. For the first time it was proposed that ICL 
sensitivity displayed by FA deficient cell lines may be associated with NEIL1 and BER (Macé-
Aimé et al., 2010).  
 
The investigation of NEIL1 PTM, identified novel ubiquitination activity and regulation of 
steady state levels by the E3-ubiquitin ligases TRIM26 and Mcl-1 ubiquitin ligase E3 (MULE), a 
known interactor of p53 (Lee and Gu, 2010; Dorn et al., 2014; Edmonds et al., 2017). MULE 
has previously been shown to ubiquitinate topoisomerase 2-binding protein 1 (TopBP1) an 
activator of ATR kinase and the DNA RSR (Herold et al., 2008) Furthermore, loss of MULE has 
been shown to increase phosphorylated ATM and p53 in MEFs (Hao et al., 2012). NEIL1 
protein was also demonstrated to be induced in response to IR in a MULE-dependent manner, 
while resistance to IR was displayed on knockdown of TRIM26, determining the regulation of 
NEIL1 by PTMs (Edmonds et al., 2017).  
 
Current lines of evidence provide insight into the possible roles in which NEIL1 may play in 
association with the DNA replication fork machinery. It would be tempting to speculate that 
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NEIL1 recognises DNA lesions at the DNA replication fork in a structure specific manner, 
recruited as part of the DNA replication stress response. 
1.13.5. Endonuclease VIII-like 2 (NEIL2) 
 
The second member of the H2TH family in mammalian cells is NEIL2. NEIL2 has a molecular 
weight of 37 kDa, possesses the H2TH domain and is bifunctional conducting β,δ-elimination. 
NEIL2 has also been proposed to possess a single C-terminal zinc finger domain (Figure 1.15: 
Das et al., 2004; Hazra and Mitra, 2006). Expression, purification and biochemical 
characterisation of NEIL2 determined it is active upon oxidised pyrimidines in the presence of 
poly nucleotide kinase phosphatase (PNKP) and NEIL2 cleaves 5-hydroxyuracil in ss, ds or 
bubble structured DNA (Dou et al., 2003; Hazra and Mitra, 2006).  Aged mice depleted of 
NEIL2 were found to accumulate oxidised bases in transcribed regions of DNA suggesting a 
role in transcription coupled repair (Chakraborty et al., 2015). NEIL2 is located in the nucleus 
and the mitochondria and displays activity on 5-OHU, with weak activity upon 5-OHC and Tg 
lesions (Hazra et al., 2002; Mandal et al., 2011). Additionally, NEIL2 has been shown to be 
associated with RNA DNA polymerase II, which taken together with structural affinity for 
oxidative lesions within a bubble structure and a constitutive expression profile, infer a role 
within transcription coupled BER (Hazra and Mitra, 2006; Wallace, 2014). It has also been 
shown that NEIL2 is regulated through PTMs, with acetylation leading to NEIL2 inactivation 
(Bhakat et al., 2004). NEIL2 was also shown to play a role in protection against carcinogens in 
second-hand smoke, with significant accumulation of mutagenic oxidative lesions on its 
depletion in human pulmonary fibroblasts (hPF) and human embryonic kidney epithelial cells 
(HEK 293) cancer cells (Sarker et al., 2014). 
Figure 1.15: Conserved domain analysis of the human endonuclease VIII like 2 (hNEIL2) DNA glycosylase. 
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1.13.6. Endonuclease VIII-like 3 (NEIL3). 
 
The NEIL3 DNA glycosylase is the third mammalian homolog of the Nei/Fpg family of bacterial 
DNA glycosylases and the NEIL3 gene is found at the chromosomal locus 4q34.3 of the human 
genome, encoding the 67.8 kDa protein NEIL3 (Hillier et al., 2005; Uniprot, 2010). NEIL3 has 
been shown to be an active DNA glycosylase with a somewhat overlapping substrate 
specificity to that of NEIL1 (Takao et al., 2009; Wallace et al., 2012). 
NEIL3 has an organ specific expression pattern and is found in the brain, the thymus, spleen, 
bone marrow and testes in mice (Morland et al., 2002; Torisu et al., 2005; Hildrestrand et al., 
2009). The protein has been shown to be overexpressed in 13 types of cancer with a positive 
correlation with somatic mutation load (Kauffmann et al., 2008; Shinmura et al., 2016; de 
Sousa et al., 2017). However, despite this correlation, triple knockout NEIL1, NEIL2 and NEIL3 
mice displayed no increase in the accumulation of spontaneous mutations under normal 
physiological conditions (Rolseth et al., 2017). It was shown through cell cycle analysis that 
hNEIL3 expression, at a transcriptional level and protein level, was cell cycle regulated in 
proliferating cells and induced in early S-phase through to G2/M phase (Neurauter et al., 
2012; Zhou et al., 2015; Zhou et al., 2017). More recently it was shown in synchronised HeLa 
cells that NEIL3 expression peaks 6 hours post release from S-phase (Zhou et al., 2017). 
NEIL3 has been shown to have multiple biological protective roles, with aged NEIL3 knockout 
mice observed to have reduced white blood cell counts, memory deficits, anxious behaviour, 
reduced neurogenesis, impairment in hippocampal synapses, increased decline in the 
neuronal nuclei (a marker for mature neurones) and a significantly reduced clinical-phase in 
a prion disease model (Torisu et al., 2005; Regnell et al., 2012; Jalland et al., 2016). In addition, 
it has been shown that deficiency of NEIL3 in mice resulted in increased apoptosis of B and T 
cells highlighting potential evidence for the protective role NEIL3 may provide against 
autoimmune diseases (Massaad et al., 2016). However, this role may be exploited by human 
immune deficiency virus (HIV), with RNAi knockdown of hNEIL3 observed to reduce HIV 
infection, which was rescued with expression of hNEIL3. It was suggested that hNEIL3 plays a 
role during viral replication or host genome integration (Zhou et al., 2008). 
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Human NEIL3 possesses a DNA glycosylase domain (1-151 aa), a H2TH domain (61-281 aa), a 
zf-RanBP domain (317-345 aa) and two zf-GRF domains (505-550 and 552- 596 aa; Figure 1.16; 
Liu et al., 2013a). The conserved N-terminal domain of hNEIL3 has been revealed to facilitate 
DNA glycosylase activity on a number of oxidised bases in ss-DNA and ds-DNA, with an 
increase in activity on ss substrates. However, inability to express and purify the full amino 
acid sequence of hNEIL3 as an active protein has prevented the full biochemical 
characterisation of hNEIL3 (Krokeide et al., 2009; Liu et al., 2010; Liu et al., 2012; Liu et al., 
2013; Krokeide et al., 2013). DNA glycosylase activity has been demonstrated by the 
glycosylase domain of hNEIL3 with additional weak β-elimination of an AP site containing 
substrate. However, the highest levels of activity have been observed on Sp and Gh DNA 
lesion substrates and moderate activity on 5-OHU containing substrates, especially in a ss-
DNA context (Takao et al., 2009; Krokeide et al., 2013; Liu et al., 2013a, 2013b). The 
glycosylase and AP-lyase activities were suggested to be undertaken in a non-concerted 
manner, with the amino acid mutation of position 2 from valine to proline restoring a 
concerted bifunctional activity profile. Consequently, it was suggested that in the presence of 
APE1 in the cell, NEIL3 would be a mainly monofunctional DNA glycosylase (Krokeide et al., 
2013). Study of the mouse ortholog of hNEIL3 (mNEIL3) and truncated glycosylase domain 
hNEIL3 by Liu et al., (2012), revealed activity on Tg, Sp, Gh and AP site in oligonucleotide 
substrates. It was consistently observed that activity was increased on ss-DNA substrates 
compared with ds-DNA (Liu et al., 2010; Liu et al., 2012; Liu et al., 2013a, 2013b). Structural 
characterisation of the glycosylase domain of mNEIL3 provided further evidence for a single-
strand affinity, with a lack of a loop that stabilises everted DNA bases and lack of two of the 
three void-filling residues possessed by NEIL1, that are suggested to stabilise the opposite 
DNA strand. Also, the possession of an electrostatic environment uncomplimentary to the 
phosphate backbone of the undamaged strand in duplex DNA, suggested a preference for ss-
DNA substrates (Liu et al., 2013b).  
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Figure 1.16: Conserved domain analysis of the human endonuclease VIII like 3 (hNEIL3) DNA glycosylase. 
Fpg/Nei superfamily domain, helix-two-turn helix (H2TH) domain, zinc finger RanB domain and zinc finger-GRF 
domain (Zf-GRF). 
Wallace’s group have made significant advances in the elucidation of the biochemical role of 
the hNEIL3 DNA glycosylase as previously discussed. More recently they have described a role 
for NEIL3 in telomeric sequence maintenance, initially showing substrate preference of 
mNEIL3 on Tg, Sp and Gh lesions when compared to hNEIL2 and NTH1 DNA glycosylases, in a 
G-quadruplex structure (Zhou et al., 2013). However, as previously mentioned NEIL1 has been 
shown to remove Sp, Gh lesions in a G-quadruplex, but not Tg, as efficiently as mNEIL3 (Zhou 
et al., 2013). More recently, the biological implications of these findings have been described 
(Zhou et al., 2017). These include a significant mitotic defect after hNEIL3 RNAi in HCT116 
cells, with telomeric dysfunction and a significant increase in metaphase arrested cells, 
leading to apoptosis. In addition, a significant increase in cells displayed anaphase bridging, 
where APE1 and NEIL3 colocalised. It was also shown that NEIL3 colocalises with telomeric 
repeat-binding factor 2 (TRF2), a shelterin complex protein which protects telomeres from 
aberrant processing as DNA breaks by the DDR, in U2OS cells (Zhou et al., 2017). It was 
subsequently proposed that NEIL3 protects genome stability through repair of oxidative 
damage in telomeres during the S/G2 phase of the cell cycle, due to maximal NEIL3 levels 
being observed 6h post release from S-phase in HeLa cells (Zhou et al., 2017). Anaphase 
bridges are associated with genomic instability and are usually found within vulnerable 
stretches of DNA such as telomeres. It is suggested anaphase bridges may be products of rapid 
proliferation and indicative of DNA damage tolerance (Bizard and Hickson, 2018). Together 
these finding may indicate a role of hNEIL3 in the facilitation of rapid proliferation of cancer 
cells and removal of DNA damage in preventing formation of chromatin bridge structures 
(Zhou et al., 2017).  
NEIL3 has also been implicated in the repair of ICLs. Semlow et al. (2016) used an X. laevis 
NEIL3 knockout cell free egg extract model to show NEIL3 can unhook psoralen ss MA, ICLs 
and AP site ICLs in an X-shaped structure in an incision-independent manner. They proposed 
Chapter I  Introduction 
55 
that NEIL3 was responsible for the removal of ICLs in a structure generated as a product of 
convergent stalled DNA replication forks. It was also shown that psoralen ICLs were repaired 
by an incision-dependent repair pathway activated by the FA pathway, when incision-
independent repair by NEIL3 was abolished. The study established a role of NEIL3 in ICL repair 
where redundancy by the FA pathway exists (Couvé-Privat et al., 2007; Couvé et al., 2009). 
Thus, it was proposed that the X-shaped structure, mimicking convergent DNA replication 
forks, places the ICL in a ss-DNA context for excision by the NEIL3 DNA glycosylase (Semlow 
et al., 2016). 
Some of the most effective chemotherapeutic agents target the DNA molecule to induce ICLs 
amongst other DNA damage, initiating cellular apoptosis through the DDR (Patrick and Turchi, 
1999; Macé-Aimé et al., 2010). hNEIL3 is proposed to be a resistance factor for this type of 
chemotherapy as cellular sensitivity after RNAi in colorectal cancer cells and NEIL3 knockout 
MEF cells was observed in response to oxaliplatin and cisplatin, respectively (Rolseth et al., 
2013; Taylor et al., 2015). The targeting of pro-survival proteins has been shown to improve 
the efficacy of cancer therapy, such as the short interfering ribonucleic acid (siRNA) 
knockdown of ERCC1 and the use of PARP inhibitors in the clinic (Seetharam et al., 2010; 
O’Connor, 2015). It has been observed that hNEIL3 co-localises with RPA in the nucleus 
(Morland et al., 2002). RPA has been shown to have in vitro activity, denaturing duplex DNA 
containing cisplatin ICLs, subsequently generating a ss cisplatin ICL substrate (Patrick and 
Turchi, 1998; 1999). An RPA associated repair model involving the recruitment of the NER 
machinery was proposed (Patrick and Turchi, 1998; 1999). Taken together this may suggest 
overlap between NER and BER pathways, as previously shown in the case of ICL remnant 
resolution (Patrick and Turchi, 1998; 1999, Morland et al., 2002; Couvé-Privat et al., 2007; 
Couvé et al., 2009). Recently, it has been shown that in highly radio- and chemo-resistant 
glioblastoma cells, hNEIL3 shRNAi leads to increased DNA replication associated DSBs and 
sensitises cells to ATR and synergistic ATR/PARP inhibition. NEIL3 depletion also resulted in 
increased spontaneous replication stress, impaired DSB repair and reduction in chromatin 
bound PCNA, DNA repair protein RAD51 homolog 1 (RAD51) and Chk1 thus, indicating an 
associated loss in DSB repair efficiency on the depletion of hNEIL3 (Klattenhoff et al., 2017).  
Therefore, current lines of evidence indicate a significant role of hNEIL3 in facilitating 
successful DNA replication. Furthermore, considerable redundancy is observed between 
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NEIL1, NEIL2, NEIL3 and NTH1 for the removal of oxidative DNA lesions (Parsons and Elder, 
2003; Couvé-Privat et al., 2007; Couvé et al., 2009; Wallace et al., 2012; Krokeide et al., 2013; 
Rolseth et al., 2017). In mammals, multiple DNA glycosylases are required for the processing 
of DNA lesions in distinct DNA structures for the maintenance of genomic stability (Wallace 
et al., 2012). However, triple knockout of the NEIL DNA glycosylases in mice, displayed no 
increase in spontaneous mutagenesis, accumulation of oxidative DNA damage and telomere 
length was not affected under normal physiological conditions, perhaps due to defined 
redundancy between the NEIL and NTH1 DNA glycosylases. It was therefore proposed that 
the NEIL DNA glycosylases may have roles beyond that of canonical repair through BER 
(Rolseth et al., 2017). These roles are suggested to be exploited by cancer cells to promote 
acquired cellular resistance to therapy. 
The next step in understanding the role of hNEIL3 in chemotherapeutic resistance, is to probe 
the biochemical activity of hNEIL3 in vitro on DNA replication blocking lesions such as Tg and 
psoralen ICL oligonucleotide substrates, as a model for the study of ICL resolution (Couvé-
Privat et al., 2007; Couvé et al., 2009). Consequently, this should provide a biochemical 
mechanism for the observed sensitisation to RSR inhibition and ICL inducing agents after 
NEIL3 knockdown or knockout (Rolseth et al., 2013; Taylor et al., 2015; Klattenhoff et al., 
2017). Elucidation of PTM by the UPS may also provide further additional information on the 
mechanism of modulation in response to DNA damage in cancer cells, in a similar manner to 
NEIL1 and NTH1 (Edmonds et al., 2017; Williams and Parsons, 2018). Furthermore, the 
generation of a hNEIL3-/- stable cancer cell line using clustered regularly interspaced 
palindromic repeats (CRISPR)/ CRISPR associated protein 9 (Cas9) gene editing should provide 
a model system for the further characterisation of the role of NEIL3 in mechanisms of genomic 
instability and modulation by PTM systems. 
Strict cellular control, lack of a mutagenic phenotype on deficiency of NEIL DNA glycosylases 
under normal physiological conditions, while sensitising cancer cells to therapy, provides a 
promising motive for the effective therapeutic targeting of the NEIL3 DNA glycosylase, for the 
treatment of cancers overexpressing NEIL3 (Morland et al., 2002; Torisu et al., 2005; 
Hildrestrand et al., 2009; Rolseth et al., 2013; Taylor et al., 2015; Klattenhoff et al.,2017; 
Rolseth et al., 2017; Zhou et al., 2017). 
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1.14. Ubiquitin proteasome system (UPS). 
 
Post-translational modification by the highly conserved 76 amino acid protein, ubiquitin, is an 
important regulatory mechanism, typically associated with the identification of target 
proteins for degradation by the 26S proteasome (Weissman, 2001; Glickman and 
Ciechanover, 2002). The 26S proteasome, made up of the 19S and 20S complexes, is an 
approximately 33 protein subunit complex, containing proteolytic sites which hydrolyse 
polypeptides to generate short peptides ranging from 2 to 10 residues (Inobe and 
Matouschek, 2014; Collins and Goldberg, 2017). This irreversible degradation of proteins is 
regulated by controlled access to these proteolytic sites by the N-termini of 20S a-subunits 
and C-termini interaction with 19S subunit complexes, allowing access to the inner chamber 
of the 20S complex (Collins and Goldberg, 2017). Additionally, ubiquitin has several other 
important roles, including the modulation of DNA damage repair and DNA replication, innate 
immune signalling and cell surface endocytosis (Mukhopadhyay and Riezman; 2007; Chen and 
Sun, 2009; Grabbe et al., 2011). It is estimated that in HeLa cells approximately 1.3% of all 
cellular protein is ubiquitin (Kulak et al., 2014)  
In human cells the ubiquitin protein is encoded by four different genes. These are ubiquitin B 
(UbB), ubiquitin C (UbC), ubiquitin A-52 residue ribosomal protein fusion product 1 (UBA52) 
and ubiquitin carboxyl extension protein 80 (UBA80). UbB and UbC are processed by DUB 
family enzymes to generate ubiquitin (Monia et al., 1989). Cellular ubiquitin can be 
considered in three distinct states, free ubiquitin, activated ubiquitin that is linked by 
thioester to ubiquitin conjugating enzymes (E2s) and conjugated ubiquitin that is isopeptide 
bound to target substrate proteins (Clague et al., 2015). 
The process of ubiquitination proceeds by adenosine triphosphate (ATP) hydrolysis and the 
release of pyrophosphate (PPi), in turn generating an ubiquitinyl adenylate intermediate 
which subsequently binds to an E1 activating enzyme. Then the E1 activating enzyme forms a 
thioester bond with ubiquitin and adenosine monophosphate (AMP) is released (Figure 1.17; 
Myung et al., 2001; Parsons and Dianov, 2013). Then, the Ub-thioester is passed to a cysteine 
residue on an E2 conjugating enzyme (Udeshi et al., 2012). Finally, the E2-Ub forms a complex 
with an E3 ubiquitin ligase and a protein target, this complex facilitates conjugation of 
ubiquitin to the protein substrate at a specific lysine residue, by formation of an isopeptide 
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bond between the ubiquitin C-terminal and a NH2 group (Figure 1.17; Parsons et al., 2008; 
Jackson and Durocher, 2013). This facilitates single ubiquitin monomer addition, termed 
mono-ubiquitination and is typically associated with cell signalling (Edmonds and Parsons, 
2014). Alternatively, successive processing by E2 unloading and reloading of charged E2-Ub 
to a target protein, forms progressive homotypic or heterotypic poly-ubiquitin chains at one 
of seven ubiquitin lysine amino acids (Lys6, Lys11, Lys27, Lys29,Lys33, Lys48, Lys63) or less 
commonly the N-terminal methionine (Ikeda and Dikic, 2008, Ye and Rape, 2009; Jackson and 
Durocher, 2013; Inode and Matouschek, 2014). Those protein substrates poly-ubiquitinated 
with homotypic Lys11, Lys29 and Lys48 ubiquitin chains are typically targeted for degradation 
by the 26S proteasome, where proteins are broken down into free peptides and ubiquitin 
(Figure 1.17; Parsons et al., 2008; Jackson and Durocher, 2013; Inode and Matouschek, 2014).  
The 26S proteasome consists of the “lid” and “base” 19s subunits and the 20S core made of 
four heptameric rings, forming a hollow barrel like structure (Myung et al., 2001). Proteins 
targeted for degradation are recognised by the ‘lid’ which has an affinity for ubiquitinated 
protein and the base unfolds and guides these protein substrates into the catalytic inner 
compartment of the 20S particle. Subsequently, peptide bonds are cleaved through hydrolysis 
by the multiple proteolytic activities possessed by the 20S core (Figure 1.17; Myung et al., 
2001; Collins and Goldberg, 2017). 
Figure 1.17: Schematic representation of the ubiquitin proteasome system. “Ub” denotes ubiquitin, “E1” 
denotes E1 ubiquitin activating enzyme, “E2” denotes E2 ubiquitin conjugating enzyme, “E3” denotes E3 
ubiquitin ligase, “ATP” denotes adenosine triphosphate, “AMP” denotes adenosine monophosphate and “PPi” 
denotes pyrophosphate. 
Chapter I  Introduction 
59 
In human cells the presence of 10 E1 activating enzymes, 40 E2 conjugating enzymes and >600 
E3 ubiquitin ligases have been estimated, with a further 90 complementary de-ubiquitinating 
enzymes (DUBs; Cohen and Tcherpakov, 2010; Sacco et al., 2010). DUBs are subdivided into 
5 distinct groups, the ubiquitin C-terminal hydrolases (UCHs), ubiquitin-specific proteases 
(USPs), Joesephines, JAMM/MPN+ metalloenzymes and ovarian tumour proteases (OTUs; 
Komander et al., 2009). These DUBs have been shown to work in direct coordination with 
specific E3 ligases, fine tuning the orchestration of ubiquitin conjugation to target proteins 
and preventing autoubiquitination by specific E3 ligases which would lead to dysfunction 
(Wilkinson, 2009). 
The UPS plays an important role within the DNA damage response and DNA repair, through 
regulation of activity, stability and the cellular localisation of numerous proteins. One well 
characterised example is the polyubiquitination of the tumour suppressor protein p53, by the 
RING family E3 ubiquitin ligase, mouse double minute 2 (MDM2) which targets Lys370, 
Lys372, Lys373, Lys381, Lys382, or Lys386 of p53 for proteasomal degradation (Haupt et al., 
1997; Rodriguez et al., 2000). This said, multiple other E3 ubiquitin ligases have been 
identified to monoubiquitinate or polyubiquitinate p53 through Lys48 and Lys63 ubiquitin 
chains independent of MDM2 (Lee and Gu, 2010). These include, the RING domain E3 ligases: 
p53-induced RING-H2 protein (Pirh2), E3 ubiquitin-protein ligase ICP0 (ICP0), constitutive 
photomorphogenesis protein 1 (COP1), Topoisomerase I-binding RING finger protein 
(TOPORS), carboxy terminus of Hsp70-interacting protein (CHIP), Synoviolin, Cell division 
cycle and apoptosis regulator protein 1 (CARP1), Cell division cycle and apoptosis regulator 
protein 2 (CARP2), male-specific lethal 2-like 1 (MSL2), the homologous to the E6AP carboxyl 
terminus (HECT) domain E3 ligases: MULE, WW domain-containing protein 1 (WWP1) and the 
non-conventional: UBE2N and E4F transcription factor 1 (E4F1; Lee and Gu, 2010). 
Highlighting the elegant level of control that the ubiquitin system orchestrates within the cell.  
Recently, the RING E3 ubiquitin ligase TRAF-interacting protein (TRAIP) has been shown to 
play a role within regulation of DNA damage response factors at stalled-replication forks in a 
PCNA dependent manner through PIP box domain interaction, co-localising with DSB 
associated γ-H2AX foci. It was also shown that protein ubiquitination is vital for ss-DNA 
formation through ATR dependent signalling and RPA loading. It is suggested that DNA 
replication fork proteins are directly ubiquitinated, highlighting the importance of the 
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maintenance of protein homeostasis of DNA replication associated proteins by the UPS, in the 
orchestration of successful DNA replication (Hoffmann et al., 2016). 
1.14.1. E3 ubiquitin ligases. 
 
E3 ubiquitin ligases facilitate and complete the conjugation of ubiquitin monomers or 
polymers to target proteins. As a result, these enzymes control specificity of the 
ubiquitination reaction and the ubiquitin pathway (Zheng and Shabek, 2017). Two distinct 
major families of E3 ubiquitin ligases have been identified, they are determined by the 
presence of either RING domains or HECT domains. The mode of action of conjugating 
ubiquitin to target proteins differs between RING and HECT E3 ubiquitin ligases (Zheng and 
Shabek, 2017).  
The E6 associated protein (E6-AP) was the first (HECT) E3 ubiquitin ligase which was 
mechanistically elucidated. It was shown that the HECT domain possesses a cysteine residue 
that accepts an E2 conjugating enzyme bound to Ub, in turn the HECT domain would facilitate 
the formation of a thioester linkage to E6-AP, followed by transfer to a lysine residue of the 
protein substrate targeted (Scheffner et al., 1995).  
The RING domain E3 ubiquitin ligases were shown to possess a different method of facilitating 
ubiquitination, demonstrated through the identification that the SCF ubiquitin ligase sub-unit, 
Rbx1, RING domain was essential for E3 ligase activity and that its coordination of zinc was a 
key feature. In addition, the Cul1 protein was identified as an important interactant with Rbx1, 
for binding and activation of the Cdc34 E2 conjugating enzyme. While HECT domain proteins 
create a thioester bound intermediate with the E3 ubiquitin ligase, studies revealed the Cul1-
Rbx1 complex facilitated direct transfer of Ub between Cdc34 and the protein substrate 
(Kamura et al., 1999; Ohta et al., 1999; Tan et al., 1999; Seol et al., 1999; Metzger et al., 2014). 
Polyubiquitination catalysed by RING domain E3s can be highly processive and is facilitated 
by consecutive transfer of single Ub monomers (Pierce et al., 2009). It has been shown that 
to extend ubiquitin chains the cooperative action of E2 and E3 ubiquitin enzymes are required 
and several E3 ubiquitin ligases have been identified to generate Ub chains with the aid of 
one E2 conjugating enzyme. In contrast, multiple E2 conjugating enzymes may also be 
engaged by a single E3 ubiquitin ligase to generate Ub chains (Christensen et al., 2007; 
Stewart et al., 2016). 
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1.14.2. Ubiquitin proteasome system and cancer. 
 
The UPS system maintains homeostasis at a protein level, orchestrating the degradation of 
damaged, misfolded and surplus proteins for proteasomal degradation (Collins and Goldberg, 
2017). In addition, the UPS system modulates protein localisation, the interaction of specific 
proteins and can initiate cellular signalling pathways. The physiological role of the UPS system 
extends to inflammatory signalling, autophagy, multi-protein complex assembly and 
regulation of DNA repair systems (Bhattacharjee and Nandi, 2017; Kattah et al., 2017).    
1.14.2.1 E2 conjugating enzymes and cancer. 
 
The E2 conjugating enzyme Ubiquitin-conjugating enzyme E2 C (UBE2C) is overexpressed in 
many different cancers, including breast, ovary, thymus, uterus, lung and prostate cells 
(Narayan et al., 2007; Fujita et al., 2009; van Ree et al., 2010; Tzelepi et al., 2012). UBE2C 
functions together with the anaphase-promoting complex/cyclosome (APC) to facilitate 
completion of chromosomal segregation and alignment during mitosis. Overexpression has 
been shown to increase the incorrect segregation of chromosomal DNA and transgenic mice 
become prone to lung and several other types of cancer (van Ree et al., 2010).  
Ubiquitin-conjugating enzyme E2 S (UBE2S) conjugating enzyme was shown to facilitate the 
polyubiquitination of the von Hippel-Lindau (VHL) protein for proteasomal degradation (Jung 
et al., 2006). VHL regulates hypoxia inducible factors (HIF) and in turn induces the expression 
of oncogenic genes (Rankin and Giaccia, 2016). In tumours, HIFα and UBE2S are 
overexpressed with reduced expression of VHL. VHL stabilises oxygen levels within the cell 
and overexpression of UBE2S dysregulates its function and leads to an increase in HIF 
transcription factors and thus an oncogenic phenotype through upregulation of associated 
oncogenes (Witkiewicz et al., 2015; Beltran et al., 2016). 
Ubiquitin-conjugating enzyme E2 N (UBE2N) and its cofactor Ubiquitin-conjugating enzyme 
E2 variant 1 (UBE2V1) are specific for Lys63 chain building and vital in the inflammatory 
response through initiation of NFkB (Chen and Chen, 2013). Indeed, UBE2N is overexpressed 
in pancreatic, breast, prostate, colon, lymphoma and ovarian carcinomas. In breast cancers 
UBE2N facilitates metastasis to the lung as a secondary site through transforming growth 
factor beta (TGF-β) activation of mitogen-activated protein kinase 11 (p38) and transforming 
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growth factor beta-activated kinase 1 (TAK1) which lead to expression of metastasis 
associated genes. Furthermore, the downregulation of UBE2N by short hairpin RNAi has been 
shown to suppress metastasis in the same manner (Wu et al., 2014). Thus, highlighting the 
role of UBE2N and UBE2V1 in inflammatory signalling through TGF-β and NFkB in promoting 
metastasis. 
1.14.2.2 E3 ubiquitin ligases and cancer. 
 
E3 ubiquitin ligases and their association with DUB enzymes have been characterised to 
regulate tumorigenic or tumour-suppression pathways, the most notable example being p53 
and its regulation by the MDM2 E3 ubiquitin ligase (Shangary and Wang, 2008; Love et al., 
2013). The tumour-suppressor protein p53, which controls cell cycle, apoptotic and DNA 
repair proteins is regulated by the RING E3 ubiquitin ligase MDM2 in healthy cells (Momand 
et al., 1992). In many forms of cancer, MDM2 is overexpressed and escalates ubiquitination 
of p53, leading to degradation by the UPS and inhibition of normal tumour-suppression 
pathways regulated by p53 (Mccann et al., 1995; Haupt et al., 1997).  
The SCF protein complex has also been shown to be overexpressed in malignant tumours, 
with its RING E3 ubiquitin ligase Rbx1 subunit facilitating degradation of cyclin-dependent 
kinase inhibitors cyclin-dependent kinase inhibitor p27 (p27KIP1), cyclin-dependent kinase 
inhibitor 1A (P21, Cip1), isoform CRA_a (p21CIP1),  Forkhead box protein O1 (FOXO1; Huang 
et al., 2005), 130 kDa retinoblastoma-associated protein (p130; Tedesco et al., 2002) and 
cyclin-dependent kinase inhibitor 1C (p57; Kamura et al., 2003), promoting cellular 
proliferation. Upstream regulators of SCF have also been shown to function in oncogenesis. 
For example, the sequestosome 1 (SQSTM1) was proposed to be a biomarker in oesophageal 
squamous cell carcinoma due to its positive correlation with SCF, a phenotype of increased 
proliferation and resistance to apoptosis being observed (Shi et al., 2018). Within the SCF 
complex, the F-box and WD repeat domain containing 7 (FBXW7) subunit also possesses E3 
ubiquitin ligase activity. In cancer cells FBXW7 is downregulated and is subsequently 
correlated with poor prognosis and metastasis (Ibusuki et al., 2011; Yang et al., 2015). It is 
suggested that downregulation of FBXW7 reduces the degradation of mTOR, a key member 
of mTORC1 and mTORC2 complexes that are involved in facilitating metastatic potential, 
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protein synthesis and cell proliferation (Hay and Sonenberg, 2004; Lipton and Sahin, 2014; 
Yang et al., 2015). 
E3 ubiquitin ligases have been shown to promote metastasis. For example, the E3 ubiquitin 
ligase Glycoprotein 78 (GP78) controls protein levels of the tetraspanin Metastasis suppressor 
Kangai-1 (KAI1) tumour suppressor through polyubiquitination. Loss of KAI1 is associated with 
metastasis through inflammatory signalling of NFkB, β-catenin and p53 (Liu and Zhang, 2006). 
Another example includes the E3 ubiquitin ligase VHL, which ubiquitinates VHF. Degradation 
through the UPS system maintains homeostasis of HIF in hypoxia conditions, however, the 
lack of VHL can lead to the adaptation of renal tumours to hypoxic conditions by facilitating 
their vascularisation (Rankin and Giaccia, 2016). 
1.14.3. Ubiquitin regulation of the Base Excision Repair pathway. 
 
The expression of BER proteins does not fluctuate dramatically in response to acute 
exogenous DNA damaging treatment, which suggests minimal capacity of BER in the 
immediate cellular response to exogenous DNA damage (Parsons and Dianov, 2013). 
However, the BER pathway has been shown to be regulated through PTMs, with the most 
common PTM identified as phosphorylation, which is primarily associated with checkpoint 
pathway signalling through specific kinases (Almeida and Sobol, 2007; Carter and Parsons, 
2016). The UPS has since been shown to play key roles in the regulation of BER proteins 
(Edmonds and Parsons, 2014). 
The end processing proteins in BER, PNKP and APE1, have been shown to be regulated 
through the UPS. PNKP is responsible for the processing of 3ʹP termini as result of β,δ-
elimination by bifunctional DNA glycosylases and for the repair of SSBs (Weinfeld et al., 2011). 
It was identified by cellular fractionation that the controlled response of PNKP to DNA damage 
was through an E3 ubiquitin ligase complex, consisting of the Cullin-4A (CUL4A), DDB1 and 
the serine-threonine kinase receptor-associated protein (STRAP; Angers et al., 2006; He et al., 
2006; Parsons et al., 2012). This complex was found to ubiquitinate PNKP at lysine 414, 417 
and 484, while STRAP-/- MEF cells displayed increased protein levels of PNKP and an increase 
in resistance to H2O2 treatment when compared to WT MEF cells (Parsons et al., 2012). PNKP 
was previously shown to be phosphorylated by ATM in response to IR and subsequently 
evidence was provided for crosstalk between ATM dependent phosphorylation and CUL4A-
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DDB1-STRAP complex dependent ubiquitination of PNKP (Barzilai et al., 2002; Segal-Raz et al., 
2011; Zolner et al., 2011). This was demonstrated through the overexpression of a PNKP 
S114/126E phosphomimetic protein that demonstrated reduced levels of ubiquitination by 
the CUL4A-DDB1-STRAP complex and was more stable (Parsons et al., 2012).  
The major E3 ligase responsible for the regulation of APE1 by polyubiquitination was shown 
to be Ubiquitin-protein ligase E3-alpha-3 (UBR3; Meisenberg et al., 2012). However, APE1 was 
previously shown to be polyubiquitinated by the MDM2 E3 ligase at Lys24, Ly25 and Lys27 of 
APE1 and was suggested to target APE1 for proteasomal degradation as the depletion of 
MDM2 resulted in an increase in APE1 protein levels (Busso et al., 2009). Interestingly, it was 
shown that the overexpression of APE1 in UBR3-/- mice resulted in genetic instability with an 
increase in the NHEJ associated 53BP1 and HR associated gamma histone 2 A X (γ-H2AX) foci, 
indicating increased DSB generation. This was suggested to be a result of the imbalance of 
SSBs and downstream gap filling and sealing enzymes (Meisenberg et al., 2012).  
The downstream gap filling enzyme Pol β has been shown to be ubiquitinated by the E3 
ubiquitin ligase CHIP. Overexpression of CHIP resulted in a decrease in Pol β protein levels 
whereas RNAi lead to an increase in Pol β protein levels. This subsequently demonstrated the 
role of CHIP in modulating Pol β protein levels within the cell (Parsons et al., 2008). In addition, 
the MULE E3 ubiquitin ligase was shown to monoubiquitinate Pol β, resulting in relocalisation 
to the cytoplasm. Furthermore, MULE dependent monoubiquitination of Pol β was required 
in advance of CHIP dependent polyubiquitination and degradation (Parsons et al., 2009). The 
knockdown of the MULE inhibiting protein, tumour suppressor ARF (ARF), was shown to 
increase cellular levels of monoubiquitinated Pol β (Chen et al., 2005; Parsons et al., 2009). It 
was revealed, that after monoubiquitination and localisation to the cytoplasm, the Pol β 
specific DUB, USP47, removes ubiquitin from Pol β subsequently reinstating availability for 
gap filling and associated lyase activity in response to DNA damage.  It was shown that USP47 
deubiquitinates both mono- and poly-ubiquitinated Pol β and USP47 RNAi, led to a decrease 
in Pol β. However, the co-knockdown of MULE and USP47 rescued exogenously expressed Pol 
β protein levels previously reduced by USP47 RNAi (Parsons et al., 2011). Thus, providing 
evidence that MULE is responsible for the regulation of newly synthesised Pol β. To highlight 
this interaction as a dynamic response to DNA damage, HeLa cells deficient in USP47 displayed 
a delay in repair kinetics in response to both MMS and H2O2 treatment and also sensitivity to 
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H2O2 treatment. Therefore, demonstrating the relevance of USP47 in the modulation of the 
cellular response to both oxidative and alkylation DNA damage (Parsons et al., 2011). 
XRCC1 protein levels influence Ligase III protein levels, as XRCC1 mutant and deficient CHO 
cells displayed a reduction in Ligase III and Pol β, while presenting a hypersensitive phenotype 
to the DNA alkylating agents ethyl methanesulfonate (EMS) and MMS (10-fold),  moderate 
sensitivity to H2O2 and camptothecin (2-5 fold), minor sensitivity to IR, UVA, UVC, near visible 
light, blue, light, heavy metals, ethylnitrosurea (ENU), N-methyl-Nʹ-nitro-N-nitrosoguanidine 
(MNNG) and MMC (Thompson et al., 1982; Christie et al., 1984; Cantoni et al., 1987; Churchill 
et al., 1991; Thompson et al., 2000; Parsons et al., 2008). XRCC1 and Ligase III were shown to 
be polyubiquitinated in vitro by the E3 ubiquitin ligase CHIP, additionally knockdown of CHIP 
resulted in stabilisation of XRCC1 and Ligase III protein levels providing evidence of targeting 
for proteasomal degradation (Parsons et al., 2008). An additional E3 ubiquitin ligase was 
implicated in the ubiquitination of XRCC1 but in a poly-(ADP-ribosyl)ation dependent manner, 
signalling  proteasomal degradation. This E3 ubiquitin ligase was termed Iduna and was found 
to have a protective role against IR and MNNG treatment. However, additional protein 
substrates were identified for Iduna and included poly(ADP-ribose)polymerase 1 (PARP-1), 
Ligase III and Ku70 indicating a more complex interaction within the DNA damage response 
(Kang et al., 2011). Taken together, CHIP and Iduna mediated ubiquitination of XRCC1-Ligase 
III are suggested to be important in influencing the cellular response to multiple forms of DNA 
damage. 
NTH1, has been recently shown to be polyubiquitinated by the E3 ubiquitin ligase, TRIM26. It 
was observed that steady state levels were increased in response to TRIM26 RNAi in both 
HCT116 and U2OS cells, implicating a role in protein stabilisation. A significant increase in 
repair kinetics and resistance in response to H2O2 after TRIM26 RNAi was also observed, with 
the phenotype complemented by transient overexpression of NTH1 (Williams and Parson, 
2018).  
It was demonstrated that OGG1 DNA glycosylase was ubiquitinated by CHIP after exposure of 
HeLa cells to mild hypothermia. This exposure to hyperthermia resulted in the inactivation of 
OGG1 and its relocalisation from the nuclear to the peri-nuclear regions of the cell. In 
addition, exposure to mild hyperthermia promoted the degradation of OGG1 and resulted in 
an impaired cellular proliferation phenotype (Fantini et al., 2013). It was also shown that 
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hyperthermia reduced the repair kinetics of DNA damage and the cellular survival of HeLa 
cells treated with the oxidative damaging agent Ro19-8022 (Will et al., 1999; Fantini et al., 
2013). It was proposed that ubiquitination of OGG1 by CHIP was in part responsible for the 
observed chemosensitivity displayed in HeLa cells exposed to hyperthermia, due to an 
impairment in the removal of OGG1 associated DNA damage (Fantini et al., 2013). 
MUTYH has been shown to be ubiquitinated by the E3 ubiquitin ligase MULE an E3 ubiquitin 
ligase also shown to ubiquitinate p53 in a MDM2 independent manner, as previously 
discussed (Lee and Gu, 2010; Dorn et al., 2014). In addition, MULE RNAi increased cellular 
MUTYH protein levels while MULE overexpression decreased protein levels of MUTYH. It was 
also shown that abolishment of ubiquitin binding through generation of a MUTYH mutant 
(KK477RR, K495R, KK506RR) increased accumulation of MUTYH on chromatin whereas the 
WT MUTYH was found to be mainly cytoplasmic (Dorn et al., 2014). It was suggested that 
MULE plays an important role in regulating the cellular response to oxidative DNA damage 
through MUTYH as it was previously shown that RNAi of MUTYH in HeLa cells resulted in 
sensitivity to H2O2 (Hwang et al., 2014; Dorn et al., 2014). 
The E3 ubiquitin ligases Cullin-1 (CUL1) and Cullin-4 (CUL4) were identified to ubiquitinate 
UNG and SMUG1, displaying stimulatory interactions with the accessory viral protein Vpr 
from HIV. These interactions are proposed to result in a reduction of the number of AP sites 
generated in reverse transcripts as a result of DNA dC->dU-editing enzyme (APOBEC3) 
catalysed cytosine deamination and subsequent uracil excision by UNG or SMUG1 
(Schröfelbauer et al., 2005). UNG, SMUG1, MBD4 and TDG have also being identified as 
substrates for ubiquitination in proteomic ubiquitination screens, however the E3 ubiquitin 
ligases responsible are yet to be determined (Danielsen et al., 2011; Kim et al., 2011a; Wagner 
et al., 2011; Udeshi et al., 2012; Oshikawa et al., 2012).  
The NEIL1 DNA glycosylase has been identified as a substrate for ubiquitination through HeLa 
cell fast protein liquid chromatography (FPLC) fractionation and liquid chromatography mass-
spectrometry (LCMS). It was shown that MULE and TRIM26 are the major E3 ubiquitin ligases 
which facilitate ubiquitination of hNEIL1, generating polyubiquitin chains at the same amino 
acid residues (Lys319, 333, 356, 357, 361, 374, 376; Edmonds et al., 2017). Additionally, it was 
shown that hNEIL1 is induced in response to IR in a MULE dependent manner but TRIM26 
siRNA led to IR resistance and increased hNEIL1 steady state protein levels in U2OS cells. 
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TRIM26 RNAi induced resistance to IR was only partially complemented up to 2 Gray by 
hNEIL1 over expression, suggesting that the observed increase in steady state levels of hNEIL1 
due to TRIM26 RNAi is only partially responsible for the observed IR resistance (Edmonds et 
al., 2017). Putative sites of ubiquitination have been identified on the hNEIL2 DNA glycosylase, 
at Lys96, Lys234 and Lys299, however E3 ubiquitin ligases which ubiquitinate hNEIL2 are yet 
to be characterised (Kim et al., 2011a; Udeshi et al., 2013). The hNEIL3 DNA glycosylase has 
been identified to possess 28 putative sites of ubiquitination amongst the 49 lysine residues 
present within the amino acid sequence, through high throughput screens (Kim et al., 2011a; 
Mertins et al., 2013; Udeshi et al., 2013; Hornbeck et al., 2015). However, to date no E3 
ubiquitin ligases have been identified to interact and modulate NEIL3 protein stability, 
localisation or activity. 
It is evident that several E3 ubiquitin ligases have multiple substrates within BER, including 
CHIP (OGG1, XRCC1, Lig III, Pol β), MULE (MUTYH, Pol β,NEIL1), Cul1 (UNG, SMUG1), Cul4 
(UNG, SMUG1 and PNKP in complex with DDB1 and STRAP), Iduna (XRCC1, Lig III and PARP-
1), while only one DUB has been identified for Pol β, which facilitated the further 
understanding  of the dynamic role of the UPS in the regulation of the cellular response to 
DNA damage through BER (Parsons et al., 2011). It is likely that E3 ubiquitin ligases which have 
multiple substrates recognise specific structural motifs present within BER proteins, 
modulating the cellular response to distinct DNA damage through the orchestration of 
multiple BER proteins. To further the understanding of the role of the UPS in modulating BER, 
the identification of interacting E3 ubiquitin ligases with TDG, NEIL2 and NEIL3 is required. 
Furthermore, the structural characterisation of motifs in BER protein substrates that are 
ubiquitinated by the same E3 ubiquitin ligase, may further the understanding of how 
dysfunction in the UPS may have knock-on effects on the protective function of multiple BER 
proteins. Finally, the identification of additional BER protein specific DUBs will further the 
understanding of the dynamic cellular response to DNA damage. 
Evidence begins to suggest the BER pathway is intrinsically involved in the repair of non-
conventional DNA lesions such as ICLs (Couvé-Privat et al., 2007; Couvé et al., 2009; Semlow 
et al., 2016; Martin et al., 2017). Therefore, the elucidation of the role of E3 ubiquitin ligases 
in modulating the cellular response to ICL inducing agents through BER, may lead to the 
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identification of novel mechanisms that promote the acquired resistance of cancer cells to ICL 
inducing agents. 
1.14.4. Tripartite motif-containing proteins. 
 
In humans approximately 70 tripartite motif-containing (TRIM) proteins have been identified 
and are mainly RING E3 ubiquitin ligases, which facilitate the ubiquitination of substrate 
proteins through the RING zinc finger domain facilitating direct transfer of Ub from an E2 
ubiquitin conjugating enzyme to the protein substrate (Metzger et al., 2014; Watanabe and 
Hatakeyama, 2017). They are also known as RING, B-Box(es),Coiled coil domain E3 ubiquitin 
ligases (RBBC) proteins due to their characteristic RING, B-box(es) and coiled-coil (CC) domain 
structure followed by a differentiated C-terminal (Reymond et al., 2001; Torok and Etjkin, 
2001). B-box domains are zinc finger domains and have been suggested to enhance RING 
dependent E3 ubiquitin ligase activity and confer E3 ubiquitin ligase activity to TRIM proteins 
which do not possess a RING domain (Bell et al., 2012). The CC domain has been indicated to 
promote homo-oligomerisation of TRIM proteins and has been advised as an essential feature 
that facilitates E3 ubiquitin ligase activity (Napolitano and Meroni, 2012).  The substrate 
specificity and recognition of TRIM proteins is also proposed to be mediated through the 
hetero-oligomerisation of closely related TRIM proteins, through the interaction of their 
differentiated C-terminal domains (Napolitano and Meroni, 2012; Esposito et al., 2017). 
Many TRIM substrates are associated with immune response signalling, including TRIM25 
which ubiquitinates retinoic acid-inducible gene 1 product (RIG-1), a detector of viral 
infection, leading to the production of type I interferons (Gack et al., 2007). Tripartite motif 
containing protein 5 alpha (TRIM5α) has also been shown to play a role in the inhibition of 
HIV-1 infection by trimerizing and coating the capsid of a virus, whereas a TRIM5α CC domain 
(ΔCC GCN4) mutant protein did not inhibit the virus and could not bind to the capsid despite 
being able to trimerize (Javanbakht et al., 2006).  
TRIM proteins have been identified as biomarkers of carcinogenesis with TRIM24, 28, 29, 32 
and 51 being shown to interact with the tumour suppressor protein p53, their dysfunction 
suggested to lead to an alteration in p53 protein levels disrupting its tumour-suppressive 
function (Yang et al., 2007; Allton et al., 2009; Kanno et al., 2014; Borlepawar et al., 2017). 
More recently, TRIM32 has also been shown to be a positive regulator of cell proliferation in 
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gastric cancer in vivo, through its enhancement of the β-catenin protein signalling pathway 
promoting metastatic potential (Wang et al., 2018). In general, dysfunction of TRIM E3 
ubiquitin ligases have been associated with cancer through differential cellular function 
including transcriptional regulation, cell proliferation, immune response signalling, apoptosis 
and metastasis (Hatakeyama, 2017). 
Interestingly, TRIM proteins have been identified to regulate DNA repair, their dysfunction 
proposed to promote genomic instability and resistance to therapeutic intervention of 
malignant tumours (Hatakeyama, 2011). TRIM29 is one such example and revealed to be a 
histone binding protein which facilitated the incorporation of DSB repair proteins, BASC, 
cohesion, DNA dependent protein kinase, catalytic subunit (DNAPKcs) and 60 kDa Tat-
interactive protein (TIP60; Masuda et al., 2015). It was also shown that TRIM29 was 
phosphorylated by ATM in response to ionising radiation supporting its role in DSB repair 
modulation (Wang et al., 2014). As previously discussed, TRIM26 has been highlighted as an 
important modulator of the NEIL1 and NTH1 DNA glycosylases and its downregulations infers 
resistance of cancer cells to IR and the ROS inducing agent H2O2, respectively (Edmonds et al., 
2017; Williams and Parsons, 2017).  
1.14.5. Tripartite motif-containing protein 26. 
 
The Tripartite motif-containing protein 26 is a 62.2 kDa E3 ubiquitin ligase of the TRIM 
subfamily C-IV-1 protein (Edmonds et al., 2017; Watanabe and Hatakeyama, 2017; Williams 
and Parsons, 2018). TRIM26 consists of a N-terminal RING finger domain, a B-box 2 domain, 
a CC domain and two C-terminal PRY domains (Watanabe and Hatakeyama, 2017).  
Human and mouse somatic cells can be reprogrammed to a pluripotent embryonic stem cell 
–like state and this facilitates the generation of inducible pluripotent stem cells (iPSCs). This 
process is achieved with the use of four transcription factors Sox transcription factor 2 (Sox2), 
octamer-binding transcription factor 4 (Oct4), Krueppel-like factor 4 (Klf4) and MYC 
(Takahashi and Yamanaka, 2006; Takahashi et al., 2007 Yu et al., 2007). Plant homeodomain 
finger protein 20 (PHF20) transcription factor was shown to regulate p53 in response to UV 
induced DNA damage (Li et al., 2013). It was identified that lysine-specific demethylase 6B 
(Jmjd3) is a negative regulator of reprogramming, partially through its recruitment of TRIM26 
for Lys48 polyubiquitination and degradation of PHF20 that results in a reduction of Oct4 and 
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thus reducing reprogramming efficiency (Zhao et al., 2013). TRIM26 silencing resulted in an 
increase in PHF20 and Oct4 and subsequently resulted in an increase in the efficiency of iPSC 
reprogramming. It was also observed that in Jmjd3-/- MEF cells, PHF20 protein levels were 
significantly increased. Jmjd3-/- MEF cells displayed reduced senescence, apoptosis and 
increases cell proliferation which may be suggested to be due to disrupted Jmjd3-TRIM26 
interaction (Zhao et al., 2013). These findings may implicate TRIM26 in inhibition of 
pluripotency which may have important implications for pluripotent models of study 
including pluripotent cancer stem cells. 
TRIM26 has been implicated in the regulation of the cellular immune response. Ran et al 
(2016) demonstrated that TRIM26 regulated the immune response to RNA virus infection. It 
was shown by coimmunoprecipitation that TRIM26 interacted with Serine/threonine-protein 
kinase (TBK1) and nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) 
essential modulator (NEMO). In the absence of viral infection TRIM26 was associated with 
TBK1 and then NEMO post infection. It was also shown that TRIM26 enhanced interferon beta 
(IFN-β) protein levels in response to viral infection, which was ablated when mutating a 
conserved Cys (C31S) within the RING domain (Ran et al., 2016). Due to previous findings that 
NEMO can bind polyubiquitin chains, it was proposed that autoubiquitinated TRIM26 in 
complex with TBK-1 is recruited to facilitate TBK1-NEMO interaction in response to RNA virus 
infection (Husnjak and Dikic, 2012; Wang et al 2015b). However, counter to these findings of 
positive regulation of IFN-β, Wang et al. (2015b) demonstrated that TBK1 negatively regulates 
IFN-β production in TRIM26 transgenic mice. They suggested that this was through 
polyubiquitination and degradation of nuclear Interferon Regulatory Transcription Factor 3 
(IRF3) and the interaction serves as an innate protective mechanism against autoimmune 
disease (Wang et al., 2015b). Ran et al. (2016) suggested that this discrepancy was due to 
either the use of different model systems used in their investigations (HeLa, human acute 
monocytic leukemia (THP-1) and MEFs vs mouse peritoneal macrophages), or that high levels 
of TRIM26 affects the substrate specificity of TRIM26. Regardless, TRIM26 seems to have a 
role in an innate immune response modulating IFN-β.  
In support of a role in the immune response and providing link to a role in cancer, Lyu et al. 
(2018) revealed that TRIM26 downregulation and the single nucleotide polymorphism 
rs117565607_A were strongly associated with nasopharyngeal carcinoma (NPC) through the 
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inhibition of transcription factor transcriptional repressor protein ying and yang 1 (YY1) 
binding. Their investigation determined that low TRIM26 NPC samples displayed association 
with immune response genes. Validation was undertaken by TRIM26 RNAi in the human 
nasopharyngeal carcinoma cell line 2 (CNE2), NPC cell line and normal peripheral blood 
mononuclear cell lines. This resulted in consistent observation of the downregulation of 
nuclear factor kappa B subunit 2 (NFkB2), Interleukin 32 (IL-32), interferon regulatory 
transcription factor 7 (IRF7), cluster of differentiation 38 (CD38), and signal transducer and 
activator of transcription 1 (STAT1). This data suggested that TRIM26 downregulation through 
YY1 transcriptional processes results in a repressed immune response, increasing NPC risk 
(Lyu et al., 2018).  
Importantly, TRIM26 has been previously shown to be associated with transcriptional 
regulation through ubiquitination of the general transcription factor IDD (TFIID) sub-unit, 
transcription initiation factor TFIID subunit 7 (TAF7) in mouse epithelial cells. It was revealed 
that TGF-β mediated proliferative arrest, induced the transcription of TRIM26 and 
subsequently TAF7 degradation. Furthermore, sustained TGF-β exposure led to inhibition of 
TRIM26 induction via MYC through TRIM26 gene promotor binding. Thus, indicating that 
TRIM26, is a negative regulator of cellular proliferation through degradation of TAF7 with 
induction of TGF-β regulated cell cycle arrest and apoptosis. However, with MYC 
overexpression observed in many cancers, it was suggested that MYC may facilitate malignant 
evasion of this TRIM26 antiproliferative mechanisms through TAF7 degradation (Nakagawa 
et al., 2017). 
Previously, TRIM26 has been identified as a possible tumour suppressor in hepatocellular 
carcinomas, with significant correlation identified between low TRIM26 levels and poor 
prognosis in patients. In agreement with Nakagawa et al. (2017) it was also demonstrated 
that TRIM26 RNAi in hepatocellular carcinoma (HCC) cell lines HepG2 and Bel-7402 enhanced 
cancer cell migration, invasion and proliferation. It was also identified that TRIM26 levels are 
reduced in cholangiocellular carcinoma which display increased resistance to radiotherapy 
and chemotherapy, eluding to the role of TRIM26 dysfunction in cancer therapeutic 
resistance (Wang et al., 2015a). 
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In support of the possible role in which TRIM26 plays as a tumour suppressor and as 
previously discussed, TRIM26 RNAi has been demonstrated to provide significant resistance 
to IR and oxidative stress inducing agent H2O2 in U2OS and HCT116 cells, respectively. 
(Edmonds et al., 2017; Williams and Parsons, 2018). Taken together it may be proposed that 
TRIM26 dysfunction may be a common feature of cancer. Parsons’ group recently identified 
that one possible mechanism of resistance to radiotherapy and chemotherapy may be 
TRIM26 regulation of BER DNA repair proteins. NEIL1 and NTH1 were recently identified as 
substrates for TRIM26 ubiquitination and TRIM26 RNAi increased protein steady state levels 
of NEIL1 and NTH1 (Edmonds et al., 2017; Williams and Parsons, 2018). 
1.15. Use of bacterial hosts for protein expression. 
 
Bacterial expression vectors can facilitate the production of recombinant proteins for in vitro 
biochemical analysis (Brown, 2010). An example of a traditional vector is the bacterial DNA 
plasmid, independent of host chromosomal DNA and utilised for gene expression through 
plasmid design, plasmid DNA purification, restriction digestion, ligation and transformation 
(Brown, 2010). E. coli remains the most commonly used host system for recombinant plasmid 
DNA models of expression (Anderson and Krummen, 2002). 
1.15.1. The pET expression system. 
 
The pET vector system permits the inducible control of protein expression, in E. coli. This 
plasmid construct has transcription driven by T7 bacteriophage RNA DNA polymerase and T7 
promoter recognition, allowing a two-part gene expression (Novagen, 2005; Kesik-Brodacka 
et al., 2012).  
Rosetta (DE3) expression hosts for pET expression vectors possess a chromosomal copy of T7 
RNA DNA polymerase and ‘rare’ tRNA genes translated from a chloramphenicol-
resistant pRARE plasmid. These tRNA codons are AGG, AGA, AUA, CUA, CCC, GGA and the 
additional CGG codon in Rosetta 2 (DE3) hosts, supplementing the tRNA pool, for improved 
translation of heterologous genes. This is particularly useful if codon bias proves restrictive in 
protein expression (Novagen, 2004; Gou et al., 2009).   
T7 RNA DNA polymerase is expressed in the presence of IPTG, due to upstream inducible 
transcription by the lacUV5 promoter, providing a pool of T7 RNA DNA polymerase and 
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permitting T7 RNA DNA polymerase binding on the pET vector activating the T7 promoter, 
then transcription and translation of the encoded complementary DNA (cDNA; Figure 1.18; 
Novagen, 2005). This system is reported to yield target protein expression levels as high as 
50% of all the bacterial cellular proteins, producing a larger total target protein than 
alternative systems (Jevsevar et al., 2005; Novagen, 2005; Tegel et al., 2011).  
 
Figure 1.18: Plasmid vector map of the pETDuet1 expression vector developed for dual expression of two 
genes. Transcription vector map with sequence landmarks, including: T7 promoters, T7 terminator, 6xHistidine, 
multiple cloning sites (MCS-1/2), Ampicillin resistance gene (AmpR), Ribosomal binding site (RBS), repressor of 
primer (ROP), LacI gene (lacI), double-strand replication of origin (ori) and single-stranded replication of origin 
(F1 ori). 
The pET vector system offers the addition of fusion tags for protein detection via western blot 
and purification via affinity purification. The pET vector has been exploited to express and 
purify active NEIL proteins (Bandaru et al., 2002; Liu et al., 2012). However, hNEIL3 has proved 
difficult to express as an active full-length protein and warranted the modification of the pET-
based vectors (Krokeide et al., 2009; Gou et al., 2009; Liu et al., 2012).  
1.15.2. Construction and use of a bicistronic pET vector for hNEIL3 recombinant protein 
expression. 
 
Issues preventing active full amino acid sequence hNEIL3 expression were previously 
identified. The initiator methionine requires removal for translation of active eukaryotic 
proteins in E. coli (Liu et al., 2012). The formation of mRNA secondary structure was also 
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highlighted to hinder translation initiation (Gou et al., 2009). A bicistronic vector construct 
was subsequently developed by Gou et al. (2009) and Liu et al. (2012) using the pETDuet-1 
vector backbone (Figure 1.18). The construct includes an open reading frame 6 (ORF6), 
comprised of 15 amino acids from the N-Terminal of the maltose binding protein and a 
modified E. coli methionine amino peptidase (EcoMap; Gou et al., 2009; Liu et al., 2012). The 
ORF6 was found to improve ribosomal binding stability in the transcription initiation region 
of the hNEIL3 cDNA. This resulted in improved transcription efficiency through the prevention 
of secondary structure formation (Guo et al., 2009). EcoMap facilitated the removal of the 
translation initiator methionine present at amino acid position 1. This amino-peptidase 
proved critical for processing, increasing translation of active mouse and hNEIL3 glycosylase 
domain protein within E. coli (Liu et al., 2012). The dual expression of EcoMap and the hNEIL3 
DNA glycosylase domain within the bicistronic vector (Figure 1.19 B) was found to result in 
76% successful methionine processing and a yield of 44% active hNEIL3 glycosylase domain 
protein (Liu et al., 2012). However, the critical role that the NdeI site plays in the bicistronic 
plasmid construction conflicted with the NdeI restriction site located within hNEIL3 at 
nucleotide position 865 (Vincze et al., 2003; Liu et al., 2012). 
 
 
Figure 1.19: Linear vector maps of the modified pET vectors used in the construction of the pETDuet2-EcoMap-
ORF6 expression vector backbone. A: The pET30b intermediate vector ORF6 region, overlapping leader 
sequence for improved transcription of desired cDNA of interest. B: The bicistronic pETDuet2-EcoMap-ORF6-
construct for mouse NEIL3 and human glycosylase domain NEIL3 (taken from Liu et al., 2012). 
Using an in vitro cell free transcription and translation, inactive full amino acid sequence 
hNEIL3 was expressed using the TNT® Coupled Reticulocyte Lysate System (Krokeide et al., 
2009). The coupled reticulocyte initiates transcription and translation simultaneously, as E. 
coli normally would (Laursen et al., 2005). In a more recent article by Krokeide et al. (2013) a 
method was presented for active hNEIL3 glycosylase domain expression, within BL21-
CodonPlus (DE3)-RIL strain E. coli hosts that supplement the tRNA pool with rare codons, 
B. 
A. 
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similar to Rosetta cells. Partial cleavage of the initiator methionine was observed, in support 
of its requirement for active protein expression. The method used unusual incubation 
conditions of 16°C to express active protein (Krokeide et al., 2009; Krokeide et al., 2013). 
 
Previously in our laboratory the cDNA for the full length human NEIL3 (hNEIL3FL) and two 
cDNA truncations of 843 base pairs (bp; hNEIL3Cat) and 1044 bp (hNEIL3Trun; Figure 1.20) were 
cloned into the pETDuet2-EcoMap-ORF6 expression vector (Figure 1.19 B; Mustafa Albelazi, 
University of Salford; Liu et al., 2012). Using a pET30b vector to construct the ORF6 region in 
fusion with the hNEIL3 cDNA sequence (Figure 1.19 A) similar to that described by Gou et al. 
(2009). This was conducted with the aim to express and purify three versions of the hNEIL3 
protein, to biochemically characterise differences in activity due to the encoded conserved 
protein domains (Figure 1.20). Plasmid vector construction was achieved using NdeI and XhoI 
restriction endonuclease digestion to prepare the pETDuet2-EcoMap-ORF6 vector backbone, 
followed by mung bean nuclease digestion to remove the 5’ cohesive end at the NdeI 
restriction site within the vector, creating a blunt end (Desai and Shankar, 2003; Rittié and 
Perbal, 2008). Using the pET30b-ORF6-hNEIL3 vector as a template, polymerase chain 
reaction (PCR) was conducted to amplify ORF6 in fusion with the respective hNEIL3 DNA 
sequence (Figure 1.20). The PCR product was digested with XhoI and ligated into the 
pETDuet2-EcoMap-ORF6 backbone after agarose gel purification. The pETDuet2-EcoMap-
ORF6-hNEIL3 expression vectors were shown to actively express both EcoMap and hNEIL3 
simultaneously when induced with IPTG. Subsequently, the three version of the human 
hNEIL3 protein were previously expressed at 16˚C overnight using 1 mM IPTG and purified 
using a HisTrap HP affinity FPLC column and the ÄKTA prime FPLC system. hNEIL3FL required 
further purification via Mono S 5/50 GL ion exchange FPLC column and the ÄKTA prime FPLC 
system. Recombinant protein products were confirmed by SDS-PAGE and immunoblot 
analysis (Appendix Figure 1; Appendix Figure 2; Appendix Figure 3). The final hNEIL3 
recombinant protein products were stored at -80˚C for use as laboratory stocks. 
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Figure 1.20: Diagrammatic representation of the hNEIL3 conserved domains encoded by the cDNA cloned into 
the pETDuet2-EcoMap-ORF6 bicistronic expression vector. A. hNEIL3Cat 843 bp cDNA truncation encoding 281 
amino acids B. hNEIL3Trun 1044 bp truncation encoding 348 amino acids and C. hNEIL3FL 1818bp full length cDNA 









It is hypothesised that the DNA glycosylases hNEIL1 and hNEIL3, or mechanisms that 
modulate them, play a distinct and fundamental role in replication associated repair of DNA 
replication blocking lesions. The null hypothesis is that hNEIL1 and hNEIL3, or the mechanisms 
that modulate them, have no replication associated repair function of replication blocking 
lesions. 
The aims of the presented study are as follows: 
1. Determine the alternate activity profiles of recombinant hNEIL1 and hNEIL3 on ss-, ds- 
and model DNA replication fork structured oligonucleotides substrates possessing 
oxidative DNA lesions. 
2. To use psoralen/UVA treatment to generate MA, three-stranded and four-stranded 
ICL DNA substrates for the biochemical characterisation of replication blocking 
interstrand crosslink unhooking by hNEIL1 and hNEIL3. 
3. Successfully generate an expression vector, express and purify from E. coli a 
catalytically inactive truncated hNEIL3Cat protein for use as control. 
4. Characterise hNEIL1, hNEIL3 and catalytically inactive truncated hNEIL3 recombinant 
protein activity on psoralen/UVA generated DNA oligonucleotides. 
5. Conduct in vitro ubiquitination assays using previously generated HeLa cell extracts to 
identify post-translational modification of recombinant hNEIL3FL. 
6. Use E. coli to express and purify an identified E3 ubiquitin ligase to validate specificity 
of its function in post-translational modification of hNEIL3FL. 
7. Knockdown an identified E3 ubiquitin ligase in U2OS cells using RNAi, to assess the 
role it may play in cisplatin resistance and modulation of the hNEIL3 DNA glycosylase. 
8. Transiently overexpress NEIL1 and NEIL3 in U2OS cells to assess the role, if any, in 
cisplatin resistance.  
9. Generate a stable U2OS hNEIL3 knockout cell line using CRISPR/Cas9 for use as a 
model system for the future characterisation of DNA replication associated   
maintenance.




For the study of the DNA replication associated repair of DNA replication blocking lesions, 
previously generated active recombinant hNEIL3FL protein was used from laboratory stocks 
(Mustafa Albelazi, University of Salford: Appendix Figure 2; Appendix Figure 3) in addition to 
expressed and purified recombinant hNEIL1 and commercial Nei and Nth (New England 
Biolabs). These recombinant proteins were used for the biochemical characterisation of DNA 
glycosylase and associated AP lyase activity to determine distinct preferences for the 
processing of specific oxidative lesions or structural preferences within a model DNA 
replication fork oligonucleotide structure. The literature and obtained data prompted the 
further investigation of hNEIL1 and hNEIL3 unhooking activity in the presence of DNA 
substrates containing DNA replication blocking psoralen ICLs. Thus, a panel of ss-MA, three- 
and four-stranded oligonucleotide structures were generated for use as substrates in the 
comparative biochemical characterisation of hNEIL3Cat, hNEIL3Trun, hNEIL3FL proteins 
(Appendix Figure 1; Appendix Figure 2; Appendix Figure 3), hNEIL1 and Nei psoralen ICL 
unhooking activity. Site-directed mutagenesis, expression, purification from Rosetta 2 (DE3) 
E. coli expression hosts and confirmation through SDS-PAGE, Immunoblot and liquid 
chromatography mass spectrometry (LC-MS) proteomic analysis were conducted for the 
production of a catalytically inactive hNEIL3Cat-K81A for use in DNA glycosylase activity control 
assays. Kinetic analysis was also conducted in a comparative manner between hNEIL1 and 
hNEIL3Cat/Trun/FL proteins on oligonucleotides containing the Sp lesion in ss-DNA and ds-DNA 
context, then hNEIL1 and hNEIL3Cat on three- and four-stranded psoralen ICL oligonucleotide 
substrates.  
The investigation and characterisation of ubiquitin mediated PTM of hNEIL3FL through 
identification of a specific E3 ubiquitin ligase was undertaken, through sequential in vitro 
ubiquitination assays using previously generated FPLC purified HeLa cell fractions, 
recombinant E1 activating and E2 conjugating enzymes from laboratory stocks. The major E3 
ubiquitin ligase activity was determined to be facilitated by TRIM26 and was subsequently 
expressed and purified by HisTrap FPLC HP column FPLC from Rosetta 2 (DE3) E. coli 
expression hosts. The effect of cellular manipulation by RNAi of TRIM26 on hNEIL1 and hNEIL3 
protein levels in the cancer cell line U2OS was investigated through immunoblot in response 
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to the oxidising agent H2O2 and the ICL inducing agent cisplatin. In addition, the effect of 
TRIM26 RNAi, hNEIL1 and hNEIL3 overexpression on clonogenic survival of U2OS cells treated 
with cisplatin was examined.  Finally, generation of an U2OS NEIL3-/- cell line was undertaken 
through use of CRISPR/Cas9 and confirmed through anti-NEIL3 immunoblot screening of 
puromycin resistant U2OS cell extracts. 
2.1. Transformation of bacterial cloning and expression hosts. 
 
Plasmid DNA constructs were transformed into bacterial hosts for propagation and for 
recombinant protein expression. Transformation of pETDuet2-EcoMap-ORF6-hNEIL3FL, 
pET30a-hNEIL1 and pET28a-TRIM26 into Rosetta 2 (DE3) E. coli expression hosts were carried 
out by the heat shock method, as described in the pET expression system manual, for use in 
recombinant protein expression (Novagen, 2005). pETDuet2-EcoMap-ORF6-hNEIL3Cat-K81A 
was transformed by electroporation into Nova XG cloning host cells and Rosetta 2 (DE3) 
expression host cells for recombinant protein expression. For electroporation, 20 μl of cell 
solution was pipetted into an electroporation cuvette, 2 μl of plasmid DNA (1-50 ng/ µl) was 
added to the cell solution and mixed. Cells were electroporated using the Nucleofector® II 
(Lonza) and transferred to 200 μl of SOC medium (2% tryptone, 0.5% yeast extract, 10 mM 
NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, and 20 mM glucose). Cells were then 
incubated for 60 min at 37°C and 180 rpm for an 1 h outgrowth period. For the propagation 
of transient mammalian expression vectors pCMV-hNEIL1-Tag3a, pCMV-ac-hNEIL3 and 
CRISPR/Cas9 plasmid vectors (pCas-Guide-gRNA1/2 and pUC-Donor), cells were transformed 
via the heat shock method into dH5a chemically competent cells (ThermoFisher). Initially, 1 
μl of 1-10 ng/µl of plasmid DNA was mixed with 50 µl of dH5a cells and placed on ice for 30 
min. Then, the plasmid cell mix was incubated for 45 s at 42˚C. Subsequently, the plasmid cell 
mix was placed on ice for 2 min, then 950 µl of LB broth was added and then incubated at 
37˚C for 1 h at 220 rpm. The competent cells were then plated on LB-agar antibiotic selective 
plates and incubated overnight at 37˚C. Single colonies were then selected for upscaling. 
Colonies were picked with a sterile 1-10 µl pipette tip which was then placed in 4 ml antibiotic 
selective LB-Broth. The 4 ml culture was then incubated at 37˚C at 220 rpm. 
For the propagation of plasmid vectors containing the antibiotic resistant gene for ampicillin, 
50 µg/ml was used. For kanamycin resistance, 34 µg/ml was used. For recombinant protein 
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expression 30 µg/ ml chloramphenicol was used for selection of the pRARE plasmid contained 
with Rosetta 2 (DE3) expression hosts. 
2.2. Recombinant protein expression of hNEIL1, hNEIL3 and TRIM26. 
 
For the expression of recombinant hNEIL1, hNEIL3FL and TRIM26 recombinant proteins in E. 
coli, the bacterial expression vectors pET30a-hNEIL1, pETDuet2-EcoMap-ORF6-hNEIL3FL and 
pET28a-TRIM26 were transformed via the heat shock method into Rosetta 2 (DE3) expression 
hosts. For antibiotic selection of expression vectors 50 µg/ml kanamycin antibiotic selection 
(pET30a-hNEIL1, pET28a-TRIM26) or 100 μg/ml ampicillin (pETDuet2-EcoMap-ORF6-hNEIL3FL) 
were used throughout. Cells were selected for on LB-agar plates containing the relevant 
antibiotic selection, with the addition of 30 µg/ml chloramphenicol and incubated at 37˚C 
overnight. For the expression of each recombinant protein a colony was chosen for culture 
growth and transferred from LB-agar plates to 4 ml LB broth containing the relevant 
antibiotics selection. Cultures were incubated overnight at 37˚C at 220 rpm. Then 400 µl of 
bacterial culture was transferred to each of three 40 ml LB broth cultures containing the 
relevant antibiotic selection, 30 μg/ml chloramphenicol and 0.1% glucose. The culture was 
then incubated at 37˚C at 220 rpm. The culture was monitored for growth with use of a 
spectrophotometer, where optical density (O.D) was measured at a wavelength of 600 nm 
and blanked using LB broth. When a 40 ml culture reached an O.D600 of 0.6-0.8, the total 
volume of the culture was transferred to 400 ml LB broth containing the relevant antibiotic 
selection and 0.1% glucose, then incubated at 37˚C and 220 rpm. The growth was monitored 
and at an O.D600 of 0.6-0.8, the cultures were induced by the addition of 1 mM IPTG. Cultures 
containing cells possessing the pET30a-hNEIL1 and pETDuet2-EcoMap-ORF6-hNEIL3FL 
expression vectors were subsequently incubated at 16˚C at 220 rpm for 20 h, whereas those 
containing the pet28a-TRIM26 expression plasmid were incubated for 3 h at 30°C. 
Each culture was then harvested by centrifugation for 10 min at 8000 rpm. Cultures that had 
been induced for expression of the same recombinant protein were resuspended in 10 ml LB 
broth and pooled by transferring to a 50 ml tube. Then, the cell suspension was centrifuged 
at 5000 rpm at 4˚C for 20 min. Excess LB broth was discarded and the Rosetta 2 (DE3) cell 
pellet was stored at -80˚C for downstream recombinant protein purification and to aid in cell 
lysis by the action of freezing and thawing.  
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2.3. Bacterial cell lysis. 
 
For the extraction of bacterial whole cell soluble protein content, previously prepared and 
induced Rosetta 2 (DE3) expression host cell pellets were thawed to room temperature to 
commence cell lysis. Bacterial cell pellet was then resuspended in lysis buffer (25 mM Tris-HCl 
pH 8, 500 mM NaCl, 5% glycerol, 5mM imidazole, 1 µg/ml Leupeptin, chemostatin, pepstatin 
a, aprotinin and 100 µM phenylmethylsulfonyl fluoride (PMSF)). The bacterial cell suspension 
was then ultrasonicated at 40% amplitude with 3 x 30 s bursts with 30 s intervals between 
each burst. The crude cell lysate was then centrifuged at 25,000 rpm for 20 min to facilitate 
separation of soluble cell lysate and insoluble cell contents. The cell lysate was then 
sequentially syringe filtered through a 1 µm, 0.44 µm and a 0.22 µm syringe filter, facilitating 
the removal of high molecular weight cell components. The filtered cell lysate was then stored 
on ice for immediate purification by FPLC chromatography using the ÄKTA prime FPLC system 
(GE healthcare). 
2.4. HisTrap HP column affinity purification. 
 
For the purification of hNEIL1, hNEIL3FL and TRIM26 C-terminal 6x Histidine tagged 
recombinant proteins, purification by use of a 1 ml HisTrap HP column was undertaken. The 
FPLC buffer pumps A and B were initially washed with dH2O using the pump wash basic input 
to remove the 20% ethanol in which the system is stored in. Subsequently, the 1 ml HisTrap 
HP column was attached to the FPLC system and washed with 3 column volumes of dH2O to 
remove storage buffer. The pump wash basic protocol was then repeated with the use of 
buffer A (25 mM Tris-HCl pH 8.0, 500 mM NaCl, 5% glycerol, 5mM imidazole and 100 µM 
PMSF), followed by washing the HisTrap HP column with 3 column volumes of buffer A. 
Previously prepared bacterial cell lysate was then transferred to a 50 ml superloop previously 
rinsed with buffer A. The superloop was then connected to the HisTrap HP column and the 
Rosetta 2 (DE3) expression host cell lysate was loaded on to the HisTrap HP column at a flow 
rate of 0.5 ml/min. The flow through was collected simultaneously. After the bacterial cell 
lysate was loaded on to the column, the superloop was disconnected and the HisTrap HP 
column was washed with 10 ml buffer A to facilitate the removal of non-specifically bound 
protein. Then, a 20 ml linear gradient between buffer A and buffer B (25 mM Tris-HCl pH 8.0, 
500 mM NaCl, 5% glycerol, 500mM imidazole and 100 µM PMSF) at a flow rate of 0.5 ml/ min 
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was undertaken, with the system set to elute fractions of 0.5 ml. The FPLC chromatogram was 
monitored, to determine elution of protein based on UV absorbance at 280 nm.  
Fractions which displayed evidence of protein elution based on the FPLC chromatogram were 
collected and transferred to 1.5 ml microcentrifuge tubes. Five microliters of each fraction 
were prepared for analysis by mixing with 5 µl 3x SDS loading dye (75 mM tris-HCl pH 6.8, 
7.5% β- mercaptoethanol, 3% SDS, 30% glycerol, 0.15mg/ml bromophenol blue, 3 mM 
Ethylenediaminetetraacetic acid (EDTA)) and 5 µl dH2O. Samples were then incubated for 5 
min at 95˚C and then analysed by SDS-PAGE. 
2.5. SDS-PAGE gel preparation.  
 
For the electrophoretic separation of proteins in a sample by electrophoresis sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was conducted. SDS gels were 
produced by initially preparing a separating gel master mix of appropriate volume for the 
number of gels required (Table 2.1; Table 2.2). The separating gel mix was then poured into 
a gel cassette (Novex) to fill ~3/4 of the cassette volume. Then, the separating gel was overlaid 
with 1 ml 100% ETOH to remove remove air bubbles and provide a level edge to the gel. The 
gel was then incubated for 30 min at room temperature to facilitate gel casting. 
The 100% ETOH was then removed and the gel cassette was rinsed with dH2O. A 5% stacking 
gel master mix, of appropriate volume for the required number of gels, was then prepared 
(Table 2.1; Table 2.2) and poured into the inner chamber on top of the separating gel. A well-
comb (10/15 wells) was then inserted and the gel was incubated for a further 30 min at room 
temperature. Once cast, the gel was wrapped in blue paper roll, soaked in dH2O, then placed 
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Table 2.1: SDS-PAGE gel mixtures for preparation of 8% SDS-PAGE gels. The volumes indicated are for the 
production of two SDS-PAGE gels. The separating gel was prepared and cast in advance of the stacking gel. Once 
stacking gel was poured a 10-well 15-well 1.5 mm width comb was inserted to facilitate well generation. 
 
Table 2.2: SDS-PAGE gel mixtures for preparation of 10% SDS-PAGE gels. The volumes indicated are for the 
production of two SDS-PAGE gels. The separating gel was prepared and cast in advance of the stacking gel. Once 


















 5% stacking gel 8% separating gel 
Reagent stock Volume (ml) Volume (ml) 
1M Tris HCl 1.25 (pH 6.8) 7.54 (pH 8.8) 
10% SDS 0.1  0.2  
0.5 M EDTA 0.040  0.080  
Acrylamide (30:0.8) 1.66  5.33  
dH2O 6.88  6.71  
APS 0.100  0.200  
TEMED 0.010  0.020  
Total volume (ml) 10 20 
 5% stacking 10% separating 
Reagent stock Volume (ml) Volume (ml) 
1M Tris HCl 1.25 (pH 6.8) 7.54 (pH 8.8) 
10% SDS 0.1  0.2  
0.5 M EDTA 0.040  0.080  
Acrylamide (30:0.8) 1.66  6.66  
dH2O 6.88  5.38  
APS 0.100  0.200  
TEMED 0.010  0.020  
Total volume (ml) 10 20 




For the analysis of whole cell extract (WCE) proteins or fractions prepared through FPLC 
purification, SDS-PAGE analysis was undertaken. An SDS-PAGE gel was prepared in advance 
and as described in section 2.5. Samples were prepared in 1x SDS loading dye (25 mM tris-HCl 
(pH 6.8), 2.5% β-mercaptoethanol, 1% SDS, 10% glycerol, 0.05mg/ml bromophenol blue, 1 
mM EDTA) and incubated at 95°C for 5 minutes. A gel stored at 4°C was unwrapped and the 
well comb was removed. The gel was then rinsed thoroughly with dH2O and placed in a SDS-
PAGE Mini Gel Tank (ThermoFisher), assembled according to manufacturer’s instructions. The 
inner and outer chamber were then filled with 1 x tris-glycine SDS (TGS; 25 mM Tris-HCl pH 
8.3, 192 mM glycine, 0.1% SDS). Samples were then loaded into the SDS-PAGE gel wells, 
starting at the second well, followed by loading 2 µl of All Blue Prestained Protein Standard 
(BioRad) or 3 µl PageRuler Prestained protein Ladder (ThermoFisher), in the first well of the 
gel. This was to prevent diffusion of the protein marker stain into the gel prior to 
electrophoresis. The Mini Gel Tank lid was attached, then connected to a powerpack and 
electrophoresis was commenced at 125 V for 120 min.  
2.7. Western-blot transfer. 
 
After electrophoretic separation of protein samples by SDS-PAGE as described in 2.6, transfer 
of proteins to Immobilon®-FL polyvinylidene difluoride (PVDF) membrane (Merk) was 
conducted, in preparation for immunoblotting. The SDS-PAGE Mini Gel Tank (ThermoFisher) 
and gel were rinsed thoroughly in dH2O. The Immobilon®-FL PVDF membrane was activated 
by rinsing in 100% methanol for 15 s, then cold dH2O for 1 min and finally >1 min in cold 
transfer buffer (20% Methanol, 1x TG (25 mM Tris-HCl pH 8.3, 192 mM glycine). Two transfer 
sponges and two pieces of filter paper, were soaked in the transfer buffer for >1 min. The 
SDS-PAGE gel was then removed from the cassette and briefly rinsed in transfer buffer. The 
western blot transfer sandwich was then prepared in a Mini Blot Module (ThermoFisher; 
Figure 2.1). During assembly excess air was removed from the sponges and the area of contact 
between the filter paper, gel and PVDF membrane stack, using a western blot roller. The blot 
module was then closed, transferred to the Mini Gel Tank and the inner chamber of the Mini 
Blot Module was filled with cold transfer buffer. The outer chamber of the Mini Gel Tank was 
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filled with cold dH2O, the lid then closed, then attached to a powerpack and transfer was 
conducted by supplying 20 V for 60 min.  
 




For the probing of specific proteins present in a sample, immunoblot analysis was conducted. 
After western blot transfer, the Mini Blot module was unassembled and the PVDF membrane 
was transferred to a western blot incubation box (Licor) and rinsed for 5 min in 1 x phosphate-
buffered saline (PBS) to remove acrylamide residue. Then the PBS was discarded and 8 ml of 
Odyssey blocking buffer:PBS (Licor) was applied and incubated at room temperature for >1 h 
with rocking at 26 rpm. The blocking buffer was then discarded and 8 ml of Odyssey blocking 
buffer:PBS (Licor) diluted in 1x PBS at a 1:1 ratio and containing 0.1% Tween-20 with the 
relevant dilution of primary antibody, was then applied to the membrane and incubated 
overnight at 4°C with rocking at 26 rpm (Table 2.3). The membrane was rinsed three times 
for 5 min each with 10 ml 1x PBS, 0.1% TWEEN-20 and then 8 ml Odyssey blocking buffer:PBS, 
diluted in 1x PBS at a 1:1 ratio,  containing 0.1% Tween-20 and the relevant dilution of 
secondary antibody was applied to the membrane and incubated at room temperature for 1 
h with rocking at 26 rpm (Table 2.4).The membrane was then rinsed three times for 5 min 
each with 10 ml 1x PBS, 0.1% TWEEN-20, followed by one 5 min wash with 1x PBS. The 
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membrane was then imaged and quantified using the Licor Odyssey Infrared scanner system 
and analysis tool. 
For analysis of recombinant hNEIL3Cat-K81A, immunoblot analysis was conducted using iBlot 2 
Nitrocellulose Regular Stacks (ThermoFisher), with the membrane substituted for methanol 
activated PVDF membrane, for protein transfer using the iBlot 2 dry blotting system 
(ThermoFisher). PVDF membrane was incubated overnight at 4°C in primary rabbit polyclonal 
anti-NEIL3 (Proteintech) antibody and 1-2 hours at room temperature with secondary donkey 
IgG anti-rabbit antibody (Sigma), respectively. Chemiluminescence was induced with 
SuperSignal West Pico stable peroxide solution and SuperSignal West Pico Luminol enhancer 
Solution (ThermoFisher scientific). The membrane was imaged using the Amersham Imager 
600 (GE healthcare). 
Table 2.3: Primary-antibodies used in this study for probing of specific proteins. Host-organism, clonality and 
dilution ratio displayed. 
Primary antibody Host-Organism Clonality Dilution ratio 
Anti-HisTag (Abcam) Mouse Mono-clonal 1:1000 
Anti-NEIL1 (Thomas 
Rosenquist) 
Rabbit Poly-clonal 1:500 
Anti-NEIL3 
(ProteinTech) 
Rabbit Poly-clonal 1:5000 
Anti-actin (Abcam) Mouse Mono-clonal 1:20000 
Table 2.4: Secondary-antibodies used in this study for probing of primary-antibodies. Host-organism, 
clonality and dilution ratio displayed. 
Primary antibody Host-Organism Target Isotype Dilution ratio 
Alexa Fluor 680 Anti-
Mouse (Invitrogen) Goat IgG 1:10000 
IR Dye 800 Anti-Mouse 
(Li-Cor) Goat IgG 1:10000 
Alexa Fluor 680 Anti-
Rabbit (Invitrogen) Goat IgG 1:10000 
IR Dye 800 Anti-Rabbit 





Donkey IgG 1:5000 
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2.9. Generation of model replication fork structured oligonucleotide substrates. 
 
For use in DNA glycosylase activity assays, ss-, ds- and DNA replication fork structured 
oligonucleotide DNA substrates were prepared. For the preparation of a ss oligonucleotide 
DNA substrate 1 µl of 10 µM 5ʹ-fluorescently labelled oligonucleotide, 8 µl 5 M NaCL and 191 
µl TE buffer were mixed. For the generation of ds and model DNA replication fork structured 
oligonucleotide substrates 1 µl of 10 µM 5ʹ-fluorescently labelled oligonucleotide, 1.5 µl of 
unlabelled complementary oligonucleotide, 8 µl 5 M NaCL and 189.5 µl TE buffer were mixed. 
DNA oligonucleotide mixtures containing labelled and complementary oligonucleotides were 
incubated at 95°C for 3 min in a heat block, then the heat block was turned off and allowed 
to cool slowly to room temperature, facilitating annealing of complementary 
oligonucleotides. The 5ʹflourescently labelled oligonucleotide contained one of three 
modified bases, either a 5-OHU, 8-OxoG or a Tg lesion. Excision of the modified base by DNA 
glycosylase activity followed by associated AP lyase activity would be visualised by 
electrophoretic separation and imaging. The 5ʹ-fluorescent tag for the 5-OHU containing 
oligonucleotide was Alexa Flour 680. The 5ʹflourescent tag for the 8-OxoG and Tg containing 
oligonucleotide was IR Dye 700. The complementarity of the complement oligonucleotide 
sequence was altered to facilitate the generation of uncomplemented regions of DNA to 
produce a model DNA replication fork structured oligonucleotide substrate after annealing. 
These substrates were termed ‘-4’, ‘Fork’ and ‘+4’, where the name denoted the position of 
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Table 2.5: DNA Oligonucleotide sequences and model DNA replication fork oligonucleotide structures used in 
BER assays. ‘X’ denotes the position of the 5-OHU, 8-OxoG and Tg oxidative DNA lesions. DNA substrates are 39 
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2.10. Radioactive labelling of DNA oligonucleotide substrates. 
 
For use in enzymatic assays, oligonucleotides were radioactively labelled with the phosphorus 
isotope 32P. A reaction mixture of  1 µM of oligonucleotide was incubated at 37°C for 40 min 
in 1x polynucleotide kinase buffer (PNKP buffer A (ThermoFisher)), 10 units of polynucleotide 
kinase (PNKP; ThermoFisher), 1 µl Ɣ 32P ATP and sterile dH20 to the final reaction volume of 
30 µl was prepared. The reaction was then desalted by preparing a spin column from a 0.5 ml 
microcentrifuge tube pierced with a sterile needle and placed in a 2 ml microcentrifuge tube, 
400 µl of G25 sedaphex dissolved in dH20 was then added to the 0.5 ml tube and the column 
was centrifuged for 2 min at 4000 rpm. The 2 ml microcentrifuge tube containing the flow 
through was discarded. The spin column was then transferred to a 1.5 ml microcentrifuge 
tube, then the labelled oligonucleotide sample was loaded on the spin column and 
centrifuged for 3 min at 4000 rpm, to facilitate the removal of excess Ɣ 32P ATP. The labelled 
oligonucleotide in the flow through was then stored at -20°C under appropriate radioactive 
protection conditions.  
2.11. Annealing of DNA oligonucleotide substrates. 
 
Complementary synthetic oligonucleotide substrates were selected based upon the DNA 
lesions they would harbour once annealed (Appendix Table 1). Annealing of oligonucleotides 
was achieved with the addition of complement non-labelled oligonucleotides at a molar ratio 
of 1:1.2 of 5ʹƔ 32P labelled to complement oligonucleotide, in 20 mM KCl and 10 mM HEPES-
KOH pH 7.6. Samples were then incubated at 95°C for 5 minutes to facilitate denaturing and 
gradient cooled at -0.5°C/30 s for up to 160 cycles in a thermocycler, unless otherwise stated. 
Products were stored at -20°C, until required for use in enzymatic assays. 
2.12. Psoralen induced DNA interstrand crosslinked oligonucleotide generation. 
 
Annealed complementary DNA oligonucleotides containing a single 5’-TpA-3’ site were 
incubated at room temperature in the dark with 500 nM HMT or 8-MOP dissolved in ~100% 
chloroform. Reaction mixtures were then transferred to a small petridish lined with Parafilm 
and irradiated at 365 nm and 240 kJ/m2 for 30 min (HMT) or 60 min (8-MOP) on ice. After 
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irradiation the final volume was adjusted to 100 µl with dH2O. Samples were then collected 
and stored at -20°C under radioactivity safe conditions until required for use in enzymatic 
assays or further construct preparation and analysis. 
2.13. Denaturing PAGE. 
 
To analyse DNA oligonucleotide substrate cleavage resulting from the DNA glycosylase and 
AP lyase activity of recombinant proteins or ICL generation and separation under denaturing 
conditions, denaturing PAGE was carried out.  
For 10% denaturing PAGE analysis, denaturing PAGE gel mixture (16.8 g of Urea, 10 ml of 40% 
Bis-Tris acrylamide, 8 ml of 5 x tris-borate EDTA (TBE) buffer (450 mM Tris-borate pH 8.3, 10 
mM EDTA) and made to a final volume of 40 ml with dH2O) was prepared and incubated at 
37˚C for 30 min. Then two glass plates were assembled with two 1.5 mm gel casting spacers 
and placed in the casting position in a SE400 electrophoresis unit (Hoefer). At this stage, 250 
µl of 10% APS was added to the denaturing PAGE mixture and vortexed, followed by the 
addition of 20 µl tetramethylethylenediamine (TEMED) and then mixed using a vortex. 
The 10% denaturing PAGE mixture was then poured between the glass plates and a 10-well 
1.5 mM well comb was placed between the plates. The gel was left to cast at room 
temperature for 45 min. Then, the gel comb was removed, and the wells were rinsed with 
dH2O. The gel was then pre-ran for 30 min at 300 V in 1x TBE. Samples containing fluorescently 
labelled oligonucleotides were prepared by the addition of 5 µl 99% formamide/1% 
bromophenol blue and incubated at 95˚C for 5 min. Samples were then loaded and separated 
by electrophoresis for 1 h 45 min at 300 V. The gel was then removed and imaged using the 
Odyssey infrared scanner (Licor). 
For 20% denaturing PAGE the PROTEAN II xi (BioRad) PAGE glass plate sandwich was 
assembled using a 20 cm x 20 cm inner and 22.3 cm x 20 cm outer glass plates, two 1.5 mm 
gel spacers and two sandwich clamps (BioRad). The glass plate sandwich was laid flat on a 
level surface with the aid of a spirit level. The 20% denaturing PAGE gel mix was prepared in 
a 50 ml tube (Table 2.6). 
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Table 2.6: Denaturing PAGE gel mixture for preparation of a 20% denaturing PAGE. The volumes indicated 
are for the production of one denaturing page gel.  
 20% denaturing PAGE gel 
Reagent stock Volume (ml) 
~21.17% Bis-Tris acrylamide/7.5 M Urea mix 28.5 
10x Tris Borate EDTA (TBE) 1.5 
20% Ammonium persulfate (APS) 0.15 
TEMED 0.015 
Total volume (ml) 30.165 
 
The solution was vortexed to mix and slowly pipetted between the glass sandwich plates, 
preventing formation of air bubbles by tapping the glass plates. A 20 well 1.5 mm comb was 
then inserted at the top of the glass plate sandwich and incubated at room temperature 
between 45 min to 1 h, to facilitate casting. The well comb was then removed, and the wells 
washed using sterile dH2O. The wells were then dried by swinging the sandwich in a 
downward motion to expel excess dH2O. The cassette was then attached to the Protean II xi 
electrophoresis tank cooling core, connected to a water bath at 42°C, with a buffer dam 
attached and was then placed into the inner chamber of the tank containing 0.5x TBE buffer. 
The inner chamber between the gel sandwich cooling core and buffer dam was filled with 0.5x 
TBE buffer. Electrophoresis was then conducted at 600 V for 1 h, to homogenise the urea in 
the gel. Samples were then loaded, and electrophoretic separation was commenced at 600 V 
for 2 h.  
After, the gel was removed from the tank and the outer glass plate was removed. The 
denaturing PAGE was wrapped in cellophane and subsequently exposed to a phospho-screen 
and imaged using the Typhoon FLA 9500 scanner (GE healthcare). 
2.14. Non-denaturing PAGE. 
 
To analyse DNA constructs under native conditions, a 5% non-denaturing PAGE was carried 
out. The glass plate sandwich was assembled as described in Section 2.13. The 5% non-
denaturing gel solution was prepared in a 50 ml tube (Table 2.7). 
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Table 2.7: Non-denaturing PAGE gel mixture for preparation of a 5% denaturing PAGE. The volumes indicated 
are for the production of one denaturing page gel. 
 5% non-denaturing PAGE gel 
Reagent stock Volume (ml) 
40% Bis-Tris Acrylamide 6 
10 x Tris-glycine (TG) 3 
20% Ammonium persulfate (APS) 0.15 
TEMED 0.014 
dH2O 20.85 
Total volume (ml) 30.014 
 
The solution was vortexed and pipetted between the inner and outer glass plates, preventing 
formation of air bubbles by tapping the glass plates. A 20 well 1.5 mm comb was then inserted 
at the top of the glass plates and was incubated at room temperature for between 1-2 h, to 
facilitate casting. The well comb was then removed, and the wells were rinsed using sterile 
dH2O. The wells were then dried by swinging the cassette in a downward motion to expel 
excess dH2O. The cassette was then inserted into a PROTEAN II xi electrophoresis tank at 4°C, 
and the inner chamber was filled with 1x Tris-glycine (TG). Gel electrophoresis was ran for 2 
h at 80 V, to remove excess ammonia persulfate ions and unpolymerised acrylamide in the 
gel. Samples were prepared with 6 µl 80% glycerol, 1x DNA gel loading dye (ThermoFisher) 
and varying volume of DNA oligonucleotide constructs that were adjusted to an equivalent 
radioactivity count using a Geiger-Muller counter. Electrophoresis was commenced at 80V, 
samples were then loaded and separated for a further 12 h.  
After, the gel sandwich was taken out of the tank and one of the glass plates was removed. 
The non-denaturing PAGE was wrapped in cellophane, then exposed to a phospho-screen and 
imaged using the Typhoon 9500 scanner. 
2.15. Single stranded mono-adducted oligonucleotide generation. 
 
The oligonucleotides R18 and D21 (Appendix Table 1) were annealed and crosslinked as 
previously described in Sections 2.11 and 2.12 . The product was then digested with 10 units 
of RNase A (ThermoFisher) in 1 x RNase A reaction buffer (ThermoFisher) at 37°C for 20 h. The 
subsequent product was then purified from denaturing PAGE. 
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2.16. Oligonucleotide purification from 20% denaturing PAGE. 
 
For the purification of ICL duplex DNA oligonucleotides, 105.3 pmol was separated by 10% 
denaturing PAGE. After, the gel was exposed to an X-ray film (Fujifilm) for 10 min in the dark. 
The film was then developed using an X-Ray developer. Bands corresponding to ICLs were 
then cut out from the film to generate a template. The template film and sterile scalpels were 
used to excise polyacrylamide strips containing the ICL DNA bands. The polyacrylamide gel 
strips were incubated in a 2 ml microcentrifuge tube in 170 µl of dH2O overnight at 37°C and 
600 rpm. Then, 1400 µl of 2% LiClO4 was added to the 170 µl of dH2O in a separate 2 ml 
microcentrifuge tube. The samples were then incubated at -20°C overnight. Then the samples 
were centrifuged at 20000 xg for 10 min. The supernatant was removed and 200 µl of 100% 
ETOH was added to each sample and centrifuged for 5 min at 20000 xg. The supernatant was 
removed and 200 µl of 70% ETOH was added to each sample and centrifuged for a further 5 
min at 20000 xg. Then the supernatant was discarded and the samples were incubated for ~1 
h at room temperature to facilitate evaporation of excess ETOH, leaving behind the DNA 
precipitate. The DNA ICL precipitate was then re-suspended in 50 µl of dH2O, mixed and 
incubated at -20°C under appropriate radioactivity safe conditions. A Geiger-Muller counter 
was used to record radioactivity before and after purification for the calculation of the 
approximate concentration of duplex DNA ICL oligonucleotide purified. Purified samples were 
subsequently used for further DNA ICL structure construction. 
2.17. Three-stranded and Four-stranded DNA ICL construction. 
 
After the purification of the duplex DNA ICL oligonucleotide from 10% denaturing PAGE, 
complementary non-labelled DNA to the larger oligonucleotide strand in the ICL substrate, 
was added at an approximate molar ratio of 1:1.2 of ICL to complement oligonucleotide. The 
reaction mix was incubated at 95°C for 5 min and gradient cooled at -0.5°C/30 s for up to 160 
cycles using a thermocycler. This facilitated the annealing of the complementary strand to the 
ICL construct, effectively flipping out the ICL at the side of the smaller oligonucleotide, 
creating a three-stranded ICL structure mimicking the repair intermediate generated during 
FA pathway initiated repair of an ICL (Figure 1.10; Figure 2.2). For the generation of four-
stranded DNA ICL oligonucleotide substrates, an oligonucleotide complementary to the small 
oligonucleotide strand, ‘flipped out’, was added at an approximate molar ratio of 1:1.2 of 
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three-stranded ICL oligonucleotide to complementary oligonucleotide (Figure 2.2). The 












Figure 2.2: Schematic representation of three-stranded and four-stranded DNA ICL oligonucleotide substrate 
generation. ‘*’ denotes the position of Ɣ 32P labelling. 
Confirmation of three-stranded and four-stranded DNA ICL substrates was carried out by 10% 
denaturing page and 5% non-denaturing PAGE analysis. The gel was exposed to a 
phosphoscreen overnight and imaged using the Typhoon FLA 9500 scanner. Oligonucleotide 
structures were stored at -20°C under radioactivity safe conditions. 
2.18. DNA glycosylase cleavage assay. 
 
To analyse enzymatic activity of hNEIL3Cat, hNEIL3Trun, hNEIL3FL, hNEIL1 and Nei, cleavage 
assays were undertaken. DNA glycosylases were diluted to working concentration in RDWB 
buffer (25 mM HEPES pH 7.9, 100 mM KCl, 12 mM MgCl2, 1 mM EDTA, 17% glycerol and 2 
mM DTT) and were incubated with 5 nM of 5'fluorescently labelled oligonucleotide DNA 
substrate for 1 h at 30 °C in the reaction mixture 40 mM HEPES pH 7.8, 5 mM MgCL2, 0.1 mM 
EDTA, 0.5 mM DTT, 2 mM ATP, 0.1 mg/ml BSA in a final volume of 10 µl. Reactions were 
stopped with the addition of 100% formamide/bromophenol blue and analysed by 10% 
denaturing-PAGE and subsequently imaged using the Odyssey infrared imaging system 
(Licor). 
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Previously prepared oligonucleotides labelled with 32P, containing ICL DNA lesions, were 
incubated with reaction specific concentrations of enzyme, diluted in RDWB buffer and 1x 
reaction buffer (25 mM HEPES-KOH- KOH pH 7.6, 100 mM KCl, 1 mM EDTA, 1 mM DTT and 
100 µg/ml bovine serum albumin (BSA)) for 30-60 min at 37°C. Reactions were stopped either 
by the addition of 0.2% SDS and 4 mM EDTA or were incubated for a further 30 min at 37°C 
in the presence of 10% piperidine, to cleave AP sites through β-elimination (light piperidine 
treatment; Couvé-Privat et al., 2007; Couvé et al., 2009). The reaction was then stopped with 
the addition of 20 mM EDTA and neutralised with 40 mM HCl. For size marker controls 10 nM 
D21-U and C47-U oligonucleotides were incubated with 10 nM UDG from laboratory stocks 
for 10 min at 37˚C. The product was then incubated with 10% piperidine for 30 min at 37˚C 
and then 20 mM EDTA was added and the reaction was neutralised with 40 mM HCl to 
generate an 8/23PAmer cleavage product processed through β-elimination. Alternatively, the 
UDG incubation product was incubated with 10% piperidine and incubated at 95˚C for 5 min 
to facilitate the generation of an 8/23Pmer cleavage product processed through β,δ-
elimination (hot piperidine treatment). Finally, UDG incubation product was alternatively 
incubated with 20 nM of recombinant Nfo from laboratory stocks at 37˚C for 15 min, to 
generate an 8/23OHmer cleavage product. This facilitated the generation of a panel of size 
marker controls for comparison with hNEIL1, hNEIL3 and Nei cleavage products. 
Samples were then desalted using a spin column prepared by piercing a 0.5 ml tube with a 
syringe needle, then placed in a 2 ml tube. Then, 400 µl of G25 sedaphex dissolved in 7.5 M 
urea/ bromophenol blue was added and the tube centrifuged for 2 min at 4000 rpm, the flow 
through was subsequently discarded. The spin column was then transferred to a 1.5 ml tube 
and the enzymatic assay product was loaded on the column and centrifuged for 3 min at 4000 
rpm. The product was then analysed by 10% denaturing PAGE.  
2.19. Kinetic analysis of hNEIL1 and hNEIL3 recombinant proteins. 
 
To study the kinetics of hNEIL3 and hNEIL1 dependent DNA lesion substrate cleavage, 
comparative time course assays were undertaken in the presence of 10 nM of the DNA 
substrate Sp1 in ss-DNA and ds-DNA context. Then, in the presence of ~10 nM of XL47 • 47 - 
21* and XL47 • 47 - 21* • 21 ICL DNA substrates using hNEIL3Cat and hNEIL1. Enzyme 
concentrations were titrated and analysed with the use of ImageGuage V4.0 (Fujifilm) to 
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select an appropriate enzyme concentration over a range of 5-500 nM, within the linear range 
of the retrieved data.  
Subsequently, reactions were carried out as described in section 2.18, however time course 
and DNA glycosylase concentrations were adjusted based on the DNA glycosylases and the 
oligonucleotide substrate used. Reaction samples were stopped as described in section 2.18 
and analysed by 20% denaturing PAGE as described in Section 2.13. Typhoon 9500 scanner 
images were then analysed with use of ImageGuage V4.0 (Fujifilm), comparing cleavage 
product values minus the relative background value, to the total sample value minus relative 
background value, converted to a final percentage.   
2.20. Generation of hNEIL3Cat-K81A catalytically inactive recombinant protein bacterial 
expression vector. 
 
The expression vector pETDuet2-EcoMap-ORF6-hNEIL3Cat was targeted for site-directed 
mutagenesis to generate the pETDuet2-EcoMap-ORF6-hNEIL3Cat-K81A expression vector to 
express the catalytically inactive glycosylase domain of hNEIL3. 
The identified nucleotides targeted for site-directed mutagenesis were at nucleotide 
positions 241 of the hNEIL3Cat cDNA, to convert adenine to a guanine and at nucleotide 
position 242 of the hNEIL3Cat cDNA to convert adenine to cytosine. At the amino acid level this 
would encode a substitution of lysine 81 to alanine, previously described by Krokeide et al. 
(2013) to remove the DNA glycosylase and AP lyase activity of hNEIL3.  
The following mutagenic primers were designed using the online Agilent technologies primer 
design tool (http://www.genomics.agilent.com/primerDesignProgram.jsp) and are displayed 
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Table 2.8: Mutagenic primers used for site-directed mutagenesis, converting A-G at nucleotide position 241 
and A-C at nucleotide position 242 of hNEIL3 cDNA. Primers are underlined, and targeted bases are underlined, 
italicised and highlighted in yellow. 
Primer name Primer-Template Duplex 
a241g_a242c  
Forward 
5 ' - t g g c g t g g a a a c t t t g g g g g c g g a g c t c t t t a t g t a c t t t - 3 '  
   | | | | | | | | | | | | | | | | | | |   | | | | | | | | | | | | | | | | | | |  
g t c a c c g c a c c t t t g a a a c c c c t t c c t c g a g a a a t a c a t g a a a c c t  
a241g_a242c  
Reverse 
c a g t g g c g t g g a a a c t t t g g g g a a g g a g c t c t t t a t g t a c t t t g g a  
   | | | | | | | | | | | | | | | | | | |   | | | | | | | | | | | | | | | | | | |  
3 ' - a c c g c a c c t t t g a a a c c c c c g c c t c g a g a a a t a c a t g a a a - 5 '  
 
Mutagenesis was carried out by preparing a stock master mixture of 1x Pfu Ultra high-fidelity 
reaction buffer (Agilent technologies), 25 ng of template plasmid DNA (pETDuet2-EcoMap-
ORF6-hNEIL3Cat), 6 µM of a241g_a242c forward primer, 6 µM of a241g_a242c  reverse primer 
and 0.6 mM dNTP mix. Then, a working reaction mixture was prepared containing 6.73 µl of 
the master mixture, 0.1 mM of dNTP mix, 1.75 units of Pfu Ultra DNA polymerase and made 
to a final volume of 20 µl with dH2O. Thermocycling conditions (Table 2.9) were carried out 
to facilitate site directed mutagenesis and amplification of a pETDuet2-EcoMap-ORF6-
hNEIL3Cat-K81A synthetic vector. The reaction product was then digested by preparing a 
reaction mixture containing 16 µl PCR product, 1x Cutsmart buffer (New England Biolabs) and 
5 units of DpnI restriction endonuclease (New England Biolabs), subsequently incubated for 
1 h 20 mins at 37°C, then 20 min at 80°C. This resulted in the digestion of the template plasmid 
DNA and inactivation of DpnI restriction endonuclease. Then, 2 µl of digested product was 
transformed via the electroporation method in to Nova XG cells, previously described in 
section 2.1 and upscaled for growth in LB broth containing 100 µg/ml ampicillin. Plasmid DNA 
was then purified via the Nucleospin Plasmid miniprep kit (Macherey-Nagel) following 
manufacturer instructions and sequenced using the GATC SUPREMErun sequencing kit (GATC 
Biotech). Mutagenesis was confirmed by sequencing chromatogram analysis. 
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Table 2.9: Thermocycling conditions used for site-directed mutagenesis and synthetic vector generation via 
PCR. 
 
2.21. Recombinant hNEIL3Cat-K81A expression and protein purification. 
 
After confirmation of the construction of the expression vector pETDuet2-EcoMap-ORF6-
hNEIL3Cat-K81A, Rosetta 2 (DE3) expression hosts were transformed by the electroporation 
method as previously described in section 2.1. Colonies were selected and grown overnight 
at 37°C with 200 rpm shaking in 4 ml LB broth under 50 µg/ml ampicillin, 34 µg/ml 
chloramphenicol antibiotic selection. Subsequently, 400 µl of overnight culture was used to 
inoculate each of three 40 ml LB broth cultures, then grown at 37°C with 200 rpm shaking to 
an O.D600 of 0.6-0.8 under 50 µg/ml ampicillin, 34 µg/ml chloramphenicol antibiotic selection. 
The entirety of the three 40 ml cultures was used to inoculate three 400 ml LB broth cultures 
under 50 µg/ml ampicillin antibiotic selection, then grown at 37°C with 200 rpm shaking to an 
O.D600 of 0.6-0.8. At this stage, cultures were induced with 1 mM IPTG and incubated for 20 
h at 16°C. 
Cells were then pelleted by centrifugation at 8000 xg for 10 minutes and then the excess LB 
broth was discarded. Then 10 ml of LB broth was used to resuspend the cells from all three 
cultures, to transfer cells to a 50 ml falcon tube and pellet by centrifugation for 10 min at 8000 
xg. The excess LB broth was then discarded, and the cell pellet was stored overnight at -80°C, 
to aid in cell lysis. Thirty millilitres of lysis buffer (25 mM Tris-HCl pH 8.0, 500 mM NaCl, 5% 
glycerol, 5 mM imidazole, 1 ug/ ml leupeptin, 1 ug/ ml chemostatin, 1 ug/ ml pepstatin, a 1 
ug/ ml aprotinin, 0.33 mM PMSF) was added to the thawed cell pellet and sonicated for 60 s 
in bursts of 15 s with 30 s intervals between each burst. The cell lysate was then centrifuged 
Step Temperature (°C) Time (s) Cycles 
Initial 
denaturation 
98 120 1 
Denaturation 98 20  
Annealing 58.5 30 21 
Extension 72 240  
Final Extension 72 600 1 
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at 25,000 rpm for 30 min at 4°C to separate insoluble and soluble cell components. FPLC 
protein purification using a HisTrap HP column and the ÄKTA Prime FPLC was undertaken as 
described in section 2.2. 
Fractions were then analysed by 10% SDS-PAGE and anti-NEIL3 immunoblot (Proteintech). 
Protein fractions of relative target protein purity were pooled and concentrated to ~0.5 ml 
using an Amicon Ultra-15 centrifugal filter with a 10 kDa cut off (Merk). The hNEIL3Cat-K81A 
candidate protein band was sent for liquid chromatography mass-spectrometry (LC-MS) 
analysis, with reference to the hNEIL3Cat protein band (Mustafa Albelazi, University of 
Salford). The Esi-Quad-TOF instrument and MS/MS Ion search were used, with a significance 
threshold of p< 0.0104 and an Ion score or cut off of 25. 
2.22. Protein-DNA covalent complex formation, ‘Schiff base’ affinity assay.  
 
Reactions were prepared as stated previously in Section 2.18, but with the addition of 50 mM 
NaBH4 prior to incubation at 37°C. The reactions were then stopped by the addition of 1x 
RunBlue LDS Sample Buffer (Expedeon) and 10 mM DTT, then incubated for 10 min at 70°C. 
Samples were then analysed by electrophoretic separation at 125V for 120 min on a RunBlue 
SDS precast protein gel (10%). The gel was subsequently exposed to a phospho-screen and 
imaged using the Typhoon 9500 scanner. 
2.23.  Characterisation of E3 ubiquitin ligase from HeLa cells and in vitro. 
 
For the identification of a hNEIL3FL interacting E3 ubiquitin ligase, previously prepared and 
sequentially purified HeLa cell extracts fractioned by phosphocellulose, HiLoad Mono Q 
Sepharose Ion exchange, Superdex 200 HR 10/30 size exclusion, 1 ml CHT ceramic 
hydroxyapatite column and Mono Q 5/50 GL were used (Williams and Parsons, 2018). 
Laboratory stocks of each fraction were then analysed by in vitro ubiquitination assays for the 
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2.23.1. In vitro ubiquitination assay. 
 
To identify in vitro PTM of recombinant hNEIL3FL by ubiquitin, in vitro ubiquitination assays 
were undertaken. The following previously purified recombinant proteins were mixed to 
form an E1, E2 and ubiquitin protein reaction master mix (Table 2.10):  
Table 2.10: Ubiquitin cascade recombinant protein master mix. Wild type Ubiquitin (Boston biochemicals, 
Cambridge, USA), GST-E1 activating enzyme, E2 conjugating enzymes (UbcH3-UbcH10). 





Ubiquitin (5 µg) 10 mg/ml 0.5  5 
E1 (100 ng) 1.9 mg/ml 0.052  0.52 
UbcH2 (40 ng) 0.975 mg/ml 0.041 0.41 
His-UbcH3 (40 ng) 0.26 mg/ml 0.153 1.53 
UbcH5a (40 ng) 0.478mg/ml 0.083 0.83 
UbcH5b (40 ng) 0.980 mg/ml 0.041  0.41 
UbcH5c (40 ng) 0.380 mg/ml 0.105 1.05 
His-UbcH6 (40 ng) 1.02mg/ml 0.039 0.39 
UbcH7 (40 ng) 0.710 mg/ml 0.056 0.56 
UbcH8 (40 ng) 0.4 mg/ml 0.1 1 
His-UbcH10 (40 ng) 0.240 mg/ml 0.166 1.66 
dH2O  0.314 3.14 
Total  1.65 16.5 
 
Individual reaction mixtures were prepared in 50 mM Tris-HCl pH 8.0, 5 mM MgCl2 200 µM 
CaCl2, 1 mM DTT, 10 µM MG-132, 4 mM ATP with the addition of 5 µg ubiquitin, 100 ng 
recombinant E1, 40 ng of each E2, 600 ng of recombinant hNEIL3FL and 1-3 µl of fractionated 
HeLa WCE. Reactions were made to a final volume of 15 µl with dH2O. 
Reaction mixtures were then incubated for 60 min at 30°C and 800 rpm. The reaction was 
then stopped with the addition of 7.5 µl of 3x SDS loading dye, followed by 5 min incubation 
at 95°C. Samples were then analysed by 8/10% SDS-PAGE and anti-NEIL3 immunoblot 
analysis.  
HeLa WCE fractions displaying ubiquitination activity were previously pooled and 
concentrated with an Amicon Ultra-15 Centrifugal Filter Unit with a 10 K cut off. The final 
MONO Q 5/50 GL purification fraction identified for E3 ubiquitin ligase activity was then sent 
for LCMS tandem mass spectrometry analysis by tandem mass spectrometry using a Q 
Exactive instrument operated in data-dependent positive (electrospray ionization+ [ESI+]) 
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mode as previously described (Appendix Table 5; Edmonds et al., 2017; Williams and Parsons, 
2018). 
2.24. Mammalian cell line culture. 
 
The osteosarcoma cell line U-2 OS (U2OS) was used for the investigation of the cellular role 
of hNEIL1 and hNEIL3 in resistance to the ICL inducing agent cisplatin and the role of the E3 
ubiquitin ligase, TRIM26, in the modulation of hNEIL1 and hNEIL3 protein levels.  
2.24.1. Thawing cells. 
 
U2OS cells were thawed by submerging a cryovial containing 1ml Dulbecco’s modified eagle 
medium (DMEM; 10% FBS, 1% penicillin/streptomycin, 2 mM L-glutamine, 1% non-essential 
amino acids), 10% DMSO, U2OS cell mixture in a water bath at 37˚C for <1 min. Then, 1ml of 
DMEM medium was added to the cryovial and the cell suspension was mixed by pipetting. 
The cell suspension was then transferred to a 15 ml tube and centrifuged at 1500 rpm for 3 
min, the DMEM medium was removed and replaced with 1 ml DMEM. The cell pellet was then 
resuspended and transferred to a T75 cell culture flask containing 10 ml DMEM medium. The 
T75 flask was then incubated at 37˚C in 5% CO2. 
2.24.2. Splitting cells. 
 
T75 flasks containing cells were periodically inspected under a light microscope to determine 
approximate confluence. At 70-90% confluency DMEM medium was removed from a T75 flask 
containing U2OS cells using an aspirator, then rinsed with 10 ml Dulbecco’s phosphate 
buffered saline (DPBS) and incubated for 5 min in 1 ml 1 x trypsin EDTA (0.12 % trypsin, 0.02% 
EDTA) at 37˚C in 5% CO2. The flask was then viewed under a light microscope to determine 
that all adherent cells had detached. Then, 9 ml of DMEM medium was added to the flask to 
neutralise the trypsin and mixed by pipetting to aid in the dissociation of individual cells. At 
this stage, 10 ml DMEM was added to a new T75 flask and a volume of U2OS cell suspension 
was transferred to the new flask, based on desired split ratio relative to the 10 ml final volume 
of the cell suspension. This method of splitting was conducted in the same manner with 
adjusted volumes based on target vessels ( 
Table 2.11).  
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T75 10 1000 9 
T25 10 1000 9 
96-well plate (individual well) 0.100 10 0.09 
24-well plate (individual well) 0.500 50 0.45 
6-well plate (individual well) 2 100 0.9 
35 mm tissue culture dish 2 100 0.9 
10 cm tissue culture dish 8 1000 7 
 
2.24.3. Freezing cells and long-term storage 
 
For long term storage of U2OS cells at -80/195˚C cells were brought into suspension following 
normal procedure outlined in section 2.24.2, neutralised with DMEM medium and transferred 
to a 15 ml tube. The cell suspension was then centrifuged at 1500 rpm for 3 min. The medium 
was then removed, and the cell pellet was resuspended in 1 ml 90% FBS/10% DMSO. The cell 
suspension was then transferred to a cryovial and placed in a ‘Mr frosty’ storage container at 
room temperature. The ‘Mr Frosty’ container was then transferred to -80˚C for 24 h. Cryovials 
were then removed from the ‘Mr Frosty’ container and logged in the -80˚C storage or 
transferred and logged for long-term storage at -195°C in liquid nitrogen. 
2.25. Tanaka protein extraction. 
 
To prepare whole cell protein extracts for immunoblot analysis, a 35 mm tissue culture dish 
containing U2OS cells at 70-80% confluency was rinsed with 2 ml PBS. A further 2ml PBS was 
added and the adherent U2OS cells were scraped and collected in a 15 ml tube.  The 15 ml 
tube was then centrifuged at 1500 rpm at 4˚C for 5 minutes and the supernatant was 
removed, the pellet was then resuspended in 1 ml cold PBS and transferred to a 1.5 ml 
microcentrifuge tube. Tubes were then frozen for at least 1 hour at -80˚C. 
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The approximate packed cell volume (PCV) was then measured and resuspended in 1 PCV of 
Tanaka buffer 1 (10 mM Tris-HCl pH 7.8, 200 mM KCl, 1 µg/ml aprotinin, 1 µg/ml chymostatin, 
1 µg/ml pepstatin A, 1 µg/ml leupeptin, 0.25 mM PMSF and 1 mM DTT). The cell suspension 
was then mixed with 2x PCV of Tanaka buffer 2 (10 mM Tris-HCl pH 7.8, 600 mM KCl, 2 mM 
EDTA, 40% glycerol, 0.2% NP-40, 1 µg/ml aprotinin, 1 µg/ml chymostatin, 1 µg/ml pepstatin 
A, 1 µg/ml leupeptin, 0.25 mM PMSF and 1 mM DTT) and the cell suspension was rotated at 
4˚C for 30 min. The cell lysate suspension was then centrifuged at 40000 rpm for 20 min to 
pellet insoluble cellular components. The supernatant was transferred to a 1.5 ml 
microcentrifuge tube and protein concentration was quantified using the Bradford assay 
(Section 2.26). 
2.26. Bradford assay. 
 
To quantify whole cell extract protein concentrations a Bradford protein assay was 
conducted. In a 1.5 ml microcentrifuge tube, 1 µl of protein sample was mixed in 39 µl dH2O 
and 960 µl of Bradford reagent (BioRad). A blank was prepared and 40 µl dH2O with 960 µl 
Bradford reagent (BioRad).  A protein concentration standard curve was then prepared by 
mixing 40 µl 0.1-1 mg/ml dilutions of BSA with 960 µl Bradford reagent. All samples were then 
incubated at room temperature in the dark for 5 min then transferred to 1 ml plastic cuvettes. 
Absorbance was then measured at a wavelength of 595 nm using a spectrophotometer. 
Initially the apparatus was blanked with the dH2O only control followed by measuring the 
absorbance of the protein standard samples. Protein samples were then measured, re-
blanking with the dH2O control between each measurement. A standard curve was plotted 
from A595 measurements of the BSA dilutions and used to determine the sample protein 
concentration after multiplying by the dilution factor used. Quantified protein extract 
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2.27. RNA interference.   
 
To facilitate knockdown of endogenous protein for downstream analysis by immunoblot or 
clonogenic assays, siRNA transfection was conducted. A 35 mm tissue culture dish was seeded 
with 100,000 U2OS cells and incubated for 24 h at 37˚C in 5% CO2.  
In a 30 ml universal tube, 33 pmol of siRNA was suspended in 125 µl of supplement free 
DMEM and mixed by pipetting (Table 2.12). In a separate 30 ml universal tube, 2 µl of 
Lipofectamine RNAiMax (ThermoFisher was suspended in 125 µl of supplement free DMEM 
and mixed by pipetting. Then, the supplement free DMEM/Lipofectamine RNAiMax mix was 
transferred to the tube containing suspended siRNA, mixed by pipetting and incubated at 
room temperature for 5 min.  
Table 2.12: Short interfering ribonucleic acid sequences used for non-targeting RNAi as control and TRIM26 
RNAi. 












DMEM medium was then removed from 35 mm dishes containing U2OS cells, then rinsed 
with DPBS and replaced with 1.750 µl DMEM medium containing supplements. Then, 250 µl 
siRNA/Lipofectamine RNAiMax/ supplement free DMEM was applied drop wise to the 35 mm 
tissue culture dish, then distributed evenly by tilting the dish forward/backwards and 
left/right. Cells were then incubated at 37˚C in 5% CO2 for 48 hours before analysis by Tanaka 
protein extraction and immunoblot or treatment as part of clonogenic assays. 
 
 
Chapter II  Methods. 
105 
2.28. Transient overexpression of NEIL1, NEIL3 and NTH1. 
To facilitate transient protein overexpression (O/E) for downstream analysis by immunoblot 
or clonogenic assays, the following transient mammalian expression vectors were used (Table 
2.13) 
Table 2.13: Transient mammalian expression vectors. Name of the mammalian expression vector, the 
encoded DNA glycosylase and C-terminal fusion tag are displayed. 
Name Encoded protein Tag 
pCMVTag3a-NEIL1 NEIL1 FLAG 
pCMV-ac-NEIL3 NEIL3 N/A 
pCMVTag3a-NTH1 NTH1 FLAG 
 
U2OS cells were seeded in 35 mm tissue culture dishes at a seeding density of 100000 
cells/dish and incubated at 37˚C in 5% CO2 for 48 h. Then, 80 ng of transient mammalian 
overexpression vector was suspended in 250 µl of supplement free DMEM medium, per 
transfection, in a 30 ml universal tube and mixed by pipetting. In a separate 30 ml universal 
tube, 2 µl Lipofectamine 2000 (ThermoFisher) was mixed in 250 µl supplement free DMEM, 
per transfection, by pipetting. 250 µl Lipofectamine 2000/supplement free DMEM mixture 
was then added to the expression vector/supplement free mixture, then mixed by pipetting 
and incubated for 10 min at room temperature.  
Medium was removed from 35 mm tissue dishes containing U2OS cells, which were then 
rinsed with DPBS. Then, 1500 µl DMEM was added to each dish and 500 µl Lipofectamine 
2000/overexpression vector/supplement free DMEM mix was applied dropwise. The complex 
was distributed evenly across the dish by tilting the dish backward/forward and left/right. 
Cells were then incubated at 37˚C in 5% CO2 for 48 h. 
2.29. Clonogenic survival assay. 
Cells were seeded 100,000 cells/35 mm tissue culture dish for each treatment condition and 
cisplatin drug concentration analysed. Cells were transfected after 24 h with NT siRNA or 
TRIM26 siRNA. After a further 24 h, cells were transfected with the relative DNA glycosylase 
mammalian transient overexpression plasmid vector. After a further 24 h, cells were treated 
with cisplatin at the relative treatment dose (0, 2.5, 5, 7.5 and 10 µM) for 24 h. Post drug 
treatment, drug containing medium was aspirated, cells were rinsed with DPBS and incubated 
Chapter II  Methods. 
106 
for 5 min at 37˚C in 100 µl trypsin EDTA. Then, 900 µl DMEM was added to each dish to 
neutralise the trypsin, cells were mixed by pipetting and counted using a haemocytometer. A 
cell suspension was prepared as a mastermix in 10 ml DMEM to achieve a seeding density of 
the relevant low seeding density per 6 well plate/ml of DMEM medium (Table 2.14). For each 
treatment (NT siRNA, TRIM26 siRNA, NEIL1 O/E and NEIL3 O/E) and relative drug 
concentration, 3 wells of a 6 well plate were seeded with the relevant seeding density 
previously mixed in 1 ml of DMEM medium and the remaining 3 wells of the plate were 
seeded with the associated higher seeding density, by pipetting 2 ml of the previously mixed 
cell suspension into the wells. Then 1 ml of DMEM medium was added to the wells containing 
1 ml of cell suspension to maintain consistent culture volume. The 6 well plates were then 
incubated at 37˚C and 5% CO2 to facilitate colony outgrowth.  
Table 2.14: Clonogenic seeding densities for each RNAi or overexpression treatment and relevant cisplatin 
concentration.  Numbers denote the two seeding densities seeded into 6 well plates after treatments for 
outgrowth of colony forming units. 
 
Number of cells seeded per 
well 




0 2.5 5 7.5 10 
NT siRNA 1000/2000 2000/4000 4000/8000 8000/16000 16000/32000 
TRIM26 siRNA 1000/2000 1000/2000 2000/4000 4000/8000 4000/8000 
hNEIL1 O/E 1000/2000 1000/2000 2000/4000 2000/4000 2000/4000 
hNEIL3 O/E 1000/2000 1000/2000 2000/4000 2000/4000 2000/4000 
 
Plates were regularly visually analysed under the light microscope to assess colony size. Two 
factors were considered for colony outgrowth period: the 0 µM cisplatin treated sample of 
each treatment condition had formed ~50 cells/ defined colony and that colonies did not 
overlap and remained defined on all plates. When both conditions were met plates were 
removed from incubation, the medium was removed, and the wells were rinsed with 2 ml 
DPBS. Plates were placed on a level surface and 1 ml of crystal violet stain was applied to each 
well and incubated at room temperature for >1h. Then the crystal violet stain was removed, 
and the plates were rinsed with H2O to remove excess staining solution. Plates were then 
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inverted and allowed to air dry for 24 hours at room temperature to facilitate evaporation of 
excess H2O. 
Colonies on each plate were then counted using the Oxford Optronix: GelCount colony 
counter selecting for stringency in colony size, shape and overlap. Values retrieved were 
exported to Microsoft excel and normalised to the original seeding density. Values were 
plotted against concentration for each condition and converted to log scale. Plating efficiency 
was calculated based on the values retrieved from the control plate, without cisplatin 
treatment:	
𝑛	𝐶𝑜𝑙𝑜𝑛𝑖𝑒𝑠
𝑆𝑒𝑒𝑑𝑖𝑛𝑔	𝐷𝑒𝑛𝑠𝑖𝑡𝑦 = 𝑃𝑙𝑎𝑡𝑖𝑛𝑔	𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 
The mean average plating efficiency was calculated and used to calculate the normalised 
surviving fractions of each condition: 
𝑛	𝐶𝑜𝑙𝑜𝑛𝑖𝑒𝑠
(𝑆𝑒𝑒𝑑𝑖𝑛𝑔𝐷𝑒𝑛𝑠𝑖𝑡𝑦 × 𝐴𝑣𝑒𝑟𝑎𝑔𝑒	𝑃𝑙𝑎𝑡𝑖𝑛𝑔	𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦)	 = 𝑆𝑢𝑟𝑣𝑖𝑣𝑖𝑛𝑔	𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 
The mean average surviving fraction was calculated for each condition, with the 0 μM cisplatin 
treated plate values now normalised to a value of 1.  
Finally, the significance between each treatment condition and the NT siRNA control treated 
samples was determined through the comparison of linear-quadratic cell survival curves. This 
was conducted using the R (3.3.1) statistical software with the CFA assay package (Braselmann 
et al., 2015). 
2.30. CRISPR/Cas9 mediated gene knockout. 
To establish a hNEIL3-/- U2OS cell lines, the Origene CRISPR/Cas9 gene knockout kit was used. 
Two circular plasmid vectors were supplied: pCAS-Guide (Figure 2.3) vector containing the 
Cas9 cDNA under a CMV promotor, and one of three guide sequences (gRNA1(G1), gRNA2 
(G2), scramble control gRNA (SC)), with ampicillin resistance for propagation in bacterial 
cloning cells and the pUC-Donor (Figure 2.4) vector containing left and right homologous 
arms, a GFP and puromycin resistance gene cassette under the control of a PGK promotor.  
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Figure 2.3: The pCas-Guide vector map. The pCas-Guide facilitated the transient mammalian expression of wild 
type Cas9 protein and transcription of target gRNA sequences in complex with gRNA scaffold complex. pCas-
Guide vector map shows G1 and G2 gRNA sequences used for targeting exon 1 of the NEIL3 gene sequence and 
scramble control (SC) gRNA sequence for negative control cell line generation (Adapted from the Origene 
CRISPR/Cas9 Genome Editing instruction manual). 
Figure 2.4: The pUC-Donor cassette map. pUC-Donor facilitated the transient expression of puromycin antibiotic 
resistance gene and provision of the homology directed repair (HDR) cassette for integration at G1, G2 or SC 
gRNA sequence site. pUC-Donor vector map shows left homologous arm (LHA), green fluorescent protein gene 
(GFP), Cre/Lox recombinase sequences (Loxp), phosphoglycerate kinase (PGK) promotor, puromycin antibiotic 
resistance gene (PURO) and right homologous arm (RHA) Adapted from the Origene CRISPR/Cas9 Genome 
Editing instruction manual). 
U2OS cells were seeded at 300,000 cells/ 35 mm tissue culture dish 24 hours prior to co-
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hNEIL3, G2 exon 1 of hNEIL3) and SC pCAS-Guide vectors were independently suspended in 
250 µl of supplement free DMEM medium in 30 ml universal tubes and mixed gently by 
pipetting. Then 1 µg of pUC-Donor was suspended in each of the same 30 ml universal tubes. 
In parallel, 7.5 µl of Lipofectamine 2000 was diluted and mixed in 750 µl of supplement free 
DMEM and mixed by gently pipetting. Then, 250 µl of Lipofectamine 2000/supplement free 
DMEM was added to each of the 30 ml universal tubes containing 250 µl of 1 µg pCAS-Guide/1 
µg pUC-Donor/supplement free DMEM mix and gently mixed by pipetting. The final mixture 
was incubated at room temperature for 10 min to facilitate vector/liposome formation. 
DMEM medium was then removed from 35 mm tissue culture dishes containing U2OS cells, 
rinsed with 2 ml of DPBS and replaced with 1.5 ml of fresh DMEM (10% FBS, 1% non-essential 
amino acids, 1% penicillin/streptomycin antibiotic mix and 1% L-glutamine). Then 500 µl of 
the pCAS-Guide/pUC-Donor/Lipofectamine 2000/supplement free DMEM mixtures were 
added drop-wise to independent 35 mm dishes containing U2OS cells prepared as 
aforementioned and labelled respectively (G1, G2 and SC). The cells were then incubated at 
37˚C in 5% CO2. 
After 48 hrs incubation each of the 35 mm dishes containing co-transfected U2OS cells were 
split at a 1 in 10 dilution, this was repeated for a further 7 passages every 72 hr. As the pUC-
Donor vector contains puromycin resistance under the control of the mammalian promotor 
PGK, removal of the episomal remnants of the puromycin resistance gene was required. At 
P8 duplicate dishes were seeded into 10 cm tissue culture dishes and incubated at 37˚C in 5% 
CO2 to reach 70-80% confluence. One set of which was taken forward for puromycin selection 
at 1 µg/ml for 14 days, with medium/selective agent replaced every 7 days. The duplicate set 
of 10 cm tissue culture dishes containing transfected U2OS was processed for long term 
storage as described in section 3.21.3 and stored at -80˚C. 
G1, G2 and SC U2OS cells incubated in puromycin selective DMEM medium were routinely 
monitored for colony formation and indication of successful integration of the puromycin 
resistance gene. Every 96 h medium was removed, cells were rinsed with DPBS and 1 µg/ml 
puromycin selective DMEM medium was replaced. After 14 days, selective medium was 
removed, cells were rinsed with DPBS and cells were incubated for 5 min in 100 µl trypsin 
EDTA at 37˚C. After, 900 µl of DMEM was added to each dish individually and suspended cells 
were transferred to a new 35 mm tissue culture dish.  
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Once G1, G2 and SC U2OS containing dishes were ~70-80% confluent, medium was removed, 
cells were rinsed with DPBS and cells were incubated for 5 min in 100 µl trypsin EDTA at 37˚C 
and 5% CO2. For each of G1, G2 and SC cultures, cells were counted and a dilution of 140 
cells/40 ml of DMEM prepared. Using a multichannel pipette 100 µl of DMEM/cell mixture 
was seeded into each well of four 96 well plates. The 96 well plates were then incubated at 
37˚C and 5% CO2 for a further 14 days. Each plate was frequently analysed with use of a light 
microscope and wells containing single colonies were noted. 
Medium was removed from colony containing wells, then rinsed with DPBS then incubated at 
37˚C and 5% CO2 in 10 µl of 1x trypsin EDTA. Then, 90 µl of DMEM was added to each colony 
containing well, gently mixed by pipetting and transferred to one well of a 24 well plate in 
500 ml DMEM, to facilitate outgrowth. Once ~80% confluent, medium was removed, cells 
rinsed with DPBS and incubated in 100 µl trypsin EDTA at 37˚C and 5% CO2 for 5 minutes. 
Then, 900 µl of DMEM was added to suspend cells, then split 1 in 2 into separate wells of 
independent 6- well plates. Once ~50-70% confluent, cells from one of each duplicate clonal 
well were harvested and WCEs were prepared by the Tanaka method (section 3.26) and 
analysed for gene knockout by immunoblot analysis. 
On confirmation of putative hNEIL3 knockout, medium was removed from the parallel well 
containing the same clonal population, rinsed with DPBS and incubated in 100 µl trypsin EDTA 
for 5 min at 37˚C. Then, 900 µl DMEM was added to neutralise the trypsin EDTA, followed by 
mixing by pipetting. The cell suspension was then split 1 in 2 between a 10 cm tissue culture 
dish and a T75 flask containing both contraining 9 ml DMEM medium. Once ~90% confluent 
the 10 cm tissue culture dish containing a positive clonal population was re-confirmed by 
parallel anti-NEIL3 immunoblot analysis while the T75 was processed and stored in liquid 
nitrogen following standard freezing procedure (section 2.24.3) 
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Results & Discussion. 
Data presented here provides in vitro biochemical evidence for differential and distinct lesion 
processing activities between recombinant hNEIL1 and hNEIL3 in the presence of oxidative 
lesions in a model DNA replication fork oligonucleotide substrate structure. In addition, 
evidence for the in vitro biochemical, ss-MA, three-stranded and four-stranded psoralen ICL 
unhooking activity of Nei, NEIL1 and NEIL3 recombinant proteins is presented. Finally, in vitro 
and cellular analysis provide evidence that hNEIL1, hNEIL3 and TRIM26 are implicated in the 
cellular response of U2OS cells to the chemotherapeutic agent cisplatin, putatively modulated 
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3. Characterisation of the hNEIL1 and hNEIL3 DNA glycosylases in the repair 
of oxidative DNA damage in association with DNA replication. 
To investigate the differential biochemical roles hNEIL1 and hNEIL3 play in the repair of 
oxidative lesions, the previously prepared pET30a-hNEIL1 expression construct was 
transformed and used to express and purify recombinant C-terminal his tagged hNEIL1. 
Protein purification products were analysed by SDS-PAGE and western blot. Recombinant 
hNEIL1 successfully purified at a relatively high purity and previously prepared active hNEIL3FL 
were used for biochemical analysis (Mustafa Albelazi, University of Salford: Appendix Figure 
2; Appendix Figure 3). Fluorescently labelled ss-DNA, ds-DNA and mock replication fork 
structured DNA oligonucleotides were used to determine cleavage activity of the oxidative 
DNA lesions 5-OHU, 8-OxoG and the replication blocking lesion Tg by hNEIL1 and hNEIL3FL in 
varied structural contexts. Comparative analysis determined a structural affinity for DNA 
replication fork structures and the replication blocking DNA lesion Tg by hNEIL3FL.  
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3.1.  Results: Characterisation of the hNEIL1 and hNEIL3 DNA glycosylases in the repair 
of oxidative DNA damage in association with DNA replication 
 
3.1.1. Recombinant hNEIL1 purification from E. coli using the pET30a-hNEIL1 
bacterial expression vector. 
 
The pET30a-hNEIL1 bacterial expression vector was kindly provided by S. S. Wallace, 
University of Vermont. The pET30a-hNEIL1 bacterial expression vector was subsequently 
transformed into Rosetta 2 (DE3) expression hosts, upscaled, induced and purified as 
described in (Section 2.2). Figure 3.1 A displays two major A280 peaks separated by HisTrap 
HP affinity chromatography. The chromatogram shows the characteristic separation of 
histidine rich bacterial proteins between fractions 4 and 10, while the second major peak 
between 11 and 22 is indicative of the successful isolation of recombinant hNEIL1. Figure 3.1 
B confirms successful isolation of major contaminant proteins from putative recombinant 
hNEIL1-His at an expected molecular weight of 44.5kDa when compared to the protein size 
marker (M). Figure 3.1 C anti-his western blot analysis confirmed that the putative isolated 
protein was His-tagged hNEIL1, confirming the expression and HisTrap HP affinity purification 
of recombinant hNEIL1. Purified fractions 17-21 were subsequently pooled and concentrated 




Chapter III  Results and Discussion. 
114 
Figure 3.1HisTrap-HP FPLC purification of hNEIL1. A. Chromatogram analysis of protein fractions generated by 
HisTrap chromatography of lysates from E.coli overexpressing hNEIL1. B. 10% SDS-PAGE analysis. C. Anti-His 
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3.1.2. hNEIL1 and hNEIL3FL recombinant protein activity analysis on oxidative DNA 
lesions containing ss- and ds- oligonucleotide DNA.  
Confirmation of recombinant hNEIL1 and hNEIL3FL protein activity on the DNA lesions 5-OHU, 
8-OxoG and Tg were undertaken to determine the DNA glycosylase and AP lyase activity 
profile. Recombinant proteins were incubated with ss-DNA and ds-DNA oligonucleotides, 39 
mer in length as substrates in BER cleavage assays (Figure 3.2). 
hNEIL1 was observed to cleave 5-OHU and Tg containing oligonucleotides in both ss-DNA and 
ds-DNA context, producing a 19 mer cleavage product (Figure 3.2 A;Figure 3.2 C) , indicative 
of bifunctional AP-lyase activity post-cleavage of the N-glycosidic bond (Figure 3.2 A). In ss-
DNA context the slower migrating band of the doublet represents a 19-mer product 
containing a 3ʹ-PUA and the lower representing a 3ʹ-PO4 group. The major cleavage product 
observed after NEIL1 incubation with 5-OHU and Tg is the lower of the doublet, 
representative of β-δ elimination AP-lyase conducted by NEIL1 in the presence of 5-OHU and 
Tg in ss-DNA. Analysis of hNEIL1 incubation with ds-DNA generated a 19 mer cleavage product 
containing a 3ʹ-P and no evidence of a cleavage product containing a 3ʹ-PUA, most likely due 
to a preference for ds-DNA generating a 3ʹP residue. hNEIL1 incubated with 8-OxoG in ss-DNA 
and ds-DNA context, exhibited no evidence of cleavage, indicating that 8-OxoG is a poor 
substrate in vitro for hNEIL1 (Figure 3.2 A; C).  
Analysis of the incubation of hNEIL3FL with ss-DNA and ds-DNA substrates revealed 
overlapping preference for the 5-OHU and Tg containing substrates as recombinant hNEIL1 
(Figure 3.2 B, D). When incubated with ss-DNA oligonucleotides containing 5-OHU and Tg 
lesions, a 19 mer cleavage product doublet can be observed representative of 3ʹ-PUA and 3ʹ-
P (Figure 3.2 B). Analysis also revealed weak cleavage activity by hNEIL3FL on the ss-DNA 8-
OxoG DNA substrate.  In contrast to hNEIL1, hNEIL3FL displays predominant β-elimination and 
nominal β,δ-elimination AP-lyase in a ss-DNA context. However, when incubated with ds-DNA 
oligonucleotides, hNEIL3FL displays weak cleavage activity on the 5-OHU and 8-OxoG 
substrates producing 19 mer cleavage products representative of associated β,δ elimination 
of the phosphodiester backbone (Figure 3.2 B; D). 
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Figure 3.2: Denaturing PAGE analysis of oligonucleotide substrates incubated with hNEIL1 (A, C) or hNEIL3 (B, 
D). A.  Analysis of 228 nM hNEIL1 incubated with 5 nM ss-DNA oligonucleotide substrates B.  Analysis of 150 nM 
hNEIL3FL incubated with 5 nM ss-DNA oligonucleotide substrates. C.  Analysis of 228 nM hNEIL1 incubated with 
5 nM ds-DNA oligonucleotide substrates. D.  Analysis of 300 nM hNEIL3FL incubated with 5 nM ds-DNA 
oligonucleotide substrates. “19PA” and “19P” denote 19 mer cleavage fragments with a 3ʹ-terminal PA or P, 
respectively. 
 
3.1.3. hNEIL1 and hNEIL3FL recombinant protein activity analysis on oxidative DNA 
lesion containing model DNA replication fork oligonucleotide DNA. 
 
Current lines of evidence suggest NEIL1 and NEIL3 initiate repair in association with DNA 
replication. Therefore, the design and generation of a set of three model replication fork 
structures, based on partially complementary oligonucleotides, to analyse variance in 
biochemical activity at the DNA replication fork was undertaken (Table 3.1). These substrates 
contained the oxidative lesions 5-OHU, 8-OxoG or Tg at one of three positions: ‘-4’, (four 
nucleotides from the replication fork junction and within ss-DNA), ‘Fork’ (at the site of the 
fork junction and in ds-DNA context) and +4 (a prereplicative position in double-stranded 
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Table 3.1: Mock DNA replication fork oligonucleotide DNA structure. Oligonucleotides 39 mer in length with 
either 5-OHU, 8-OxoG or Tg at 20 mer, DNA glycosylase cleavage products generate a 19 mer cleavage product. 
-4 Fork +4 
   
Oligonucleotide cleavage assays with mock DNA replication fork structured DNA 
oligonucleotides (Table 3.1) incubated with recombinant hNEIL1 protein revealed distinct 
preferences for structural context. Denaturing PAGE analysis of hNEIL1 reaction products with 
5-OHU revealed a preference for ds-DNA compared to ss-DNA with 25 percent more cleavage 
of the ds-DNA substrate (Figure 3.3 A). hNEIL1 mediated cleavage was 57% more efficient 
when incubated with the ds-DNA +4 substrate compared to the ss-DNA -4 substrate, however 
only 25% more efficient at the fork junction position. While analysis revealed robust cleavage 
of the ds-DNA substrate, hNEIL1 displayed a preference for fork structured oligonucleotide 
DNA, with a 17% increase in cleavage of the +4 DNA substrate. Interestingly, hNEIL1 cleaves 
the ‘Fork’ substrate with 39% less efficiency compared to that of the +4 structure, while 
qualitatively presenting a smeared DNA product, representative of the degradation of an AP-
site generated after monofunctional DNA glycosylase activity (Figure 3.3 A). hNEIL1 
demonstrates a consistent β,δ-elimination AP-lyase activity in the presence of 5-OHU DNA 
lesions (Figure 3.3 A). 
Analysis of 8-OxoG substrates incubated with hNEIL1, demonstrated weak activity on ss and 
ds-DNA substrates (Figure 3.3 B). Nominal activity is observed on the fork DNA substrates, 
with 7% cleavage of the +4 substrate, 3.5% cleavage of the -4 substrate and 2% cleavage of 
the ‘fork’ substrate (Figure 3.3 B).  
Incubation of hNEIL1 with Tg DNA substrates provides the strongest contrast in substrate 
preference. hNEIL1 cleaves the +4 substrate with 56% more efficiency than -4 substrate and 
73% more efficiently than the fork junction substrate. Additionally, similar cleavage activity is 
observed between the ds-DNA and the +4 substrate (Figure 3.3 C).Unique to the Tg substrate 
hNEIL1 displays evidence of β-elimination in the presence of the ds-DNA and +4 DNA 
substrate when compared to the cleavage control Nth, previously characterised to conduct 
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β-elimination AP-lyase, wheras hNEIL1 displays evidence of weaker β,δ-elimination activity at 
in the presence of ss-DNA and -4 Tg DNA lesions substrates(Figure 3.3 C). 
Figure 3.3: Denaturing PAGE analysis of fork structured oligonucleotides incubated with hNEIL1. A. 10% 
denaturing PAGE analysis of 228 nM hNEIL1 incubated with 5 nM 5-OHU containing oligonucleotide substrates 
B. 10% denaturing PAGE analysis of 228 nM hNEIL1 incubated with 5 nM 8-OxoG containing oligonucleotide 
substrates. C. 10% denaturing PAGE analysis of 228 nM hNEIL1 incubated with 5 nM Tg containing 
oligonucleotide substrates. D.   Quantification of 5-OHU, 8-OxoG and Tg oligonucleotide substrate cleavage by 
hNEIL1. Ctrl sample in the absence of recombinant hNEIL1. Bacterial Nei and Nth provide reference for 
associated β,δ-elimination and β-elimination, respectively. Representative images of three experiments. 
Oligonucleotide cleavage assays with mock DNA replication fork structured DNA 
oligonucleotides (Table 3.1) incubated with recombinant hNEIL3FL protein, undertaken by 
Mustafa Albelazi (University of Salford), revealed distinct differences in cleavage activity to 
that demonstrated by recombinant hNEIL1. Denaturing PAGE analysis of hNEIL3FL reaction 
products with 5-OHU containing oligonucleotide, underlined the overlapping oxidative lesion 
substrate preference with hNEIL1 (Figure 3.4 A). However, hNEIL3FL displayed increased 
activity on ss-DNA substrates vs ds-DNA. Incubation of hNEIL3FL with the -4 DNA substrate 
displayed an increase in activity when compared to the +4 DNA substrate. hNEIL3FL displays a 
bifunctional DNA glycosylase profile in the presence of 5-OHU containing DNA substrates, 
with a mainly β-eliminating activity producing 19 mer cleavage products with a 3ʹPUA (Figure 
3.4 A). However, it is observed that hNEIL3FL excises the 5-OHU lesion in ds-DNA conformation 
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Incubation of hNEIL3FL with 8-OxoG containing DNA substrates displayed minor activity levels, 
with cleavage efficiency being at its greatest in the presence of the ds-DNA substrate (Figure 
3.4 B). Qualitatively, weak bifunctional DNA glycosylase activity is displayed on the ds-DNA 
substrate, suggesting weak processivity of 8-OxoG in a ds-DNA conformation in vitro (Figure 
3.4 B). 
Analysis of cleavage activity of hNEIL3FL of Tg containing DNA oligonucleotide substrates 
exhibited overlapping lesion preference with hNEIL1 (Figure 3.4 C). hNEIL3FL displays a 
preference for Tg in a ss-DNA context. An affinity for fork structured DNA is also observed 
with hNEIL3FL processing -4, Fork and +4 oligonucleotide substrates with 12%, 7% and 5% 
cleavage efficiency, respectively. Unique to the Tg substrate, hNEIL3FL displays consistent 
associated β-elimination.  
Figure 3.3 and Figure 3.4 underline the structural preference of hNEIL3FL for DNA lesions in 
open replication and fork junction mock DNA replication fork oligonucleotide structure when 
compared to hNEIL1. In addition, hNEIL3 processes the Tg lesion at all three positions within 
the mock DNA replication fork with relatively robust activity when compared to standard 
duplex oligonucleotide DNA (Figure 3.4 C). As result, Figure 3.4 C provides evidence for 
hNEIL3FL possessing an affinity for the DNA replication blocking lesion Tg at all positions 
analysed within a DNA replication fork structure, when compared to conventional ds-DNA 
oligonucleotide substrate (Figure 3.3 C). 
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Figure 3.4: Denaturing PAGE analysis of fork structured oligonucleotides incubated with hNEIL3FL. A. 10% 
denaturing PAGE analysis of 150 nM hNEIL3FL incubated with 5 nM 5-OHU containing oligonucleotide substrates 
B. 10% denaturing PAGE analysis of 150 nM hNEIL3FL incubated with 5 nM 8-OxoG containing oligonucleotide 
substrates. C. 10% denaturing PAGE analysis of 150 nM hNEIL3FL incubated with 5 nM Tg containing 
oligonucleotide substrates. D.  Quantification of 5-OHU, 8-OxoG and Tg oligonucleotide substrate cleavage 
percentages. Ctrl sample in the absence of recombinant hNEIL3FL. Bacterial Nei and Nth provide reference for 
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3.2. Discussion: Characterisation of the hNEIL1 and hNEIL3 DNA glycosylases in the 
repair of oxidative DNA damage in association with DNA replication. 
 
The data presented here demonstrates the different AP-lyase activity of the hNEIL1 and 
hNEIL3 DNA glycosylases in the presence of the 5-OHU and Tg oxidative lesions in a structure 
specific manner. hNEIL1 and hNEIL3 display overlapping substrate preference for 5-OHU and 
Tg but display different processing efficiencies depending on the DNA lesion context. hNEIL1 
maintains a preference for lesions in a ds-DNA context while hNEIL3 displays a preference for 
ss-DNA. However, within a DNA replication fork structured oligonucleotide substrate hNEIL1 
displays a preference for the “+4” ds-DNA, in a prereplicative position. hNEIL3 displays a 
preference for oxidative lesions in a single-stranded “-4” open DNA replication fork context 
and at the ds-DNA “Fork” junction. Where NEIL1 displays a mainly β,δ-elimination AP lyase 
activity NEIL3 displays β-elimination in the single-stranded DNA context lesions substrates 
including “-4” in the presence of 5-OHU. Conversely In the presence of 5-OHU in ds-DNA 
context and “+4” the AP lyase activity is observed to switch to β,δ-elimination AP-lyase. 
However, in the presence of the DNA replication blocking Tg lesion, distinct differences in 
processing are observed. hNEIL1 displays a lack of activity at the ds-DNA “Fork” with robust 
activity at “+4” while NEIL3 displays robust activity on Tg regardless of its position at the DNA 
replication fork. Furthermore, hNEIL3 exhibits consistent β-elimination AP lyase activity in the 
presence of Tg at the DNA replication fork. This demonstrates that lesion type and structural 
context are important for the discriminatory associated lyase activity of hNEIL1 and hNEIL3. 
Concurrently, this may have important implications in terms of the downstream proteins and 
their interactors recruited to the DNA replication fork due to differential AP lyase activities of 
bifunctional DNA glycosylases. 
Previous finding by Mitra’s group determined, that hNEIL1 acts as a ‘cowcatcher’ for the 
replication machinery in the presence of a DNA replication fork (Hegde et al., 2013). It was 
demonstrated that hNEIL1 functionally interacts with PCNA, RPA, WRN, RFC, Pol δ and Lig1. 
Furthermore, hNEIL1 was purified in multiprotein complexes from mammalian cells, which 
displayed efficient BER in vitro on a 5-OHU lesion and hNEIL1 is proposed to facilitate 
regression back to a prereplicative ds-DNA structure, in collaboration with the WRN helicase 
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as part of a ‘cowcatcher model’ (Das et al., 2007; Theriot et al., 2010; Hegde et al., 2015). The 
lack of additional cofactors and interacting proteins in our in vitro analysis may explain why 
reduced activity at the -4 and fork junction positioned 5-OHU lesion is observed (Table 3.1). 
However, it is unknown how these interactions may influence the activity of hNEIL1 in the 
presence of Tg as Hegde et al. (2013; 2015) used 5-OHU as a model oxidative lesion. Despite 
this, it was shown that nascent DNA chain growth was retarded in NEIL1 depleted cells when 
treated with H2O2, which is known to induce oxidative DNA damage and Tg lesions (Hegde et 
al., 2013). Thus, it is highly possible that in vivo NEIL1 may efficiently repair 5-OHU and Tg 
oxidative lesions with the aid of the identified protein partners within multiprotein complexes 
at the DNA replication fork (Hegde et al., 2015). It is postulated that NEIL1 would bind to ss-
DNA and promote DNA replication fork regression to place the DNA lesion in a favourable ds-
DNA context, mimicking the “+4” structure examined here (Table 3.1; (Hegde et al 2013). In 
this context the “Fork” junction substrate would not be produced in vivo, as DNA replication 
fork regression would facilitate bypass to generate a ds-DNA structure mimicking the “+4” 
substrate. Further biochemical analysis is required to elucidate the biochemical activity of 
hNEIL1 on differentially positioned Tg within a DNA replication fork structure, in the presence 
of recombinant WRN, PCNA, RFC, Pol δ, Lig I and RPA to determine how these interactions 
may overcome the observed inhibition of DNA glycosylase activity at the DNA replication fork 
(Das et al., 2007; Theriot et al., 2010; Hegde et al., 2013; Hegde et al., 2015). In contrast, 
NEIL3FL displays robust activity on -4, Fork and +4 regions of DNA containing Tg (Figure 3.4 C). 
In addition, NEIL3 displays consistent associated β-elimination of the phosphodiester 
backbone, demonstrating that the type of lesion encountered is important for associated AP-
lyase activity undertaken by NEIL3. Interestingly, Tg can be removed with relative efficiency 
when compared to the ds-DNA Tg containing oligonucleotide, where relatively no cleavage is 
observed, suggesting a preference for the replication fork structure. Furthermore, Where 
NEIL1 fails to process the legion at the fork junction, NEIL3 does so with comparable activity 
to that displayed in the presence of the -4 Tg substrate. This raises the question of how 
hNEIL3, independent of protein partners, may excise Tg at any of the examined positions 
within a DNA replication fork examined here. The data presented here suggests that hNEIL3 
displays a preference for Tg in a DNA replication fork structure context when compared to 
linear duplex DNA, advocating an associated role within the maintenance of faithful DNA 
replication. Despite, hNEIL3 previously being indicated to possess weak, non-concerted, β-
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elimination AP-lyase activity and proposed to be a mainly monofunctional DNA glycosylase in 
vivo in the presence of APE1, it is observed that hNEIL3 displays robust associated AP-lyase in 
the presence of 5-OHU and Tg lesions (Takao et al., 2009; Krokeide et al., 2013). When 
examining the processing of 5-OHU or Tg at the “-4” or “Fork” DNA replication fork structured 
substrate, the associated AP lyase activity demonstrated by hNEIL3 has important 
implications for the potential generation of replication associated DSB generation. Indeed, 
previous investigation by Klattenhoff et al. (2017), demonstrated that hNEIL3 co-localises at 
DNA replication associated DSBs and its depletion lead to an increase in these DSBs. It may 
be proposed that hNEIL3 has an important role in the efficient processing of oxidative DNA 
lesions at the DNA replication fork. The identification of a hNEIL3 BERosome, similar to 
hNEIL1, may indicate relatively fast repair kinetics of oxidative lesions in a “-4” or “Fork” 
structural context in vivo which may protect against the formation of single ended DSBs 
(Hegde et al., 2015). 
Taken together it is proposed that NEIL3 is the primary DNA glycosylase associated with the 
removal of the replication blocking Tg lesion at the DNA replication fork, while NEIL1 plays a 
primary role in pre-replicative repair (Aller et al., 2007; Yoon et al., 2010; Rolseth et al., 2013; 
Hegde et al., 2013; Hegde et al., 2015). It is proposed that NEIL1 and NEIL3 play distinct roles 
at the DNA replication fork and therefore redundancy in activity is observed between the 
constitutively expressed NTH1 and S-phase dependent NEIL1/NEIL3 DNA glycosylases in 
processing oxidised pyrimidines (Wallace et al., 2012). These findings support previous 
suggestions made by Rolseth et al. (2013), that NEIL3 is involved in the removal of DNA 
replication blocks within proliferating cells, as they observed that NEIL3-/- MEFs display 
sensitivity to the oxidative agent paraquat and cisplatin. Indeed, it was shown by Bjørås et al. 
(2017) that NEIL1 and NTH1 are detected on nascent DNA, suggested to be outside of the 
DNA replication fork, while NEIL3 was enriched with the replisome, supporting a role close to 
or at the DNA replication fork. Taking in to account these findings it is suggested that NEIL1 
may indeed be a ‘cowcatcher’ -like protein, removing DNA damage in a prereplicative manner, 
while NEIL3 has a specialised role within the maintenance of open DNA replication forks and 
NTH1 is a costitutively active DNA glycosylase facilitating repair outside the context of DNA 
replication (Hegde et al., 2013; 2015; Wallace, 2014). This points to a specialised and 
redundant set of tools available within the cell for the resolution of oxidised pyrimidines, 
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where structural context may dictate the DNA glycosylase employed. The essentiality for the 
repair of oxidised DNA is eluded to by embryonic lethality observed in downstream repair BER 
proteins Pol β, APE1, XRCC1 and Lig III (Hegde et al., 2012). Therefore, it may be suggested 
that comprehensive and redundant mechanisms of oxidative DNA repair are required to 
combat the 10,000 oxidative lesions generated per cell per day and the associated genomic 
instability through the mispairing of DNA (Klaunig et al., 2011; Hegde et al., 2012). However, 
these redundant pathways may in turn provide multiple targets for exploitation by cancer for 
mechanisms of acquired cellular resistance to therapeutic treatment (Rolseth et al., 2013; 
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4. Characterisation of the hNEIL1 and hNEIL3 DNA glycosylases in the repair                         
of psoralen interstrand DNA crosslinks. 
To further elucidate the role of hNEIL1 and hNEIL3 in the repair of DNA replication blocking 
lesions, 32P labelled synthetic psoralen/UVA generated MA, three-stranded and four-stranded 
ICL DNA structures were generated and confirmed. Enzymatic activity of hNEIL3Cat, hNEIL3Trun, 
hNEIL3FL, hNEIL1 and Nei on psoralen/UVA generated ICL structures was assessed. Kinetic 
analysis of hNEIL3Cat and hNEIL1 was conducted on ss-, ds-Sp1, three- and four-stranded 
psoralen ICL substrates. A catalytically inactive hNEIL3Cat-K81A mutant was generated, activity 
on ss-, ds-Sp1, three- and four-stranded ICL substrates was assessed. Enzyme-DNA covalent 
complex affinity assays were undertaken with Sp1 substrates, using hNEIL3Cat and hNEIL1. An 
enzyme-DNA covalent complex affinity assay was undertaken with a three-stranded psoralen 
ICL substrate, using hNEIL3Cat, hNEIL3Trun, hNEIL3FL, Nei, hNEIL1 and hNEIL3Cat-K81A 
recombinant proteins. 
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4.1. Results: Characterisation of the hNEIL1 and hNEIL3 DNA glycosylases in the repair 
of psoralen interstrand DNA crosslinks. 
 
4.1.1. Generation of ICL oligonucleotide DNA substrates. 
 
As NEIL3 -/-MEF cells display sensitivity to the ICL agent cisplatin, ICL lesions block the 
progression of DNA replication and previous observations display an activity for the removal 
of the DNA replication blocking lesion Tg (Rolseth et al., 2013; Figure 3.4), the hypothesis that 
hNEIL3 plays a role in the repair of ICL lesions was investigated. Model ICL DNA 
oligonucleotide substrates were generated with use of psoralen/UVA treatment as described 
in sections 2.9, 2.11, 2.12, 2.15, 2.16 and 2.17.  A shift in the relative size observed after 
psoralen treatment, was characteristic of ICL formation due to opposing DNA strands 
remaining covalently bound under denaturing conditions. As shown by Figure 4.1 the 
generation of ICL substrates with 18 mer, 21 mer or 47 mer 32P labelled oligonucleotide DNA, 
generating 21–47 or 18-21 mer DNA or DNA RNA hybrid duplex was observed post psoralen 
(HMT)/UVA treatment. However, 100% of component labelled oligonucleotides was not 
observed to generate a psoralen ICL DNA duplex, warranting gel purification. 
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Figure 4.1: Denaturing PAGE analysis of ICL construct preparation. (X) Denotes ICL duplex substrate product 
band.  “*” Denotes 5ʹ 32P-labelled oligonucleotide strand, “•” Duplex DNA formed by annealing, “-“ 
psoralen/UVA treated annealed duplex DNA oligonucleotide, “+” Mixture of ss-DNA oligonucleotides, “/” 
psoralen/UVA treated ss-DNA oligonucleotides. 
 
To improve the purity of ICL oligonucleotides prior to construction of three-stranded ICL 
substrates, labelled duplex ICL oligonucleotides were separated by denaturing PAGE and then 
gel purified as described in section 2.16. Figure 4.2 displays the confirmation of the excision 
of ICL DNA oligonucleotide duplexes composed of 21 mer psoralen crosslinked to 47 mer and 
47 mer psoralen crosslinked to 101 mer oligonucleotides, by the excision of the upper band 
associated with psoralen bound oligonucleotides. Figure 4.2 lanes 5 and 6 display extensive 
band smearing above the upper band, which is suggested to be a result of the large size of 
the construct and retardation entering the polyacrylamide gel during electrophoresis. 
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Figure 4.2: Denaturing PAGE analysis of ICL construct gel excision. (Lanes 1-2) Before excision of ICL DNA D21* 
- C47 and D21 - C47* HMT ICL oligonucleotides. (Lanes 3-4) After excision of D21* - C47 and D21 - C47* ICL 
oligonucleotides. (Lanes 5-6) Before and after excision of the C47* - D101 ICL oligonucleotide. Upper bands 
represent covalently bound ICL DNA, whilst lower bands represent non-crosslinked DNA. “*” Denotes 5ʹ 32P 
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After purification of psoralen ICL bound duplex oligonucleotides, construction of three-
stranded and four-stranded ICL DNA oligonucleotides were performed using 21-47 mer based 
constructs, whilst three-stranded constructs were generated using 47-101 duplex psoralen 
ICL constructs.  
To confirm three-stranded and four-stranded psoralen ICL oligonucleotide generation under 
native conditions, non-denaturing PAGE analysis was undertaken (Figure 4.3). The generation 
of an ICL in duplex was marked by a small shift, as the construct migrated slower than the 
duplex due to incorporation of the psoralen (HMT) molecule. The generation of a three-
stranded structure was displayed by a relatively large shift in the position of the band. This 
was due to slower migration in the gel, representative of an increase in the size of the 
oligonucleotide construct after a 47/101 mer complementary DNA oligonucleotide was 
annealed. The generation of a four-stranded structure was marked by a relatively smaller shift 
in the position of the band, which represented an increase in the size of the construct, due to 
addition of a 21 mer complementary DNA oligonucleotide.  
Migration was relative to constructs of the same size component oligonucleotides. Single 
stranded labelled oligonucleotides (21* mer, 47* mer, 101* mer) and possible alternate 
products, based on the incorrect construction of ICLs (21* - 21 mer, 47* - 47 mer), were 
loaded as size markers and control.  
Figure 4.3, demonstrates successful generation of target constructs with high efficiency as 
the major product DNA bands generated in each sample migrate at their expected relative 
position, with nominal additional contaminant DNA bands detected. 
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Figure 4.3: Non-denaturing PAGE analysis of psoralen/UVA oligonucleotide DNA structures. Oligonucleotide 
construct key included below the gel image. “*” Denotes 5ʹ 32P labelled oligonucleotide DNA oligonucleotide, 
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Figure 4.4 shows that the psoralen generated ICL was maintained after oligonucleotide 
purification and annealing reactions that generated three-stranded and four-stranded 
structures. This was shown by a shift and slower migration in the gel in comparison to non-
crosslinked duplex oligonucleotide samples. Figure 4.3 and Figure 4.4 show the successful 
generation of three- and four-stranded ICL structures for use in biochemical assays to 
elucidate unhooking activity of recombinant proteins. 
Figure 4.4: Denaturing PAGE analysis of psoralen/UVA treated, duplex, three and four-stranded 
oligonucleotide structures.  Psoralen ICL lesion remain stable after gel purification. DNA substrates were 
analysed by denaturing PAGE. (X). Denotes DNA oligonucleotide containing psoralen ICL. “*” Denotes 5ʹ 32P 
labelled oligonucleotide DNA oligonucleotide, “•” hydrogen bond DNA complementation, “-“ psoralen/UVA 
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4.1.2. hNEIL3 protein concentration titration for activity on three-stranded ICL 
oligonucleotides. 
 
Due to difficulties in the production of hNEIL3 recombinant proteins, previously prepared 
hNEIL3Cat, hNEIL3Trun and hNEIL3FL recombinant proteins of high purity from laboratory stocks 
were used for biochemical characterisation. These proteins were previously analysed through 
SDS-PAGE, western blot (Mustafa Albelazi, University of Salford: Appendix Figure 1; Appendix 
Figure 2; Appendix Figure 3) and enzymatic activity assays. 
As hNEIL1 has been previously confirmed to process three-stranded ICLs (Couvé et al., 2009), 
enzymatic activity analysis was carried out on alternatively labelled XL47 • 47 – 21 three-
stranded ICL substrates, generated as described in 2.17. This was to determine if hNEIL3 was 
also capable of resolving an ICL adduct in three-stranded context. After generation of three-
stranded ICL substrates, activity of hNEIL3Cat, hNEIL3Trun and hNEIL3FL was assessed on the 
XL47 • 47 - 21* three-stranded ICL DNA oligonucleotide construct, with and without light 
piperidine treatment.  
As observed in Figure 4.5, the addition of increasing concentrations of hNEIL3 recombinant 
protein resulted in a smeared cleavage product. With use of light piperidine treatment which 
conducts β-elimination of the phosphodiester backbone, the smeared product became 
defined as a single band. This is suggested to represent the unhooking of the 21* mer strand 
of the three-stranded ICL, generating an AP site on the 21* mer strand, which degrades under 
standard reaction conditions to produce a smear. Subsequently, light Piperidine treatment 
processes the AP-site by β-elimination to generate an 8PAmer product. While hNEIL3 was 
previously characterised to possess an associated weak β-elimination, hNEIL3 recombinant 
proteins demonstrate a monofunctional profile. This is indicated by unhooking the psoralen 
ICL, generating an AP site on the 21* labelled oligonucleotide site of cleavage. Furthermore, 
without the addition of piperidine, an increase in a cleavage product doublet was observed in 
the centre of the gel, while in the presence of piperidine the doublet was consistently 
produced. The lower band of the doublet is proposed to be unhooked 21* mer strand 
containing an unprocessed AP site which has not degraded, generated from the unhooking 
activity discussed above. The upper band of the doublet is suggested to be representative of 
a second hNEIL3 unhooking activity, which unhooked the ICL from the 47 mer oligonucleotide 
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side of the ICL, presumably generating an AP site. The 21*mer strand then retained the ICL 
adduct resulting in a slower migration in line with the Nei control product and thus 
representative of a ss-MA product. Piperidine is proposed to generate the doublet as product 
of unhooking at both sides of the ICL construct as observed when conducting hot alkali 
treatment of ICLs (Couvé-Privat et al., 2007).  
The data indicates hNEIL3 possesses unhooking activity on both sides of the three-stranded 
ICL, thus generating an unhooked 21* mer strand with an AP site and simultaneously an 
unhooked 21* mer strand with the ICL retained, which represented a 21* mer MA migrating 
in line with the 21-MA product produced by Nei. Nei was previously characterised to display 
the later described activity (Couvé et al., 2009). Finally, it is apparent that hNEIL3Cat was more 
active than hNEIL3Trun and hNEIL3FL recombinant proteins at comparable concentrations, 
while all recombinant proteins possessed some residual activity on the XL47 • 47 - 
21*substrate. This indicates that the glycosylase domain of recombinant hNEIL3 is responsible 
for the observed unhooking activity, that the C-terminal domain possesses uncharacterised 
inhibitory domains or promotes inherent instability and therefore loss of activity at 
comparable concentrations. 
Figure 4.5: Denaturing PAGE analysis of XL47 • 47 - 21* DNA oligonucleotides incubated with hNEIL3 proteins. 
hNEIL3 proteins unhook psoralen ICLs in a three-stranded DNA context with a monofunctional profile. hNEIL3Cat, 
hNEIL3Trun, hNEIL3FL and Nei protein activity on ~10 nM XL47 • 47 - 21*mer generated three-stranded DNA ICL.  
A. (lanes 1-15) Reactions were without piperidine treatment. B. Reactions were with light piperidine treatment. 
B. Ctrl sample is in the absence of recombinant protein. Nei as control for previously characterised psoralen ICL 
unhooking activity. “X”denotes substrate, A. “21-MA” denotes 21 mer fragment containing psoralen-derived 
MA, A. “21-mer” B.”47-mer” denote cleavage fragments containing an AP (Lanes 2-13), A. “8PA”, denotes 8 mer 
fragments containing a 3ʹ-terminal PA.   
B. A. 
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Figure 4.6 displays the percentage cleavage of the XL47 • 47 - 21* oligonucleotide by 
recombinant hNEIL3 poteins, determined through use of ImageGuage V4.0 (Fujifilm). It was 
observed that up to a concentration of 300 nM the increase in cleavage product is relatively 
linear. Therefore, a concentration within the linear range of the graph was selected for 
downstream time course analysis for the determination of protein kinetics as the reaction is 
not saturated by recombinant protein. At 500 nM the cleavage percentage reached a maximal 
activity plateau for all recombinant proteins analysed and resulted in > 40% cleavage. 
Consequently, 500 nM of recombinant hNEIL3 proteins was selected for downstream 
qualitative analysis to achieve comparative maximal cleavage of oligonucleotides substrates 
for mechanistic elucidation. The observation that cleavage reached a plateau before 
complete cleavage of the oligonucleotide substrate, indicated that the reaction was limited 
by an external factor. It may suggest that recombinant hNEIL3 protein requires protein 
partners or co-factors to increase enzyme processivity. 
 
Figure 4.6: Quantification of the percentage cleavage of XL47 • 47 - 21* three-stranded DNA ICL substrate by 
hNEIL3Cat, hNEIL3Trun and hNEIL3FL. “*” Denotes 5ʹ 32P labelled oligonucleotide DNA oligonucleotide, “•” 
hydrogen bond DNA complementation, “-“ psoralen/UVA treated and ICL bound DNA. 
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4.1.3. hNEIL3, Nei and hNEIL1 protein concentration titration for activity on Sp1 
substrates. 
 
Nei family protein activity on Sp DNA lesions has been previously established (Krokeide et al., 
2013). Therefore, the titration of recombinant hNEIL3 cleavage activity in the presence of Sp 
containing oligonucleotide substrates was required for the determination of control enzyme 
kinetics. This in turn would facilitate comparison and characterisation of recombinant hNEIL3 
kinetics in the presence of three- and four-stranded psoralen ICL oligonucleotides.  
As observed in Figure 4.7 A and B, cleavage of the ss-Sp1 oligonucleotide substrate by 
hNEIL3Cat was greater than that facilitated by hNEIL3Trun and hNEIL3FL. However, all hNEIL3 
recombinant proteins displayed robust activity when processing the ss-Sp1 oligonucleotide 
when compared to three-stranded psoralen ICL oligonucleotide (Figure 4.5). 
As observed in Figure 4.7 C, linear cleavage activity by hNEIL3Cat and hNEIL3Trun is observed at 
concentrations of up to ~100 nM, with hNEIL3FL maintaining linear behaviour cleavage up to 
the maximum concentration of 300 nM. At 100 nM hNEIL3Cat, hNEIL3Trun and 300 nM hNEIL3FL 
a greater cleavage product percentage was generated compared to the maximal percentage 
achieved by 500 nM hNEIL3Cat in the presence of the three-stranded psoralen ICL 
oligonucleotide substrate (Figure 4.6). This suggests that hNEIL3 recombinant proteins have 
a preference for Sp substrates rather than three-stranded ICLs, displaying a difference in 
protein kinetics.  In the case of Nei a plateau at 5 nM was produced, whereas this was 
achieved at 20 nM for hNEIL1 (Figure 4.7 B; D). Therefore, recombinant hNEIL1 and Nei 
demonstrate increased activity on ds Sp1 substrates compared hNEIL3 proteins on ss Sp1, 
saturating at lower concentrations. Alternatively, Nei and NEIL1 proteins may possess 
increased stability in reaction compared to hNEIL3 proteins which are observed to be unstable 
(Appendix Figure 1; Appendix Figure 2; Appendix Figure 3), accounting for requirement of 
higher concentrations for comparable cleavage. As demonstrated by all but hNEIL3FL, 
recombinant proteins analysed in Figure 4.7, achieve a cleavage percentage plateau before 
cleaving 100% of the oligonucleotide substrate. This may indicate that the recombinant 
proteins examined require protein partners or co-factors to improve enzymatic turnover and 
processivity in the presence of Sp containing lesions.  
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Figure 4.7: Denaturing PAGE analysis of Sp1 containing DNA oligonucleotides incubated with hNEIL3Cat, 
hNEIL3Trun, hNEIL3FL, hNEIL1 and Nei. A. hNEIL3Cat, hNEIL3Trun and hNEIL3FL protein activity upon 10 nM ss Sp1 
substrate. B. Nei and hNEIL1 activity upon 10 nM ds Sp1 substrate. “17 mer” denotes substrate, A-B. “8PA” and 
“8P” denotes 8 mer fragments containing a 3ʹ-terminal PA and P, respectively. C.  Quantification of NEIL3Cat, 
hNEIL3Trun and hNEIL3FL generated cleavage product percentages after enzymatic cleavage assay on 10 nM ss 
Sp1 substrate. D. Quantification of Nei and hNEIL1 generated cleavage product percentages after enzymatic 
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4.1.4. hNEIL3 unhooking activity of a single-stranded HMT generated MA.  
 
As NEIL3 has been observed to display a preference for ss oxidative lesion containing 
substrates, enzymatic activity analysis was carried out on a ss MA substrate, generated as 
described in section 2.15. Figure 4.8 shows active cleavage by hNEIL3 of the XL21* - 1 
substrate, with increased efficiency by hNEIL3Cat compared to hNEIL3Trun and hNEIL3FL. A small 
cleavage product was observed at ~8 mer as a smear without piperidine treatment, defined 
after light piperidine treatment. This is representative of the unhooking of the 21* mer strand 
at the site of the MA, producing an AP site, which degrades under standard reaction 
conditions. It is suggested that small oligomers remain present, due to incomplete digestion 
by RNase A, thus a faint upper and lower band were observed surrounding the major ~8 mer 
product generated after light piperidine treatment. Nei and hNEIL1 displayed minimal activity 
on the XL21* - 1 ss MA substrate. hNEIL3 proteins unhook ss MAs with a monofunctional 
profile. 
Figure 4.8: Denaturing PAGE analysis of  ~ 10 nM (X): XL21* - 1 ss MA substrate incubated with hNEIL3Cat, 
hNEIL3Trun, hNEIL3FL, hNEIL1 and Nei. Samples were incubated for 1 h at 37°C with 500 nM of protein. For 
positive control 20 nM of bacterial Nei was used and 500 nM hNEIL1.  (Lanes 1-8) Reactions were without 
piperidine treatment. “Ctrl” sample in the absence of recombinant protein. (Lanes 9-12) Reactions with light 
piperidine treatment. “X” denotes substrate, A. “21-MA” denotes 21 mer fragment containing a psoralen-
derived MA, “21-mer” denote cleavage fragments containing an AP (Lanes 2-4), “8PA” denote 8 mer fragments 
containing a 3ʹ-terminal PA respectively. 
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4.1.5. hNEIL1, hNEIL3 and Nei unhooking activity of a three-stranded HMT generated 
ICL oligonucleotide substrate. 
 
To elucidate the mechanism of recombinant hNEIL3 protein resolution of three-stranded 
psoralen ICL oligonucleotide substrates, qualitative analysis of cleavage activity was 
undertaken. The use of XL47 • 47 – 21 psoralen ICL oligonucleotide substrate, alternatively 
5ʹ32P labelled on either the 21 mer or 47 mer side of the ICL would allow for determination of 
the cleavage profile presented by recombinant proteins. 
Figure 4.9 A shows cleavage by hNEIL3 of the XL47 • 47 - 21* substrate, with increased 
efficiency by hNEIL3Cat compared to hNEIL3Trun and hNEIL3FL. A small cleavage product was 
observed at ~8 mer as a smear without Piperidine treatment. After light piperidine treatment 
this smear became defined as an 8PA mer in reference to the activity control D21-U+UDG+LP 
treatment which also yields an 8 mer fragment with a 3ʹ terminal PA. This is representative of 
unhooking on the 21* mer strand side of the ICL, producing an AP site, which degrades under 
standard reaction conditions to yield a smeared pattern. After light Piperidine treatment the 
AP site becomes further processed by β-elimination, generating an 8 mer 3ʹ-terminal PA. A 
doublet of cleavage products was also observed in the centre of the gel, the upper of which 
migrated in line with 21*-MA substrate and is proposed to be the 21* mer strand with the ICL 
remaining attached (ss-MA), unhooked at the 47 mer strand side of the ICL. The lower band 
represents the 21* mer strand with an AP site and the ICL unhooked, which migrated in line 
with D21 size control. Nei and hNEIL1 however resulted in the formation of the upper band 
of the doublet, representing the 21* mer strand with the ICL attached, unhooked at the 47 
mer strand only and in agreement with previous observations (Couvé et al., 2009). 
In reference to D21, C47 and the D21-U+UDG 3ʹ terminal markers, these results suggest that 
hNEIL3 possesses the same DNA glycosylase unhooking activity as Nei and hNEIL1, however 
hNEIL3 proteins do not demonstrate incision of the phosphodiester backbone. Additionally, 
hNEIL3 can unhook an ICL from the 21* mer strand side of the structure generating an AP site. 
Finally, hNEIL3 processes the unhooked three-stranded ICL through a mainly monofunctional 
profile rather than bifunctional as presented by hNEIL1 and Nei. Thus, hNEIL3 mediated 
cleavage of a three-stranded psoralen ICL is independent of ss-DNA breaks. 
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Figure 4.9 B. shows cleavage by hNEIL3 of the XL47 • 47* - 21 substrate, with increased 
efficiency by hNEIL3Cat compared to hNEIL3Trun and hNEIL3FL. A small cleavage product was 
observed at ~23 mer as a smear without piperidine treatment. After light piperidine 
treatment this smear became defined as a 23PA mer in reference to the activity control C47-
U with UDG and light piperidine treatment which also yields a 23 mer fragment with a 3ʹ 
terminal PA. This is representative of unhooking on the 47* mer strand side of the ICL, 
producing an AP site, which degrades under standard reaction conditions to yield a smeared 
pattern. After light piperidine treatment the AP site becomes further processed by β-
elimination generating a 23 mer 3ʹ terminal PA. A cleavage product which migrated in line 
with both the C47 size marker and the band representing the 47-47* MA substrate marker 
was observed. This is proposed to be the 47* mer strand with the ICL attached (ds-MA), 
unhooked at the 21 mer strand side and an indistinguishable band representing the 47* mer 
strand with an AP site and the ICL unhooked. Nei and hNEIL1 however resulted in the 
formation of one band, representing the ~23 mer strand after unhooking at the 47 mer strand, 
creating an AP site, cleaved by the associated β,δ-elimination AP lyase.  
In reference to D21, C47 and the D47-U+UDG 3ʹ terminal markers, these results suggest that 
hNEIL3 can unhook the same thymine from the 47 mer side of the structure as Nei and hNEIL1. 
Additionally, hNEIL3 can unhook an ICL from the 21* mer strand side of the structure 
generating an AP site. Finally, hNEIL3 processes the unhooked three-stranded ICL through a 
mainly monofunctional profile rather than bifunctional, as presented by hNEIL1 and Nei. Thus, 
hNEIL3 mediated cleavage of a three-stranded psoralen ICL is independent of ss-DNA breaks. 
Chapter IV  Results and Discussion. 
140 
Figure 4.9: Denaturing PAGE analysis: A. ~10 nM (X): XL47 • 47 - 21* B. ~10 nM (X) XL47 • 47* - 21 HMT 
generated three-stranded DNA ICL incubated with of hNEIL3Cat, hNEIL3Trun, hNEIL3FL, hNEIL1 and Nei protein. 
Samples were incubated for 1 h at 37°C with 500 nM of protein. For positive control 50 nM of hNEIL1 was used. 
(Lanes 1-7) Reactions without piperidine treatment. (Lanes 7-12) Reactions with light piperidine treatment. 
(Lane 7) 21* mer ds-MA substrate digested with Nei cleavage, product control. (Lane 8) 47* mer ds-MA substrate 
digested with Nei, cleavage product control. (Lane 6) A. 21 C21* MA B.47 • 47* ss oligonucleotide size marker. 
(Lane 10) D47, 47 mer ss oligonucleotide size marker. (Lane 12) A. 21* B. 47* mer oligonucleotides. (Lane 13-15) 
A. 21 U • A duplex B. 47 U • A duplex with UDG/Hot Piperidine treatment, UDG/Nfo and UDG/light Piperidine, 
respectively. Substrate and cleavage products sizes are indicated to the right of the gel. “X”denotes substrate, 
A. “21-MA” denotes 21 mer fragment containing a psoralen-derived MA, A. “21-mer” B.”47-mer” denote 
cleavage fragments containing an AP (Lanes 2-4), A. “8PA”, “8OH” and “8P” denote 8 mer B. 23PA”, “23OH” and 
“23P” denote 23 mer, fragments containing a 3ʹ-terminal PA, OH and P, respectively.   
 
Data obtained and displayed in Figure 4.9 facilitated further mechanistic insight into the 
biochemical action of hNEIL3 recombinant protein resolution of three-stranded psoralen ICL 
oligonucleotides. This facilitated the schematic representation of the mechanistic action of 
recombinant Nei, hNEIL1 and hNEIL3 in relation to one another (Figure 4.10). 
Nei and hNEIL proteins unhook the three-stranded psoralen ICL oligonucleotide structure 
uniquely from the thymidine within the duplex, releasing the ss-MA portion of the structure. 
In addition, the associated β,δ-elimination by Nei and hNEIL1 induces a ss nick at the AP site 
within the duplex portion of three-stranded structure after removal of the thymidine. Counter 
to this hNEIL3 can unhook the psoralen ICL from the thymidine within the ss or duplex portion 
B. A. 
Chapter IV  Results and Discussion. 
141 
of the structure. The activity of hNEIL3 is monofunctional and subsequently results in the 
generation of AP sites rather than ss-nicks after unhooking of the covalently linked thymidine. 
In addition, it is proposed that the ds-MA generated as a product of hNEIL3 mediated 
cleavage, may be processed downstream by the previously characterised activity of hNEIL1 
(Couvé-Privat et al., 2007).  
Figure 4.10: Schematic representation of the mechanistic biochemical action of Nei, hNEIL1 and hNEIL3 DNA 
glycosylases on three-stranded psoralen ICL oligonucleotide substrates. A. Mechanism of action of the Nei, 
hNEIL1 and hNEIL3 recombinant DNA glycosylases on three-stranded psoralen ICL oligonucleotides. B. Skeletal 
formula of an unhooked ss-21* mer HMT MA with thymine from opposite complementary DNA strand, produced 
by Nei, hNEIL1 and hNEIL3 facilitated DNA glycosylases excision. C. Skeletal formula of proposed thymine-HMT-
thymine excision product generated post hNEIL3 facilitated unhooking and subsequent downstream processing 
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4.1.6. hNEIL3 and Nei unhooking activity of four-stranded HMT generated ICL 
oligonucleotide substrate. 
 
It has previously been shown that TLS DNA polymerases can bypass an ICL lesion with primer 
extension facilitated by Rev1/Polζ, in addition the FANCM protein has been shown to possess 
translocase activity, facilitating replication traverse and fork restart (Huang et al., 2013; 
Budzowska, et al., 2015). This may suggest that continuation of replication past an ICL 
without the Fanconi anemia mediated incision step may take place in vivo. Thus, synthesis on 
both strands during DNA replication may yield a long four stranded ICL structure. Therefore, 
enzymatic activity analysis was carried out on alternatively 5ʹ32P labelled 8-MOP (Appendix 
Figure 4) or HMT XL47 • 47 - 21 • 21 four-stranded ICL DNA oligonucleotides, generated as 
described in 2.17. This was to determine if hNEIL1 and hNEIL3 were capable of resolving an 
ICL adduct in four-stranded context. 
Figure 4.11 A shows cleavage by hNEIL3 of the XL47 • 47 - 21* • 21 substrate, with increased 
efficiency by hNEIL3Cat compared to hNEIL3Trun and hNEIL3FL. A small cleavage product was 
observed at ~8 mer as a smear without Piperidine treatment. After light piperidine treatment 
this smear became defined as an 8PAmer in reference to the activity control D21-U with UDG 
and light piperidine treatment which also yields an 8 mer fragment with a 3ʹ terminal PA. This 
is representative of unhooking on the 21* mer strand side of the ICL, producing an AP site, 
which degrades under standard reaction conditions to yield a smeared pattern. After light 
piperidine treatment the AP site becomes further processed by β-elimination generating an 
8 mer 3ʹ-terminal PA. A doublet of cleavage products was also observed in the centre of the 
gel, the upper of which migrated in line with the 21*-MA substrate and is proposed to be the 
21* mer strand with the ICL remaining attached (ss-MA), unhooked at the 47 mer strand side 
of the ICL. The lower band represents the 21* mer strand with an AP site and the ICL 
unhooked, which migrated in line with the D21 size control. Nei however resulted in the 
formation of an 8pmer product with reference to the D21-U+UDG+HP 3ʹ terminal cleavage 
marker. This is suggested due to initial unhooking of the ICL from either side of the duplex 
followed by further processing of the ds-MA product formed and or production of a nick 
through associated β,δ-elimination of the phosphodiester backbone. 
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In reference to D21, C47 and the D21-U+UDG 3ʹ terminal markers, these results suggest that 
hNEIL3 possesses the same initial unhooking activity of Nei. However, hNEIL3 processes the 
four-stranded ICL through a monofunctional profile rather than β,δ-elimination as presented 
by Nei. Thus, hNEIL3 mediated cleavage of a four-stranded psoralen ICL is independent of ss-
DNA breaks. Figure 4.11 B. shows cleavage by hNEIL3 of the XL47 • 47* - 21 • 21 substrate, 
with increased efficiency by hNEIL3Cat compared to hNEIL3Trun and hNEIL3FL. A small cleavage 
product was observed at ~23 mer as a smear without piperidine treatment. After light 
piperidine treatment this smear became defined as a 23PAmer in reference to the activity 
control C47-U with UDG and light piperidine treatment which also yields a 23 mer fragment 
with a 3ʹ terminal PA. This is representative of unhooking on the 47* mer strand side of the 
ICL, producing an AP site, which degrades under standard reaction conditions to yield a 
smeared pattern. After light Piperidine treatment the AP site becomes further processed by 
β-elimination generating a 23 mer 3ʹ terminal PA. A cleavage product which migrated in line 
with both the C47 size marker and the band representing the 47-47* MA substrate marker 
was observed. This is proposed to be the 47* mer strand with the ICL attached (ds-MA), 
unhooked at the 21 mer strand side and an indistinguishable band representing the 47* mer 
strand with an AP site and the ICL unhooked. Nei however resulted in the formation of a 
23pmer product with reference to the D47-U+UDG+HP 3ʹ terminal cleavage marker. This is 
suggested to be due to initial unhooking of the ICL from the either side of the duplex followed 
by further processing of the ds-MA product formed and or production of a nick by associated 
β,δ-elimination. hNEIL1 displayed inhibited cleavage of the HMT generated four-stranded ICL 
oligonucleotides. However, robust activity was observed on alternatively labelled (21*/ 47 *) 
8-MOP generated four-stranded ICL oligonucleotides (Appendix Figure 4). hNEIL1 displays 
unhooking activity by excising the thymine present on the 21 or 47 mer duplex, generating a 
ss-nick through associated β,δ-elimination of the phosphodiester backbone. 
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In reference to D21, C47 and the D47-U+UDG 3ʹ terminal markers, these results suggest that 
hNEIL3 can unhook the same thymine as Nei and hNEIL1. However, hNEIL3 processes the four-
stranded ICL through a mainly monofunctional profile rather than bifunctional as presented 
by hNEIL1 and Nei. Thus, hNEIL3 mediated cleavage of a four-stranded psoralen ICL is 
independent of ss-DNA breaks. 
Figure 4.11: Denaturing PAGE analysis of hNEIL3Cat, hNEIL3Trun, hNEIL3FL, hNEIL1 and Nei protein activity on: A. 
~10 nM (X): A. XL47 • 47 - 21* • 21. B. ~10 nM (X): XL47 • 47* - 21 • 21 HMT generated three-stranded DNA 
ICL. Samples were incubated for 1 h at 37°C with 500 nM of protein. For positive control 20 nM of bacterial Nei 
was used and 500 nM hNEIL1. (Lanes 1-7) Reactions without Piperidine treatment. (Lanes 7-12) Reactions with 
light piperidine treatment (Lane 7) 21* mer ds-MA substrate digested with Nei cleavage, product control. (Lane 
8) 47* mer ds-MA substrate digested with Nei, cleavage product control. (Lane 6) A. 21 C21* MA B.47 • 47* ss 
oligonucleotide size marker. (Lane 10) D47, 47 mer ss oligonucleotide size marker. (Lane 12) A. 21* B. 47* mer 
oligonucleotides. (Lane 13-15) A. 21 U • A duplex B. 47 U • A duplex treated with UDG/Hot Piperidine, UDG/Nfo 
and UDG/light Piperidine, respectively. Substrate and cleavage products sizes are indicated to the right of the 
gel. “X”denotes substrate, A. “21-MA” denotes 21 mer fragment containing a psoralen-derived MA, A. “21-mer” 
B.”47-mer” denote cleavage fragments containing an AP (Lanes 2-4), A. “8PA”, “8OH” and “8P” denote 8 mer B. 
23PA”, “23OH” and “23P” denote 23 mer, fragments containing a 3ʹ-terminal PA, OH and P, respectively.  
Data obtained and displayed in Figure 4.11 and Appendix Figure 4 facilitated further 
mechanistic insight into the biochemical action of hNEIL1/3 recombinant protein resolution 
of four-stranded psoralen ICL oligonucleotides. This facilitated the schematic representation 
of the mechanistic action of recombinant Nei, hNEIL1 and hNEIL3 in relation to one another 
(Figure 4.12). Nei and hNEIL1 DNA glycosylases unhook an ICL from both sides of the four-
stranded structure, producing a ss-nick through associated β,δ-elimination by Nei and hNEIL1, 
B. A. 
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generating a 3ʹ-terminal P. Counter to this hNEIL3 can unhook the psoralen ICL from both 
sides of the ICL structure, but with a monofunctional profile and subsequently results in the 
generation of an AP site rather than a ss-nick after unhooking of the covalently linked 
thymidine. In addition, it is proposed that the ds-MA generated as a product of the initial 
cleavage by hNEIL1/hNEIL3, may be processed downstream by the previously characterised 
activity of hNEIL1 (Figure 4.12; Couvé-Privat et al., 2007). 
Figure 4.12: Schematic representation of the mechanistic biochemical action of Nei, hNEIL1 and hNEIL3 DNA 
glycosylases on four-stranded psoralen ICL oligonucleotide substrates. A. Mechanism of action of the Nei, 
hNEIL1 and hNEIL3 recombinant DNA glycosylases on three-stranded psoralen ICL oligonucleotides. B. Skeletal 
formula of an unhooked ss-21* mer HMT MA with thymine from opposite complementary DNA strand, produced 
by Nei, hNEIL1 and hNEIL3 facilitated DNA glycosylases excision. C. Skeletal formula of proposed thymine-HMT-
thymine excision product generated post hNEIL3 facilitated unhooking and subsequent downstream processing 
of ds-MA product by hNEIL1. 
C. B. 
A. 
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4.1.7. hNEIL1, hNEIL3 and Nei unhooking activity of a long three-stranded HMT 
generated ICL oligonucleotide substrate. 
 
To examine if the length of the psoralen ICL structure was crucial for recognition by the Nei, 
hNEIL1 and hNEIL3 DNA glycosylases, further enzymatic activity analysis was carried out on a 
XL101 • 101 – 47* labelled long three-stranded ICL DNA substrate, generated as described in 
3.16. This was to determine if hNEIL1 and hNEIL3 can resolve an ICL adduct larger in size, 
closer in representation to DNA in vivo in replication fork bypass context than as a product of 
MUS81-EME1 and ERCC1-XPF incision of 47 mer followed by TLS.  
Figure 4.13 demonstrates cleavage by hNEIL3 of the XL101 • 101 – 47* substrate, with 
increased efficiency by hNEIL3Cat compared to hNEIL3Trun and hNEIL3FL. A small cleavage 
product was observed at ~23 mer as a smear without light piperidine, which became defined 
after light piperidine treatment as a 23PAmer. This is representative of the unhooking on the 
47*mer strand side of the ICL, producing an AP site which degrades under normal reaction 
conditions generating a smear. The light piperidine treatment subsequently facilitates 
cleavage of the AP site to generate a 23 mer containing a 3ʹ-terminal PA. Additionally, despite 
a mainly monofunctional profiled presented by hNEIL3 recombinant proteins, the definition 
of a 23PAmer product without addition of piperidine is more apparent, indicative of a weak 
associated β-elimination acitivty. A doublet of cleavage products was observed in the centre 
of the gel, the upper of which is proposed to be the 47* mer strand with the ICL attached 
unhooked at the 101 mer strand side of the ICL, which migrated in line with the 47*-MA 
substrate band. The lower being the 47*mer strand with an AP site which migrated in line 
with the C47 size reference. Nei and hNEIL1 however resulted in the formation of the upper 
band representing the 47* mer strand with the ICL attached, unhooked at the 101 mer strand, 
generating a ss-nick through associated β,δ-elimination.  
In reference to C47 size marker, these results suggest that hNEIL3 can unhook the same 
thymine from the 101 mer side of the structure as Nei and hNEIL1. Additionally, hNEIL3 can 
unhook an ICL from the 47* mer strand side of the structure. However, hNEIL3 proteins 
display a mainly monofunctional profile, generating an AP site independent of ss-nicks. This 
said, compared to previous observations hNEIL3 recombinant proteins display a weak β-
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elimination with the observation of a more defined 23PAmer cleavage product, which may 
indicate a preference for the processing of long three-stranded ICL structures. 
 
 
Figure 4.13: Denaturing PAGE analysis hNEIL3Cat, hNEIL3Trun, hNEIL3FL, hNEIL1 and Nei proteins on ~10 nM (X): 
XL101 • 101 – 47* HMT generated three-stranded DNA ICL. Samples were incubated for 1 h at 37°C with 500 
nM of protein. For positive control 20 nM of bacterial Nei was used and 500 nM hNEIL1. (Lanes 1-10) Reactions 
without piperidine treatment. (Lanes 11-14) Reactions with light piperidine treatment (Lane 7) 21* mer ds-MA 
substrate digested with Nei cleavage, product control. (Lane 8) 47* mer ds-MA substrate digested with Nei, 
cleavage product control. (Lane 9) C21, 21 mer ss oligonucleotide size marker. (Lane 10) D47, 47 mer ss 
oligonucleotide size marker. “X” denotes substrate, A. “47-MA” denotes 47 mer fragment containing a psoralen-
derived MA,”47-mer” denote cleavage fragments containing an AP (Lanes 2-4). ”23PA” and “23P” denote 23 mer, 






Chapter IV  Results and Discussion. 
148 
4.1.8. hNEIL1, hNEIL3 and Nei protein unhooking activity of an 8-MOP generated 
three-stranded ICL oligonucleotide substrate. 
 
Further enzymatic activity analysis was carried out on a XL47 • 47 – 21* labelled three-
stranded ICL DNA substrate, generated as described in 3.16. This was to determine if hNEIL3 
can resolve an ICL adduct generated by 8-MOP rather than HMT only, to determine if activity 
was psoralen ICL specific rather than HMT specific. 
Figure 4.14 shows cleavage by hNEIL3 of the XL47 • 47 – 21* substrate, with increased 
efficiency by hNEIL3Cat compared to hNEIL3Trun and FL. A small cleavage product was observed 
at ~8 mer as a smear without piperidine, defined in the presence of piperidine. This is 
representative of unhooking on the 21* mer strand side of the ICL, producing an AP site, that 
degrades under standard reaction conditions to form a smeared patter. Subsequently, light 
piperidine treatment cleaves the AP site through β-elimination. A doublet of cleavage 
products was observed in the centre of the gel, the upper of which migrated in line with 21*-
MA substrate and is proposed to be the 21* mer strand with the ICL attached, unhooked at 
the 47 mer strand side of the ICL. The lower band represents the 21* mer strand with an AP 
site and the ICL unhooked, migrating in line with D21 size control. Nei and hNEIL1 however 
resulted in the formation of the upper band of the doublet, representing 21* mer strand with 
the ICL attached, unhooked at the 47 mer strand. 
In reference to D21 and C47 size markers these results suggest that hNEIL3 can unhook the 
same thymine as Nei and hNEIL1 on the 47 mer side of the structure. Additionally, hNEIL3 can 
unhook an ICL from the 21* mer strand side of the structure. However, hNEIL3 processes the 
unhooked three-stranded ICL with a monofunctional profile, generating an AP site, while Nei 
and hNEIL1 generate a ss-nick through associated β,δ-elimination. 
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Figure 4.14: Denaturing PAGE analysis of hNEIL3Cat, hNEIL3Trun, hNEIL3FL, hNEIL1 and Nei protein on ~10 nM 
(X): XL47 • 47 – 21* 8-MOP generated three-stranded DNA ICL. Samples were incubated for 1 h at 37°C with 
500 nM of protein. For positive control 20 nM of bacterial Nei was used and 500 nM hNEIL1. (Lanes 1-10) 
Reactions without piperidine treatment. (Lanes 11-14) Reactions with light piperidine treatment (Lane 7) 21* 
mer ds-MA substrate digested with Nei cleavage, product control. (Lane 8) 47* mer ds-MA substrate digested 
with Nei, cleavage product control. (Lane 9) C21, 21 mer ss oligonucleotide size marker. (Lane 10) D47, 47 mer 
ss oligonucleotide size marker. “X” denotes substrate, “21-MA” denotes 21 mer fragment containing a psoralen-
derived MA, “21-mer” denote cleavage fragments containing an AP (Lanes 2-4), “8PA” and “8P” denote 8 mer 
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4.1.9. hNEIL1 and hNEIL3 protein kinetics on ss and ds Sp1 substrate.  
 
To establish a protein kinetic reference for recombinant hNEIL3 repair of three-stranded 
structures and also establish kinetics for uncharacterised hNEIL3Trun and hNEIL3FL proteins, 
kinetics analysis through time course experiments was carried out on ss Sp1 DNA 
oligonucleotide substrate 
Figure 4.15 shows hNEIL3Cat cleaved the most substrate up until 20 s. hNEIL3Trun cleaved 
marginally less substrate over the same time, compared to hNEIL3Cat. However, hNEIL3Trun 
was observed to cleave ~3% more of the substrate over 60 s. hNEIL3FL displayed a far slower 
kinetic profile, only cleaving ~10% of the substrate over 90 s. These results suggest that 
recombinant hNEIL3Cat and hNEIL3Trun are more active than hNEIL3FL on a ss-DNA Sp 
containing oligonucleotide. This is suggested to be due to the inherent instability possessed 
by hNEIL3FL and loss of activity in comparison to the truncated versions. Additionally, the 
presence of uncharacterised inhibitory domains found in the extended C-terminal of hNEIL3FL 
may limit activity.  Finally, the increased size of the hNEIL3FL protein could inhibit recognition 
of the substrate. This said, a maximal cleavage of ~67% and ~71% was observed for hNEIL3Cat 
and hNEIL3Trun over the duration of the time course, respectively. Due to the lack of 
exponential kinetics and a plateau being observed, the reaction became increasingly 
inhibited. This suggests that in vivo hNEIL3 may require co-factors to increase the turnover of 
enzymatic processing of lesions. 
Figure 4.15:  Time dependent cleavage of ss-DNA containing Sp, by hNEIL3Cat, hNEIL3Trun, hNEIL3FL. A.  
Denaturing PAGE analysis of 50 nM hNEIL3Cat, 50 nM hNEIL3Trun and 100 nM hNEIL3FL recombinant protein 
activity on 20 nM of ss Sp1 DNA. Cleavage observed on generation of an 8 mer product. “0*” Reaction was 
without recombinant protein. “X” denotes substrate, “8PA” denotes an 8 mer fragments containing a 3ʹ-terminal 
PA.  B. Quantification of generated cleavage product percentages after enzymatic cleavage assay. Reaction 
products were treated with light piperidine.  
BA
. 
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For the comparison of cleavage efficiency of hNEIL3 and hNEIL1, time dependent cleavage of 
ss and ds Sp1 oligonucleotide substrates were analysed in the presence of hNEIL3Cat and 
hNEIL1 recombinant proteins. hNEIL3Cat was used due to observed robust activity when 
compared to hNEIL3Trun and hEIL3FL displayed in Figure 4.15,  to mitigate the effect of the 
inactive component of the recombinant protein, due to inherent c-terminal instability.  
Figure 4.16 displays time dependent cleavage of the Sp1 oligonucleotide lesion in either a ss 
or ds DNA context by hNEIL3Cat and hNEIL1. Quantification determined linear kinetics was 
observed in the first 10 seconds of the reaction by hNEIL3Cat in the presence of ss-Sp and by 
hNEIL1 in the presence of ss and ds-Sp (Figure 4.16 D; E).  However, in the presence of ds-Sp, 
hNEIL3Cat displays relatively slow kinetics compared to ss and hNEIL1 mediated ds-Sp 
cleavage. These findings suggest that hNEIL1 processes ss-Sp and ds-Sp with relatively fast 
kinetics, while hNEIL3Cat only processes ss-Sp with relatively fast kinetics. It was observed that 
hNEIL3Cat processed 59% more ss-Sp compared to ds-Sp at 60 s, providing evidence for 
increased affinity and enzymatic processing of ss-DNA substrates. In comparison hNEIL1 
displays similar kinetics for both ss and ds Sp substrates reaching a plateau in cleavage activity 
relatively quickly, however a preference for ds-DNA substrates is observed cleaving 13% more 
ds-Sp substrate at 60 s compared to ss-Sp. Both hNEIL1 and hNEIL3Cat do not complete the 
processing of the substrate in either ss or ds-DNA context before reaching a plateau in kinetics 
(Figure 4.16 D). This indicates that hNEIL1 and hNEIL3 DNA glycosylases may require co-
factors or protein partners to improve enzymatic turnover for the completion of the reaction, 
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Figure 4.16: Time dependent cleavage of ss-DNA and ds-DNA containing the Sp lesion by hNEIL1 and hNEIL3Cat. 
A-B. Denaturing PAGE analysis of 20 nM hNEIL1 and 50 nM recombinant protein activity on 20 nM of ss Sp1 
DNA. C. Denaturing PAGE analysis of 20 nM hNEIL1 and 50 nM recombinant protein activity on 20 nM of ds Sp1 
DNA. Reactions containing NEIL1 were not treated with piperidine. Reactions containing recombinant hNEIL3Cat 
underwent light piperidine treatment.  “0*” Reactions were without recombinant protein. “X”denotes substrate, 
“8 PA” 3ʹ-terminal PA. “X”denotes substrate, “8PA” and “8P” denote 8 mer fragments containing a 3ʹ-terminal PA 
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4.1.10. hNEIL1 and hNEIL3Cat protein kinetics on three-stranded ICL compared to ss 
and ds Sp substrates. 
 
To establish the kinetic profile of the hNEIL3Cat protein and recombinant hNEIL1 protein in 
the presence of the XL47 • 47 – 21* three-stranded ICL substrates and compare to Sp lesion 
processivity displayed in Figure 4.16, a time course analysis was undertaken. 
Figure 4.17 shows that hNEIL3Cat and hNEIL1 cleave the three-stranded psoralen ICL in a time 
dependent manner. Over 1 h hNEIL1 cleaves ~75% of the substrate while hNEIL3Cat plateaus 
at ~20%. Due to the lack of exponential kinetics and a plateau being observed, the reaction 
became increasingly inhibited in the presence of hNEIL3Cat. This suggests that in vivo hNEIL3 
may require co-factors to increase the turnover of enzymatic processing of three-stranded 
ICL DNA. To understand whether hNEIL3Cat and hNEIL1 possess different kinetics on Sp and 
three-stranded ICL DNA substrates. Results from time course experiments on Sp1 and XL47 • 
47 – 21* three-stranded ICL DNA substrates were compiled and compared, for each enzyme.  
Figure 4.17 shows that hNEIL3Cat can process the ss Sp1 lesion more efficiently over a shorter 
time than the three-stranded substrate. At 60 s ~67% of the ss Sp1 substrate is cleaved 
whereas only ~10% is resolved in the case of the three-stranded ICL substrate. It can be 
observed that a maximum of ~67% and ~20% for ss Sp1 and three-stranded ICL substrate 
processing, respectively, is achieved over the time course. This taken with the gradual plateau 
reached in both time courses suggests that hNEIL3Cat can process ss Sp1 more efficiently than 
the three-stranded ICL substrate, with the reaction being inhibited to a lesser extent.  
These data suggest alternate kinetics by hNEIL3Cat in the processing of ss Sp1 and three-
stranded ICL substrates and may suggest different mechanisms of lesion resolution by hNEIL3. 
It is suggested that recognition of the lesion is delayed in the case of the three-stranded ICL 
substrate in comparison to ss Sp1, due to hNEIL3 possessing strong affinity for ss substrates 
and Sp lesions. It may also be posited that due to the size difference of ss Sp1 (17 mer) and 
three-stranded ICL substrate (XL47 • 47 – 21*), lesion recognition is extended as hNEIL3 takes 
longer to ‘scan’ the substrate and recognise the lesion, delaying cleavage. 
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Figure 4.17 shows that hNEIL1 can process the ds Sp1 substrate more efficiently over a shorter 
time than the three-stranded ICL substrate. At 150 s ~79% of the ds Sp1 substrate is cleaved, 
whereas only ~12% is resolved in the case of the three-stranded ICL substrate. It can be 
observed that a maximum of ~68% over 60s and ~75% for ds Sp1 and three-stranded ICL 
substrate over 1 h are cleaved, respectively. This taken with the gradual plateau reached in 
both reactions suggests that hNEIL1 can process ds Sp1 more efficiently than the three-
stranded ICL substrate  
These data suggest alternate kinetics by hNEIL1 in the processing of ds Sp1 and three-
stranded ICL substrates and may suggest an alternate method of lesion resolution by hNEIL1. 
It is suggested that recognition of the lesion is delayed in the case of the three-stranded ICL 
substrate in comparison to ds Sp1, which can be explained by hNEIL1 possessing strong 
affinity for double stranded substrates and Sp lesions. It may also be proposed that due to 
the size difference of Sp1 (17 mer) and three-stranded ICL substrate (XL47 • 47 – 21*), lesion 
recognition is extended as the hNEIL1 takes longer to ‘scan’ the substrate and recognise the 
lesion, delaying cleavage. 
Figure 4.17 provide a general understanding of the processing capacity of hNEIL3 and hNEIL1 
of Sp and three-stranded ICL substrates. hNEIL1 can process a far greater proportion of the 
three-stranded psoralen ICL substrate compared to hNEIL3Cat, which is inhibited much earlier 
in the reaction. This may suggest that hNEIL3Cat activity is much more reliant on co-factors or 
protein partners to increase processivity in vivo. Whilst further experiments are required for 
full characterisation of protein kinetics, they provide initial evidence that Sp lesions are more 
readily processed than three-stranded ICL lesions by hNEIL1/3 proteins.  
As the further oxidation products of 8-OxoG, Sp and Gh, are more common in vivo than the 
generation of ICL lesions, the relatively low processing of three-stranded ICL lesions is 
expected. Due to gaps within the current understanding of ICL repair, it is difficult to infer why 
processing of three-stranded ICL lesions differs substantially to Sp lesions. Possible reasons 
for the differences observed have been discussed, however further experimentation on 
substrates of different sizes and containing different lesions are required to fully elucidate. 
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Figure 4.17: Time dependent cleavage of psoralen (HMT)/ UVA treated XL47 • 47 – 21* three-stranded ICL 
DNA substrate by hNEIL1 and hNEIL3Cat. A. Denaturing PAGE analysis of 20 nM hNEIL1 and 50 nM hNEIL3Cat 
recombinant protein activity on ~10 nM (X): XL47 • 47 – 21* three-stranded DNA ICL substrate. Reaction samples 
were without Piperidine treatment. “0*” Reactions without recombinant protein. “21-MA” denotes 21 mer 
fragment containing a psoralen-derived MA, A. “21-mer” denotes AP-site containing unhooked fragment. B. 
Quantification of hNEIL3Cat and hNEIL1 generated cleavage product percentages after enzymatic cleavage of 
XL47 • 47 – 21*. C Quantification of hNEIL3Cat and hNEIL1 generated cleavage product percentages after 
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4.1.11. Generation and confirmation of catalytically inactive mutant hNEIL3Cat. 
 
Up to 500 nM of hNEIL3 recombinant protein was required to observe activity on three- and 
four-stranded substrates. Therefore, minor bacterial contaminant protein may have been 
responsible for observed activity. To provide evidence to counter this, the generation of 
catalytically inactive hNEIL3Cat recombinant protein was required, to show the abolishment of 
observed activity and therefore provide evidence that WT hNEIL3 was responsible for the 
observed activity.  
Site-directed mutagenesis was undertaken as described in section 2.20  to convert amino acid 
residue 81 from lysine to alanine. Purified plasmid DNA was sent for Sanger sequencing 
analysis. Figure 4.18 shows the 230-268 region of the nucleotide sequence of the hNEIL3 
cDNA, with targeted nucleotides at nucleotide positions 241 and 242. The sequence in black 
shows the original cDNA sequence and highlighted in red is the targeted nucleotides. The 
sequencing chromatogram shows the conversion of the nucleotides to G and C, therefore 
encoding the desired amino acid change of lysine to alanine at aa position 81.  
Figure 4.18: Sanger sequencing chromatogram analysis of pETDUET2-EcoMap- ORF6-hNEIL3Cat-K81A and the 
corresponding wild type hNEIL3Cat nucleotide sequence region, 230-268. Targeted nucleotides at position 241 
and 242, highlighted in red. Targeted mutations AAG-GCG encode for amino acid residue 81, lysine to alanine 
mutation, for expression and purification of the catalytically inactive hNEIL3Cat-K81A recombinant protein. 
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4.1.12. hNEIL3Cat-K81A recombinant protein ÄKTA FPLC purification.  
 
After transformation and expression of the hNEIL3Cat-K81A recombinant protein, HisTrap HP 
column FPLC separation of cell lysate was carried out as described in section 3.20 in an 
attempt to purify hNEIL3Cat-K81A.  
Figure 4.19 shows the FPLC chromatogram, 10%SDS and anti-NEIL3 western blot analysis of 
protein fractions. The chromatogram displays a characteristic trace for recombinant hNEIL3Cat 
elution from E. coli lysate using an imidazole gradient, with a peak of ~200 mAU observed 
between fractions 19 and 24, where hNEIL3Cat was previously eluted (Appendix Figure 1). The 
identified peak is in the same position in which WT protein was eluted and therefore was 
expected to be the K81A mutant hNEIL3Cat protein.  
SDS-PAGE and hNEIL3 western blot analysis, revealed limited separation of contaminant 
proteins and the target protein expected at ~32 kDa. This said, fractions 20, 21 and 22 were 
of improved purity, but with low molecular weight bacterial contaminant proteins present. 
Figure 4.19 provides evidence for partial purification of a candidate protein and therefore 
protein fractions between 19 and 24 were pooled and concentrated with a 10k cut off, to 










































Figure 4.19: HisTrap HP FPLC Purification of hNEIL3Cat-K81A from E. coli. A. Chromatogram analysis of protein 
fractions generated from E.coli lysates overexpressing hNEIL1. B. SDS-PAGE analysis and Instant Blue protein 
staining. C. Anti-His western blot analysis of hNEIL3Cat-K81A FPLC purification fractions. (M) Page ruler prestained 
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The K81A mutant was subsequently analysed by 10% SDS-PAGE. Figure 4.20 B displays the 
fraction purity after Amicon Ultra-15 10 K cut off concentration, which contained the putative 
K81A mutant purification product. The putative hNEIL3Cat-K81A was approximately the same 
molecular weight as the WT hNEIL3Cat protein at ~32 kDa. However, the candidate protein 
band was close in molecular weight to that expected of bacterial Nei (30 kDa), which is a 
possible contaminant that would yield ICL repair capabilities. hNEIL3Cat and hNEIL3Cat-K81A 
were subsequently sent for LC-MS analysis and detected peptides were aligned with the 
target K81A mutant protein Figure 4.20 A. hNEIL3Cat-K81A possessed a sequence match of 49% 
and was the highest scoring protein match in the generated list of possible proteins with an 
Ion score of 8345 (Appendix Table 3). This said, the peptide containing the K81A mutation 
was not detected. However, with the confirmation of site-directed mutagenesis at nucleotide 
level, it is suggested that the purification of recombinant hNEIL3Cat-K81A was successful. 
Additionally, the VEGPGCTLNGEK peptide corresponds to the first peptide chain of hNEIL3 
and was detected without the initiator methionine, confirming active processing by the co-
expressed EcoMap (Appendix Table 3). 
Figure 4.20: Confirmation of purification of hNEIL3Cat-K81A protein. A. Proteomic analysis by LC-MS, peptide 
sequences detected in hNEIL3Cat-K81A purification product which match target amino acid sequence highlighted 
in red. MS/MS Ion search of matched proteins detected with highest mascot score hNEIL3Cat and hNEIL3 in each 
sample (full lists displayed in Appendix Table 3). B. SDS-PAGE analysis of final recombinant hNEIL3 protein 
products stained with instant-blue. “M” Page ruler prestained protein ladder (ThermoFisher).  
 
B. A. 
Chapter IV  Results and Discussion. 
160 
4.1.13. hNEIL3Cat-K81A protein catalytic knockout of DNA glycosylase activity on ss- and 
ds- Sp1 DNA. 
 
To confirm the successful catalytic inactivation of hNEIL3Cat through site-directed 
mutagenesis, expression and purification of hNEIL3Cat-K81A, enzymatic activity analysis on the 
ss Sp1 substrate was undertaken.  
Figure 4.21 shows hNEIL3, Nei, hNEIL1 and hNEIL3Cat-K81A activity on the ss-DNA Sp1 substrate 
with and without the addition of 10% piperidine. Cleavage of the ss-DNA Sp1 was observed 
for WT hNEIL3 and hNEIL1 recombinant proteins, which generated an 8 mer product at the 
site of the Sp lesion. However, hNEIL1 generated a pronounced band below the 8 mer 
product. This is suggested to be a result of further processing by associated β,δ-elimination 
by hNEIL1. hNEIL3Cat-K81A generated no cleavage of the ss-DNA Sp1 substrate whereas 
hNEIL3Cat, hNEIL3Trun and hNEIL3FL did. This suggests successful catalytic inactivation of 
hNEIL3Cat through site-directed mutagenesis, expression and purification. However, the 
possible bacterial contaminant, Nei, is characterised to lack activity on ss Sp1. Therefore, 
activity on ds Sp1 was also required for confirmation catalytic knockout through site-directed 
mutagenesis. 
Figure 4.21: Denaturing PAGE analysis of hNEIL3Cat, hNEIL3Trun, hNEIL3FL, hNEIL1, Nei and hNEILCat-K81A protein 
activity on 10 nM ss Sp1 DNA oligonucleotide. Samples were incubated for 1 h at 37°C with 500 nM of protein. 
For positive control 20 nM of bacterial Nei was used and 500 nM of hNEIL1 was used. (Lanes 1-7) Reactions were 
without piperidine treatment. (Lanes 8-15) Reactions were with light piperidine treatment. “Ctrl” samples in the 
absence of recombinant protein. “8PA” and “8P” denote 8 mer fragments containing 3ʹ-terminal PA and P, 
respectively.  
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Figure 4.22 shows hNEIL3, Nei, hNEIL1 and hNEIL3Cat-K81A activity on the ds -DNA Sp1 substrate 
with and without the addition of 10% piperidine. Cleavage of the ds-DNA Sp1 substrate was 
observed for the WT hNEIL3 recombinant proteins, which generated an 8 mer product at the 
site of the Sp lesion. Nei and hNEIL1 show cleavage of the ds-DNA Sp1 substrate and 
generated a pronounced band below the identified 8 mer product. This is suggested to be a 
result of further processing by associated β,δ-elimination by Nei and hNEIL1. hNEIL3Cat-K81A 
generated no cleavage of the ds-DNA Sp1 substrate whereas hNEIL3Cat, hNEIL3Trun and 
hNEIL3FL did. This suggests successful catalytic inactivation of hNEIL3Cat through site-directed 
mutagenesis. The lack of activity on ds-DNA Sp1 confirmed the absence of active Nei 
contamination which possesses ICL repair capabilities. 
Figure 4.22: Denaturing PAGE analysis of hNEIL3Cat, hNEIL3Trun, hNEIL3FL, hNEIL1, Nei and hNEIL3Cat-K81A protein 
activity on 10 nM (X): ds Sp1 substrate. Samples were incubated for 1 h at 37°C with 500 nM of protein. For 
positive control 20 nM of bacterial Nei was used and 500 nM of hNEIL1 was used. (Lanes 1-7). Reactions without 
piperidine treatment. (Lanes 8-15) Reactions were with light piperidine treatment. “Ctrl” samples in the absence 
of recombinant protein. “17 mer” denotes substrate, “8PA” and “8P” denote 8 mer fragments containing a 3ʹ-
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4.1.14. hNEIL3Cat-K81A catalytic knockout of unhooking activity on HMT generated 
three-stranded ICL DNA oligonucleotide. 
 
To provide further evidence for hNEIL3 possessing ICL repair capabilities and the generation 
of hNEIL3Cat-K81A catalytically inactive mutant, an enzymatic assay was undertaken on the XL47 
• 47 – 21* three-stranded ICL DNA substrate.  
Figure 4.23 shows hNEIL3, NEIL3Cat-K81A and Nei activity on the XL47 • 47 – 21* three-stranded 
ICL substrate with and without the addition of 10% piperidine. Cleavage of the three-stranded 
ICL substrate was observed for the WT hNEIL3Cat recombinant protein, which generated an ~8 
mer smear, indicating the presence of a 21 mer AP site which degrades under standard 
reaction conditions. After light piperidine treatment this AP site is cleaved by β-elimination to 
yield an 8PAmer. The generation of a cleavage product doublet in the centre of the gel was 
also observed. The lower band of the doublet represents the 21* mer strand with an AP site 
unhooked at the 21* mer strand side of the ICL. The upper band of the doublet represents 
the 21* mer strand with the ICL adduct attached after unhooking at the 47 mer strand side of 
the ICL, representing a 21 mer ss-MA. Nei resulted in unhooking of the 21* mer labelled strand 
with the addition of the ICL adduct, unhooked at the 47 mer strand side of the ICL to produce 
a 21 mer ss-MA, consistent with previous observations. hNEIL3Cat-K81A was not observed to 
facilitate cleavage of the three-stranded ICL substrate, with concentrations up to 1 µM. These 
observations display successful catalytic inactivation of hNEIL3Cat through site-directed 
mutagenesis, expression and purification. It also provided evidence that WT hNEIL3 was 
responsible for the observed unhooking and cleavage of three-stranded ICL substrates 
previously demonstrated (Figure 4.9). 
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Figure 4.23: Denaturing PAGE analysis of hNEIL3Cat and hNEIL3Cat-K81A protein activity on ~10 nM (X): XL47 • 47 
– 21* HMT generated three-stranded DNA ICL. Samples were incubated for 1 h at 37°C. For hNEIL3Cat, 500 nM 
of protein was used. For the hNEIL3Cat-K81A, 300 nM, 500 nM or 1000 nM of protein was used.  For positive control 
20 nM of bacterial Nei was used. (Lanes 1-6) Reactions were without piperidine treatment. (Lanes 7-12) 
Reactions were with light piperidine treatment. “Ctrl” samples in the absence of recombinant protein. “X” 
denotes substrate, “21-MA” denotes 21 mer fragment containing psoralen-derived MA, “21-mer” denote 
cleavage fragments containing an AP site (Lane 2), “8PA” denote 8 mer fragments containing a 3ʹ-terminal PA.   
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4.1.15. hNEIL3Cat-K81A catalytic knockout of unhooking activity on HMT generated four-
stranded ICL DNA oligonucleotide. 
 
To provide further evidence for hNEIL3 possessing ICL repair capabilities and the generation 
of the hNEIL3Cat-K81A catalytically inactive mutant, an enzymatic assay was undertaken on the 
XL47 • 47 - 21* • 21 four-stranded ICL DNA substrate.  
Figure 4.24 shows hNEIL3Cat, NEIL3Cat-K81A and Nei activity on the XL47 • 47 - 21* • 21 four-
stranded ICL substrate with and without the addition of 10% piperidine. Cleavage of the four-
stranded ICL substrate was observed for the WT hNEIL3Cat recombinant protein, which 
generated an ~8 mer smear, indicating the presence of a 21 mer AP site which degrades under 
standard reaction conditions. After light piperidine treatment this AP site is cleaved by β-
elimination to yield an 8PAmer. The generation of a cleavage product doublet in the centre of 
the gel was also observed. The lower band of the doublet represents the 21* mer strand with 
an AP site unhooked at the 21* mer strand side of the ICL. The upper band of the doublet 
represents the 21* mer strand with the ICL adduct attached after unhooking at the 47 mer 
strand side of the ICL, representing a 21 mer ds-MA. Nei resulted in unhooking of the 21* mer 
labelled strand with the addition of the ICL adduct, unhooked at the 47 mer strand side of the 
ICL to produce a 21 mer ds-MA which was processed as a secondary substrate for Nei to yield 
an 8Pmer cleavage product. hNEIL3Cat-K81A was not observed to facilitate cleavage of the four-
stranded ICL substrate, at concentrations up to 1 µM. These observations display successful 
catalytic inactivation of hNEIL3Cat through site-directed mutagenesis, expression and 
purification. It also provided evidence that WT hNEIL3 was responsible for observed 
unhooking and cleavage of four-stranded ICL substrates as previously demonstrated (Figure 
4.11). 
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Figure 4.24: Denaturing PAGE analysis of hNEIL3Cat and hNEIL3Cat-K81A protein activity on ~10 nM (X): XL47 • 47 
– 21* • 21 HMT generated three-stranded DNA ICL. Samples were incubated for 1 h at 37°C. For hNEIL3Cat, 500 
nM of protein was used. For the hNEIL3Cat-K81A, 300 nM, 500 nM or 1000 nM of protein was used.  For positive 
control 20 nM of bacterial Nei was used. (Lanes 1-6) Reactions were without piperidine treatment. (Lanes 7-12) 
Reactions were with light piperidine treatment. “Ctrl” samples in the absence of recombinant protein. “X” 
denotes substrate, “21-MA” denotes 21 mer fragment containing psoralen-derived MA, “21-mer” denote 
cleavage fragments containing an AP site (Lane 2), “8PA” denote 8 mer fragments containing a 3ʹ-terminal PA.   
Chapter IV  Results and Discussion. 
166 
4.1.16. hNEIL3Cat and hNEIL1 recombinant protein, protein-DNA substrate covalent 
complex generation with ss and ds Sp1. 
 
To provide further evidence for the observed activity of hNEIL3 and hNEIL1 on ss and ds Sp1 
DNA substrates, protein-DNA affinity assays were conducted by NaBH4 trapping assay, as 
previously described in section 2.22. A covalent complex between labelled DNA and enzyme 
should form upon generation of a ‘Schiff’ base intermediate when DNA glycosylase cleavage 
had taken place followed by NaBH4 facilitated reduction and covalent binding of the DNA 
substrate to the amino acid residue of the protein. Relative band migration based on the total 
molecular weight of the complex, separated by 10% SDS-PAGE, provides evidence for 
cleavage by recombinant proteins. Contaminant interacting proteins would result in the 
generation of complexes with an unexpected migration pattern and presence of additional 
bands. 
Figure 4.25 shows that covalent enzyme-substrate DNA complexes are formed by hNEIL3Cat 
and hNEIL1 in the presence of ss and ds Sp1 DNA substrates. At the bottom of the gel free 
substrate DNA was observed. hNEIL3Cat is ~32 kDa and hNEIL1 is ~42 kDa, therefore the 
covalent complex of hNEIL3Cat and substrate was expected to migrate below the complex 
generated by hNEIL1. Figure 4.25 indicates that recombinant hNEIL3Cat mediated cleavage 
was responsible for the observed activity in previous enzymatic assays. Furthermore, as 
hNEIL3 is suggested to have increased affinity for ss substrates and hNEIL1 is suggested to 
have increased affinity for ds substrates, a band of increased intensity should be observed for 
the favoured substrate. This comparison was clearly observed in Figure 4.25 and provided 
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Figure 4.25: SDS-PAGE analysis of NaBH4 trapping complexes of hNEIL3Cat and hNEIL1 protein formation with 
10 nM ss and ds Sp1 DNA lesions. Reactions were without Piperidine treatment. “Ctrl” samples were without 
recombinant protein. “DNA-Protein complex” denotes recombinant protein bound by NaBH4 facilitated 
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4.1.17. hNEIL3Cat, hNEIL3Trun, hNEIL3FL, Nei, hNEIL1 and hNEIL3Cat-K81A protein-DNA 
substrate covalent complex generation with a three stranded HMT ICL. 
 
To provide further evidence for the observed activity of hNEIL3Cat, hNEIL3Trun, hNEIL3FL, 
hNEIL1, Nei and hNEIL3Cat-K81A on three-stranded ICL substrates, protein-DNA affinity assays 
were conducted, as previously described in 2.22. 
Figure 4.26 shows that covalent protein-DNA complexes are formed between hNEIL3Cat, 
hNEIL3Trun, hNEIL3FL and hNEIL1 in the presence of the XL47 • 47 - 21* three-stranded ICL DNA 
substrate. At the bottom of the gel free oligonucleotide substrate was observed. hNEIL3Cat is 
~32 kDa, hNEIL3Trun ~42 kDa, hNEIL3FL ~68 kDa. Nei ~30 kDa and hNEIL3Cat-K81A ~32 kDa. 
Therefore, the covalent complex of hNEIL3Cat was expected to migrate below the complex 
generated by hNEIL1, the hNEIL3Trun complex in line with hNEIL1 and hNEIL3FL above. Nei was 
expected to generate a band migrating below the hNEIL1 complex and hNEIL3Cat-K81A was 
expected to generate no complex, due to catalytic inactivation. 
Figure 4.26 suggests recombinant hNEIL3 proteins facilitated cleavage of the three-stranded 
ICL DNA substrate in previous assays. Furthermore, the generation of no complex with 
hNEIL3Cat-K81A provided further indication of the successful inactivation and responsibility of 
WT hNEIL3 for observed activity. It is suggested that Nei did not generate a complex, due to 
the complete resolution of substrate before successful reduction of the Schiff base 
intermediate. The signal intensity of DNA-protein complexes analysed Figure 4.26 is 
significantly reduced in comparison to that observed in Figure 4.25. This is suggested to be a 
result of the characterised differences in Sp and three-stranded psoralen ICL processivity 
displayed by NEIL1 and NEIL3 proteins This data provided further evidence for the 
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Figure 4.26: SDS-PAGE analysis of NaBH4 of hNEIL3Cat, hNEIL3Trun, hNEIL3FL, Nei, hNEIL1 and hNEIL3Cat-K81A 
formation with ~10 nM 21*x47-47 HMT generated three-stranded ICL DNA substrate. 500 nM of recombinant 
hNEIL1, hNEIL3 and 20 nM of Nei recombinant protein was used. “Ctrl” samples were without recombinant 
protein. “DNA-Protein complex” denotes recombinant protein bound by NaBH4 facilitated reduction of protein 
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4.2. Discussion: Characterisation of the hNEIL1 and hNEIL3 DNA glycosylases in the 
repair of psoralen interstrand DNA crosslinks. 
 
Previous analysis of the biochemical activity of hNEIL1 and hNEIL3FL in the presence of model 
DNA replication fork DNA structured oligonucleotides containing an oxidative lesion (5-OHU, 
8-OxoG and Tg) demonstrated differential roles in the presence of alternative oxidative 
lesions. It was observed that NEIL3 could excise Tg with robust activity regardless of the DNA 
replication fork position in which the lesion was placed whereas within a conventional ds-
DNA oligonucleotide it could not. This subsequently eluded to a preference of hNEIL3 for the 
replication blocking lesion Tg within a DNA replication fork structure. 
Interstrand DNA crosslinks block DNA replication and transcription and must be removed to 
avoid the loss of genomic stability (Muniandy et al., 2010; Deans and West, 2011). 
Subsequently, mammalian cells have evolved repair mechanisms that remove ICLs in 
quiescent cells through NER and replication dependent ICL repair pathways which 
conventionally remove ICLs in a DNA replication stress response and FA pathway initiated 
manner (Figure 1.10; Wang et al., 2007; Clauson et al., 2013; Ceccaldi et al., 2016). However, 
NEIL1 has previously been shown to unhook psoralen MAs in ds-DNA context and ICLs in a 
three-stranded DNA structure, that mimic the repair intermediates generated through FA 
pathway-initiated repair. Recently, with the use of an X. laevis NEIL3-/- egg extract model 
system, NEIL3 was shown to be the primary repair pathway for the resolution of AP site ICLs 
and psoralen ICLs in a plasmid-based X shaped DNA structure, representative of a convergent 
DNA replication fork event (Semlow et al., 2016). It was proposed that FA pathway-initiated 
repair could not be activated when a single DNA replication fork collided with an ICL and 
repair required the convergence of two replication forks (Zhou et al., 2015; Semlow et al., 
2017).  
Subsequently it was hypothesised due to the observations of overlapping complementarity 
of hNEIL1 and hNEIL3 processing of oxidised pyrimidines, that hNEIL3 would also share three-
stranded psoralen ICL crosslink unhooking activity while also possessing the ability to excise 
psoralen monoadducts. A panel of psoralen ICL substrates were generated (Figure 4.1; Figure 
4.2; Figure 4.3; Figure 4.4) and used as substrates for biochemical analysis of hNEIL1, 
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hNEIL3Cat, hNEIL3Trun, hNEIL3FL and Nei recombinant proteins (Figure 4.5; Figure 4.8; Figure 
4.9; Figure 4.11; Figure 4.13; Figure 4.14).  
Denaturing PAGE analysis demonstrated the ability of Nei and hNEIL1 recombinant proteins 
to unhook three-stranded ICL structures, which mimic DNA repair intermediates generated 
by the FA pathway, with a bifunctional activity profile conducting associated β,δ-elimination 
of the phosphodiester backbone. All three versions of recombinant hNEIL3 protein also 
displayed the ability to unhook the same structure but with a monofunctional activity profile. 
Uniquely, the hNEIL3 recombinant proteins could unhook the psoralen ICL not only from the 
duplex portion of the three-stranded structure but also the ss-ICL/oligomer portion of the 
structure, subsequently producing a ds-MA as a repair product. It is hypothesised based on 
previous characterisation, that hNEIL1 may further process the ds-DNA monoadduct repair 
product (Couvé-Privat et al., 2007). It was also observed that hNEIL3 proteins displayed robust 
activity in the presence of a long three-stranded psoralen ICL structure consisting of an 101 
mer duplex covalently linked to a ss-47 mer oligonucleotide by a single HMT molecule. These 
observations provided the foundation for a putative FA independent pathway for the 
resolution of ICLs by NEIL proteins as a large three-stranded structure may not be generated 
through conventional FA initiated unhooking and associated TLS by polymerases 
characterised to fill a gap of only a small number of nucleotides (Wang, 2007; Sale et al., 2012; 
Clauson et al., 2013). 
Therefore, an additional oligonucleotide was annealed to generate a four-stranded ICL 
structure, with two duplex DNA covalently bound by a single HMT molecule. This structure 
may represent the crosslinking of independent chromosomes after ICL bypass by TLS or 
translocase activity by FANCM, preventing the separation of DNA during the metaphase of 
the cell cycle due to the covalently bound intact daughter chromatin (Shen et al., 2006; 
Minko et al., 2008; Huang et al., 2013; Budzowska, et al., 2015; Xu et al., 2015; Roy et al., 
2016; Zhou et al., 2017). hNEIL3, NEIL1 and Nei proteins displayed a conserved unhooking 
activity in the presence of the alternatively 32gP labelled four-stranded ICL DNA 
oligonucleotide substrate, with Nei and NEIL1 proteins displaying a bifunctional profile 
through β,δ-elimination of the phosphodiester backbone and the generation of a ss-nick 
(Figure 4.11; Figure 4.27; Appendix Table 4). hNEIL3 proteins however, displayed consistent 
monofunctional DNA glycosylase activity generating an AP site. Interestingly all recombinant 
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proteins analysed were able to indiscriminately unhook from both sides of the HMT molecule. 
Additionally, Nei demonstrated the ability to unhook the four-stranded ICL structure and then 
unhook the ds-MA product as a secondary substrate. As a result, it was proposed that in vivo 
hNEIL1 and hNEIL3 proteins may independently initiate BER for the resolution of a four-
stranded ICL structure, with hNEIL1 unhooking ds-MA cleavage products as a secondary 
substrate. This model would suggest complementarity and redundancy shared between 
hNEIL1 and hNEIL3 DNA glycosylases. To provide control for these observations, a catalytically 
null mutant hNEIL3Cat protein was generated and was confirmed to be void of ICL unhooking 
capabilities (Figure 4.18; Figure 4.19; Figure 4.20; Figure 4.21; Figure 4.22; Figure 4.23; Figure 
4.24).  
Figure 4.27: Schematic representation of the mechanisms of action of Nei-like DNA glycosylases on ICLs. A. 
Mechanisms of action of Nei-like DNA glycosylases on three-stranded DNA structure containing single psoralen-
derived ICL. B. Mechanisms of action of Nei-like DNA glycosylases on four-stranded DNA structure containing 
single psoralen-derived ICL. C. Skeletal formula of 21 mer fragment containing single thymidine crosslinked to 
free thymine base by HMT (DNA(T)-HMT-T), an excision product generated by Nei-like DNA glycosylases 
catalysed repair of ICL in three-stranded DNA structure. D. Skeletal formula of thymine-HMT-thymine cross-link 
(T-HMT-T), an excision product generated by Nei-like DNA glycosylases catalysed repair of ICL in three- and four-
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The formation of a four-stranded structure in vivo may have important implications for 
genomic stability and chromosomal rearrangement events, due to FA initiated incision-
dependent repair and subsequent repair of DSBs by HR (Bishop and Schiestl, 2002; Semlow 
et al., 2016). Cross-linked chromosomes, in tri-radial and quad-radial structure have been 
described after an anthramycin-crosslinker treatment of cells (Matsumoto et al., 1999). G-
quadruplex structures also exist in human DNA and interact with cisplatin, forming 
quadruplexes with increased stability (Ju et al., 2016). It has also been shown that crosslinking 
agents can form stable quadruplex ICL structures in vitro and have been shown to exert strong 
cytotoxicity in human tumour cell lines with a mode of action which generates two cross-
linked DNA duplex (Ourliac-Garnier et al., 2005; Nováková et al., 2009). As cisplatin has been 
shown to generate ICLs at parallel G-G sites, it may be proposed that four-stranded ICLs may 
form in G-quadruplex structures. It has been shown that NEIL1 and NEIL3 can remove 
oxidative damage from a G-Quadruplex DNA in a telomeric context (Zhou et al., 2013). This 
said, the role of ICL repair and NEIL proteins is not understood in the context of a G-
quadruplex. 
Interstrand crosslinks are considered to be absolute blocks to DNA replication and 
transcription processes (Deans and West, 2011; Clauson et al., 2013). Subsequently the 
generation of long and three- and four-stranded DNA structures in vivo would require 
specialised bypass or traverse DNA damage tolerance pathways. Indeed, TLS past a duplex ICL 
by Polκ, Polη and Polν with subsequent primer extension facilitated by the REV1/Polζ complex 
has been shown (Shen et al., 2006; Minko et al., 2008; Budzowska, et al., 2015; Xu et al., 
2015; Roy et al., 2016). It was previously shown that movement past an ICL in an intact duplex 
is facilitated by the translocase activity of prokaryotic DnaB replication helicase (Bastia et al., 
2008). Subsequently, traverse of an ICL in a similar manner was shown by eukaryotic FANCM 
and was proposed to allow the continuation of replication past an ICL, stimulated by PCNA 
interaction with the PIP-box domain of the protein (Huang et al., 2013). Additionally, it was 
proposed that signal transduction mediated by FANCM translocase activity, would signal 
replication restart at the distal side of the ICL (Figure 4.28 ; Huang et al., 2013; Rohleder et 
al., 2016). The FANCM/MHF complex was demonstrated to promote replication traverse 
across an ICL in DNA, with DNA combing analysis revealing that ~85% of MA and HMT ICLs 
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that were encountered did not block DNA replication after a 60 min period. Traverse of an 
ICL was subsequently inhibited in FANCM-/- DT40 cells. Importantly deficiency in 
downstream FA pathway components FANCA, FANCE, FANCF or FANCG did not influence 
the frequency of replication traverse (Huang et al., 2013). It was then shown that FANCM 
displayed transient interaction with PCNA, which was stimulated 10-fold under replicative 
stress induced by HU in HeLa cells (Rohleder et al., 2016). hNEIL1 also interacts with PCNA 
and its associated RFC loading protein is coimmunoprecipitated in a multiprotein complex 
proficient in complete BER activity from HEK293 cells (Hegde et al., 2015). This may provide 
a link between NEIL proteins and the FA pathway in support of previous findings which 
demonstrated that FA deficient cell lines display depleted hNEIL1 protein levels (Macé-
Aimé et al., 2010). 
The continuation of DNA replication past an ICL, by a translocase such as FANCM, would 
facilitate the continuation of strand synthesis on both sides of the parental duplex. Thus, 
providing a suitable context for the generation of the three- and four-stranded ICL structures 
described here (Figure 4.28).  Data presented here indicates a specific affinity for the repair 
of long three-stranded and four-stranded ICL structures by hNEIL1 and hNEIL3 (Figure 4.9; 
Figure 4.11; Figure 4.13; Figure 4.14). As the three-stranded ICL remnants shown here are 
relatively large, TLS activity is unlikely to fill the incised gap generated in a FA pathway context, 
additionally current models of replication associated ICL repair do not facilitate the 
generation of four-stranded ICL DNA structures (Sale et al., 2012; Yang et al., 2017). Taken 
together the data provides evidence for a possible hNEIL1 and hNEIL3 initiated ICL repair 
mechanism that may take place after DNA replication fork bypass or traverse (Huang et al., 
2013; Rolseth et al., 2013). 
Therefore, it is proposed that the CMG complex encounters an ICL, recruiting the 
FANCM/MHF complex. FANCM may then promote conventional FA pathway-initiated repair 
or replication machinery traverse. In the latter, replication machinery on the leading strand 
may traverse an ICL, generating a second replication fork after the ICL, generating an X-shaped 
structure, continuing replication and producing a long three-stranded structure (Huang et al., 
2013; Rohleder et al., 2016). In the newly generated replication fork, replication machinery 
from the lagging strand may traverse the ICL after FANCM recruitment, generating a long 
four-stranded structure. Subsequently, hNEIL1 and hNEIL3 are recruited for the repair of the 
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ICL bypass products in a post-replicative manner (Figure 4.27; Figure 4.28). Downstream BER 
may then be initiated, avoiding generation of the major toxic DSBs associated with fork 
collapse and structure specific endonuclease cleavage as consequence of FA pathway repair 
(Figure 4.28; Hanada et al., 2006; Zeman and Cimprich, 2014; Cortez, 2015). It is suggested 
that when hNEIL1 and hNEIL3 initiated BER proteins become exhausted, the more toxic FA 
pathway repair is initiated (Semlow et al., 2016). Evidence for this may be provided by the 
protein kinetics data that demonstrate hNEIL1 and hNEIL3 display relatively slow three- and 
four-stranded ICL unhooking activity compared to the excision of the oxidative lesion Sp  in 
ss-DNA and ds-DNA (Figure 4.15; Figure 4.16; Figure 4.17). Furthermore, the resolution of AP-
site and psoralen ICLs in NEIL3 deficient X. laevis egg extracts has been shown to be 
undertaken by the FA pathway in a redundant manner (Semlow et al., 2016).  
Figure 4.28: Schematic representation of the proposed model of three- and four-stranded ICL DNA generation 
and subsequent resolution by hNEIL1 and hNEIL3 proteins. 1. Leading strand replication machinery stall, 2. 
Recruitment of FANCM translocase, 3. Continuation of replication fork and strand synthesis, 4. Lagging strand 
replication machinery stall and recruitment of FANCM translocase, 5. Continuation of replication fork and strand 
synthesis. 
In support of this hypothesis a recent study by Wallace’s group determined that depletion 
of hNEIL3 in HCT116 cells by RNAi lead to an increase in metaphase arrest and chromosome 
bridging (Zhao et al., 2017). Chromosome bridging has been demonstrated in CHO cells 
treated with HMT/UVA (Rizzoni et al., 1993). It has also been shown that dysfunction in the 
FA pathway leads to an increase in the formation of chromatin bridges. Furthermore, 
FANCM has also been found to localise at DNA bridges (Chan and Hickson, 2011). 
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Therefore, it is postulated that FANCM may dictate the mode of resolution of an ICL at a 
stalled DNA replication fork. Conventionally FANCM may recruit the FA pathway in 
response to exogenously or endogenously generated ICLs but may also promote replication 
machinery traverse which may then require NEIL1/3 dependent intiation of repair of ICLs 
(Deans and West, 2011; Clauson et al., 2013; Huang et al., 2013). In addition, FANCM is 
stimulated through interaction with PCNA, that has been previously identified to interact 
with the hNEIL1 DNA glycosylase (Theriot et al., 2010; Huang et al., 2013). It may be 
tempting to speculate that transient interaction between FANCM and PCNA under 
replicative stress conditions, may lead to the association of the hNEIL1 multiprotein 
‘BERosome’ complex to facilitate the repair of an ICL (Hegde et al., 2015; Rohleder et al., 
2016; Martin et al., 2017). Consequently, it would be important to establish if any 
interaction is observed between the FANCM protein and the hNEIL1 DNA glycosylases. 
Similarly, it would be important to establish if hNEIL3 displays a similar mode of interaction 
with PCNA and FANCM to establish the dynamic cellular response to the resolution of ICLs 
during DNA replication. 
hNEIL3 expression has been shown to be restricted to highly proliferating cells such as 
testes, thyroid, neuronal progenitor cells and in cancers, while being specifically expressed 
through the S-phase of the cell cycle (Morland et al., 2002; Torisu et al., 2005; Hildrestrand 
et al., 2009; Neurauter et al., 2012; Zhou et al., 2015). Subsequently, in the context of 
cancer, upregulation of hNEIL1 and hNEIL3 DNA glycosylases would in turn promote the 
proposed NEIL1/3 dependent repair of ICLs, avoiding toxic DSB repair intermediates (Figure 
4.27; Figure 4.28). The FA pathway however, induces multiple DSBs leaving the cell 
vulnerable to replication fork collapse, chromosomal rearrangement and apoptosis 
(Clauson et al., 2013; Ceccaldi et al., 2016). It is therefore suggested that certain cancer 
cells upregulate hNEIL3 to provide a relatively elegant solution to bypass DNA replication 
blocks, enhance proliferation and minimise the consequences of the significant intiation of 
the DDR through induction of multiple DSBs typically associated with FA initiated repair 
(Shinmura et al., 2013; Martin et al., 2017). Indeed, it has been shown that depletion of 
NEIL3 in glioblastoma cells enhances the sensitivity to ATR and ATR/PARP inhibition, 
suggesting that in the absence of hNEIL3 the dependence on ATR signalling increases 
(Klattenhoff et al., 2017).  
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Psoralen treatment of oligonucleotides may be used to generate model DNA substrates for 
the study of ICL repair, due to the relatively high percentage of induction of ICLs and relatively 
low induction of other types of DNA damage when compared to cisplatin (Dronkert and 
Kanaar, 2001; Couvé-Privat et al., 2007; Couvé et al., 2009; Deans and West, 2011). 
Sensitisation to cisplatin being observed in mNEIL3-/- MEFs may indicate that hNEIL3 can also 
resolve cisplatin adducts in complex with other proteins in vivo or has an associated non-
canonical function that facilitates cisplatin induced DNA damage repair (Rolseth et al., 2013). 
hNEIL3 was shown to co-localise with RPA, a protein involved in ATR mediated DDR, RSR, HR, 
and NER repair in complex with other DNA replication associated proteins (Patrick and Turchi, 
1998; 1999, Morland et al., 2002). Furthermore, it has since been shown that mutation of the 
Zf-GRF domain of APE2 prevents efficient APE2 dependent RPA recruitment to chromatin in 
X. laevis egg extracts (Wallace et al., 2016). hNEIL3 possesses a Zf-GRF domain, in the 
extended C-terminal, that has strong homology with the Zf-GRF domain of APE2. This could 
indicate a similar interaction between RPA and hNEIL3 (Wallace et al., 2016). Given the ability 
of RPA to denature duplex cisplatin ICLs in vitro, in turn generating a cisplatin adducted ss-
DNA substrate, it is posited that hNEIL3 may proceed to preferentially initiate repair of single-
stranded cisplatin MA lesions through BER (Patrick and Turchi, 1999). To gain a greater insight 
into the role the NEIL1 and NEIL3 DNA glycosylases play in cisplatin repair, 
coimmunoprecipitation of hNEIL1 and hNEIL3 protein complexes from untreated and cisplatin 
treated cells, followed by the identification of protein partners by immunoblot or LC-MS is 
necessary. Reconstitution of identified protein partners may begin to provide novel insights 
into the role in which the BER pathway may contribute to the acquired resistance of cancer 
cells to cisplatin (Rolseth et al., 2013; Taylor et al., 2015). 
The data presented here provides a biochemical mechanistic rationale for the findings that 
hNEIL3 is over expressed in highly proliferating and cancerous cells (Shinmura et al., 2016; de 
Sousa et al., 2016; Kim et al., 2016). Where the avoidance of persistent replication arrest and 
generation of DSBs is of benefit to cell survival and thus, NEIL upregulation would 
fundamentally unlock low toxicity proliferative capacity in cells. Indeed, depletion of hNEIL3 
has been shown to increase the formation of spontaneous replication associated DSBs 
(Klattenhoff et al., 2017). Therefore, hNEIL1 and hNEIL3 expression levels are highlighted as 
putative biomarkers of resistance to chemotherapeutic crosslinking agents (Macé-Aimé et al., 
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2010; Rolseth et al., 2013; Taylor et al., 2015; Martin et al., 2017). Strict cellular control of 
expression, lack of a mutagenic phenotype on deficiency of the NEIL DNA glycosylases under 
normal physiological conditions, while sensitising cancer cells to ICL inducing and DDR 
inhibitor therapy, provides a promising rationale for therapeutic targeting of the NEIL DNA 
glycosylases, for the treatment of cancers displaying abnormal NEIL expression levels and 
resistance to DNA crosslinking agents (Morland et al., 2002; Torisu et al., 2005; Hildrestrand 
et al., 2009; Rolseth et al., 2013; Taylor et al., 2015; Klattenhoff et al.,2017; Rolseth et al., 
2017; Zhou et al., 2017). 
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5. Characterisation of post-translational modification of hNEIL3 by the 
ubiquitin proteasome system. 
 
For the investigation of post translational modification and modulation of hNEIL3 by the 
ubiquitin proteasome, HeLa cell pellets were previously fractionated by Ion exchange and size 
exclusion chromatography using the ÄKTA Prime FPLC system (Williams and Parsons, 2017). 
Cell fractions were then analysed by anti-NEIL3 western blot after in vitro ubiquitination 
assays, facilitating the reconstitution of the ubiquitin conjugating cascade. 
To investigate the post-translational regulation of hNEIL3FL by the UPS, recombinant hNEIL3FL 
was purified and confirmed by SDS-PAGE and anti-NEIL3 immunoblot analysis. HeLa cells were 
previously sequentially fractionated by Phosphocellulose ion exchange, HiLoad MonoQ 
sepharose ion exchange, Superdex 200 HR 10/30 gel filtration, CHT ceramic hydroxyapatite 
and Mono Q 5/50 GL ion exchange chromatography. Laboratory stocks of previously 
generated fractions were subsequently used for in vitro reconstitution with recombinant 
ubiquitin E1 ubiquitin-activating and recombinant E2 conjugating enzymes from laboratory 
stocks, for analysis by immunoblot, for the identification of a hNEIL3FL interacting E3 ubiquitin 
ligase. A novel interaction between hNEIL3FL and the TRIM26 was elucidated as result. To 
determine the putative functional role the interaction between endogenous hNEIL3 and 
TRIM26 plays, immunoblot analysis of previously prepared U2OS WCE treated with TRIM26 
siRNA and H2O2 was conducted. This revealed that TRIM26 modulates hNEIL1 and hNEIL3 
steady state levels, but they are not induced over time after H2O2 treatment. Previously 
generated data describing the novel ICL repair capabilities of hNEIL1 and hNEIL3 led to the 
investigation of the cellular response of U2OS cells to cisplatin. The effect of TRIM26 RNAi on 
hNEIL3 steady state levels was confirmed and putative evidence of hNEIL3 being inducible in 
response to cisplatin was determined through immunoblot. TRIM26 RNAi and transient 
overexpression of hNEIL1 and 3 was undertaken to assess U2OS cell survival after cisplatin 
treatment by clonogenic survival assays. Complementation is observed between TRIM26 
RNAi induced cisplatin resistance and hNEIL1/3 overexpression, highlighting a resistant 
phenotype to cisplatin, modulated through TRIM26. Finally, a putative CRISPR/Cas9 hNEIL3 
U2OS knockout cell line was generated for use as a model for the further investigation of the 
role of hNEIL3 in TRIM26 modulated cisplatin resistance and genomic stability in U2OS cells. 
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5.1. Results: Characterisation of post-translational modification of hNEIL3 by the 
ubiquitin proteasome system. 
 
5.1.1. Recombinant hNEIL3FL purification from E. coli for in vitro ubiquitination 
assays. 
 
To investigate in vitro post-translational modification of recombinant hNEIL3FL by the 
ubiquitin proteasome, expression and purification of hNEIL3FL from E. coli was undertaken. 
The pET-Duet2-EcoMap-ORF6-hNEIL3FL expression vector was transformed, colonies selected 
and upscaled before induction. Cultures were then incubated overnight at 16°C, harvested, 
lysed and purified as described in section 3.4.  
As observed in Figure 5.1 A, bacterial contaminant proteins were eluted between fractions 5-
9, followed by an A280 shoulder suggestive of target protein elution. Futher analysis by 10% 
SDS-PAGE confirmed the co-elution of canditate recombinant hNEIL3FL and a hNEIL3FL 
degradation product between fractions 10-19, at the expected moleculare weights of ~68 kDa 
and 52 kDa, respectively. Anti-His and anti-NEIL3 immunoblot analysis confirmed the identity 
of the candidate recombinant proteins eluted by HisTrap HP column FPLC purification (Figure 
5.1 C;D). Anti-His immunoblot analysis determined that the recombinant hNEIL3FL 
degradation product was the ~52 kDa C-terminal portion of the recombinant hNEIL3FL protein, 
as the C-terminally fused His Tag was retained (Figure 5.1 C). 
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Figure 5.1: HisTrap-HP FPLC purification of recombinant hNEIL3FL from Rosetta 2 (DE3) E. coli expression hosts. 
A. Chromatogram analysis of protein fractions generated by HisTrap chromatography of lysates from E. coli 
overexpressing hNEIL3FL. B. SDS-PAGE and Instant Blue protein staining. C. Anti-His, D. anti-NEIL3 immunoblot 
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5.1.2. Phosphocellulose purified HeLa WCE fraction in vitro ubiquitination of 
recombinant hNEIL3FL.  
 
Previous HeLa cell fractionation by phosphocellulose column FPLC elution at 150 mM and 
1000 mM KCl facilitated the separation of whole cell extracts based on affinity to DNA 
(Williams and Parsons, 2018). Reconstitution of ubiquitin, E1 ubiquitin activating and E2 
conjugating enzymes in the presence of laboratory stocks of HeLa WCE, PC150 or PC1000 
phosphocellulose column elution and recombinant hNEIL3FL, were analysed by immunoblot. 
Figure 5.2 displays putative ubiquitination of hNEIL3FL. Figure 5.2 A displays recombinant His 
tagged E1 and E2 conjugating enzymes, however recombinant His tagged hNEIL3FL is probed 
with weak affinity by the anti-his primary antibody in comparison. Figure 5.2 B however 
displays anti-hNEIL3 probing of recombinant hNEIL3FL. Evidence of ubiquitination of hNEIL3FL 
is detected above the band representative of hNEIL3FL, in the presence of WCE and PC150 
samples. A single band is observed at ~75 kDa and indicative of a mono-ubiquitination activity, 
highlighted by the red arrow and in agreement with the approximate expected molecular 
weight of hNEIL3FL (~68 kDa) with the addition of ubiquitin (~8 kDa). An increase in a smearing 
pattern can also be observed in the sample lane containing 10 µg of the PC150 fraction, 
providing evidence for poly-ubiquitination of recombinant hNEIL3FL. Negative controls in the 
absence of recombinant hNEIL3FL, E1, E2, ubiquitin or cellular extract display no observed 
putative ubiquitination, evidence of ubiquitination is specific to the recombinant hNEIL3FL  
protein (Figure 5.2 A; B).  
Figure 5.2: Immunoblot analysis of hNEIL3FL incubated with phosphocellulose FPLC purification fractions of 
HeLa whole cell extracts. Analysis of reconstituted in vitro ubiquitination reactions of PC150 and PC1000 
fractions from laboratory stocks in the presence of 600 ng recombinant hNEIL3FL (Williams and Parsons, 2017) 
A. anti-His immunoblot B. anti-NEIL3 immunoblot.  “M” All Blue Prestained Protein Standards (BioRad). 
A. B. 
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5.1.3. HiLoad Mono Q Sepharose Ion exchange fraction in vitro ubiquitination of 
recombinant hNEIL3FL.  
 
To further purify proteins that were present in the eluted PC150 fraction which facilitated in 
vitro hNEIL3FL ubiquitination, the PC150 fraction was previously buffer exchanged and 
fractionated using a 20 ml HiLoad Mono Q Sepharose ion exchange column.  Every second 
fraction from laboratory stocks was then analysed by in vitro ubiquitination reaction in the 
presence of recombinant hNEIL3FL and subsequently analysed by anti-NEIL3 immunoblot 
(Figure 5.3 B; C). Multiple fractions display evidence of hNEIL3FL ubiquitination, with reference 
to section (Figure 5.2 A; B). Minor activities are observed between fractions 14-18 and 24-34. 
However, the fractions displaying the strongest observable putative ubiquitination range 
from fraction 50 to 62, with the strongest activity observed in fractions 56 and 58. As observed 
in Figure 5.3 activity observed in the presence of fractions 56-58 aligned with the largest 
eluted peak identified by the A280 elution trace during previous FPLC chromatography. 
Evidence of mono-ubiquitination is observed and highlighted with red arrows at ~ 75 kDa, 
with consistent increase in the appearance of a smeared pattern within the sample lane, that 
is indicative of poly-ubiquitination of recombinant hNEIL3FL (Figure 5.3 A; B). Figure 5.3 
provides evidence for proteins present between fractions 56-58 which facilitated 
ubiquitination of hNEIL3FL, when reconstituted with recombinant Ub, E1 activating and E2 
conjugating enzymes. 
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Figure 5.3: Ubiquitination analysis of HiLoad Mono Q Sepharose column FPLC purification fractions of PC150 
elution of HeLa WCE. A. Chromatogram analysis of previously purified HiLoad Mono Q Sepharose fractions 
(Williams and Parsons, 2018). In vitro ubiquitination reaction of 600 ng recombinant hNEIL3FL in the presence of 
HiLoad Mono Q Sepharose fractionated PC150 laboratory stocks. B. Anti-NEIL3 immunoblot imaged at low scan 
intensity (5.0), C. anti-NEIL3 immunoblot imaged at high scan intensity (6.5) using the Licor Odyssey InfraRed 
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5.1.4. Superdex 200 HR 10/30 gel filtration fraction in vitro ubiquitination of 
recombinant hNEIL3FL.  
 
To isolate proteins, present in fractions 51-58 after HiLoad Mono Q Sepharose Ion exchange 
elution, fractions were previously pooled, and buffer exchanged (Williams et al.,2018). Pooled 
samples were then fractionated based on protein size, using the Superdex 200 HR 10/30 size 
exclusion column. Fractions 14-36 from laboratory stocks were analysed based on the FPLC 
chromatogram A280 elution trace, by in vitro ubiquitination and anti-NEIL3 immunoblot 
analysis.  
Figure 5.4 displays evidence of ubiquitination facilitated by isolated proteins present between 
fractions 20-24. An increase in the associated band for mono-ubiquitination at ~75 kDa and 
increased lane smearing indicative of poly-ubiquitination activity were observed (Figure 5.4 
B). In Figure 5.4 C, an increase in the ubiquitination of the hNEIL3FL degradation product is 
also observed. Fractions that display activity align inbetween two observable elution peaks 
detected by the A280 elution trace as displayed in Figure 5.4 A. Observation of ubiquitination 
of hNEIL3FL in the presence of fractions 20, 22 and 24, suggested successful purification and 
isolation of cellular protein which facilitates ubiquitination of hNEIL3 in vitro. Previous anti-
His immunoblot of recombinant hNEIL3FL displayed probing of the hNEIL3FL degradation 
product and confirmed retention of the C-terminal His tag (Figure 5.1; Appendix Figure 2; 
Appendix Figure 3). Consequently, ubiquitination of the hNEIL3FL degradation product 
suggested that ubiquitination is dependent on lysine residues present in the ~52 kDa portion 
















Figure 5.4: Ubiquitination analysis of Superdex 200 HR 10/30 FPLC purification fractions. A. Chromatogram 
analysis of previously purified HiLoad Mono Q Sepharose fractions (Williams and Parsons, 2018). In vitro 
ubiquitination reaction in the presence of 600 ng recombinant hNEIL3FL and Superdex 200 HR 10/30 gel filtration 
fractions from laboratory stocks analysed by B. Anti-NEIL3 immunoblot imaged at low scan intensity (5.0), C. 
anti-NEIL3 immunoblot image at high scan intensity (6.5), using the Licor Odyssey InfraRed scanner.  “M” All Blue 
Prestained Protein Standards (BioRad). 
B. C. 
A. 
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5.1.5. Mono Q 5-50 GL Ion exchange fraction in vitro ubiquitination of recombinant 
hNEIL3FL.  
 
Fractions which displayed ubiquitination activity in Section 5.3 were previously pooled buffer 
exchanged and purified further by a CHT ceramic hydroxyapatite column (Appendix Figure 4; 
Williams and Parsons, 2018). Subsequently, fractions 18-20 were previously pooled and 
diluted 10-fold in Mono Q 5/50 GL column buffer A for ion exchange chromatography as a 
final polishing step (Williams and Parsons, 2018). Based on A280 FPLC chromatogram trace, 
laboratory stocks of fractions 22-30 were analysed by in vitro ubiquitination reaction and anti-
NEIL3 western blot analysis. Figure 5.5 B displays probing of hNEIL3FL with the anti-His 
antibody however evidence of ubiquitination was difficult to detect. As shown in Figure 5.5 
C, anti-NEIL3 immunoblot analysis revealed that multiple fractions displayed evidence of 
ubiquitination activity. All of the analysed fractions displayed differential levels of evidence 
of ubiquitination in vitro. Fraction 25 however, displayed the greatest evidence of mono-
ubiquitination activity with a band appearing at ~75 kDa, while maintaining relative poly-
ubiquitination activity. Additionally, fraction 25 aligned with the major peak detected by the 
A280 elution trace and displayed in Figure 5.5 A. Fraction 25 was therefore selected for 
analysis by LC-MS.  Results are displayed in Appendix Table 5 and identify tripartite motif 
containing 26 (TRIM26), which was the only protein detected that has previously been 
characterised to possess associated E3 ubiquitin-ligase activity that was present in fraction 
25. Figure 5.5 and Appendix Table 5 provide putative evidence of the successful identification 
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Figure 5.5: Ubiquitination analysis of Mono Q 5/50 GL purification fractions. A. Chromatogram analysis of 
previously purified HiLoad Mono Q 5/50 GL fractions (Williams and Parsons, 2018). In vitro ubiquitination 
reactions in the presence of 600 ng recombinant hNEIL3FL and Mono Q 5/50 GL ion exchange fractions from 
laboratory stocks were analysed by B. Anti-His immunoblot and C. Anti-NEIL3 immunoblot “M” All Blue 
Prestained Protein Standards (BioRad). 
B. C. 
A. 
Chapter V  Results and Discussion. 
189 
5.1.6. Identification and purification of recombinant the TRIM26 E3 ubiquitin ligase. 
Mono Q 5/50 GL purified fraction 25 analysis by LC-MS (Appendix Table 5) identified TRIM26 
as a novel interacting protein with recombinant hNEIL3FL. To confirm E3 ubiquitin ligase 
activity of TRIM26 in the presence of recombinant hNEIL3FL the pET28a-TRIM26 bacterial 
expression plasmid was transformed into Rosetta 2 (DE3) E. coli expression hosts and used to 
express and purify recombinant TRIM26 for in vitro ubiquitination assays. Bacterial colonies 
were selected, scaled and bacterial cultures induced as described in 2.2. HisTrap HP FPLC 
affinity chromatography was undertaken to isolate recombinant C-terminally His-tagged 
TRIM26 from bacterial proteins. 
Figure 5.6 A displays the FPLC chromatogram after gradient elution of E. coli protein lysate. A 
major peak associated with histidine rich bacterial proteins was eluted between fraction 5 
and 13. A trace shoulder was identified between fractions 14 and 25. Fractions 5-25 were 
collected and analysed by 8% SDS-PAGE and anti-His immunoblot analysis (Figure 5.6 B; C). 
SDS-PAGE analysis provided putative evidence for successful separation of extracted proteins, 
however no candidate band was identified for TRIM26. Figure 5.6 C displays, anti-His 
immunoblot analysis that confirmed the successful isolation of His-tagged TRIM26, at the 
expected molecular weight of ~63 kDa, with the majority of recombinant TRIM26 eluted 
between fractions 17 and 25. Fractions 17 to 25 were subsequently pooled and buffer 
exchanged against (50 mM Tris-HCl pH 8, 50 mM KCl, 1 mM EDTA, 10% glycerol) and the 
concentration was determined as 0.434 mg/ml. 
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Figure 5.6: HisTrap-HP FPLC purification of the recombinant TRIM26 from Rosetta 2 (DE3) E. coli expression 
hosts. A. Chromatogram analysis of protein fractions generated by HisTrap chromatography of lysates from 
E.coli overexpressing TRIM26. B. 8% SDS-PAGE and Instant Blue protein staining. C. Anti-His immunoblot 
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5.1.7. In vitro ubiquitination of hNEIL3 by TRIM26 E3 ubiquitin ligase. 
 
To confirm E3 ubiquitin ligase activity of recombinant His-tagged TRIM26 in the presence of 
hNEIL3FL an in vitro ubiquitination reaction was conducted and subsequently analysed by anti-
NEIL3 western blot analysis. In Figure 5.7 A, it can be observed that increasing the 
concentration of TRIM26 increased the observable evidence of mono-ubiquitination with an 
increase in the signal intensity of the single band shown at ~75 kDa. Additionally, Figure 5.7 
B displays a gradual increase in the intensity of a smearing pattern in each lane, in the 
presence of increasing amounts of recombinant TRIM26, indicative of poly-ubiquitination 
activity. However, minor mono-ubiquitination and poly-ubiquitination activity was observed 
in the absence of the TRIM26 sample lane, suggested to be due to sample contamination 
during loading of the SDS gel. Despite this an observable titration of ubiquitination activity 
was demonstrated, with an increase in the concentration of recombinant TRIM26. This 
subsequently provides evidence of E3 ubiquitin-ligase activity in the presence of hNEIL3FL by 
TRIM26 that is above background control levels. In addition, this data provides evidence for 
the successful isolation, identification and recombinant protein purification from E. coli, of an 
interacting protein that facilitates the post-translational modification of recombinant 
hNEIL3FL.   
  
Figure 5.7: Immunoblot analysis of ubiquitination of hNEIL3FL in the presence of recombinant TRIM26. Anti-
NEIL3 immunoblot analysis of in vitro ubiquitination reactions with increasing concentrations of recombinant 
TRIM26 in the presence of 600 ng recombinant hNEIL3FL. A. anti-NEIL3 immunoblot imaged at low scan intensity 
(5.0), B. anti-NEIL3 imaged at high scan intensity (6.5) using the Licor Odyssey InfraRed scanner. 
A. B. 
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5.1.8. Analysis of hNEIL1 and hNEIL3 protein levels post H2O2 and TRIM26 siRNA 
 
To investigate the functional role of TRIM26 in the PTM and modulation of hNEIL3 in a cellular 
context, laboratory stocks of WCE from U2OS cells treated with either a NT or TRIM26 specific 
siRNA and the oxidising agent H2O2 were analysed by immunoblot.  
Initial analysis was conducted on a known substrate of TRIM26, hNEIL1 (Figure 5.8). Steady 
state levels of hNEIL1 were observed to be increased in TRIM26 siRNA treated U2OS WCE, 
consistent with previous observations, however significant induction of hNEIL1 in response to 
H2O2 was not observed in TRIM26 siRNA treated cells (Edmonds et al., 2017). However, minor 
induction of hNEIL1 is observed between 0 and 0.5 h post treatment in NT siRNA treated cells. 
Figure 5.8 provides evidence that steady state levels of hNEIL1 protein are partially 
modulated by TRIM26 in U2OS cells. 
Figure 5.8: Anti-NEIL1 immunoblot analysis of U2OS cells treated with TRIM26 siRNA and harvested 0-4 h after 
treatment with 150µM H2O2. A. NEIL1/Actin ratios were quantified from results of two independent 
experiments displayed. B-C Anti-NEIL1 immunoblot of U2OS cell extract lysates treated with 33 pmol NT or 
TRIM26 siRNA for 48 h and treated with 150 µM H2O2 for 15 min. “C” in the without of H2O2 treatment. Error 
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The same U2OS WCEs were then analysed for differences in hNEIL3 protein levels between 
NT or TRIM26 siRNA treated cells, by anti-NEIL3 immunoblot (Figure 5.9 B; C). A significant 
increase in steady state levels of endogenous hNEIL3 was observed immediately after H2O2 
treatment (p=0.000149923), 0.5 (p= 0.0463634) and 1 h post treatment (p= 0.0213931; Figure 
5.9 A) but not at 4 h post treatment (p=0.412032). Despite steady state levels being 
significantly elevated immediately post treatment and up to 1 h H2O2 after treatment, 
induction of hNEIL3 in response to H2O2 was not observed in TRIM26 RNAi cells. This data 
suggests that TRIM26 regulates steady state levels of hNEIL3. However, only minor iduction 
of hNEIL3 can be observed in NT siRNA treated cells between 0-4 h after H2O2 treatment. 
Therefore, Figure 5.9 demonstrates that TRIM26 modulates hNEIL3 protein levels in U2OS 
cells treated with H2O2.  
Figure 5.9: Anti-NEIL3 immunoblot analysis of U2OS cells treated with TRIM26 siRNA and harvested 0-4 h after 
treatment with 150µM H2O2 A. Quantification of NEIL3: Actin ratios from results of two independent 
experiments displayed. B-C Anti-NEIL3 immunoblot of U2OS cell extract lysates treated with 33 pmol NT or 
TRIM26 siRNA for 48 h and treated with 150 µM H2O2 for 15 min. “C” in the without of H2O2 treatment. T-tests 
between NT and TRIM26 siRNA at: 0 h p= 0.000149923, 0.5 h p= 0.0463634, 1 h p= 0.0213931, 4 h p=0.412032. 
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5.1.9. Analysis of hNEIL3 protein levels in response to cisplatin and TRIM26 siRNA 
treatment. 
 
To investigate if TRIM26 modulates the response of hNEIL3 protein levels to the ICL inducing 
agent cisplatin, U2OS cells were treated with TRIM26 siRNA and increasing concentrations of 
cisplatin. Figure 5.10 demonstrates elevated hNEIL3 steady state levels post TRIM26 siRNA 
treatment, in agreement with previous observations (Figure 5.9). Figure 5.10 A indicates that 
hNEIL3 is not induced in response to cisplatin in a dose dependent manner in TRIM26 RNAi 
U2OS cells. However, in NT RNAi cells minor induction of hNEIL3 was observed between 0 and 
7.5 µM cisplatin. 
Figure 5.10 B provides preliminary evidence that hNEIL3 steady state levels are modulated by 
TRIM26 in U2OS cells treated with cisplatin and hNEIL3 may be recruited in response to 
cisplatin induced DNA damage in NT siRNA treated U2OS cells. However, no significant 
differences in hNEIL3/actin ratio protein levels were observed between NT siRNA and TRIM26 
siRNA treated cells overall (Figure 5.10 A).  
Figure 5.10: Anti-NEIL3 immunoblot dose response analysis of U2OS whole cell extracts treated with TRIM26 
siRNA and cisplatin treatment. A. Quantification of NEIL3/Actin from results of two independent experiments 
displayed. B-C Anti-NEIL3 immunoblot of U2OS cell extract lysates treated with 33 pmol NT or TRIM26 siRNA for 
48 h and treated with 0-10 µM cisplatin for 24 h. “C” without cisplatin treatment. 
B. A. 
C. 
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5.1.10. Cisplatin clonogenic analysis of the effect of TRIM26 RNAi or overexpression 
of hNEIL1/hNEIL3 on U2OS cell survival. 
 
Previously it has been shown that NEIL1 is a substrate for ubiquitination by the E3 ubiquitin 
ligase TRIM26. A resistant phenotype to X-ray IR of U2OS cells post TRIM26 depletion by siRNA 
was also observed, however complementation was not observed when transiently 
overexpressing NEIL1.  
To investigate if TRIM26 may modulate hNEIL1 and hNEIL3 protein levels in response to 
cisplatin as a DNA damage response to cisplatin, clonogenic analysis was undertaken. NT 
siRNA, TRIM26 siRNA, NEIL1 and NEIL3 transient overexpression were compared in attempt 
to observe whether a resistant phenotype was observed. NEIL1-3xFLAG overexpression was 
confirmed by anti-FLAG immunoblot analysis of U2OS WCEs transfected with the pCMV-
hNEIL1-Tag3a transient mammalian expression vector (Figure 5.11 B). hNEIL3 overexpression 
was also confirmed by anti-NEIL3 immunoblot analysis of U2OS WCEs transfected with the 
pCMV-ac-hNEIL3 transient mammalian expression vector (Figure 5.11 C). Quantification of 
colony forming units after treatment revealed a significant resistant phenotype of U2OS cells 
after TRIM26 siRNA when compared to NT siRNA treated cells (p=<2.2x10-16) (Figure 5.11 F.). 
U2OS cells treated with overexpression of NEIL1 and NEIL3 also displayed a resistant 
phenotype when compared to NT siRNA, determined by use of CFAssay package within the R 
program (p=<2.2x10-16 and p=<2.2x10-16, respectively; Figure 5.11 D-E). Figure 5.11 provides 
evidence of a role of NEIL1 and NEIL3 in U2OS cell resistance to cisplatin, presumably through 
their ICL repair capabilities. In addition, Figure 5.11  provides evidence for a novel role of the 
E3 ubiquitin ligase TRIM26 in modulating the response of U2OS cells to the interstrand 
crosslinking agent cisplatin through its ubiquitination activity. 
Chapter V  Results and Discussion. 
196 
Figure 5.11: Clonogenic survival assay analysis: cisplatin dose response of U2OS cells pre-treated with NT 
siRNA, TRIM26 siRNA, NEIL1 or NEIL3. A. Representative clonogenic plate images. B. Anti-FLAG and anti-actin 
Immunoblot analysis of overexpression of NEIL1. C. Anti-NEIL3 and ant-actin immunoblot analysis of NEIL3 
overexpression, NEIL3/actin ratios displayed below each sample lane. (D-G) Mean surviving fraction is shown 
with standard errors from the results of three independent experiments. P=<2.2 x10-16 (NT siRNA vs TRIM26 
siRNA), P= <2.2 x10-16 (NT siRNA vs NEIL1 OE) and P=<2.2 x10-16 (NT siRNA vs NEIL3 OE) as analysed by the CFAssay 
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5.1.11. CRISPR/Cas9 mediated knockout of endogenous hNEIL3. 
 
To provide a model to for the investigation of the role of hNEIL3 in U2OS cells, attempts were 
made to knockout hNEIL3 with CRISPR/Cas9 in U2OS cells. As described in section 2.27, U2OS 
cells were established for subsequent screening of hNEIL3 protein levels after CRISPR /Cas9 
treatment, by SDS-PAGE and anti-NEIL3 immunoblot analysis. 
As displayed in Figure 5.11 variability in hNEIL3 protein levels was observed across single 
clonal colony U2OS WCEs, providing evidence for CRISPR/Cas9 interaction. In support of this 
all clonal populations screened were able to continue proliferation in the presence of 1 µg/ml 
puromycin during antibiotic selection (section 2.27). This indicated puromycin resistance via 
integration of the donor cassette containing the puromycin resistance gene. However, 84 of 
the screened WCE displayed presence of hNEIL3 protein indicating low efficiency of 
Cas9/gRNA interaction, subsequent homology directed repair at the correct locus targeted at 
exon 1 of the NEIL3 gene sequence. Non-target interaction of the Cas9/gRNA complex is 
proposed, as cells display puromycin resistance. However, 5 putative knockout clones were 
identified and highlighted in red in Figure 5.11, displaying significant depletion of hNEIL3 
protein levels. Subsequently, clones: G1 38, G2 1, G2 12, G2 24 and G2 30 were transferred 
to 10 cm tissue culture dishes for upscaling for repeated analysis. All but the clonal population 
G2 30 of putative clones failed to re-establish and continue to proliferate at this stage. This 
may suggest that the clones that did not continue to proliferate were non-viable due to the 
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Figure 5.12: Anti-NEIL3 immunoblot analysis of puromyicin resitant U2OS cells.  “G1” denotes whole cell 
extracts from U2OS cells treated with gRNA sequence 1. “G2” denotes whole cell extracts from U2OS cells 
treated with gRNA sequence 2. “G2*” Denotes  gRNA 2 containing plasmid treated U2OS clonal populations 
which were upscaled for screening in a second round of screening. 
Putative clonal population G2 30 successfully re-established, proliferated and was 
subsequently split 1: 2 at 70% confluence to a further 10 cm tissue culture dish and a T75 
culture flask. At 70% confluency cells were harvested from the 10 cm tissue culture dish and 
WCE was prepared as described in 2.25  for analysis by western blot comparably to WT U2OS 
WCE. Figure 5.13 shows significantly reduced hNEIL3 in 20 µg WCE when compared to WT 
U2OS WCE, providing further evidence for successful Cas9/gRNA knockout and integration of 
the donor sequence at the site of the hNEIL3 gene sequence. Minor background smearing can 
be observed in the G2 30 clonal population WCE sample, which may indicate that the clonal 
population is a partial knockout rather than a complete gene knockout of hNEIL3 or that the 
NEIL3 antibody has cross reactivity with other proteins at a similar molecular weight. The T75 
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flask containing G2 C30 clonal cellular population was subsequently upscaled and processed 
for long term storage in liquid nitrogen, for further characterisation in the future. 
Figure 5.13: Immunoblot analysis of the U2OS cell G2 30 clone. “WT” denotes whole cell extracts from wild 
type and non-treated U2OS cells. “G2” denotes whole cell extracts from U2OS cells treated with gRNA 
sequence 2. 
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5.2. Discussion: Characterisation of post-translational modification of hNEIL3 by the 
ubiquitin proteasome system. 
 
In the present study, it was investigated if hNEIL3 was also regulated by the ubiquitin PTM 
and the possible functional role in which this modification may play in the cellular response 
to DNA damage in U2OS cells. Previously generated HeLa cell fractions were subsequently 
analysed and characterised for the possession of E3 ubiquitin ligase activity in the presence 
of recombinant hNEIL3FL, through ubiquitination assays and anti hNEIL3 immunoblot analysis 
(Figure 5.2; Figure 5.3; Figure 5.4; Figure 5.5). Interestingly, the same fractions which 
facilitated E3 ubiquitin ligase activity and ubiquitination of NEIL1 and NTH1 were also 
observed to facilitate the ubiquitination of recombinant hNEIL3FL. It was identified that 
TRIM26 was the only candidate E3 ubiquitin ligase present within Mono Q 5/50 GL fraction 
25, previously analysed by LC-MS (Appendix Table 5). Recombinant TRIM26 was then 
expressed from a pET28a-TRIM26 expression vector in the expression host Rosetta 2 (DE3) 
and subsequently purified by HisTrap HP affinity column FPLC. Purification fractions were 
confirmed for successful purification of TRIM26 by immunoblot analysis, pooled and 
concentrated for use in vitro ubiquitination assays (Figure 5.6; Figure 5.7). It was observed 
that TRIM26 facilitated mono-ubiquitination and polyubiquitination of hNEIL3FL (Figure 5.7). 
TRIM26 RNAi in U2OS cells and analysis of WCE by immunoblot revealed that TRIM26 also 
regulated the steady state levels of NEIL3 (Figure 5.9; Figure 5.10). Furthermore, exposure of 
cells to H2O2 and cisplatin demonstrated minor induction of NEIL3 in NT RNAi treated control 
cells, with NEIL3 protein levels remaining high after TRIM26 RNAi treatment (Figure 5.9; 
Figure 5.10).  
It has been shown that the end processors, gap fillers and nick sealing enzymes of BER are 
regulated by the UPS system (Edmonds and Parsons, 2016). More recently it has been shown 
that the DNA glycosylases which initiate the BER pathway are also regulated by the UPS. NEIL1 
was shown by Parsons’ group to be ubiquitinated by the E3 ubiquitin ligases MULE and 
TRIM26. It was shown that both MULE and TRIM26 regulate protein stability in the cell while 
TRIM26 contributed to cellular resistance to IR in U2OS cells, however transient over 
expression of NEIL1 in U2OS cells did not compliment the observed phenotype. This said, 
MULE RNAi in U2OS cells demonstrated that induction of NEIL1 was MULE dependent 
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(Edmonds et al., 2017). It is suggested that complementation by NEIL1 to TRIM26 RNAi 
induced IR is attributed to the multiple forms of DNA damage induced on exposure to IR, 
including SSB, DSBs and oxidative DNA damage and thus the multiple contributory DNA repair 
pathways that may be activated in the cellular response (Pouget et al., 2002; Yoon et al., 2010; 
Santivasi and Xia, 2014). It may be possible that other DNA repair proteins from BER and DSB 
repair pathways are also regulated by TRIM26, accounting for the observed resistance to IR 
(Edmonds et al., 2017). However, the role of TRIM26 in the cellular response to oxidative DNA 
damaging agents and ICL inducing agents remained unclear. 
Recently, Parsons’s group showed that NTH1 was also regulated by TRIM26 in vitro. TRIM26 
RNAi in HCT116 cells resulted in an increase in steady state protein levels and also an increase 
in chromatin bound NTH1. Furthermore, clonogenic cell survival assays demonstrated that 
TRIM26 RNAi resulted in cellular resistance to the oxidising agent H2O2, with the phenotype 
complemented by transient overexpression of NTH1. Taken together, it was proposed that 
TRIM26 is also an important regulator in the response to both oxidative DNA damage and IR 
(Edmonds et al., 2017; Williams and Parsons, 2018). 
As it was previously shown that hNEIL1 was induced in a MULE dependent manner in response 
to IR but hNEIL1 transient overexpression did not complement TRIM26 RNAi mediated cellular 
resistance to IR, the role of TRIM26 ubiquitination of hNEIL1 in response to cellular stress 
remained uncharacterised. Previous investigation revealed that hNEIL1 and hNEIL3 DNA 
glycosylases possess an innate ability to unhook psoralen MAs and ICLs in a three- and four-
stranded DNA structure (Couvé-Privat et al., 2007; Couvé et al., 2009; Semlow et al., 2016; 
Martin et al., 2017). Furthermore, it has been shown that NEIL1 overexpression provides 
partial resistance in FA pathway deficient cell lines, to the ICL agents MMC and 8-MOP, while 
FA deficient cells display a reduction in hNEIL1 protein levels (Macé-Aimé et al., 2010). In 
addition, MEFs from NEIL3-/- mice displayed increased sensitivity to the ICL agent cisplatin 
(Rolseth et al., 2013). Taken together it was hypothesised that hNEIL1 and hNEIL3 regulation 
by TRIM26 may also modulate the cellular response to ICL inducing agent DNA damage. 
Subsequently, U2OS cisplatin clonogenic survival assays were undertaken and revealed that 
TRIM26 RNAi resulted in significant resistance to cisplatin (p= <2.2 x 10-16), with significant 
resistance to cisplatin also observed after NEIL1 overexpression (p= <2.2 x 10-16) and NEIL3 
overexpression (p= <2.2 x 10-16; Figure 5.11).  
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The findings presented here demonstrate the cellular role in which hNEIL1 and hNEIL3 play in 
cellular resistance to cisplatin. Taken together with previous biochemical findings that hNEIL1 
and hNEIL3 may unhook psoralen ICLs it may be suggested they also play a role in cisplatin 
DNA damage repair, despite being suggested to be refractory to repair by X. laevis NEIL3 
(Semlow et al., 2017). Furthermore, it has been demonstrated that TRIM26 plays a role in the 
regulation of the cellular resistance to cisplatin in U2OS cancer cells. It is characterised that 
cancer cells display UPS dysfunction (Mansour, 2018). Thus, it is proposed that TRIM26 
dysfunction in cancer cells may prove to be an important biomarker for the resistance of 
cancer cells to multiple types of therapeutic strategy including IR, ROS and ICL inducing agents 
(Yang et al., 2009; Edmonds et al., 2017; Williams and Parsons, 2018). This taken together 
with the previous observation that NEIL3 depletion sensitises glioblastoma cells to ATR and 
PARP inhibition, may indicate that TRIM26 status may provide insight into the resistance or 
sensitivity of cells to DDR inhibition (Klattenhoff et al., 2017). MYC has been identified as one 
of the most frequently amplified oncogenes which may negatively regulate genes which 
promote proliferative arrest and upregulate those which promote cellular proliferation 
(Beroukhim et al., 2010; Tusell et al., 2010; Dang, 2012; Kress et al., 2015). Furthermore, it 
has been shown that TRIM26 expression is induced by TGF-β and negatively regulates cellular 
proliferation and TRIM26 transcription may be inhibited by MYC when cells experience 
persistent TGF-β exposure (Nakagawa et al., 2017). Indirect increase in steady state levels of 
NEIL1, NTH1 and NEIL3 as result of MYC dependent TRIM26 downregulation would facilitate 
significant cellular resistance to IR, H2O2 and cisplatin (Edmonds et al., 2017; Williams and 
Parsons, 2018). It would be interesting to determine the relationship between MYC protein 
levels and hNEIL1, hNEIL3 and NTH1 protein levels in dysfunctional cells, to elaborate on this 
dynamic association between MYC, TRIM26 and the BER pathway. Furthermore, TRIM26 has 
been highlighted as a tumour suppressor in hepatocellular carcinomas and cholangiocellular 
carcinomas, highly radio- and chemo-resistant cancer types (Wang et al., 2015a). As 
previously discussed it has been shown in cancer cells that hNEIL3 depletion results in mitotic 
defects, with U2OS cells demonstrating increased recruitment to telomeric DNA sequences in 
response to oxidative DNA damage (Zhou et al., 2017). Telomeric maintenance is an 
important mechanism within the cell as dysfunction may lead to the formation of telomere-
dependent anaphase bridges which are a hallmark of genomic instability, promoting 
oncogenesis (Tusell et al., 2010; Bizard and Hickson, 2018). Thus, it would be interesting to 
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observe the effect of TRIM26 upregulation on spontaneous genomic instability, through the 
formation of anaphase bridges and mitotic dysfunction complementing observations made 
on hNEIL3 RNAi (Zhou et al., 2017). Together, these findings provide novel insight into 
possible mechanisms of oncogenesis and acquired therapeutic resistance in cancer cells 
displaying MYC overexpression. In addition, this may indicate that hNEIL1, hNEIL3 and NTH1 
are biomarkers of therapeutic resistance in cancer cells displaying MYC overexpression. 




In this study the role of the human endonuclease VIII like 1 and 3 (hNEIL1 and hNEIL3) DNA 
glycosylases in the removal of replication blocking lesions was explored. Previous studies have 
determined that hNEIL1 and hNEIL3 display increased expression levels in the S/G2M phases 
of the cell cycle, indicating a primary role in DNA replication (Hazra and Mitra, 2006; 
Neurauter et al., 2012; Zhou et al., 2015; Zhou et al., 2017). Furthermore, the literature has 
revealed that hNEIL1 and hNEIL3 are immunoprecipitated on newly synthesised DNA, with 
hNEIL3 enriched with the replisome and hNEIL1 shown to interact with the DNA replication 
machinery components RPA, RFC and PCNA in a multiprotein complex, while hNEIL3 was also 
shown to co-localise with RPA (Moorland et al., 2002; Theriot et al., 2010; Hegde et al., 2015; 
Bjørås et al., 2017). RPA is recruited to DNA replication forks experiencing replication stress 
due to the stalling of the replicative machinery at replication blocking DNA lesions, 
subsequently inducing the DNA damage response sub-pathway the RSR, through ATR 
signalling (Nam and Cortez, 2011). 
This evidence points to a possible role for these proteins within the replication stress response 
and DNA replication maintenance. Thus, providing rationale for the hypothesis that hNEIL1 
and hNEIL3 may demonstrate distinct biochemical roles at a DNA replication fork, working in 
concert to maintain genomic stability prior to completion of mitosis and indeed, depletion of 
hNEIL3 in cancer cells has been shown to perpetuate mitotic defects including a significant 
increase in metaphase arrest (Zhou et al., 2017). Therefore, the biochemical activity of 
recombinant hNEIL1 and hNEIL3 was characterised in the presence of a model DNA 
replication fork structure containing a 5-OHU, 8- OxoG and Tg. It was determined that 5-OHU 
and Tg are likely to be the most biologically relevant oxidative lesions processed by hNEIL1 
and hNEIL3 (Figure 3.3; Figure 3.4). Furthermore, distinct differences for lesion processing 
was dependent on the location of the oxidative lesion at the DNA replication fork structure 
by hNEIL1 and hNEIL3. Interestingly, hNEIL1 and hNEIL3 display discriminatory associated AP-
lyase activity based on the lesion type and lesion position within the DNA molecule. 
Furthermore, hNEIL3 displays robust cleavage of the Tg lesion within a DNA replication fork 
structure at all DNA lesion positions tested. In contrast, virtually no incision of Tg was 
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observed in linear ds-DNA, thus implying preference for the removal of the replication 
blocking lesion Tg in a DNA replication fork structure context. 
The involvement of hNEIL1 in the maintenance of cellular resistance to DNA interstrand 
crosslinking agents was previously demonstrated (Couvé-Privat et al., 2007; Couvé et al., 
2009; Macé-Aimé et al., 2010; Martin et al., 2017). Saparbaev’s group provided initial 
biochemical evidence that hNEIL1 could process 8-MOP induced ds-DNA monoadducts 
providing the first evidence of BER proteins removing lesions generated by ICL agents (Couvé-
Privat et al., 2007). However, hNEIL1 did not remove ICLs in a conventional duplex structure 
(Couvé-Privat et al., 2007). Subsequently, AAG was shown to provide a protective role against 
the ICL agents 8-MOP, BCNU and MMC demonstrated through the sensitivity of AAG-/- mouse 
embryonic stem cells to these agents (Maor-Shoshani et al., 2008). However, analysis in vitro 
could not establish a direct biochemical role for AAG in the repair of ICLs (Maor-Shoshani et 
al., 2008). hNEIL1 was then shown to unhook three-stranded oligonucleotide DNA structures 
containing an 8-MOP ICL, that mimicked the three-stranded intermediate generated through 
conventional FA replication associated or NER dependent ICL repair. Subsequently, 
overexpression of hNEIL1 in FA deficient cells was found to complement MMC and 8-MOP 
sensitivity (Couvé et al., 2009; Macé-Aimé et al., 2010). This demonstrated the cross-talk 
between BER and FA pathways for the first time. Rolseth et al. (2013) successfully generated 
NEIL3-/- mice and showed that their MEF cells displayed sensitivity to the ICL agent cisplatin. 
With the use of a X. laevis NEIL3 knockout egg extract model Semlow et al. (2016) revealed 
that X. laevis NEIL3 repaired psoralen induced ICL crosslinks and AP site ICLs in an X-shaped 
DNA structure, which represented convergent DNA replication forks. Furthermore, it was 
demonstrated that this repair was backed up by the FA pathway on the deficiency of NEIL3, 
thus indicating that NEIL3 dependent ICL resolution was the primary cellular response in X. 
laevis egg extracts, in this system. However, direct biochemical evidence for hNEIL3 ICL 
resolution was not addressed and the question remained whether hNEIL3 possessed 
overlapping structural affinity for psoralen ICLs with hNEIL1 in unhooking psoralen 
monoadducts and ICLs (Couvé-Privat et al., 2007; Couvé et al., 2009). Due to overlapping 
lesion preference and complementary structural affinity displayed in the presence of 
oxidative lesions within a DNA replication fork structure, it was hypothesised that hNEIL3 may 
play a complementary biochemical role to hNEIL1 in the presence of psoralen induced 
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monoadducts and ICLs. Thus, a panel of DNA substrates containing a site-specific psoralen 
induced ICL were generated and used as substrates for biochemical characterisation of hNEIL3 
activity in the repair of ICLs. 
Thus, it is reported here that hNEIL3 demonstrated unhooking activity on ss-DNA 
monoadducts, with hNEIL1 and hNEIL3 displaying complementary unhooking of three-
stranded psoralen interstrand crosslinks, typical of the repair intermediates generated by the 
FA pathway and in agreement with Couvé et al. (2009). Interestingly, hNEIL1 demonstrated a 
bifunctional activity profile, conducting β,δ-elimination of the phosphodiester backbone, 
while hNEIL3 proteins maintained a monofunctional profile and as result did not generate 
DNA breaks (Martin et al., 2017). However, hNEIL3 displayed preference for long three-
stranded psoralen ICL structures, unlikely to be produced through TLS and the conventional 
FA pathway of ICL repair (Sale et al., 2012; Clauson et al., 2013). This then raised the possibility 
that hNEIL1 and hNEIL3 activity was independent and distinct from the downstream 
processing and generation of repair intermediates by FA ICL repair and in agreement with the 
suggestions of pathway independent processing of ICLs by Semlow et al. (2016). Therefore, a 
four-stranded DNA oligonucleotide was constructed, containing a site-specific psoralen ICL 
and used as a substrate in these assays. Analysis revealed the ability of hNEIL1 and hNEIL3 
proteins to unhook four-stranded ICL structures. Again, hNEIL1 displayed a bifunctional 
activity profile conducting β,δ-elimination, while hNEIL3 displayed a monofunctional profile 
and again did not generate DNA breaks. A catalytically inactive recombinant mutant of 
hNEIL3Cat was generated and lacked unhooking activity on three- and four-stranded psoralen 
ICL substrates, indicating the genuine unhooking activity of hNEIL3. This provided further 
evidence for a NEIL-dependent psoralen ICL processing pathway, independent of the FA 
pathway and complementing previous findings (Semlow et al., 2016).   
Based on the work of Seidman’s laboratory, a model was proposed which suggests that 
FANCM mediated replication traverse and the continuation of DNA replication would 
generate the model three- and four-stranded ICL oligonucleotide structures analysed here 
(Huang et al., 2013). Interestingly, depletion of NEIL3 in cancer cells has been showed to 
promote genetic instability through mitotic dysfunction and chromosomal aberration (Zhou 
et al., 2017). The model proposed here would suggest that hNEIL1 and hNEIL3 post-replicative 
repair of four-stranded DNA structures proceeds after FANCM facilitated ICL traverse, to 
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facilitate the separation of daughter chromatids during the metaphase stage of the cell cycle 
(Huang et al., 2013; Rohleder et al., 2016). In agreement with this depletion of hNEIL3 was 
shown to result in a significant increase in chromatin bridges and an increase in metaphase 
arrest, suggested to be the result of the failure to resolve chromosomal linkages (Zhou et al., 
2017). In addition, FANCM was shown to colocalise at chromatin bridges and deficiency in FA 
pathway proteins is characterised to promote genetic instability with increased observations 
of chromatin bridging (Chan and Hickson, 2011; Tusell et al., 2010; Bizard and Hickson, 2018). 
Therefore, it is proposed that hNEIL1 and hNEIL3 DNA glycosylases play fundamental roles in 
the maintenance of genomic stability in association with DNA replication. These roles may be 
exploited in cancer cells to maintain proliferative capacity, in turn evading significant 
activation through the generation of DNA breaks associated with the FA pathway and thus 
possible cell cycle arrest and apoptosis on DNA replication fork collapse. In addition, the 
finding that X. laevis NEIL3 may resolve AP site ICLs and observations of the activation of the 
FA pathway in the presence of endogenous aldehydes, provides rationale for the evolution of 
distinct ICL repair mechanisms (Sczepanski et al., 2008; Macé-Aimé et al., 2010; Garaycoechea 
et al., 2012; Pontel et al., 2015; Semlow et al., 2016). Furthermore, it appears that the 
observed ds-DNA-MA and three-stranded psoralen ICL unhooking activity is an evolutionary 
conserved activity within the Fpg/Nei family of DNA glycosylases. This indicates that the 
resolution of endogenous ICLs in both prokaryotes and higher eukaryotic organisms is 
required for genomic stability (Couvé-Privat et al., 2007; Couvé et al., 2009). 
Previous investigation by the Parsons’ group determined PTM regulation of hNEIL1 by the E3 
ubiquitin ligases MULE and TRIM26 (Edmonds et al., 2017). MULE has previously been shown 
to interact and ubiquitinate the tumour suppressor p53 and is involved in ATR signalling 
modulation (Chen et al., 2005). This link to ATR signalling through MULE may further implicate 
hNEIL1 in the RSR. In addition, TRIM26 is suggested to promote proliferative arrest within the 
cell and has been identified as a possible tumour suppressor in some forms of cancer 
(Nakagawa et al., 2017). It was shown that the oncogene MYC inhibits the transcription of 
TRIM26 and was suggested to be a mechanism of the evasion of proliferative arrest, a 
Hallmark of Cancer (Wang et al., 2015; Nakagawa et al., 2017). In addition, TRIM26 down 
regulation was observed to induce resistance to IR and oxidative DNA damage by H2O2, with 
the latter being complemented by NTH1 overexpression (Edmonds et al., 2017; Williams and 
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Parsons, 2018). The present investigation revealed that hNEIL3 steady state levels are also 
regulated by the E3 ubiquitin ligase TRIM26 in U2OS cells. It was then hypothesised that 
hNEIL1 and hNEIL3 were ubiquitinated by TRIM26 to modulate the cellular response to ICL 
agents based on the previously observed complementary ICL unhooking activity (Martin et 
al., 2017). Subsequently, it was observed that hNEIL1 and hNEIL3 over expression 
complemented the cisplatin resistance observed after TRIM26 RNAi in U2OS cells thus 
providing further cellular evidence that hNEIL1 and hNEIL3 play a role in the resistance to ICL 
agents in vivo and are modulated by TRIM26 through the UPS. However, the biochemical 
mechanism of hNEIL1 and hNEIL3 DNA glycosylases in the presence of cisplatin ICLs has yet 
to be established. Semlow et al. (2016) demonstrated that the cisplatin ICL was refractory to 
repair by the NEIL3 DNA glycosylase in an X. laevis egg extract cell free system. This may 
indicate that the involvement of hNEIL1 and hNEIL3 in the cellular resistance to cisplatin ICLs 
may be due to an associated secondary function or recruitment of interacting proteins. To 
elucidate these functions would require the identification of protein partners 
coimmunoprecipitated from cisplatin treated cells which demonstrate both the upregulation 
of the NEIL DNA glycosylases and resistance to cisplatin. The sequential reconstitution of 
proteins in these complexes, in the presence of a cisplatin treated oligonucleotide substrate, 
may enable the identification of the distinct roles of hNEIL1, hNEIL3 and identified protein 
partners in the biochemical mechanisms behind cellular resistance to cisplatin treatment in 
this context. 
However, it is tempting to propose a model which links the MYC transcription factor with 
regulation of the NTH1, hNEIL1 and hNEIL3 DNA glycosylases through TRIM26. In healthy cells 
TGF-β may stimulate the transcription of TRIM26, inducing proliferative arrest and 
upregulating UPS mediated degradation of the NTH1, hNEIL1 and hNEIL3 DNA glycosylases 
(Edmonds et al., 2017; Nakagawa et al., 2017; Williams and Parsons, 2018). In dysfunctional 
cells, overexpression of MYC may inhibit TRIM26 transcription facilitating the continuation of 
proliferation and increase in the steady state levels of the NTH1, hNEIL1 and hNEIL3 DNA 
glycosylases (Nakagawa et al., 2017). The latter example is mimicked by TRIM26 RNAi and is 
presented here (Figure 5.8; Figure 5.9; Figure 5.10; Figure 5.11). As a result, TRIM26 
downregulation may lead to the acquisition of cellular resistance in cancer cells to IR, H2O2 
and cisplatin, in part due to the increase in steady state levels of the NTH1, NEIL1 and NEIL3 
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DNA glycosylases (Edmonds et al., 2017; Williams and Parsons, 2018). This is in agreement 
with a previous study that showed that MYC transgenic mice displayed increased cDNA 
expression levels of NTH1, OGG1, as well as proteins involved in NER and DSB repair, with the 
observation of a reduction in oxidative DNA damage (Hironaka et al., 2003).   Interestingly, 
MYC has also been shown to regulate the Ras dependent ERK-MAP kinase signalling pathway 
which can promote oncogenesis if dysregulated (Gramling and Eischen, 2012). In agreement 
with this, hNEIL3 DNA glycosylase expression has been shown to be induced by the Ras 
dependent ERK-MAP kinase pathway (Neurauter et al., 2012). This putative link between MYC 
and the BER pathway in cellular resistance within dysfunctional cells, requires further 
investigation, but may provide insight into the dysregulation of DNA glycosylases and 
resistance to therapeutic intervention within cancer (Shinmura et al., 2016).  
However, as hNEIL1 induction was shown to be dependent on the MULE E3 ubiquitin ligase 
in response to IR, it is essential to elucidate the mechanism in which hNEIL1 and hNEIL3 are 
induced in response to cisplatin (Edmonds et al., 2017). This may help establish the distinct 
signalling pathways that regulate the induction of DNA glycosylases in response to specific 
types of DNA damage. Furthermore, an important line of enquiry, is the identification of the 
distinct structural similarities shared between the DNA glycosylases hNEIL1, hNEIL3 and NTH1 
which enable them to be recognised by TRIM26. This in turn may aid in the development of 
novel biological agents such as proteolysis targeting chimeras (PROTACs) for the targeted 
ubiquitination of hNEIL1, hNEIL3 and NTH1, thus reducing cellular resistance in UPS 
dysfunctional cells (Bondeson and Crews, 2017; Cromm and Crews, 2017). 
 




7. Conclusion and Future Perspectives. 
 
The findings of this study underline hNEIL1, hNEIL3 and TRIM26 as markers of cellular 
resistance to ICL inducing agent therapeutics. Initially, the biochemical role of hNEIL1 and 
hNEIL3 in the repair of oxidative DNA lesions was explored and confirmed a preference for 
the DNA replication blocking lesion Tg in a model DNA replication fork structure by hNEIL3FL. 
Furthermore, the biochemical activity of hNEIL1 and hNEIL3 DNA glycosylases in the 
unhooking of an ICL from three- and four-stranded structures was revealed (Martin et al., 
2017). Additionally, TRIM26 was shown to ubiquitinate recombinant hNEIL3FL in vitro, with 
confirmation that steady state levels of hNEIL1 and hNEIL3 are modulated by TRIM26 in U2OS 
cells. Furthermore, TRIM26, hNEIL1 and hNEIL3 were implicated in the cellular response to 
the ICL inducing agent cisplatin. Taken together, the replication associated functions of 
hNEIL1 and hNEIL3 were confirmed, in agreement with the literature. It is suggested that 
hNEIL1 and hNEIL3 in collaboration with NTH1 provide a robust and complementary 
mechanisms for the removal of oxidative damage. In addition, hNEIL1 and hNEIL3 display 
distinct structural preferences, which may indicate non-canonical roles within the 
maintenance of genomic stability in association with DNA replication, akin to structure 
specific endonucleases (Martin et al., 2017).  
Depletion of hNEIL3 in cancer cells results in a significant increase in anaphase bridges, 
instability and also a significant increase in metaphase arrest (Zhou et al., 2017). Taken 
together with biochemical data, a model is proposed in which long three- and four-stranded 
DNA ICL structures may be produced in vivo, involving the DNA translocase activity of FANCM 
(Huang et al., 2013, Rohleder et al., 2016). On persistence of these four stranded structures, 
representing crosslinked daughter chromatids, metaphase is likely to arrest due to the 
inability to separate the two DNA duplex, in agreement with Zhou et al. (2017). It is proposed 
that this mechanism may be modulated by MYC overexpression and TRIM26 dysfunction 
within cells, promoting cellular resistance to ICL inducing agents and increased proliferative 
capacity (Nakagawa et al., 2017). Therefore, this study may provide insights into the 
mechanisms of acquired cellular resistance in cancer cells through TRIM26, hNEIL1 and 
hNEIL3. It will be important to establish the relationship between MYC expression levels and 
the hNEIL1, hNEIL3 and NTH1 DNA glycosylase expression levels in human malignant tumours 




to elaborate on this proposed mechanism of acquired resistance through TRIM26 
transcription inhibition. 
The findings of this study provide motive for the therapeutic targeting of this mechanism in 
dysfunctional cancer cells, displaying upregulation of hNEIL1 or hNEIL3 and downregulation 
of TRIM26. Indeed, depletion of hNEIL3 has been shown to significantly improve the efficacy 
of ATR and PARP inhibitors in highly resistant glioblastoma cells, indicating a protective role 
within the response to replication stress and prevention of DNA strand breaks (Klattenhoff et 
al., 2017). hNEIL3 depletion also sensitises HCT116 cells to oxaliplatin and NEIL3 knockout 
sensitises MEFs to cisplatin, while the findings of this study provide biochemical mechanistic 
rationale and indicate significant resistance of cancer cells to cisplatin in a hNEIL1 and hNEIL3 
dependent manner (Rolseth et al., 2013; Taylor et al., 2015). The establishment of a 
CRISPR/Cas9 hNEIL3 knockout in the U2OS cancer cell line, will provides a model system for 
the further study of sensitisation to crosslinking agents through ICL inducing agent treatment 
and cell viability assays. In addition, providing a model in which the contribution of hNEIL3 to 
cisplatin resistance in TRIM26 siRNA treated U2OS cells may be confirmed. 
The lack of a mutagenic phenotype in NEIL DNA glycosylase deficient mice and the restricted 
expression of hNEIL3 in normal cells, provides strong motivation for the therapeutic targeting 
of the NEIL DNA glycosylases in the treatment of cancer, while minimising the detrimental 
impact on healthy cells (Morland et al., 2002; Torisu et al., 2005; Hildrestrand et al., 2009; 
Rolseth et al., 2013; Taylor et al., 2015; Klattenhoff et al., 2017; Rolseth et al., 2017; Zhou et 
al., 2017). Therefore, the data presented here provides further evidence for the clinical 
relevance of the hNEIL1 and hNEIL3 DNA glycosylases as important biomarkers of resistance 
and therapeutic targets for the treatment of cancer.






Aizawa, K., Liu, C., Tang, S. et al. (2016) Tobacco carcinogen induces both lung cancer and 
non-alcoholic steatohepatitis and hepatocellular carcinomas in ferrets which can be 
attenuated by lyncopene supplementation. International Journal of Cancer, 139, 1171-
1181. 
Aller, P., Rould, M. A., Hogg, M., Wallace, S. S. & Doublié. (2007) A structural rationale for 
stralling of a replicative DNA DNA polymerase at the most common oxidative thymine 
lesion thymine glycol.  Proceedings of the National Academy for Sciences of the U.S.A., 
104, 814-818.  
Allton, K., Jain, A. K., Herz, H.M.  et al. (2009) Trim24 targets endogenous p53 for 
degradation. Proceedings of the National Academy for Sciences of the U.S.A, 106, 11612–
11616.  
Almeida, K.H. & Sobol, R.W. (2007) A unified view of BER: lesion dependent protein 
complexes regulated by post-translational modification, DNA Repair (Amst.), 6, 695–711 
Ameziane, N., May, P., Haitjema, A. et al. (2015) A novel Fanconi anaemia subtype 
associated with a dominant-negative mutation in RAD51. Nature Communications. 6, 
8829. 
Anderson, D. & Krummen, L. (2002) Recombinant protein expression for therapeutic 
applications. Current Opinion in Biotechnology, 13,117-123. 
Andreassen, P. R., D’Andre, A. D. & Taniguchi, T. (2004) ATR couples FANCD2 
monoubiquitination to the DNA-damage response. Genes & Development, 18, 1958—
1963. 
Angers, S., Li, T., Yi, X., MacCoss, M.J., Moon, R.T., & Zheng, N. (2006) Molecular 
architecture and assembly of the DDB1–CUL4A ubiquitin ligase machinery. Nature. 443, 
590–593. 
Ayala, A., Muñoz, M. & Argüelles, S. (2014) Lipid peroxidation: Production, Metabolism, 
and Signalling Mechanisms of Malondialdehyde and 4-Hydroxy-2-Nonenal. Oxidative 
Medicine and Cellular Longevity, 2014, 1-31.  
Balakrishnan, L. & Bambara, R. (2013) Flap endonuclease 1. Annual Review of 
Biochemistry, 82, 119-138. 
Bandaru, V., Sunkara, S., Wallace, S. & Bond, J.P. (2002) A novel human DNA glycosylase 
that removes oxidative damage and is homologous to Escherichia coli endonuclease VIII. 
DNA Repair, 1, 517-529. 
Barzilai, A., Rotman, G., & Shiloh, Y. (2002) ATM deficiency and oxidative stress: a new 
dimension of defective response to DNA damage. DNA Repair (Amst.), 1, 3–25. 
Bastia, D., Zzaman, S., Krings, G., Saxena, M., Peng, X. et al. (2008) Replication termination 
mechanism as revealed y Tus-mediated polar arrest of a sliding helicase. Proceeding of 
the National Academy of Sciences of the United States of America, 105, 12831-12836. 




Bell, J., Malyukova, A., Holien, J. K. et al. (2012) TRIM16 acts as an E3 ubiquitin ligase and 
can heterodimerize with other TRIM family members. PLoS One, 7, e37470. 
Beltran, H., Prandi, D. Mosquera, J.M. et al. (2016) devergent clonal evolution of 
castration-resistant neuroendocrine prostate cancer. Nature Medicine, 22, 298-305. 
Beroukhim, R., Mermel, C, H. Porter, D. et al. (2010) The landscape of somatic copy-
number alteration across human cancers. Nature, 463, 899-905. 
Bessho, T., Roy, R., Yamamoto, K. et al. (1993) Repair of 8-hydroxyguanine in DNA by 
mammalian N-methylpurine-DNA-glycosylase. Proceedings of the National Academy of 
Sciences of the U.S.A, 90, 8901-8904. 
Bhagwat, M. & Gerlt, J. A. (1996) 3'- and 5'-strand cleavage reactions catalyzed by the Fpg 
protein from Escherichia coli occur via successive beta- and delta-elimination 
mechanisms, respectively. Biochemistry, 35, 659-665. 
Bhakat, K. K., Hazra, T. K. & Mitra, S. (2004) Acetylation of the human DNA glycosylase 
NEIL2 and inhibition of its activity. Nucleic Acids Research, 32, 3033-3039. 
Bhattacharjee, S. & Nandi, S. (2017) DNA damage response and cancer therapeutics 
through the lens of the Fanconi Anemia DNA repair pathway. Cell. Commun. Signal, 15, 
41. 
Bishop, A. J. R. & Schiestl, R. H. (2002) Homologous Recombination and Its Role in 
Carcinogenesis. Journal of Biomedicine and Biotechnology, 2, 75-85. 
Bizard, A. H. & Hickson, I. D. (2018) Anaphase: a fortune-teller of genomic instability. 
Current Opinion in Cell Biology, 52,112-119. 
Bjørås, K. A., Sousa, M. M. L., Sharma, A. et al. (2017) Monitoring of the spatial and 
temporal dynamics of BER/SSBR pathway proteins, including MYG, UNG2, MPG, NTH1 and 
NEIL1-3, during DNA replication. Nucleic Acids Research, 45, 8291-8301. 
Blaisdell, J. O., Hatahet, Z. & Wallace, S. S. (1999) A novel role for Escherichia coli 
endonuclease VIII in the prevention of spontaneous G-T transversions. Journal of 
Bacteriology, 181, 6396-6402. 
Boiteux, S. & Radicella, J. (2000) The Human OGG1 Gene: Structure, Functions, and Its 
Implication in the Process of Carcinogenesis. Archives of Biochemistry and Biophysics, 377, 
1-8. 
Boiteux, S., Gajewski, E., Laval, J., Dizdaroglu, M. (1992) Substrate specificity of the 
Escherichia coli Fpg protein (formamidopyrimidine-DNA glycosylase): excision of purine 
lesions in DNA produced by ionizing radiation or photosensitization. Biochemistry, 31,  
106–110. 
Bondeson, D. P. & Crews, C. M. (2017) Targeted Protein Degradation by Small Molecules.  
Annual Review of Pharmacology and Toxicology, 57, 107-123. 
Boos, D., Frigola, J. & Diffley, J. F. (2012) Activation of the replicative DNA helicase: 
breaking up is hard to Do. Current Opinions in Cell Biology, 24, 423-430. 




Borlepawar, A., Rangrez, A. Y., Bernt, A. et al. (2017) TRIM24 protein promotes and 
TRIM32 protein inhibits cardiomy- ocyte hypertrophy via regulation of dysbindin protein 
levels. Journal of Biological Chemistry,292, 10180–10196. 
Braselmann, H., Michna, A., Heb, & Unger, K. (2015) CFAssay: statistical analysis of the 
colony formation assay. Radiation Oncology, 10, 223. 
Brookes, P. & Lawley, P. D. (1960) The reaction of mustard gas with nucleic acids in vitro 
and in vivo. Biochemical Journal, 77, 478-484. 
Brookes, P. & Lawley, P. D. (1964) Evidence for the Binding of Polynuclear Aromatic 
Hydrocarbons to the Nucleic Acids of Mouse Skin: Relation Between Carcinogenic Power 
of Hydrocarbons and their Binding to Deoxyribonucleic Acid. Nature, 202, 781-784. 
Brooks, P. J. & Zahkari, S. (2003) Acetaldehyde and the genome: Beyond nuclear DNA 
adducts and carcinogenesis. Journal of the American Chemical Society, 125, 50-61. 
Brown, T. (2010) Gene Cloning & DNA Analysis: An Introduction. Wiley-Blackwell, Oxford. 
Budzowska, M., Graham, T. G., Sobeck, A., Waga, S. & Walter, J. C. Regulation of the Rev`-
pol zeta complex during bypass of a DNA interstrand cross-link. The EMBO Journal, 34, 
1971-1985. 
Busso, C.S., Iwakuma, T. & Izumi, T. (2009) Ubiquitination of mammalian AP endonuclease 
(APE1) regulated by the p53-MDM2 signalling pathway. Oncogene, 28, 1616–1625.  
Byun, T. S., Pacek, M., Yee, M., Walter, J. C. & Cimprich, K. A. (2005) Functional uncoupling 
of MCM helicase and DNA DNA polymerase activities activates the ATR-dependent 
checkpoint.  Genes & Development, 19, 1040-1052. 
Cadet, J. & Wagner, J. R. (2013) DNA Base Damage by Reactive Oxygen Species, Oxidizing 
Agents, and UV Radiation. Cold Spring Harbour Perspectives in Biology, 5, a012559. 
Cancer Research UK. (2015) Cancer statistics for the UK, 
https://www.cancerresearchuk.org/health-professional/cancer-statistics-for-the-uk 
[Accessed 25 August, 2018]. 
Cancer Research UK. (2016) Cancer statistics for the UK, 
https://www.cancerresearchuk.org/health-professional/cancer-statistics-for-the-uk 
[Accessed 25 August, 2018]. 
Cantoni, O., Murray, D., Meyn, R.E. (1987) Induction and repair of DNA single-strand 
breaks in EM9 mutant CHO cells treated with hydrogen-peroxide. Chem.-Biol. Interact, 63, 
29–38. 
Carter, R. J. & Parsons, J. L. (2016) Base Excision Repair, a Pathway Regulated by 
Posttranslational Modifications. Mol. Cell. Biol, 36, 1426-1437. 
Chakraborty, A., Wakamiya, M., Venkoca-Canova, T. et al. (2015) Neil2-null Mice 
Accumulate Oxidized DNA Bases in the Transcriptionally Active Sequences of the Genome 
and are Susceptible to Innate Inflammation. Journal of Biological Chemistry, 250, 24636-
24648. 




Chan, K. L. & Hickson, I. D. (2011) New insights into the formation and resolution of ultra-
fine anaphase bridges. Seminars in cell & Developmental Biology, 22, 906-912. 
Chanoux, R. A., Yin, B., Urtishak, K. A., Asare, A.,Bassing, C. H. et al. (2009) ATR and H2AX 
cooperate in maintaining genome stability under replication stress. J. Biol. Chem. 284, 
5994–6003. 
Cheadle, J. & Sampson, J. (2007) MUTYH- associated polyposis- From defect in BER to 
clinical genetic testing. DNA Repair, 6, 274-279. 
Chen, D., Kon, N., Li, M., Zhang, W., Qin, J., & Gu, W. (2005) ARF-BP1/Mule is a critical 
mediator of the ARF tumour suppressor. Cell, 121, 1071–1083. 
Chen, J. & Chen, Z. J. (2013) Regulation of NF-KappaB by ubiquitination. Current opinions 
in immunology, 25, 4-12. 
Chen, X. B., Melchionna, R. Denis, C. M. et al. (2001) Human Mus81- associated 
endonuclease cleaves Holliday junctions in vitro. Mol. Cell, 8, 1117-1127. 
Chen, Z. J., & Sun, L. J. (2009) Nonproteolytic functions of ubiquitin in cell signalling. Mol. 
Cell, 33, 275–286 
Chetsanga, C.J. & Lindahl, T. (1979) Release of 7-methylguanine residues whose imidazole 
rings have been opened from damaged DNA by a DNA glycosylase from Escherichia coli. 
Nucleic Acids Res, 6, 3673–3684. 
Cheung, R. S. & Taniguchi, T. (2017) recent insight into the molecular basis of Fanconi 
anemia: genes, modifiers, and drivers. International Journal of Haematology, 106, 335-
344. 
Cho, Y. J., Wang, H., Kozekov, I. D. et al. (2006) Stereospecific formation of interstrand 
carbinolamine DNA cross-links by crotanaldehyde and acetaldehyde-derived alpha-CH3-
gamma-OH-1,N2,propano2’-deoxyguanosine adducts in the 5 ́ CpG-3ʹ sequence. Chemical 
Research in Toxicology, 19, 195-208. 
Chou, W., Wang, H., Wong, F. et al. (2008) Chk2-depenent phosphorylation of XRCC1 in 
the DNA damage repose promotes BER. The EMBO Journal, 27, 3140-3150. 
Christensen, D. E., Brzovic, P. S. & Klevit, R. E. (2007) E2-BRCA1 RING interactions dictate 
synthesis of mono- or specific polyubiquitin chain linkages. Nat. Struct. Mol. Biol, 14, 941-
948. 
Christie, N.T., Cantoni, O., Evans R.M., Meyn, R.E. & Costa, M. (1984) Use of mammalian 
DNA repair-deficient mutants to assess the effects of toxic metal compounds on DNA, 
Biochem. Pharmacol, 33, 1661–1670. 
Christmann, M., Verbeek, B., Roos, W. P. & Kaina, B. (2011) O(6)-Methylguanine-DNA 
methyltransferase (MGMT) in normal tissues and tumours: enzyme activity, promoter 
methylation and immunohistochemistry. Biochimica et biophysica acta, 1816, 179-190. 
Churchill, M.E., Peak, J.G. & Peak, M.J. (1991) Correlation between cell-survival and DNA 
single-strand break repair proficiency in the Chinese hamster ovary cell-lines aa8 and EM9 
irradiated with 365-nm ultraviolet—a radiation. Photochem. Photobiol, 53, 229–236. 




Ciccia, A. & Elledge, S. (2010) The DNA Damage Response: Making It Safe to Play with 
Knives. Molecular Cell, 40, 179-204.  
Cipak, L., Watanabe, N. & Bessho, T. (2006) The role of BRCA2 in replication-coupled DNA 
interstrand cross-link repair in vitro. Nature structural & molecular biology, 18, 729-733. 
Clauson, C., Schärer, O. D. & Niedernhofer, L. (2013) Advances in Understanding the 
Complex Mechanisms of DNA Interstrand Cross-Link Repair. Cold Spring Harbour 
Perspectives in Biology, 5, 1-25. 
Cohen, P., & Tcherpakov, M. (2010) Will the Ubiquitin System Furnish as Many Drug 
Targets as Protein Kinases? Cell, 143, 686–693.  
Collins, G. A. & Goldberg, A. K. (2017) The Logic of the 26S Proteasome. Cell, 169, 792-806. 
Compe, E. & Egly, J. M. *2012) TFIIH: When transcription met DNA repair. Nature Reviews, 
13, 343-354. 
Compe, E. & Egyl, J. M. (2012) TFIIH: when transcription met DNA repair. Nature Reviews 
Molecular Cell Biology, 13, 343-345. 
Cortez, D. (2015) Preventing Replication Fork Collapse to Maintain Genome Integrity. DNA 
Repair, 32, 149-157. 
Couvé, S., Macé-Aimé, G., Rosselli, F. & Saparbaev, M. (2009) The Human Oxidative DNA 
Glycosylase NEIL1 Excises Psoralen-induced Interstrand DNA Cross-links in a Three-
stranded DNA Structure. The Journal of Biological Chemistry, 284, 11963-11970. 
Couvé-Privat, S., Gaëtane, M., Rosselli, F. & Saparbaev, M. (2007) Psoralen-induced DNA 
adducts are substrates for the BER pathway in human cells. Nucleic Acids Research, 17, 
5672-5682. 
Cromm, P. M. & Crews, C. M. (2017) Targeted Protein Degradation: from Chemical Biology 
to Drug Discovery. Cell Chemical Biology, 24, 1181-1190. 
Dang, C. V. (2012) MYC on the path to cancer. Cell, 149, 22-35. 
Danielsen, J.M., Sylvestersen, K.B., Bekker-Jensen, S. et al. (2011) Mass spectrometric 
analysis of lysine ubiquitylation reveals promiscuity at site level. Mol. Cell. Proteomics, 10, 
M110.003590. 
Das, A., Boldogh, I., Lee, J. W. et al. (2007) The Human Werner Syndrome Protein 
Stimulates Repair of Oxidative DNA Base Damage by the DNA Glycosylase NEIL1. The 
Journal of Biological Chemistry, 282, 26591-26602. 
Das, A., Rajagopalant, L. Mathura, V. S., Rigby, S. J., Mitra, S. & Hazra, T. K. (2004) 
Identification of a Zinc Finger Domain in the Human NEIL2 (Nei-like-2) Protein. The Journal 
of Biological Chemistry, 279, 47132-47138. 
de Silva, I. U., McHugh, P. J., Clingen, P. H. & Hartley, J. A. (2000) Defining the roles of 
nucleotide excision repair and recombination in repair of DNA interstrand cross-links in 
mammalian cell. Molecular Cell Biology, 20, 7980-7990. 




de Sousa, J. F., Torrieri, R., Serafim, R. B. et al. (2017) Expression signature of DNA repair 
genes correlate with survival prognosis of astrocytoma patients. Tumour Biology, 39, 1-
11. 
de Waard, H, de Wit, J., Andressoo, J. et al. (2004) Different Effects of CSA and CSB 
deficiency on Sensitivity to oxidative DNA Damage. Molecular and Cellular Biology, 24, 
7941-7948. 
Deans, J. & West, S. (2011) DNA interstrand crosslink repair and cancer. Nature Reviews, 
11, 467-480. 
Desai, N.A. & Shankar, V. (2003) Single-strand-specific nucleases. FEMS Microbiology 
Reviews, 26, 457-491. 
Dianov, G., Bischoff, C., Sunesen, M & Bohr, V. A. (1999) Repair of 8-oxoguanine in DNA is 
deficient in Cockayne syndrome group B cells. Nucleic Acids Research, 27, 1365-1368. 
Dorn, J., Ferrari, E., Imhof, R., Ziegler, N., & Hubscher, U. (2014) Regulation of human 
MutYH DNA glycosylase by the E3 ubiquitin ligase Mule. J. Biol. Chem, 289, 7049–7058. 
Dou, H., Mitra, S. & Hazra, T. K. (2003) Repair of Oxidized Bases in DNA Bubble Structures 
by Human DNA glycosylases NEIL1 and NEIL2. Journal of Biological Chemistry, 278, 49679-
49684. 
Douwel, K., Boonen, R. A. C. M, Long, D. T. et al. (2014) ERCC1-XPF acts in unhooking DNA 
interstrand crosslinks in cooperation with FANCD2 and FANCP/SLX4. Mol. Cell, 54, 460-
471. 
Douwel, K., Hoogenboom, W. S., Boonen, R. A. C. M. & Knipscheer, P. (2017) Recruitment 
and positioning determine the specific role of the ERCC1-XPF endonuclease in interstrand 
crosslink repair. The EMBO Journal, 36, 2034-2046. 
Dronkert, M. & Kanaar, R. (2001) Repair of DNA interstrand cross-links. DNA Repair, 486, 
217-247. 
Duncan, T., Trewick, S. C., Koivisto, P., Bates, P. A., Lindahl, T. & Sedgwick. (2002) Reversal 
of DNA alkylation damage by two human dioxygenases. Proceedings of the National 
Academy of Sciences of the U.S.A, 99, 16660-16665. 
Dutta, S., Chowdhury, G. & Gates, K. S. (2006) Interstrand Cross-Links Generated by Abasic 
Sites in Duplex DNA.  Journal of The American Chemical Society, 129, 1852-1853. 
Duxin, J. P. & Walter, J. C. (2015) What is the DNA repair defect underlying Fanconi 
anemia? Current Opinion in Cell Biology, 37, 49-60. 
Edmonds, M. J. & Parsons, J. L. (2016) Regulation of BER proteins by ubiquitylation. 
Experimental Cell Research, 329, 132-138. 
Edmonds, M. J., Carter, R.J., Nickson, C.M., Williams, S.C., Parsons, J.L., (2017) 
Ubiquitylation-dependent regulation of NEIL1 by Mule and TRIM26 is required for the 
cellular DNA damage response. Nucleic Acids Res, 45, 726-738.  




Elder, R. H., Jansen, J. G., Weeks, R. J. et al. (1998) Alkylpurine-DNA-N- Glycosylase 
Knockout Mice Show Increased Susceptibility to Induction of Mutations by Methyl 
Methanesulfonate. Molecul and Cellular Biology, 18, 5828-5837. 
Elledge, S. (2015) The DNA Damage response- self-awareness for DNA. American Medical 
Association, 314, 1111-1112.  
Engelward, B. P., Dreslin, A., Christensen, J., Huszar, D. & Samson, L. D. (1996) Repair-
deficient 3-methyladenine DNA glycosylase homozygous mutant mouse cells have 
increased sensitivity to alkylation-induced chromosome damage and cell killing. The 
EMBO Journal, 15, 945-952. 
Engelward, B. P., Weeda, G., Wyatt, M. D. et al. (1997) Base excision repair deficient mice 
lacking the Aag alkylation DNA glycosylase. Proceeding of the National Academy of 
Sciences of the U.S.A, 94, 13087-13092. 
Enoiu, M., Jiricny, J. & Schärer, O. D. (2012) Repair of cisplatin-induced DNA interstrand 
crosslinks by a replication-independent pathway involving transcription-coupled repair 
and translesion synthesis. Nucleic Acids Research, 40, 8953-8964. 
Esposito, D., Kolipoulos, M. G. & Rittinger, K. (2017) Structural determinants of TRIM 
protein function.  Biochemical Society Transactions, 45, 183-191. 
Esteller, M., Garcia-Foncillas, J., Andion, E. et al. (2000) Inactivation of the DNA-repair 
gene MGMT and the clinical response of gliomas to alkylating agents. New England 
Journal of Medicine, 343, 1350-1354. 
Fagbemi, A. F., Orelli, B., Scharer, O. D. (2011) Regulation of endonuclease activity in 
human nucleotide excision repair. DNA Repair, 10, 722-729. 
Fagerlie, S. R. & Bagby, G. C. (2006) Immune defects in Fanconi anemia. Critical Reviews 
in Immunology, 26, 81-96. 
Fantini, D., Moritz, E., Auvre, F. et al. (2013) Rapid inactivation and proteasome mediated 
degradation of OGG1 contribute to the synergistic effect of hyperthermia on genotoxic 
treatments. DNA Repair, 12, 227–237. 
Fekairi, S., Scaglione, S., Chahwan, C. et al. (2009) Human SLX4 is a Holliday junction 
resolvase subunit that binds multiple DNA repair/recombination endonucleases. Cell, 138, 
78-89. 
Fernandez-Capetillo, O. & Nussenzweig, A. (2013) Naked replication forks break apRPArt. 
Cell, 155, 979-980. 
Foo, J. & Michor, F. (2014) Evolution of acquired resistance to anti-cancer therapy. Journal 
of Theoretical Biology, 0, 10-20. 
Fousteri, M., Vermeulen, W., van Zeeland, A. A. & Mullenders, L. H. (2006) Cockayne 
syndrome A and B proteins differentially regulate recruitment of chromatin remodelling 
and repair factors to stalled RNA DNA polymerase II in vivo. Molecular Cell, 23, 471-482. 




Fu, D., Calvo, J. A. & Samson, L. D. (2012) Genomic instability in cancer Balancing repair 
and tolerance of DNA damage caused by alkylating agents. Nature Reviews Cancer, 12, 
104-120. 
Fuchs, R. P. & Fujii, S. (2013) Translesion DNA synthesis and Mutagenesis in Prokaryotes. 
Cold Spring Harbor Perspectives in Biology, 5, a012682. 
Fujita, T., Ikeda, H., Kawasaki, K., et al. (2009) Clinicopathological relevance of UbcH10 in 
breast cancer.  Cancer Science, 100, 238-248. 
Gack, M. U., Albrecht, R. A., Urano, T. et al. (2007) TRIM25 RING-Finger E3 ubiquitin ligase 
is essential for RIG-I-mediated acntiviral activity. Nature, 446, 916-920. 
Galick, H. A., Kathe, S., Liu, M. et al. (2013) Germ-line variant of human NTH1 DNA 
glycosylase induces genomic instability and cellular transformation. Proceedings of the 
National Academy of Sciences of the U. S. A, 110, 14314–14319. 
Gambus A., Khoudoli, G. A., Jones, R. C. & Blow, J. J. (2011) MCM2-7 form double 
hexamers at licensed origins in Xenopus egg extract. Journal of Biological Chemistry, 286, 
11855-11864. 
Garaycoechea, J, L., Crossan, G. P., langevin, F., Daly, M., Arends, M. J. et al. (2012) 
Genotoxic consequences of endogenous aldehydes on mouse haematopoietic stem cell 
function. Nature, 489, 571-575. 
Garcia, C. C., Angeli, J. P., Freitas, F. et al. (2011) [13C2]-Acetaldehyde promotes 
unequivocal formation of 1, N2-propano, 2’deoxyguanosine in human cells. Journal of the 
American Chemical Society, 133, 9140-9143. 
Gari, K., Décaillet, C., Delannoy, M., Wu, L. & Constantinou, A. (2008) Remodelling of DNA 
replication structures by the branch point translocase FANCM. Proceeding of the National 
Academy of Sciences of the United States of America, 42, 16107-16112. 
Ghosal, G. & Chen, J. (2013) DNA damage tolerance: a double-edged sword guarding the 
genome. Translational Cancer Research, 2, 107-129. 
Giri, N., Batista, D. L., Alter, B. P. & Stratakis, C. A. (2007) endocrine abnormalities in 
patients with Fanconi anemia. Journal of Clinical Endocrinology and Metabolism, 92, 2624-
2631. 
Glickman, M. H., and Ciechanover, A. (2002) The ubiquitin-proteasome proteolytic 
pathway: destruction for the sake of construction. Nat. Rev. 82, 373–428  
Glover, T. (2017) Fragile Sites in Cancer: More Than Meets the Eye. Nature reviews cancer, 
17, 489-501. 
Grabbe, C., Husnjak, K., and Dikic, I. (2011) The spatial and temporal organization of 
ubiquitin networks. Nat. Rev. Mol. Cell. Biol. 12, 295–307 
Gramling, M. W. & Eischen, C. M. (2012) Suppression of Ras/Mapk pathway signalling 
inhibits Myc- induced lymphomagenesis. Cell Death & Differentiation, 19, 1220-1227. 




Groisman, R., Polanowska, J., Kuraoka, I. et al. (2003) The ubiquitin ligase activity in the 
DDB2 and CSA complexes is differentially regulated by the COP9 signalosome in response 
to DNA damage. Cell. 113, 357-367. 
Guo, Y., Wallace, S. & Bandaru, V. (2009) A novel bicistronic vector for overexpressing 
Mycobacterium tuberculosis proteins in Escherichia coli. Protein Expression and 
Purification, 65, 230-237. 
Guo, Y., Bandaru, V., Jaruga, P., Zhao, X., Burrows, C.J., Iwai, S. et al. (2010) The oxidative 
DNA glycosylases of Mycobacterium tuberculosis exhibit different substrate preferences 
from their Escherichia coli counterparts. DNA Repair (Amst), 9, 177–190.  
Hanada, K., Budzowska, M., Davies, S. L. et al. (2007) The structure-specific endonuclease 
Mus81 contributes to replication restart by generating double-strand DNA breaks. Nature 
Structural and Molecular Biology, 14, 1096-1104. 
Hanada, K., Budzowska, M., Modesti, M. et al. (2006) The structure-specific endonuclease 
MUS81-EME1 promotes conversion of interstrand DNA crosslinks into double-strand 
breaks. The EMBO Journal, 14, 1096-1104. 
Hanahan, D. & Weinbergm R, A. (2011) Hallmarks of cancer : the next generation. Cell, 
144, 646-674. 
Hang, B., Singer, B., Margison, G. P. & Elder, R. H. (1997) Targeted deletion of alkylpurine-
DNA-N-glycosylase in mice eliminates repair of 1,N6-ethenoadenine and hypoxanthine 
but not of 3,N4-ethenocytosine or 8-oxoguanine. Proceedings of the National Academy of 
Sciences of the U.S.A, 94, 12869-12874. 
Hao, Z., Duncan. G. S., Su, Y. W. et al. (2012) The E3 ubiquitin ligase Mule acts through the 
ATM-p53 axis to maintain Lymphocyte homeostasis 
Haracska, L., Prakash, S. & Prakash, L. (2002) Yeast Rev1 Protein Is a G Template-specific 
DNA Polymerase. J Biol Chem, 277, 15546–15551. 
Hassanpour, S. H. & Dehghani, M. (2017) Review of cancer from perspective of molecular. 
Journal of Cancer Research and Practice, 4, 127-129.  
Hatakeyama, S. (2011) TRIM proteins and cancer. Nature Reviews Cancer, 11, 792-804. 
Hatakeyama, S. (2017) TRIM Family Proteins: Roles in Autophagy, immunity and 
carcinogenesis. Trends in Biochemical Science, 42, 297-311. 
Haupt, Y., Maya, R., Kazaz, A. & Oren, M. (1997) Mdm2 promotes the rapid degradation 
of p53. Nature 387, 296–299. 
Hay, N. & Sonenberg, N. (2004) Upstream and downstream of mTOR. Genes & 
Development, 18, 1926-1945. 
Hazra, T. & Mitra, S. (2006) Purification and Characterization of NEIL1 and NEIL2, Members 
of a Distinct Family of Mammalian DNA glycosylases for Repair of Oxidized Bases. Methods 
In Enzymology, 408, 33-48. 
Hazra, T. K., Izumi, R., venkataraman, R., Kow, Y. W., Dizdaroglu, M. & Mitra, S. (2000) 
Characterization of a novel 8-oxoguanine-DNA glycosylase activity in Escherichia coli and 




identification of the enzyme as endonuclease VIII. Journal of Biological Chemistry, 275, 
27762-27767. 
Hazra, T. K., Izumi, T., Boldogh, I. et al. (2002a) Identification and characterization of a 
human DNA glycosylase for repair of modified bases in oxidatively damaged DNA. 
Proceeding of the National Academy of Sciences of the U.S.A, 99, 3523-3528. 
Hazra, T., Kow, Hatahet, Z. et al. (2002b) Identification and Characterization of a Novel 
Human DNA glycosylase for the repair of Cytosine-derived Lesions. The Journal of 
Biological Chemistry, 277, 30417-30420. 
He, Y.J., McCall, C.M., Hu, J., Zeng, Y. & Xiong, Y. (2006) DDB1 functions as a linker to 
recruit receptor WD40 proteins to CUL4-ROC1 ubiquitin ligases. Genes Dev, 20, 2949–
2954. 
Hegde, M. L., Hegde, P. M., Bellot, L. J. et al., (2013) Prereplicative repair of oxidized bases 
in the human genome is mediated by NEIL1 DNA glycosylase together with replication 
proteins. Proceedings of the National Academy for Sicences of the U. S. A.,  110 , 3090-
3099. 
Hegde, M. L., Izumi, T. & Mitra, S. (2012) Oxidized Base Damage and Single-Strand Break 
Repair in Mammalian Genomes: Role of Disordered Regions and Posttranslational 
Modifications in Early Enzymes. Progress in molecular biology and translational science, 
110, 1236-153. 
Hegde, M., Hazra, T. & Mitra, S. (2008) Early steps in the DNA base excision/single-strand 
interruption repair pathway in mammalian cells. Cell Research, 18, 27-47. 
Hegde, P. M., Dutta, A., Sengupta, S. et al. (2015) The C-terminal Domain (CTD) of Human 
DNA Glycosylase NEIL1 is Required for Forming BERosome Repair Complex with DNA 
replication Proteins at the Replicating Genome. The Journal of Biological Chemistry, 290, 
20919-20933. 
Hegi, M. E., Diserens, A. C., Goria, T. et al. (2005) MGMT gene silencing benefit from 
temozolomide in glioblastoma. New England Journal of Medicine, 352, 997-1003. 
Herold, S., Hock, A., Herkert, B. et al., (2008) Miz1 and HectH9 regulate the stability of the 
checkpoint protein TopBP1. The EMBO Journal, 27, 2851-2861. 
Hicks, J. K., Chute, L. C., Paulsen, M. et al. (2010) Differential Roles for DNA Polymerases 
Eta, Zeta, and REV1 in Lesion Bypass of Intrastrand versus Interstrand DNA Cross-links. 
Molecular and Cellular Biology, 30, 1217-1230.  
Hildrestrand, G., Neurauter, C., Diep, D. et al. (2009) Expression patterns of NEIL3 during 
embryonic brain development and neoplasia. BMC Neuroscience, 10, 1-8. 
Hillier, L., Graves, T., Fulton, F. et al. (2005) Generation and annotation of the DNA 
sequences on chromosomes 2 and 4. Nature, 434, 724-731. 
Hinz, J. M. (2010) Role of Homologous Recombination in DNA Interstrand Crosslink Repair. 
(2010) Role of Homologous Recombination in DNA Interstrand Crosslink Repair. 
Environment and Molecular Mutagenesis, 51, 582-603. 




Hironak, K., Factor, V. M., Calvisi, D. F., Conner, E. A. & Thorgeirsson, S. S. (2003) 
Dysregulation of DNA repair Pathways in Transforming Growth Factor α/c-myc Transgenic 
Mouse Model of Accelerated Hepatocarcinogenesis. Laboratory Investigation, 83, 643-
645. 
Ho, T. V. & Schärer, O. D. (2010) Translesion DNA Synthesis Polymerases in DNA 
Interstrand Crosslink Repair. Environment and Molecular Mutagenesis, 51, 552-566. 
Ho, T.V., Guainazzi, A., Derkunt, S.B. et al. (2011) Structure-dependent bypass of DNA 
interstrand crosslinks by translesion synthesis DNA polymerases. Nucleic Acids Research, 
39, 7455-7464. 
Hoffmann, S., Smedegaard, S., Nakamura, K., et al. (2016) TRAIP is a PCNA-binding 
ubiquitin ligase that protects genome stability after replication stress. Journal of Cell 
Biology, 2, 63-75. 
Hornbeck, P.V., Zhang, B., Murray, B., Kornhauser, J.M, Latham, V., & Skrzypek, E. (2015) 
PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res, 43, D512-
20. 
Huang, H. & Hopkins, P. B. (1993) DNA interstrand cross-linking by formaldehyde: 
nucleotide sequence preference and covalent structure of the predominant cross-link 
formed in synthetic oligonucleotides. Journal of the American Chemistry Society, 115, 
9402-9408. 
Huang, H., Regan, K. M., Wang, F., et al. (2005) Skp2 inhibits FOXO1 in tumour suppression 
through ubiquitin-mediated degradation. Proceedings of the National Academy of 
Sciences of the U.S.A, 102, 1649-1654. 
Huang, J., Liu, S., Bellani, M. et al. (2013) The DNA Translocase FANCM/MHF Promotes 
Replication Traverse of DNA interstrand Crosslinks. Molecular Cell, 52,  
Huang, Y. & Li, L. (2013) DNA crosslinking damage and cancer – a tale of friend and foe. 
Translational Cancer Research, 2, 144-154. 
Huen, M. & Chen, J. (2008) The DNA damage response pathways: at the crossroad of 
protein modifications. Cell Research, 18, 8-16. 
Husnjak, K. & Dikic, I. (2012) Ubiquitin-binding proteins: decoders of ubiquitin-mediated 
cellular functions. Annual Review of Biochemistry, 8, 291-322. 
Hwang, B. J., Shi, G. & Lu, A. L. (2014) Mammalian MutY homolog (MYH or MUTYH) 
protects cells from oxidative DNA damage. DNA Repair (Amst), 13, 10-21. 
Ibusuki, M., Yamamoto, Y., Shinriki S, Ando, Y. & Iwase, H. (2011) Reduced expression of 
ubiquitin ligase FBXW7 mRNA is associated with poor prognosis in breast cancer patients. 
Cancer Science, 102, 439-445. 
Ikeda, F. & Dikic, I. (2008). Atypical ubiquitin chains: new molecular signals. ‘Protein 
modifications: beyond the usual suspects’ review series. EMBO Rep, 9, 536–542. 




Ikeda, S., Biswas, T., Roy, R. et al. (1998) Purification and Characterization of Human NTH1, 
a Homolog of Escherichia coli Endonuclease III: Direct Identification of Lys-212 as the 
active nucleophilic residue. The Journal of Biological Chemistry, 273, 21585-21593. 
Ilves, I., Petojevic, T., Pesavento, J. J. & Botchan M. R. (2010) Activation of the MCM2-7 
helicase by association with Cdc45 and GINS proteins. Mol. Cell, 37, 247-258. 
International Agency for Research on Cancer (2018) IARC Monographs on the Evaluation 
of Carcinogenic Risks to Humans https://monographs.iarc.fr/agents-classified-by-the-
iarc/ [Accessed 03 August 2018]. 
Izumi, T., Brown, D. B., Naidu, C. V. et al. (2005). Two essential but distinct function of the 
mammalian abasic endonuclease. Proceedings of the National Academy of Sciences of the 
U.S.A, 102, 5739-5743. 
Jackson, S. P, & Durocher, D. (2013) Regulation of DNA Damage Responses by Ubiquitin 
and SUMO, Mol. Cell, 49, 795-807.  
Jalland, C., Scheffler, K., Benestad, S. et al. (2016) NEIL3 induced neurogenesis protects 
against prion disease during the clinical phase. Scientific Reports, 6, 37844. 
Javanbakht, H., Yuan W, Yeung. D. F. et al. (2006) Characterisation of the TRIM5alpha 
trimerization and its contribution to human immunodeficiency virus capsid binding. 
Virology, 353, 234-2346. 
Jena, N. & Mishra, P. C. (2012) Formation of ring-opened and rearranged products of 
guanine: Mechanisms and biological significance. Free Radical Biology and Medicine, 53, 
81-94. 
Jena, N. & Mishra, P. C. (2013) Is FapyG Mutagenic?: Evidence from the FT Study. 
ChemPhysChem, 14, 3236-3270. 
Jena, N. (2012) DNA damage by reactive species: Mechanisms, mutation and repair. 
Journal of Bioscience, 37, 503-517. 
Jevsevar, S., Gaberc-Porekar, V., Fonda, I. et al. (2005) Production of Nonclassical Inclusion 
Bodies from Folded Protein Can Be Extracted. Biotechnology Progress, 21, 632-639. 
Jiang, D., Hatahet, Z., Blaisdell, J. O., Melamede, R. J. & Eallace, S. S. (1997a) Escherichia 
coli endonuclease VIII: cloning, sequencing, and overexpression of the Nei structural gene 
and characterization of nei and nei nth mutants. Journal of Bacteriology, 179, 3773-3782. 
Jiang, D., Hatahet, Z., Melamede, R., Kow, Y. & Wallace, S. (1997b) Characterisation of 
Escherichia coli Endonuclease VIII. The Journal of Biological Chemistry, 272, 32230-32239. 
Jiang, Y., Hong, H., Cao, H. & Wang, Y. (2007) In vivo formation and invitro replication of a 
guanine-thymine intrastrand cross-link lesion. Biochemistry, 46, 12757-12763. 
Johnson, R.E., Yu, S.L., Prakash, S. & Prakash, L. (2003) Yeast DNA DNA polymerase zeta 
(α) is essential for error-free replication past thymine glycol. Genes & Development, 17, 
77–87.  
Ju, H. P., Wang, Y., You, J. et al. (2016) Folding Kinetics of Single Human Telomeric G-
Quadruplex Affected by Cisplatin. American Chemical Society Omega, 1, 244-250. 




Jung, C., R. Hwang, K. S., Yoo, J. (2006) E2-EPF UCP targets pVHL for degradation and 
associates with tumour growth and metastasis. Nature Methods, 12, 809-816. 
Kamura, T., Hara, T., Kotoshiba, S., Yada, M., Ishida, N., Imaki, H. (2003) Degradation of 
p57kip2 mediated by SCFSkp2-dependent ubiquitylation. Proceedings of the National 
Academy of Sciences of the U.S.A, 100, 10231-10236. 
Kamura, T., Koepp, D. M., Conrad, M. N., et al. (1999) Rbx1, a component of the VHL 
tumour suppressor complex and SCF ubiquitin ligase. Science, 284, 657-661. 
Kang, H.C., Lee, Y.I., Shin, J.H., et al. (2011) Iduna is a poly(ADP-ribose) (PAR)-dependent 
E3 ubiquitin ligase that regulates DNA damage, Proc. Natl. Acad. Sci. USA, 108, 14103–
14108. 
Kanno, Y., Watanabe, M., Kimura, T., Nonomura, K., Tanaka, S. & Hatakeyama, S. (2014) 
TRIM29 as a novel prostate basal cell marker for diagnosis of prostate cancer. Acta 
Histochem 116, 708–712.  
Kannouche, P. L., Wing, J. & Lehmann, A.R. (2004) Interaction of Human DNA DNA 
polymerase η with Monoubiquitinated PCNA: A possible Mechanism for the Polymerase 
Switch in Response to DNA Damage. Mol. Cell, 14, 491-500. 
Karakaya, A., Jaruga, P., Bohr, V.A., Grollman, A.P. & M. Dizdaroglu. (1997) Kinetics of 
excision of purine lesions from DNA by Escherichia coli Fpg protein. Nucleic Acids 
Research, 25, 474–479. 
Kattah, M.G., Malynn, B.A., Ma, A. (2017) Ubiquitin-modifying enzymes and regulation of 
the inflammasome. J. Mol. Biol, 429, 3471–3485. 
Kauffmann, A., Rosselli, F., Lazar, V. et al. (2008) High expression of DNA repair pathways 
is associated with metastasis in melanoma patients. Oncogene, 27, 565-573.  
Kee, Y. & D’Andrea, A. D. (2012) Molecular pathogenesis and clinical management of 
Fanconi anemia. Journal of Clinical Investigation, 122, 3799-3806. 
Kelley, R., Logsdon, D. & Fishel, M. (2014) Targeting DNA repair pathways for cancer 
treatment: what’s new? Future Oncology, 10, 1215-1237. 
Kesik-Brodacka, M., Romanik, A., Mikiewicz-Sygula, D. et al. (2012) A novel system for 
stable, high-level expression from the T7 promotor. Microbial Cell Factories, 11, 1-7. 
Kino, K., Hirao-Suzuki, M., Morikawa, M., Sakaga, A. & Miyazawa. (2017) Generation, 
repair and replication of guanine oxidation. Genes and Environment, 39, 1-8. 
Kim, J. M, Kee, Y., Gurtan, A. & D’Andrea, A. D. (2008) Cell cycle-dependent chromatin 
loading of the Fanconi anemia core complex by FANCM/FAAP24. Blood, 10, 5215-5222. 
Kim, W., Bennet, E.J, Huttlin, E.L., et al. (2011a) Systematic and quantitative assessment 
of the ubiquitin-modified proteome. Mol Cell, 44, 325-340. 
Kim, Y. & Wilson, D. (2012) Overview of Base Excision Repair Biochemistry. Current 
Molecular Pharmacology, 5, 3-13. 




Kim, Y., Lach, F. P., Desetty, R. et al. (2011b) Mutations of the SLX4 gene in Fanconi 
anemia. Nature Genetics, 43, 142-146. 
Kim, Y., Spitz, G. S., Veturi, U., Lach, F. P., Auerbach, A. D. & Smogorzewska, A. (2013) 
Regulation of multiple DNA repair pathways by the Fanconi anemia protein SLX4. Blood, 
121, 54-63. 
Kim, Y.S., Kim, Y, Choi, J., Oh, H. & Lee, J. (2016) Genetic variants and risk of prostate 
cancer using pathway analysis of a genome-wide association study. Neoplasma, 63, 629-
634. 
Klattenhoff, A. W., Thakur, M., Chu, C. S., Ray, D., Habib, S. L. & Kidane, D. (2017) Loss of 
NEIL3 DNA glycosylase markedly increases replication associated double strand breaks 
and enhances sensitivity to ATR inhibitor in glioblastoma cells. Oncotarget, 8, 112942-
112958. 
Klaunig, J., Xu, Y., Isenberg, J. et al. (1998) The Role of Oxidative Stress in chemical 
Carcinogenesis. Environmental Health Perspectives, 106, 289-295. 
Klaunig, J.E., Wang, Z., Pu, X. et al. (2011) Oxidative stress and oxidative damage in 
chemical carcinogenesis. Toxicology and Applied Pharmacology, 254, 86-99. 
Komander, D., Clague, M. J., and Urbé, S. (2009) Breaking the chains: structure and 
function of the deubiquitinases. Nat. Rev. Mol. Cell Biol. 10, 550–563 
Kottemann, M. C. & Smorgorzewska, A. (2013) Fanconi anaemia and the repair of Watson 
and Crick DNA crosslinks. Nature, 493, 356-363. 
Kraemer, K. H., Patronas, N. J., Schiffmann, R. et al. (2007) Xeroderma pigmentosum, 
Trichothiodystrophy and Cockayne syndrome: A complex genotype-phenotype 
relationship. Neuroscience, 145, 1388-1396. 
Kress, T. R., Sabo, A. &Amanti, B. (2015) MYC: connecting selective transcriptional control 
to global RNA production. Nature Reviews Cancer, 15, 593-607.  
Krishnamurthy, N., Zhao, X., Burrows, C. & David, S. (2008) Superior Removal of Hydantoin 
Lesions Relative to Other Oxidized Bases by the Human DNA glycosylase hNEIL1. 
Biochemistry, 47, 7137-7146. 
Krokan, H., E. & Bjørås, M. (2013) Base Excision Repair. Cold Spring Harbor Perspectives in 
Biology, 5, a012583. 
Krokeide, S.Z., Bolstad, N., Laerdahl, J.K., Bjørås, M. & Luna, L. (2009) Expression and 
purification of NEIL3, a human DNA glycosylase homolog, Protein Expression and 
Purification, 65, 160-164. 
Krokeide, S.Z., Laerdahl, J.K., Salah, M. et al. (2013) Human NEIL3 is mainly a 
monofunctional DNA glycosylase removing spiroiminodihydantoin and 
guanidinohydantoin. DNA Repair, 12, 1160- 1164. 
Kuiper, R. & Hoogerbrugge, N. (2015) NTH1 defines novel cancer syndrome. Oncotarget, 
6, 34069-34070. 




Kulak, N.A., Pichler, G., Paron, I., Nagaraj, N. & Mann, M. (2014) Minimal, encapsulated 
proteomic-sample processing applied to copy-number estimation in eukaryotic cells. Nat. 
Methods, 11, 319–324 
Kuraoka, I., Kobertz, W. R., Ariza, R. R., Biggerstaff, M., Essigmann, J. M. & Wood, R. D. 
(2000) Repair of an interstrand DNA cross-link initiated by ERCC1-XPF 
repair/recombination nuclease. Journal of Biological Chemistry, 275, 26632-26636. 
Kuzminov, A. (2001) Single-strand interruptions in replicating chromosomes cause 
double-strand breaks. Proceedings of the National Academy of Sciences of the U.S.A, 98, 
8241-8246. 
Langevin, F., Crossan, G., Rosado, I., Arends, M. & Patel, K. (2011) Fancd2 counteracts the 
toxic effects of naturally produced aldehydes in mice. Nature, 475, 53–58.  
Laursen, B., Sørensen, H., Mortensen, K. & Sperlin-Petersen, H. (2005) Initiation of Protein 
Synthesis in Bacteria. Microbiology and Molecular Biology Reviews, 69, 101-123. 
Lawley, P. & Phillips, D. (1996) DNA adducts from chemotherapeutic agents. Mutation 
Research, 355, 13-40. 
Lee, J. T. & Gu, W. (2010) The multiple levels of regulation by p53 ubiquitination. Cell 
Death Differ. 17, 86–92.  
Li, Y., Park, J., Piao, L. (2013) PHB-mediumteed PHF20 phosphorylation on Ser291 is 
required for p53 function in DNA damage. Cell Singalling, 25, 74-84. 
Liang, C., Li, Z., Lopez-Martinez. et al. (2016) The FANCD2-FANCI complex is recruited to 
DNA interstrand crosslinks before monubiquitination of FANCD2. Nature 
Communications, 7, 1-10. 
Liang, Y., Lin, S. & Brunicardi, C. (2009) DNA Damage Response Pathways in Tumour 
Suppression and Cancer Treatment. World Journal of Surgery, 33, 661-666. 
Lindahl, T. (1990) Repair of intrinsic DNA lesions. Mutation Research, 223, 305-311. 
Lindahl, T. (1993) Instability and decay of the primary structure of DNA. Nature, 362, 709-
715. 
Lindahl, T. (1974) An N-Glycosidase from Escherichia coli That Releases Free Uracil from 
DNA Containing Deaminated Cytosine Residues. Proceedings of the National Academy of 
Sciences of the United States of America, 9, 3649-3653. 
Lipton, J. O. & Sahin, M. (2014) The neurology of mTOR. Neuron, 84, 275-291. 
Liu, M., Bandaru, V., Bond, J. P. et al. (2010) The mouse ortholog of NEIL3 is a functional 
DNA glycosylase in vitro and in vivo. Proceedings of the National Academy of Sciences of 
the United States of America, 107, 4925-4930. 
Liu, M., Bandaru, V., Holmes, A. et al. (2012) Expression and purification of active mouse 
and human NEIL3 proteins. Protein Expression and Purification, 84, 130-139. 
Liu, M., Doublié, S. & Wallace, S. (2013a) NEIL3, the final frontier for the DNA glycosylases 
that recognize oxidative damage. Mutation Research, 743, 4-11. 




Liu, M., Imamura, K., Averill, A. M., Wallace, S. S. & Doublié, S.  (2013b) Structural 
characterization of a mouse ortholog of human NEIL3 with a marked preference for single-
stranded DNA. Structure, 5, 247-256. 
Liu, W. M. & Zhang, X, A. (2006) KAI1/CD82, a tumour metastasis suppressor. Cancer 
Letters, 240, 183-194. 
Ljungman, M. & Zhang, F. (1996) Blockage of RNA DNA polymerase as possible trigger for 
U. V. light induced apoptosis. Oncogene, 13, 823-831. 
Lobitz, S. & Velleuer, E. (2006) Guido Fanconi (1892–1979): a jack of all trades. Nature 
Reviews Cancer, 6, 893–898. 
Lopez-Contreras, A. J. & Fernandez-Capetillom A. (2010) The ATR barrier to replication-
born DNA damage. DNA repair, 9, 1249-1255. 
Love, L. M., Shi, D. & Grossman, S. R. (2013) p53 Ubiquitination and proteasomal 
degradation. Methods Mol. Biol, 962, 63-73. 
Lu, R., Nash, H. M. & Verdine, G. L. (1997) A mammalian DNA repair enzyme that excises 
oxidatively damaged guanines maps to a locus frequently lost in lung cancer. Current 
Biology, 7, 397-407. 
Lu, W., Ogasawara, M. & Huang, P. (2007) Models of reactive oxygen species in cancer. 
Drug Discovery Today: Disease Models, 4, 67-73. 
Luo, W., Muller, J.G., Rachlin, E.M. & Burrows, C.J. (2000) Characterization of 
spiroiminodihydantoin as a product of one-electron oxidation of 8-Oxo-7,8-
dihydroguanosine. Org Lett,2, 613–616.  
Lyu, X. M., Zhu, X. W., Zhao, X. B. et al. (2018) A regulatory mutant on TRIM26 confering 
risk of nasopharyngeal carcinoma by inducing low Immune response. Cancer Medicine, 7, 
3848-3861. 
Macé-Aimé, G., Couvé, S., Khassenov, B., Rosselli, F. & Saparbaev, M. K. (2010) The 
Fanconi Anemia Pathway Promotes DNA Glycosylase-Dependent Excision of Interstrand 
DNA Crosslinks. Environmental and Molecular Mutagenesis, 51, 508-519. 
Maki, H. & Sekiguchi, M. (1992) MutT protein specifically hydrolyses a potent mutagenic 
substrate for DNA synthesis. Nature, 355, 273–275. 
Mandal, S., Hegde, Chatterjee, A. et al. (2011) Role of Human DNA Glycosylase Neilike2 
(NEIL2) and Single Strand Break Repair Protein Polynucleotide Kinase 3’-Phosphatase in 
Maintenance of Mitochondrial Genome. The Journal of Biological Chemistry, 287, 2819-
2829. 
Mansour, M. A. (2018) Ubiquitination: Friend and foe in cancer. International Journal of 
Biochemistry and Cell Biology, 101, 80-93. 
Maor-Shoshani, A., Meira, L. B., Yang, X. & Samson, L. (2008) 3-Methyladenine DAN 
glycosylase is important for cellular resistance to psoralen interstrand cross-links. DNA 
repair (Amst), 7, 1399-1406. 




Margulies, C. M., Chaim, I. A., Mazumder, A., Criscione, J. & Samson, L. D. (2017) Alkylation 
induced cerebellar degeneration dependent on Aag and Parp! Does not occur via 
previously established cell death mechanisms. PLoS One, 12, e0184619. 
Marietta, C. Thompson, L. H., Lamerdin, J. E. & Brooks, P. J. (2009) Acetaldehyde 
stimulates FANCD2 monoubiquitination, H2AX phosphorylation, and BRCA1 
phosphorylation in human cells in vitro: implications for alcohol-related carcinogenesis. 
Mutation Research, 664, 77-83. 
Markkanen, E., Dorn, J. & Hϋbscher, U. (2013) MUTYH DNA glycosylase: the rationale for 
removing undamaged bases from the DNA. Frontiers in Genetics, 4, 1-20. 
Marteijn, J. A., Lans, H., Vermeulen, W., Hoeijmakers, J. H. (2014) Understanding 
nucleotide excision repair and its roles in cancer and ageing. Nature Reviews Molecular 
Cell Biology, 15, 465-481. 
Martin, P. R., Couvé, S., Zutterling, C., et al. (2017) The Human DNA glycosylase NEIL1 and 
NEIL3 Excise Psoralen-Induced-DNA-DNA Cross-Links in a Four-Stranded DNA Structure. 
Scientific Reports, 7, 17438. 
Massaad, M., Zhou, J., Tsuchimoto, D. et al. (2016) Deficiency of BER enzyme NEIL3 drives 
increased predisposition to autoimmunity.  Journal of clinical investigation, 126, 4219-
4236. 
Masuda, Y., Takahashi, H., Sato, S.  et al. (2015) TRIM29 regulates the assembly of DNA 
repair proteins into damaged chromatin. Nature Communications, 6, 1-13. 
Masutani, C., Sugasawa, K., Yanagisaw, J. et al. (1994) Purification and cloning of a 
nucleotide excision repair complex involving the xeroderma pigmentosum group C 
protein and a human homologue of yeast RAD23 EMBO Journal, 13, 1813-1843. 
Mathieu, N., Kaczmarek, N., Rüthermann, P., Luch, A. & Naegeli, H. (2013) DNA quality 
control by a lesion sensor pocked of the xeroderma pigmentosum group D helicase 
subunit of TFIIH. Current Biology, 23, 204-212. 
Maynard, S., Schurman, S., Harboe, C. et al. (2009). Base excision repair of oxidative DNA 
damage and association with cancer and aging. Carcinogenesis, 30, 2-10. 
Mazouzi, A., Velimezi, G. & Loizou, J. I. (2014) DNA replication stress: Causes, resolution 
and disease. Experimental Cell Research, 329, 85-93. 
McCabe, K. M., Olson, S. B. & Moses, R. E. (2009) DNA Interstrand Crosslink Repair in 
Mammalian Cells. Journal of Cellular Physiology, 220, 569-573. 
Mccann, A. H., Kirley, A., Garney, Corbally, N., Magee, H. M. et al. (1995) Amplification of 
the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein 
status. British Journal of Cancer, 71, 981-985. 
Meira, L.B., Moroski-Erkul, C. A., Green, S. L. et al. (2009) Aag-initiated BER drives 
alkylation-induced retinal degeneration in mice. Proceeding of the National Academy of 
Sciences of the U.S.A, 106, 888-893. 




Meisenberg, C., Tait, P.S., Dianova, I.I. et al. (2012) Ubiquitin ligase UBR3 regulates cellular 
levels of the essential DNA repair protein APE1 and is required for genome stability, 
Nucleic Acids Res, 40, 701–711. 
Melamede, R. J., Hatachat, Z., Kow, Y. W., Ide, H. & Wallace, S. S. (1994) Isolation and 
characterization of endonuclease VIII from Esherichia coli. Biochemistry, 33, 1255-1264. 
Mertins, P., Qiao, J. M., Patel, J., et al. (2013) Integrated proteomic analysis of post-
translational modifications by serial enrichment. Nat Methods. 10, 634-637.  
Metzger, M. B., Pruneda, J. N., Klevit, R. E. & Weissman, A. M. (2014) RING-type E3 ligases: 
Master manipulators of E2 ubiquitin-conjugating enzymes and ubiquitination. Biochimica 
et Biophysica Acta, 1843, 47-60. 
Michaels, M.L. & Miller, J.H. (1992) The GO system protects organisms from the mutagenic 
effect of the spontaneous lesion 8-hydroxyguanine (7,8-dihydro-8-oxoguanine). J 
Bacteriol, 174, 6321– 6325.  
Michaels, M.L., Cruz, C., Grollman, A.P. & Miller, J.H. (1992) Evidence that MutY and MutM 
combine to prevent mutations by an oxidatively damaged form of guanine in DNA. Proc 
Natl Acad Sci USA. 89, 7022–7025.  
Michl, J., Zimmer, J. & Tarsounas, M. (2016) Interplay between Fanconi anemia and 
homologous recombination pathways in genome integrity. EMBO Journal, 35, 909-923. 
Mijic, S., Zellweger, R., Chappidi, N., et al. (2017) Replication fork reversal triggers fork 
degredation in BRCA2-defective cells. Nature Communications, 8, 859. 
Min, J., & Pavletich, N. P. (2007) Recognition of DNA damage by the Rad4 nucleotide 
excision repair protein. Nature, 449, 570-575. 
Minko, I. G., Harbut, M. B. Kozekov, ID. et al. (2008) Role for DNA polymerase kappa in the 
processing of N2-N2-guanine interstrand cross-links. Journal of Biological Chemistry, 283, 
17075-17082. 
Mojas, N., Lopes, M. & Jiricny, J. (2007) Mismatch repair-dependent processing of 
methylation damage gives rise to persistent single-stranded gaps in newly replicated DNA. 
Momand, J., Zambetti, G. P., Olson, D. C., George, D. & Levine, A. J. (1992) The mdm-2 
oncogene product forms a complex wit hthe p53 protein and inhibits p53-mediated 
transactivation. Cell, 69, 1237-1245. 
Monia, B.P. et al. (1989) Gene synthesis, expression, and processing of human ubiquitin 
carboxyl extension proteins. J. Biol. Chem. 264,4093–4103 
Morland, I., Rolseth, V., Luna, L. et al. (2002) Human DNA glycosylases of the bacterial 
Fpg/MutM superfamily: an alternative pathway for the repair of 8-oxoguanine and other 
oxidation products in DNA. Nucleic Acids Research, 30, 4926-4936. 
Mortusewicz, O., Herr, P. & Helleday, T. (2013) Early replication fragile sites: where 
replication-transcription collisions cause genetic instability.  EMBO Journal, 32, 493-495. 




Mosammaparast, N. & Shi, Y. (2010) Reversal of histone methylation: biochemical and 
molecular mechanisms of histone demethylases. Annual Review of Biochemistry, 79, 155-
179. 
Moser, J., Kool, H., Giakzidis, I. et al. (2007) Sealing of chromosomal DNA nicks during 
nucleotide excision repair requires XRCC1 and DNA ligase III alpha in a cell-cycle-specific 
manner. Molecular Cell, 27, 311-323. 
Mukhopadhyay, D., and Riezman, H. (2007) Proteasome-independent functions of 
ubiquitin in endocytosis and signalling. Science, 315, 201–205 
Muniandy, P., Liu, J., Majumdar, A., Liu, S. & Seidman, M. (2010) DNA Interstrand Crosslink 
Repair in Mammalian cells: Step by Step.  Critical Reviews in Biochemistry and Molecular 
Biology, 45, 23-48. 
Myung, J., Kim, K. B. & Crews, C. M (2001) The Ubiquitin-Proteasome Pathway and 
Proteasome Inhibitors. Medicinal Research Reviews, 21, 245-273. 
Naim, V., Willhelm, T., Debatisse, M. & Roselli, F. (2013) ERCC1 and MUS81-EME1 promote 
sister chromatid separation by processing late replication intermediates at common 
fragile sites during mitosis. Nature Cell Biology, 15, 1008-1015. 
Nakagawa, T., Hosogane, M., Nakagaw, M. et al. (2017) TGF-β-Induced proliferative arrest 
mediated by TRIM26-Dependent TAF7 degradation and Its antagonism by MYC. Mol. Cell. 
Biol. 38, e00449-17 
Nakamura, J. & Swenberg, J. A. (1999) Endogenous Apurinic/Apyrimidinic Sites in Genomic 
DNA of Mammalian Tissues. Cancer Research, 59, 2522-2526. 
Nalepa, G. & Clapp, D. W. (2018) Fanconi anaemia and cancer: an intricate relationship. 
Nature Reviews Cancer, 18, 168-185. 
Nam, E. & Cortez, D. (2011) ATR signalling: more than meeting at the fork.  Biocchemical 
Journal, 436, 527-536. 
Napolitano, L.M. and Meroni, G. (2012) TRIM family: pleiotropy and diversification 
through homomultimer and heteromultimer formation. IUBMB Life, 64, 64–71. 
Narayan, G., Bourden, V., Chaganti, S., et al. (2007) gene dosage alterations revealed by 
cDNA microarray analysis in cervical cancer: identification of candidate amplified 
overexpressed genes. Genes Chromosomes Cancer, 46, 373 -384. 
Neurauter, C., Luna, L. & Bjørås, M. (2012) Release from quiescence stimulates the 
expression of human NEIL3 under the control of the Ras dependent ERK-MAP kinase 
pathway. DNA Repair, 11, 401-409. 
Neveling, K., Endt, D., Hoehn, H. & Schindler, D. (2009) Genotype-phenotype correlations 
in Fanconi anemia. Mutation Research, 668, 73-91. 
Naim, V., Wilhelm, T., Debatisse, M. & Roselli, F. (2013) ERCC1 and MUS81-EME1 promote 
sister chromatid separation by processing late replication intermediates at common 
fragile sites during mitosis. Nature Cell Biology, 15, 1008-1015. 




Niedzwiedz, W., Mosedale, G., Johnson, M., Ong, C. Y., Pace, P. & Patel, K. J. (2004) The 
Fanconi Anaemia gene FANCC Promotes Homologous Recombinantion and Error-Prone 
DNA repair. Mol. Cell,  15, 607-620. 
Nijman, S. M., Huang, T. T., Dirac, A. M. et al. (2005) The deubiquitinating enzyme USP1 
regulates the Fanconi anemia pathway. Mol. Cell, 17, 331–339. 
Niles, J. C., Wishnok, J.S. & Tannenbaum, S.R. (2004) Spiroiminodihydantoin and 
Guanidinohydantoin are the dominant products of 8-oxoguanosine oxidation at low fluxes 
of peroxynitrite: mechanistic studies with 18O. Chemical research in toxicology, 17, 1510-
1519. 
Novagen. (2004) Competent Cells: User Protocol. EMD Biosciences, Darmstadt, Germany. 
Novagen. (2005) pET system manual. EMD Biosciences, Darmstadt, Germany. 
Nováková, O., Nazarov, A. A., Hartinger, C. G., Keppler, B. H., Brabec, V. (2009) DNA 
interactions of a dinuclear RUII arene antitumor complexes in cell-free medium. 
Biochemical Pharmacology, 77, 364-374. 
O’Connor, M. (2015) Targeting the DNA Damage Response in Cancer. Molecular Cell, 60, 
547-560. 
Ogi, T., Limsirichaikul, S., Overmeer, R. M. et al. (2010) Three DNA polymerases, recruited 
by different mechanisms, carry out NER repair synthesis in human cells. Nature Cell 
Biology, 8, 714-727.  
Ohta, T. Michel, J. J., Schottelius, A. J. & Xiong, Y. (1999) ROC1, a homolog of APC11, 
represents a family of cullin partners with an associated ubiquitin ligase activity.  Mol. Cell, 
3, 535-541. 
Olsson, M. & Lindahl, T. (1980) Repair of alkylated DNA in Escherichia coli. Methyl group 
transfer from O6-methylguanine to a protein cysteine residue. The Journal of Biological 
Chemistry, 255, 10569-10571. 
Oshikawa, K., Matsumoto, M., Oyamada, K., & Nakayama, K.I. (2012) Proteome-wide 
identification of ubiquitylation sites by conjugation of engineered lysine-less ubiquitin. J. 
Proteome Res, 11, 796–807. 
Ourliac-Garnier, I., Elizondo-Riojas, M., Redon, S., Farrell, N. P. & Bombard, S. (2005) Cross-
Links of Quadruplex Structures from Human Telomeric DNA by Dinuclear Platinum 
Complexes Show the Flexibility of Both Structures. Biochemistry, 44, 10620-10634. 
Palles, C., Cazier, J., Howarth, K. et al. (2013) Germline mutations in the proof-reading 
domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nature 
Genetics, 45, 136-144. 
Palovcak, A., Liu, W., Yuan, F. & Zhang, Y. (2017) Maintenance of genome stability by 
Fanconi anemia proteins. Call Bioscience, 7, 8. 
Parsons, J. L, Tait, P. S, Finch, D., Dianova, I. I, Allinson, S. L, Dianov, G. L. (2008) CHIP-
mediated degradation and DNA damage-dependent stabilization regulate BER proteins. 
Mol. Cell, 4, 477-487. 




Parsons, J. L. & Elder, R. H. (2003) DNA N-glycosylase deficient mice: a tale of redundancy. 
Mutation Research, 531, 165-175. 
Parsons, J. L., Dianova, I. I., Khoronenkova, S. V. et al. (2011) USP47 Is a Deubiquitylating 
Enzyme that Regulates Base Excision Repair by Controlling Steady-State Levels of DNA 
Polymerase b. Mol. Cell, 41, 609-615. 
Parsons, J.L., Khoronenkova, S.V., Dianova, I.I., et al. (2012) Phosphorylation of PNKPP by 
ATM prevents its proteasomal degradation and enhances resistance to oxidative stress. 
Nucleic Acids Res 40, 11404–11415.  
Parsons, J.L., Tait, P.S., Finch, D., Dianova, I.I., Allinson, S.L., & Dianov, G.L. (2008) CHIP-
mediated degradation and DNA damaged dependent stabilization regulate BER proteins. 
Mol. Cell, 29, 477–487. 
Parsons, J.L., Tait, P.S., Finch, D., et al. (2009) Ubiquitin ligase ARF-BP1/Mule modulates 
BER. EMBO J. 28, 3207–3215. 
Pascucci, B., Russo, M. T., Crescenzi, M., Bignami, M. & Dogliotti, E. (2005) The 
accumulation of MMS-induced single strand breaks in G1 phase is recombinogenic in DNA 
polymerase beta defective mammalian cells. Nucleic Acids Research, 33, 280-288. 
Patrick, S. & Turchi, J. (1998) Human replication protein A preferentially binds cisplatin-
damaged duplex DNA in vitro. Biochemistry, 37, 8808-8815. 
Patrick, S. & Turchi, J. (1999) Replication Protein A (RPA) Binding To Duplex Cisplatin-
damaged DNA is Mediated through the Generation of Single-stranded DNA. The Journal 
of Biological Chemistry, 274, 14972-14978. 
Pesola, F., Ferlay, J. & Sasieni, P. (2017) Cancer incidence in English children, adolescents 
and young people: past trends and projections to 2030. British Journal of Cancer, 117, 
1865-1873. 
Petermann, E. & Helleday, T. (2010) Pathways of mammalian replication fork restart. 
Nature Reviews Molecular Cell Biology, 11, 683–687. 
Pierce, N. W., Kleiger, G., Shan, S. O. & Deshaies, R. J. (2009) Detection of sequential 
polyubiquitylation on a millisecond timescale. Nature, 462, 615-619. 
Pizzolato, J., Mukherjee, S., Shärer, O. D. & Jiricny, J. (2015) FANCD2-associated Nuclease 
1, but Not Exonuclease 1 or Flap Endonuclease 1, Is Able to Unhook DNA Interstrand 
Cross-links In Vito. The Journal of Biological Chemistry, 290, 22602-22611. 
Pontel. L. B., Rosado, I. V., Burgos-Barragan, G. et al. (2015) Endogenous Formaldehyde is 
a Hematopoietic Stem Cell Genotoxin and Metabolic Carcinogen. Mol. Cell, 60, 177-188. 
Poon, S. L., McPherson, J. R., Tan, P., Teh, B. T. & Rozen, S. G. (2014). Mutation signatures 
of carcinogen exposure: genome-wide detection and new opportunities for cancer 
prevention. Genome Medicine, 6, 1-14. 
Popuri, V., Croteau, D. L. & Bohr, V. A. (2010) Substrate specific stimulation of NEIL1 by 
WRN but not the other human RecQ helicases. DNA Repair (Amst), 9, 636-642. 




Pouget, J. O., Frelon, S. Ravanat, J. L., Testard, I., Odin, F. et al. (2002) Formation of 
modified DNA bases in cells exposed either to gamma radiation or to high-LET particles. 
Radiation Research, 157, 589-595. 
Poulogiannis, G., McIntyre, R., Dimitriadi, M., et al. (2010) PARK2 deletions occur 
frequently in sporadic colorectal cancer and accelerate adenoma development in Apc 
mutant micr.  Proceedings of the National Academy of Sciences of the U.S.A., 107, 15145-
15150. 
Prakash, A. & Doublié, S. (2015) Base Excision Repair in the Mitochondria. Journal of 
Cellular Biochemistry, 116, 1490-1499. 
Prakash, A., Doublié, S. & Wallace, S. S. (2012) The Fpg/Nei Family of DNA glycosylases: 
Substrates, Structures and Search for Damage. Progress in molecular biology and 
translational science, 110, 71-91. 
Price, N. E., Catalano, M. J., Liu, S., Wang, Y. & Gates, K. S. (2015) Chemical and structural 
characterization of interstrand cross-links formed between abasic sites and adenine 
residues in duplex DNA. Nucleic Acids Research, 13, 3434-3441. 
Purmal, A. A., Lampman, G. W., Bond, J. P., Hatahet, Z. & Wallace, S. S. (1998) Enzymatic 
processing of uracil glycol, a major oxidative product of DNA cytosine.  Journal of 
Biological Chemistry, 273, 10026-10035. 
Quaresma, M., Coleman, M. P. & Rachet, B. (2015) 40-year trends in an index of survival 
for all cancers combined and survival adjusted for age and se for each cancer in England 
and Wales, 1971-2011: a population-based study. Lancet, 385, 1206-1218. 
Quintet, A., Lemacon., D. & Vindigni, A. (2017) Replication Fork Reversal: Players and 
Guardians. Mol. Cell, 68, 830-833. 
Quiros, S., Roos, W. P. & Kaina, B. (2010) Processing of O6-methylagunanine into DNA 
double-strand breaks requires two rounds of replication whereas apoptosis is also 
induced in subsequent cell cycles. Cell Cycle, 9, 168-178. 
Ragland, R. L., Patel, S., Rivard, R. S., et al. (2013) RNF4 PLK1 are required for replication 
fork collapse in ATR-deficient cells. Genes & Development, 27, 2259-2273. 
Ran, Y., Zhang, J., Liu, L. et al. (2016) Autoubiquitination of TRIM26 links TBK1 to NEMO in 
RLR-mediated innate antiviral immune response. Journal of molecular cell biology, 8, 31-
43. 
Rankin, E. B. & Giaccia, A. J. (2016) Hypoxic control of metastasis. Science, 352, 175-182. 
Regnell, C., Hildrestrand, G., Sejersted, Y. et al. (2012) Hippocampal Adult Neurogenesis Is 
Maintained by NEIL3-Dependent Repair of Oxidative DNA Lesions in Neural Progenitor 
Cells. Cell Reports, 2, 503-510. 
Reymond, A., Meroni, G., Fantozzi, A. et al. (2001) The tripartite motif family identifies cell 
compartments. The EMBO Journal, 20, 2140-2151. 
Rittié, L. & Perbal, B. (2008) Enzymes used in molecular biology: a useful guide. Journal of 
Cell Communication and Signalling, 2, 25-45. 




Rizzoni, M., Cundari, E., Perticone, P. & Gustavino, B. (1993) Chromatin Bridges between 
Sister Chromatids Induced in Late G2 Mitosis in CHO cells by Trimethylpsoralen+ UVA. 
Experimental Cell Research. 209, 149-155. 
Rodriguez, M.S., Desterro, J.M., Lain, S, Lane, D.P. & Hay, R.T. (2000) Multiple C-terminal 
lysine residues targetp53 for ubiquitin-proteasome-mediated degradation. Mol Cell Biol, 
20, 8458–8467.  
Rohleder, F., Huang, J., Xue, Y. et al. (2016) FANCM interacts with PCNA to promote 
replication traverse of DNA interstrand crosslinks. Nucleic Acids Research, 44, 3219-3232. 
Rolseth, V., Krokeide, S., Kunke, D. et al. (2013) Loss of NEIL3, the major DNA glycosylase 
activity for removal of hydantoins in single stranded DNA, reduces cellular proliferation 
and sensitises cells to genotoxic stress. Biochimica et biophysica acta, 1833, 1157-64. 
Rolseth, V., Luna, L., Olsen, A. K. et al. (2017) No cancer predisposition or increased 
spontaneous mutation frequencies in NEIL DNA glycosylase-deficient mice. Scientific 
Reports, 7, 4384 
Ronson, G. E., Piber, A. L., Higgs, M. R., et al. (2018) PARP1 and PARP2 stabilise replication 
forks at BER intermediates through Fbh-dependent Rad51 regulation. Nature 
Communications, 9, 1-12. 
Rosado, I., Langevin, F., Crossan, G., Takata, M. & Patel, K. (2011) Formaldehyde 
catabolism is essential in cells deficient for the Fanconi anemia DNA-repair pathway. Nat. 
Struct. Mol. Biol. 18, 1432–1434. 
Rosenberg, P. S., Tamary, H. & Alter, B. P. (2011) How high are carrier frequencies of rare 
recessive syndromes? Contemporary estimates for Fanconi anemia in the United States 
and Israel. Am. J. Med. Genet. A, 155A, 1877–1883. 
Rosenquist, T., Zaika, E., Fernandes, A. et al. (2003) The novel DNA glycosylase, NEIL1, 
protects mammalian cells from radiation-mediated cell death. DNA Repair, 2, 581-591. 
Roy, U., Mukherjee, S., Sharma, A., Frank, E. G. & Scharer, O. D. (2016) The structure and 
duplex context of DNA interstrand crosslinks affects the activity of DNA polymerase eta. 
Nucleic Acids Research. 44, 7281-7297. 
Sacco, E., Hasan, M. M., Alberghina, L. & Vanoni, M. (2012) Comparative analysis of the 
molecular mechanisms controlling the initiation of chromosomal DAN replication in yeast 
and in mammalian cells. Biotchnology Advances, 30, 73-93. 
Sacco, J. J., Coulson, J. M., Clague, M. J. & Urbé, S. (2010) Emerging roles of 
deubiquitinases in cancer-associated pathways. IUBMB Life, 62, 140–157 
Sale, J. E., Lehmann, A. R. & Woodgate, R. (2012) Y-family DNA polymerases and their role 
in tolerance of cellular DNA damage. Molecular Cell Biology, 13, 141-152. 
Santivasi, W. L. & Xia, F. (2014) Ionizing Radiation-Induced DNA Damage, Response, and 
Repair. Antioxidants & Redox Signalling, 21, 251-259. 




Saparbaev, M., Kleibl, K. & Laval, L. (1995) Escherichia coli, Saccharomyces cerevisiae, rat 
and human 3-methyladenine DNA glycosylases repair 1, N6-ethonoadenine when present 
in DNA. Nucleic Acids Research, 23, 3750-3755. 
Sarkar, S., Davies, A. A., Ulrich, H. D. & McHugh, P. J. (2006) DNA interstrand crosslink 
repair during G1 involves nucleotide excision repair and DNA polymerase zeta. The EMBO 
Journal, 25, 1285-1294. 
Sarker, A. H., Chatterjee, A., Williams, M. et al. (2014) NEIL2 protects against Oxidative 
DNA Damage Induced by Sidestream Smoke in Human Cells. PLoS One, 9, e90261. 
Sastry, S.S., Ross, B. & P’arraga, A. (1997) Cross-linking of DNA-binding Proteins to DNA 
with Psoralen and Psoralen Furan-side Monoadducts. The Journal of Biological Chemistry, 
272, 3715-3723. 
Schärer, O. (2003) Chemistry and Biology of DNA Repair. Angewandte Chemie 
International Edition, 42, 2946-2974. 
Schärer, O. D. (2013) Nucleotide Excision Repair in Eukaryotes. Cold Spring Perspectives in 
Biology, 5, a012609. 
Scheffner, M., Nuber, U. & Huibregtse, J. M. (1995). Protein ubiquitination involving an 
E1-E2-E3 enzyme ubiquitin thioester cascade. Nature, 373, 81-83. 
Scrima, A., Koníčková, R., Czyzewski, B. K. et al. (2008) Structural basis of UV DNA damage 
recognition by the DDB1-DDB2 complex. Cell, 135, 1213-1223. 
Sczepanski, J. T., Jacobs, A. C. & Greenberg, M. M. (2008) Self-promoted DNA interstrand 
cross-link formation by an abasic site. Journal of American Chemical Society, 130, 9646-
9647. 
Sczepanski, J. T., Jacobs, A. C., Van Houten, B. & Greenberg, M. M. (2009) Double Strand 
Break Formation During Nucleotide Excision Repair of a DNA Interstrand Cross-lin.  
Biochemistry, 48, 7565-7567. 
Seetharam, R., Sood, A., Basu-Mallick, A. et al. (2010) Oxaliplatin Resistance Induced by 
ERCC1 Up-regulation Is Abrogated by siRNA-mediated Gene Silencing in Human Colorectal 
Cancer Cells. Anticancer Research, 30, 2531-2538.  
Segal-Raz, Mass, G., Baranes-Bachar, K. et al. (2011) ATM-mediated phosphorylation of 
polynucleotide kinase/phosphatase is required for effective DNA double-strand break 
repair. EMBO reports, 12, 713-719. 
Semlow, D. R., Zhang, J., Budzowska, M., Drohat, A. C. & Walter, J. C. (2016) Replication-
Dependent Unhooking of DNA interstrand Cross-Links by the NEIL3 Glycosylase. Cell, 167, 
498-511. 
Seol, J. H., Feldman, R. M. R., Zachariae, W., et al. (1999). Cdc53/cullin and the essential 
Hrt1 RING-H2 subunit of SCF define a ubiquitin ligase module that activates the E2 enzyme 
Cdc34. Genes & Development, 13, 1614-1626. 
Shangary, S. & Wang, S. (2008). Targeting the MDM2-p53 Interaction for Cancer Therapy. 
Clin. Cancer Res, 14, 5318-5324.  




Shen X., Jun, S., O’Neal, L. E. et al. (2006) REV3 and REV1 play major roles in 
recombination-independent repair of DNA interstrand cross-links mediated by 
monoubiquitinated proliferating cell nuclear antigen (PCNA). Journal of Biological 
Chemistry, 281, 13869-13872. 
Shen, D., Pouliot, L. M., Hall, M. D., & Gottesman, M. M. (2012) Cisplatin Resistance: A 
Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic 
Changes. Pharmacological Reviews, 64, 706-721. 
Shen, L., Song, C. X., He, C. & Zhang, Y. (2014) Mechanism of function of oxidative reversal 
of DNA and RNA methylation. Annual Review of Biochemistry, 83, 585-614. 
Shi, C., Pan, B. Q., Shi, F. et al. (2018). Sequestosome 1 protects oesophageal squamous 
carcinoma cells from apoptosis via stabilizing SKP2 under serum starvation condition. 
Oncogene, 37, 3260-3274. 
Shimamura, A. Montes de Oca, R., Svenson, J. L. et al. (2002) A novel diagnostic screen for 
defects in the Fanconi anemia pathway. Blood, 100, 4649–4654. 
Shinmura, K., Kato, H., Kawanishi, Y. et al. (2016) Abnormal Expressions of DNA glycosylase 
Genes NEIL1, NEIL2 and NEIL3 Are Associated with Somantic Mutation Loads in Human 
Cancer. Oxidative Medicine and Cellular Longevity, 2016, 1-10. 
Shrivastav, N., Li, D. & Essigmann, J. M. (2010) Chemical biology of mutagenesis and DNA 
repair: cellular responses to DNA alkylation. Carcinogenesis, 31, 59-70. 
Siddik, Z. (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. 
Oncogene, 22, 7265-7279. 
Siegel, R. L., Miller, K. D. & Jemal, A. (2018) Cancer Statistics, 2018. CA: A cancer journal 
for clinicians, 68, 7-30. 
Singh, T. R., Ali, A. M., Paramasivam, M. et al. (2013) ATR-dependent phosphorylation 
of FANCM at serine 1045 is essential for FANCM functions. Cancer Res. 73, 4300–4310 
Singleton, M. R., Scaife, S. & Wigley, D. B. (2001) Structural analysis of DNA replication 
fork reversal by RecG. Cell,  107, 79-89. 
Smith, F. W. & Feigon, J. (1992) Quadruplex structure of oxytricha telomeric DNA 
oligonucleotides. Nature, 356, 164-168. 
Smith, S. A. & Engelward, B. P. (2000) In vivo repair of methylation damage in AAG 3-
methyladenine DNA glycosylase null mouse cells. Nucleic Acids Research, 28, 3294-3300. 
Soll, J. M., Sobol, R. W. & Masommaparast, N. (2017) Regulation of DNA Alkylation 
Damage Repair: Lessons and Therapeutic Opportunities. Trends in Biochemical Sciences, 
42, 206-218. 
Staresincic, L., Fagbemi, A., Enzlin, J. H. et al. (2009) Coordination of dual incision and 
repair synthesis in human nucleotide excision repair. The EMBO Journal, 28, 1111-1120. 
Stelter, P. & Ulrich, H. D. (2003) Control of spontaneous and damage-induced mutagenesis 
by SUMO and ubiquitin conjugation. Nature, 425, 188-191. 




Stevnsner, T., Muftuoglu, M., Aamann, M. D. & Bohr, V. A. (2008) The role of Cockayne 
Syndrome Group B (CSB) protein in BER and aging.  Mechanisms of ageing and 
development, 129, 441-448. 
Stevnsner, T., Nyaga, S., de Souza-Pinto, N. C. (2002) Mitochondrial repair of 8-oxoguanine 
is deficient in Cocakyne syndrome group B. Oncogene, 21, 8675-8682. 
Stewart, M. D., Ritterhoff, T., Klevit, R. E. & Brzovic, P. S. (2016) E2 enzymes: more than 
just middle men. Cell Res, 26, 423-440. 
Summerfield, S. W. & Tappel, A. L. (1984) Detection and measurement by high-
performance liquid chromatography of malondialdehyde crosslinks in DNA. Analytical 
Biochemistry, 143, 1482-1485. 
Suhasini, A. N. & Brosh, R. M. (2010) Mechanistic and Biological Aspects of Helicase Action 
on Damaged DNA. Cell Cycle, 9, 2317-2329. 
Suhasini, A. N., Sommers, J. A., Mason, A, C. et al. (2009) FANCJ Helicase Uniquely Senses 
Oxidative Base Damage in Either Strand of Duplex DNA and Is Stimulated by Replication 
Protein A to Unwind the Damaged DNA substrate in a Strand-specific Manner. Journal of 
Biological Chemistry, 284, 18458-18470. 
Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse 
embryonic and adult fibroblast cultures by defined factors. Cell, 126, 663–676. 
Takahashi, K., Tanabe, K., Ohnuki, M. et al. (2007). Induction of pluripotent stem cells from 
adult human fibroblasts by defined factors. Cell, 131, 861–872. 
Takao, M., Oohata, Y., Kitadokoro, K. et al. (2009) Human Nei-like protein NEIL3 has AP 
lyase activity specific for single-stranded DNA and confers oxidative stress resistance in 
Escherichia coli mutant. Genes to Cells, 14, 261-270. 
Tan, P., Fuchs, S. Y., Chen, A., et al., (1999) Recruitment of a ROC1-CUL1 ubiquitin ligase 
by Skp1 and HOS to catalyse ubiquitination of I kappa B alpha. Mol. Cell, 3, 527-333. 
Tanaka. S., & Araki, H. (2010) Regulation of the initiation step of DNA replication by cyclin 
dependent kinases. Chromosoma, 119, 565-574. 
Taniguchi, T., Tischkowitz, M., Ameziane, N. et al. (2003) Disruption of the Fanconi-
anemia-BRCA pathway in cisplatin sensitive ovarian tumours. Nature Methods, 9, 568-74. 
Taylor, J., Ferry, N. & Elder, R. (2015) RNA interference-based target validation of NEIL3 
for use in a cancer selective lectin fusion delivery system. Tomas Lindahl Conference on 
DNA Repair, 17-21 June 2015, Oslo. 
Tedesco, D., Lukasm J. & Reed, J. I. (2002) The pRb-related protein p130 is regulated by 
phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCF (Skp2). Genes 
& Development, 16, 1504-1509. 
Tegel, H., Ottoson, J. & Hober, S. (2011) Enhancing the protein production levels in 
Escherichia coli with a strong promoter. The FEBS Journal, 278, 729-739. 




Theriot, C., A, Hegde, M. L., Hazra, T. & Mitra, S. (2010) RPA physically interacts with the 
human DNA glycosylase NEIL1 to regulate excision of oxidative DNA base damage in 
primer-template structures.  DNA Repair, 9, 643-652. 
Thiviyanathan, V., Somasunderam, A., Volk, D. E. et al. (2008) Base-pairing Properties of 
the Oxidized Cytosine Derivative, 5-Hydroxy Uracil. Biochemical and Biophysical Research 
Communications, 366, 752-757.  
Thompson, L.H. & West, M.G. (2000) XRCC1 keeps DNA from getting stranded. Mutation 
Research, 459, 1–18. 
Thompson, L.H., Brookman, K.W., Dillehay, L.E., et al. (1982) A CHO-cell strain having 
hypersensitivity to mutagens, a defect in DNA strand-break repair, and an extraordinary 
baseline frequency of sister-chromatid exchange, Mutation Research, 95, 427–440. 
Thorslund, T., von Kobbe, C., Harrigan, J. A., Indig, F. E., Christiansen, M. et al. (2005) 
Cooperation of the Cockayne syndrome group B protein and poly (ADP-ribose) DNA 
polymerase 1 in the response to oxidative stress. Molecular and Cellular Biology, 25, 7625-
7636. 
Torisu, K., Tsuchimoto, D., Ohnishi, Y. & Nakabeppu, Y. (2005) Hematopoietic tissue-
specific expression of mouse NEIL3 for endonuclease VIII-like protein. Journal of 
Biochemistry, 138, 763-772. 
Torok, M. & Etkin, L. D. (2001) Two B or not two B? Overview of the rapidly expanding B-
box family of proteins. Differentiation, 67, 63-71.  
Torres-Garcia, S. J., Cousineau, L., Caplan, S. & Panasci, L. (1989). Correlation of resistance 
to nitrogen mustards in chronic lymphocytic leukemia with enhanced removal of 
melphalan-induced DNA cross-links. Biochmical Pharmacology, 38, 3122-3123. 
Trakselis, M. A., Cranford, M. T. & Chu, A. M. (2017) Coordination and Substitution of DNA 
polymerases in Response to Genomic Obstacles. Chemical Research in Toxicology, 30, 
1956-1971. 
Tusell, L., Pampalona, J., Soler, D., Frias, C. & Genescà, A. (2010) Different outcomes of 
telomere-dependent anaphase bridges. Biochemical Society Transactions, 38, 1698-1703. 
Tzelepi, V., Zhang, J., Lu, J. F., et al. (2012) Modeling a lethal prostate cancer variant with 
small-cell carcinoma features. Clincal Cancer Research, 18, 666-677. 
Udeshi, N.D., Mani, D.R., Eisenhaure, T., et al. (2012) Methods for quantification of in vivo 
changes in protein ubiquitination following proteasome and deubiquitinase inhibition. 
Mol. Cell. Proteomics, 11, 148–159. 
Udeshi, N.D., Svinkina, T., Mertens, P., et al. (2013) Refined preparation and use of anti-
diglycine remnant (K-ε-GG) antibody enables routine quantification of 10,000s of 
ubiquitination sites in single proteomics experiments. Mol Cell Proteomics, 12, 825-831. 
Uniprot. (2010) UniProtKB - Q8TAT5 (NEIL3_HUMAN). 
http://www.uniprot.org/uniprot/Q8TAT5 [Accessed 20 June 2016]. 




van Loon, B., Markkanen, E. & Hübscher, U. (2010) Oxygen as a friend and enemy: How to 
combat the mutational potential of 8-oxo-guanine. DNA Repair, 9, 604-616. 
van Ree, J.H., Jeganathan, K., Malureanu, L. & van Deursen, J. M. (2010) Overexpression 
of the E2 ubiquitin-conjugating enzyme UbcH10 causes chromosome missegregation and 
tumour formation. Journal of Cell Biology, 188, 83-100. 
Vincze, T., Posfai, J. & Roberts, R.J. (2003) NEBcutter: a program to cleave DNA with 
restriction enzymes. Nucleic Acids Research, 31, 3688-3691. 
Voulgaridou, G., Anestopoulos, I., Franco, R. Panayiotidis, M. J. & Pappa, A. (2011) DNA 
damage induced by endogenous aldehydes: Current state of knowledge. Mutation 
Research, 711, 13-17. 
Wagner, S.A., Beli, P., Weinert, B.T., et al. (2011) A proteome-wide, quantitative survey of 
in vivo ubiquitylation sites reveals widespread regulatory roles. Mol. Cell. Proteomics, 10, 
M111.013284. 
Wakasugi, M., Sasaki, T., Matsumoto, M. et al. (2014) Nucleotide Excision Repair-
dependent DNA Double-strand Break Formation and ATM Signalling Activation in 
Mammalian Quiescent Cells.  Journal of Biological Chemistry, 289, 28730-28737. 
Wallace, B. D., Berman, Z., Mueller, G. A. et al. (2016) Ape2 Zf-GRF facilitates 3’-5’ 
resection of DNA damage following oxidative stress. Proceedings of the National Academy 
of Sciences of the United States of America, 114, 304-309. 
Wallace, S. (2014). Base excision repair: A critical player in many games. DNA repair, 19, 
14-26. 
Wallace, S., Bandaru, V., Kathe, S. & Bond, J. (2003) The enigma of endonuclease VIII. DNA 
Repair, 13, 441-453. 
Wallace, S., Murphy, D. & Sweasy, J. (2012). Base excision repair and cancer. Cancer 
Letters, 327, 73-89. 
Wang, A. T., Sengerová, B., Catell, E. et al. (2011) Human SNM1A and ERCC1-XPF 
collaborate to intiate DNA interstrand cross-link repair. Genes and Development, 25, 
1859-1870. 
Wang, C., Xu, J., Fu, H. et al. (2018) TRIM32 promotes cell proliferation and invasion by 
activating β-catenin signalling in gastric cancer. Journal of Cellular and Molecular 
Medicine, 1-9. 
Wang, J. C. & Gautier, J. (2010) The Fanconi anemia pathway and ICL repair: implications 
for cancer therapy. Critical reviews in biochemistry and molecular biology, 45, 424-439. 
Wang, L., Li, S. & Dorf, M. E. (2012) NEMO binds ubiquitinated TANK-binding Kinase 1 
(TBK1) to regulate innate immune responses to RNA viruses. PLoS One, 7, e43756. 
Wang, L., Yang, H., Palmbos, P.L. et al. (2014) AtDC/TRIM29 phosphorylation by 
ATM/MAPKAP kinase 2 mediates readioresistance in pancreatic cancer cells. Cancer 
Research, 74, 1778-1788. 




Wang, Y., He, D., Yang, L. et al. (2015a) TRIM26 functions as a novel tumour suppressor of 
hepatocellular carcinoma and its downregulation contributes to worse prognosis. 
Biochemical and biophysical research communications, 463, 458-465. 
Wang, P., Zhao, W., Zhao, K., Zhang, L. & Gao, C. (2015b) TRIM26 Negatively Regulates 
Interferon-β Production and Antiviral response through Polyubiquitination and 
Degradation of Nuclear IRF3. PLoS Pathogens, 11, e1004726 
Wang, W. (2007) Emergence of a DNA-damage response network consisting of Fanconi 
anemia and BRCA proteins. Nature reviews genetics, 8, 735-748. 
Watanabe, M. & Hatakeyama, S. (2017) TRIM proteins and diseases. Journal of 
Biochemistry, 161, 135-144.  
Weinfeld, M., Mani, R.S., Abdou, I., Aceytuno, R.D., Glover, J.N. (2011) Tidying up loose 
ends: the role of polynucleotide kinase/phosphatase in DNA strand break repair, Trends 
Biochem. Sci, 36, 262–271. 
Weiss, J., Goode, J., Ladiges, W. & Ulrich, C. (2005) Polymorphic variation in hOGG1 and 
risk of cancer: a review of the functional and epidemiological literature. Molecular 
Carcinogenesis, 42, 127-141. 
Weissman, A. M. (2001) Themes and variations on ubiquitylation. Mol. Cell Biol. 2, 169–
178. 
Weller, M., Stupp, R., Reifenberger, G., Brandes, A. A, van den Bent, M. J. et al. (2010) 
MGMT promoter methylation in malignant gliomas: ready for personalized medicine? 
Nature Reviews Neurology, 6, 39-51. 
Wenzel, E. S. & Singh, A. T. K. (2018) Cell-cycle Checkpoints and Aneuploidy on the Path 
to Cancer. In Vivo, 32, 1-5. 
Wilkinson, K. D. (2009). DUBs at a glance. J. Cell Sci, 122, 2325–2329. 
Will, O., Gocke, I., Eckert, I. et al., (1999) Oxidative DNA damage and mutations induced 
by a polar photosensitizer, Ro19-8022. Mutation Research, 435, 89-101. 
Williams, H. L., Gottesman, M. E. & Gautier, J. (2012) Replication-independent repair of 
DNA interstrand crosslinks. Mol Cell, 47, 140-147. 
Williams, S. C. & Parsons, J. L. (2018) NTH1 is a new target for ubiquitylation-dependent 
regulation by TRIM26 required for the cellular response to oxidative stress. Molecular and 
Cellular Biology, 38, e00616-17. 
Williamson, J. R., Raghuraman, M. K. & Cech, T. R. (1989) Monovalent cation-induced 
structure of telomeric DNAL The G-quartet model. Cell, 59, 871-880. 
Witkiewicz, A. K., McMillan, E. A., Balaji, U. et al. (2015) Whole-exome sequencing of 
pancreatic cancer defines genetic diversity and therapeutic targets. Nature 
Communications, 6, 6744. 
Wong, H. K., Muftuoglu, M., Beck, G., Imam, S. Z., Bogr, V, A. et al. (2007) Cockayne 
syndrome B protein stimulates apurinic endonuclease 1 activity and protects against 
agents that introduce BER intermediates. Nucleic Acids Research, 35, 4103-4113. 




Wood, R. D. (2010) Mammalian nucleotide excision repair proteins and interstrand 
crosslink repair. Environmental and Molecular Mutagenesis, 51, 520-526. 
Wu, Z., Shen, S., Zhang, Z., Zhang, W. & Xiao, W. (2014). Ubiquitin-conjugating enzyme 
complex Uev1-Ubc13 promotes breast cancer metastasis through nuclear factor-small ka, 
CyrillicB mediated matrix metalloproteinase-1gene regulation. Breast Cancer Research, 
16, R75. 
Xin, B. (2015) Mechanisms of DNA damage tolerance. World Journal of Biologocial 
Chemistry, 6, 48-56. 
Xu, W., Ouellette, A., Shosh, S., O’Neil, T. C., Greenberg, M. M. & Zhao, L. (2015) Mutagenic 
bypass of an Oxidized Abasic lesion induced DNA interstrand cross-link Analogue by 
Human Translesion Synthesis DNA polymerases. Biochemistry, 54, 7409-7422. 
Yamamoto, K. N., Kobayashi, S., Tsuda, M. et al. (2011) Involvement of SLX4 in interstrand 
cross-link repair is regulated by the Fanconi anemia pathway. Proceeding of the National 
Academy of Sciences of the U.S.A, 108, 6492-6496. 
Yamamoto, R., Ohshiro, Y., Shimotani, T. et al. (2014) Hypersensitivity of mouse NEIL1-
knockdown cells to hydrogen peroxide during S phase. Journal of Radiation Research, 55, 
707-712. 
Yamazaki, S., Hayano, M. & Masai, H. (2013) Replication timing regulation of eukaryotic 
replicons: Rif1 as a global regulator of replication timing. Trends in Genetics, 29, 449-460. 
Yang, B., O’Herrin, S.M., Wu, J., et al. (2007) MAGE-A, mMage-b, and MAGE-C proteins 
form complexes with KAP1 and sup- press p53-dependent apoptosis in MAGE-positive cell 
lines. Cancer Res, 67, 9954–9962.  
Yang, H., Lu, X., Liu, Z. et al. (2015) FBXW7 suppresses epithelial-mesenchymal transition, 
stemness and metastatic potential of cholangiocarcinoma cells. Oncotarget, 6, 6310-
6325. 
Yang, Y., Kitagaki, J., Wang, H., Hou, D. & Perantoni, A. O. (2009) Targeting the ubiquitin-
proteasome system for cancer therapy. Cancer Science, 100, 24-28. 
Yang, Z., Nejad, M. I., Varela, J. G., Price, N. E., Wang, Y. & Gates, K. S. (2017) A role for the 
BER enzyme NEIL3 in replication-dependent repair of interstrand DNA cross-links derived 
from psoralen and abasic sites. DNA Repair, 52, 1-11. 
Yao, Y. & Dai, W. (2014) Genomic Instability and Cancer. Journal of carcinogenesis & 
mutagenesis, 5, 1-17. 
Ye, Y. & Rape, M. (2009) Building ubiquitin chains: E2 enzymes at work. Nature Rev. Mol. 
Cell Biol, 10, 755–764.  
Yokoi, M., Masutani, C., Maekawa, T. et al. (2000) The xeroderma pigmentosum group C 
protein complex XPC HR23B plays and important role in the recruitment of transcription 
factor IIH to damaged DNA. Journal of Biological Chemistry, 275, 9870-9875.  




Yoon, J., Bhatia, G., Prakash, S. & Prakash, L. (2010) Error-free replicative bypass of 
thymine glycol by the combined action of DNA polymerases κ and ζ in human cells. 
Proceedings of the National Academy of Sciences of the U.S.A, 107, 14116-14121. 
Yoshioka, K., Yoshioka, Y. & Hsieh, P. (2006) ATR kinase activation mediated by MutSalpha 
and MutLalpha in response to cytotoxic O6-methylguanine adducts. Mol Cell. 22, 501-510. 
Yu, J., Vodyanik, M.A., Smuga-Otto, K. et al. (2007). Induced pluripotent stem cell lines 
derived from human somatic cells. Science, 318, 1917–1920. 
Zafar, M. K. & Eoff, R. L. (2017) Translesion DNA synthesis in Cancer: Molecular 
Mechanisms and Therapeutic Opportunities. Chemical Research in Toxicology, 30, 1942-
1955. 
Zeman, M. K. & Cimpirch, K. A. (2014) Causes and consequences of replication stress. 
Nature Cell Biology, 16, 2-9. 
Zhang, J., Dewar, J. M., Budzowzska, M. et al. (2015) DNA interstrand cross-link repair 
requires replication-fork convergence. Nature structural and molecular biology, 22, 242-
247. 
Zhao, W., Li, Q., Ayers, S. et al. (2013) Jmjd3 Inhibits Reprogramming by Upregulating 
expression of Ink4a/Arf and Targeting for Ubiquitination. Cell, 152, 1037-1050. 
Zheng, N. & Shabek, N. (2017) Ubiquitin Ligases: Structure, Function, and Regulation. 
Annual Review of Biochemistry,  86, 129-157. 
Zhou, H., Xu, M., Huang, Q. et al. (2008) Genome-Scale RNAi Screen for Host Factors 
Required for HIV Replication. Cell Host & Microbe, 4, 495-504. 
Zhou, J., Chan, J., Lambelé, M. et al. (2017) Neil3 repairs Telomere Damage during SPhase 
to Secure Chromosome Segregation at Mitosis. Cell Reports, 20, 2044-2056. 
Zhou, J., Liu, M., Fleming, A. M., Burrows, C. J. & Wallace, S. (2013) NEIL3 and NEIL1 DNA 
Glycosylases Remove Oxidative Damages from Quadruplex DNA and Exhibit Preferences 
for Lesions in the Telomeric Sequence Context.  Journal of Biological Chemistry, 288, 
27263–27272. 
Zolner, A. E., Abdou, I., Ye, R. et al. (2011) Phosphorylation of polynucleotide 
kinase/phosphatase by DNA- dependent protein kinase and ataxia-telangiectasia mutated 
regulates its association with sites of DNA damage. Nucleic Acids Research,  39, 9224-
9237. 
Zou, L. & Elledge, S. (2003) Sensing DNA damage through ATRIP recognition of RPA-ss-
DNA complexes. Science,  300, 1542-1548. 





Appendix Table 1: Sequences of oligonucleotides used in the “characterisation of the hNEIL1 and hNEIL3 
DNA glycosylases in the repair of psoralen interstrand DNA crosslinks”. 
Oligonucleotide 
name 
Oligonucleotide sequence (5’-3’) 
TpA site position and 
possible cleavage product 
size. 
R18, 18 mer GCUCUCGUCUGTACACCG 
TpA position 12-13; excision of 
T12 generates an 11 mer 
cleavage product. 
D21, 21 mer CTTCGGTGTACAGACGAGAGC 
TpA position 9-10; excision of 
T9 generates 8 mer cleavage 
product 
C21, 21 mer GCTCTCGTCTGTACACCGAAG) 
TpA position 12-13; excision of 
T12 generates 11 mer 
cleavage product  
C47, 47 mer 
GACGACGACAAGGCTCTCGTCTGTA
CAC CGAAGAGCTGCTCTGCCTG 
TpA position 24-25; excision of 
T24 generates 23 mer 
cleavage product  
D47, 47 mer 
CAGGCAGAGCAGCTCTTCGGTGTAC
AGACGAGAGCCTTGTCGTCGTC 
TpA position 23-24; excision of 
T23 generates 22 mer 
cleavage product   
 






TpA position 51-52; excision of 
T51 generates 50 mer 
cleavage product  






TpA position 50-51; excision of 
T50 generates 49 mer 
cleavage product 
Sp1, 17 mer CCACCAAC[Sp1]CTACCACC 
Sp1 position 9; excision of 
Sp19 generates 8 mer 
cleavage product 





Appendix Table 2: LC-MS proteomic analysis results, showing matched proteins after database alignment with 
detected peptides. An ion score cut off of 25 was used. hNEIL3Cat is expected to be ~32 kDa, however is detected 
at ~33 kDa. This is accounted for with the addition of C-terminal polyhistidine tag present in fusion with the 
recombinant protein. Major protein contaminants include keratin proteins, characteristically detected after 
handling procedures and in trypsin used in the protein band purification process. The lowest scoring protein 
detected in this list was the co-expressed E. coli MAP1 (EcoMap) protein. (Accession)  Protein Accession number. 
(Score) MS/MS Ion score, matched to amino acid sequences, higher score indicates increased confidence.  
Appendix Table 3: LC-MS proteomic analysis results, showing matched proteins after database alignment with 
detected peptides. An ion score cut off of 25 was used. hNEIL3Cat is expected to be ~32 kDa, however is detected 
at ~33 kDa. This is accounted for with the addition of C-terminal polyhistidine tag present in fusion with the 
recombinant protein. Major protein contaminants include keratin proteins, characteristically detected after 
handling procedures and in trypsin used in the protein band purification process. The second highest scoring 
protein detected in this list was the co-expressed E. coli MAP1 (EcoMap) protein. (Accession)  Protein Accession 






Cytosine complementary to 
Sp1 at position 10 
D21-U, 21 mer CTTCGGTGUACAGACGAGAGC 
U position 9; excision of U9 
generates 8 mer cleavage 
product 
C47-U, 21 mer 
GACGACGACAAGGCTCTCGTCTGUA
CACCGAAGAGCTGCTCTGCCTG 
U position 24; excision of U24 
generates 23 mer cleavage 
product 
Accession Score Mass Number of 
sequences 
Description
hNEIL3 (843) 7578 33471 15 hNEIL3 (843) provided reference sequence
sp|P04264|K2C1_HUMAN 6951 66170 37 sp|P04264|K2C1_HUMAN Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 SV=6
sp|P13645|K1C10_HUMAN 4043 59020 28 sp|P13645|K1C10_HUMAN Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6
sp|P35527|K1C9_HUMAN 3688 62255 20 sp|P35527|K1C9_HUMAN Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3
sp|Q6IMF3|K2C1_RAT 2751 65190 9 sp|Q6IMF3|K2C1_RAT Keratin, type II cytoskeletal 1 OS=Rattus norvegicus GN=Krt1 PE=2 SV=1
sp|P35908|K22E_HUMAN 2701 65678 28 sp|P35908|K22E_HUMAN Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2
sp|Q3MHN7|NEIL3_BOVIN 1808 69222 6 sp|Q3MHN7|NEIL3_BOVIN Endonuclease 8-like 3 OS=Bos taurus GN=NEIL3 PE=2 SV=2
sp|P00761|TRYP_PIG 1299 25078 3 sp|P00761|TRYP_PIG Trypsin OS=Sus scrofa PE=1 SV=1
sp|P04259|K2C6B_HUMAN 896 60315 19 sp|P04259|K2C6B_HUMAN Keratin, type II cytoskeletal 6B OS=Homo sapiens GN=KRT6B PE=1 SV=5
sp|P02533|K1C14_HUMAN 814 51872 17 sp|P02533|K1C14_HUMAN Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4
sp|P08779|K1C16_HUMAN 702 51578 16 sp|P08779|K1C16_HUMAN Keratin, type I cytoskeletal 16 OS=Homo sapiens GN=KRT16 PE=1 SV=4
sp|P02538|K2C6A_HUMAN 600 60293 20 sp|P02538|K2C6A_HUMAN Keratin, type II cytoskeletal 6A OS=Homo sapiens GN=KRT6A PE=1 SV=3
sp|P13647|K2C5_HUMAN 596 62568 24 sp|P13647|K2C5_HUMAN Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 SV=3
sp|Q04695|K1C17_HUMAN 380 48361 14 sp|Q04695|K1C17_HUMAN Keratin, type I cytoskeletal 17 OS=Homo sapiens GN=KRT17 PE=1 SV=2
sp|P0AA43|RSUA_ECOLI 221 25963 3 sp|P0AA43|RSUA_ECOLI Ribosomal small subunit pseudouridine synthase A OS=Escherichia coli (strain K12) GN=rsuA PE=1 SV=1
sp|P76422|THID_ECOLI 120 28787 2 sp|P76422|THID_ECOLI Hydroxymethylpyrimidine/phosphomethylpyrimidine kinase OS=Escherichia coli (strain K12) GN=thiD PE=1 SV=1
sp|P15924|DESP_HUMAN 95 334021 7 sp|P15924|DESP_HUMAN Desmoplakin OS=Homo sapiens GN=DSP PE=1 SV=3
sp|P81605|DCD_HUMAN 81 11391 2 sp|P81605|DCD_HUMAN Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2
sp|P0AE18|MAP1_ECOLI 55 29711 2 sp|P0AE18|MAP1_ECOLI Methionine aminopeptidase OS=Escherichia coli (strain K12) GN=map PE=1 SV=1
Accession Score Mass Number of 
sequences 
Description
hNEIL3 (843 K81A) 8345 33471 13 hNEIL3 (843 K81A) provided reference sequence
sp|P0AE18|MAP1_ECOLI 3941 29711 16 sp|P0AE18|MAP1_ECOLI Methionine aminopeptidase OS=Escherichia coli (strain K12) GN=map PE=1 SV=1
sp|P04264|K2C1_HUMAN 3609 66170 26 sp|P04264|K2C1_HUMAN Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 SV=6
sp|P13645|K1C10_HUMAN 2868 59020 21 sp|P13645|K1C10_HUMAN Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6
sp|Q3MHN7|NEIL3_BOVIN 2166 69222 5 sp|Q3MHN7|NEIL3_BOVIN Endonuclease 8-like 3 OS=Bos taurus GN=NEIL3 PE=2 SV=2
sp|P35527|K1C9_HUMAN 1826 62255 16 sp|P35527|K1C9_HUMAN Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3
sp|P00761|TRYP_PIG 1807 25078 3 sp|P00761|TRYP_PIG Trypsin OS=Sus scrofa PE=1 SV=1
sp|P35908|K22E_HUMAN 1719 65678 24 sp|P35908|K22E_HUMAN Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2
sp|Q6IMF3|K2C1_RAT 1406 65190 9 sp|Q6IMF3|K2C1_RAT Keratin, type II cytoskeletal 1 OS=Rattus norvegicus GN=Krt1 PE=2 SV=1
sp|P0AA43|RSUA_ECOLI 1104 25963 7 sp|P0AA43|RSUA_ECOLI Ribosomal small subunit pseudouridine synthase A OS=Escherichia coli (strain K12) GN=rsuA PE=1 SV=1
sp|P0A7V0|RS2_ECOLI 832 26784 7 sp|P0A7V0|RS2_ECOLI 30S ribosomal protein S2 OS=Escherichia coli (strain K12) GN=rpsB PE=1 SV=2
sp|P02533|K1C14_HUMAN 509 51872 9 sp|P02533|K1C14_HUMAN Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4
sp|P0A9K9|SLYD_ECOLI 298 21182 2 sp|P0A9K9|SLYD_ECOLI FKBP-type peptidyl-prolyl cis-trans isomerase SlyD OS=Escherichia coli (strain K12) GN=slyD PE=1 SV=1
sp|P0A7V8|RS4_ECOLI 200 23512 4 sp|P0A7V8|RS4_ECOLI 30S ribosomal protein S4 OS=Escherichia coli (strain K12) GN=rpsD PE=1 SV=2
sp|A5A6M8|K2C5_PANTR 134 62728 15 sp|A5A6M8|K2C5_PANTR Keratin, type II cytoskeletal 5 OS=Pan troglodytes GN=KRT5 PE=2 SV=1
sp|C0Q0B0|RS3_SALPC 112 25967 2 sp|C0Q0B0|RS3_SALPC 30S ribosomal protein S3 OS=Salmonella paratyphi C (strain RKS4594) GN=rpsC PE=3 SV=1
sp|C0Q6K4|LPXA_SALPC 106 28357 2 sp|C0Q6K4|LPXA_SALPC Acyl-[acyl-carrier-protein]--UDP-N-acetylglucosamine O-acyltransferase OS=Salmonella paratyphi C (strain RKS4594) GN=lpxA PE=3 SV=1
sp|P81605|DCD_HUMAN 84 11391 2 sp|P81605|DCD_HUMAN Dermcidin OS=Homo sapiens GN=DCD PE=1 SV=2
sp|A0KRL9|RS12_SHESA 51 13809 2 sp|A0KRL9|RS12_SHESA 30S ribosomal protein S12 OS=Shewanella sp. (strain ANA-3) GN=rpsL PE=3 SV=1





Appendix Figure 1: ÄKTA FPLC HisTrap HP purification analysis of recombinant hNEIL3Cat and hNEIL3Trun. A. 
10% SDS-PAGE analysis stained with Instant-blue coomasie blue (Merk). B. Anti-His western blot analysis. 
Target protein bands annotated. (M) BioRad All Blue Prestained Protein Standard (Mustafa Albelazi). 
 
Appendix Figure 2: ÄKTA FPLC HisTrap HP purification analysis of recombinant hNEIL3FL. A. 10% SDS-PAGE 
analysis stained with Instant-blue coomasie blue (Merk). B. Anti-His western blot analysis. Target protein 
bands annotated. (M) BioRad All Blue Prestained Protein Standard (Mustafa Albelazi).  
 
A. B. 




Appendix Figure 3: ÄKTA FPLC Mono S 5/50 GL purification analysis of recombinant hNEIL3FL. A. 10% SDS-
PAGE analysis stained with Instant-blue coomasie blue (Merk). B. Anti-His western blot analysis. C. Anti-NEIL3 









Appendix Figure 4: Denaturing PAGE analysis of hNEIL1 and Nei protein incubated with  XL47 • 47 - 21*, 
XL47 • 47* - 21 • 21,  XL47 • 47 - 21* • 21, or XL47 • 47* - 21 • 21 (Sophie Couvé, Gustave Roussy Institute). 
Samples were incubated for 1 h at 37°C. For positive control 20 nM of bacterial Nei was used and hNEIL1. 
C21/D47 hot alkali treated duplex ICL MA product control. D21 and C11 3ʹ OH size markers. Substrate and 
cleavage products sizes are indicated to the right of the gel. Substrate and cleavage products sizes are 
indicated to the right of the gel. "X" denotes substrate, "47 mer" denotes alkaline cleavage product containing 
either MA or regular thymine residue, "21-MA" denotes 21 mer fragment containing 8-MOP-derived MA. "21 
mer" denotes 21 mer size marker, and "11 mer" denotes 11 mer size marker. “11Pmer” denotes cleavage 













Appendix Table 4: The skeletal formula of HMT generated MAp, MAf, ICLs and DNA products generated by 
Nei-like DNA glycosylases, UNG, Nfo mediated cleavage and piperidine treatments. 
Cleavage 






























































































































































































Appendix Figure 5: CHT ceramic hydroxyapatite column (Bio-Rad, Hemel Hempstead, United Kingdom) FPLC 




















Appendix Table 5: LC-MS tandem mass spectrometry analysis. Q Exactive instrument operated in data-
dependent positive (electrospray ionization+ [ESI+]) mode was used, showing matched proteins after database 
alignment with detected peptides in final Mono Q (2 mL) fraction 25 (Edmonds et al.,2017; Williams and Parsons, 
2018). Tripartite motif-containing protein 26 highlighted in bold and only E3 ubiquitin-ligase detected in fraction.  
Matched amino acids are highlighted in red (taken from Williams and Parsons, 2018). 
 




Scientific Research Articles. 
 
Contents of the thesis, in part, have been previously published. 
Data presented in chapter 3, describing the differential and distinct excision capabilities of 
recombinant hNEIL1 and hNEIL3FL in the presence of oxidative lesions within a mock DNA 
replication fork oligonucleotide structure is currently in preparation for submission to the 
international peer reviewed journal Genes. 
Data presented in chapter 4, describing the novel ICL unhooking activities possessed by 
recombinant hNEIL1 and hNEIL3 proteins was published in the international peer reviewed 
journal Scientific Reports on the 12th of December 2017. 
“Martin, P. R., Couvé, S., Zutterling, C., et al. (2017) The Human DNA glycosylase NEIL1 
and NEIL3 Excise Psoralen-Induced-DNA-DNA Cross-Links in a Four-Stranded DNA 
Structure. Scientific Reports, 7, 17438.” 
 
 
